=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehac262.pdf",
  "converted_date": "2026-01-31T14:46:17.918957",
  "file_size_bytes": 12750583,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehac262.pdf"
}

=== СОДЕРЖАНИЕ ===

ESC GUIDELINES
EuropeanHeartJournal(2022)43,3997–4126

2022 ESC Guidelines for the management of
patients with ventricular arrhythmias and the
prevention of sudden cardiac death
Developed by the task force for the management of patients with
ventricular arrhythmias and the prevention of sudden cardiac
death of the European Society of Cardiology (ESC)
Endorsed by the Association for European Paediatric and
Congenital Cardiology (AEPC)
Authors/Task Force Members: Katja
Zeppenfeld*†
(Chairperson) (Netherlands),
Jacob Tfelt-Hansen *† (Chairperson) (Denmark), Marta de Riva** (Task Force
Coordinator) (Netherlands), Bo Gregers Winkel** (Task Force Coordinator)
(Denmark), Elijah R. Behr (United Kingdom), Nico A. Blom1 (Netherlands),
Philippe Charron (France), Domenico Corrado (Italy), Nikolaos Dagres
(Germany), Christian de Chillou (France), Lars Eckardt (Germany), Tim Friede
(Germany), Kristina H. Haugaa (Norway), Mélèze Hocini (France), Pier
D. Lambiase (United Kingdom), Eloi Marijon (France), Jose L. Merino (Spain),
PetrPeichl(CzechRepublic),SilviaG.Priori(Italy),TobiasReichlin(Switzerland),
Jeanette Schulz-Menger (Germany), Christian Sticherling (Switzerland),
Stylianos Tzeis (Greece), Axel Verstrael (Belgium), Maurizio Volterrani (Italy),
fi
and ESC Scienti c Document Group
*Correspondingauthors:KatjaZeppenfeld,DepartmentofCardiology,LeidenUniversityMedicalCentre,Albinusdreef2,2333ZALeiden,Netherlands.Tel+31715262020,E-mail:
K.Zeppenfeld@LUMC.nl
JacobTfelt-Hansen,TheDepartmentofCardiology,TheHeartCentre,CopenhagenUniversityHospital,Rigshospitalet,Blegdamsvej9,2100,Copenhagen,Denmark.Tel+4561360399,
E-mail:jacob.tfelt@regionh.dk
†Thetwochairpersonscontributedequallytothedocumentandarejointcorrespondingauthors.
**ThetwotaskforceCoordinatorscontributedequallytothedocument.
Author/taskforceMemberaffiliationsarelistedinAuthorinformation.
1RepresentingtheAssociationforEuropeanPaediatricandCongenitalCardiology(AEPC).
ESCClinicalPracticeGuidelines(CPG)Committee:listedintheAppendix.
ESCsubspecialtycommunitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AssociationforAcuteCardioVascularCare(ACVC),AssociationofCardiovascularNursing&AlliedProfessions(ACNAP),EuropeanAssociationofCardiovascular
Imaging(EACVI),EuropeanAssociationofPercutaneousCardiovascularInterventions(EAPCI),EuropeanHeartRhythmAssociation(EHRA),HeartFailureAssociation(HFA).
WorkingGroups:CardiacCellularElectrophysiology,MyocardialandPericardialDiseases.
PatientForum
ThecontentoftheseEuropeanSocietyofCardiology(ESC)Guidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuseisauthorized.NopartoftheESC
GuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESC.PermissioncanbeobtaineduponsubmissionofawrittenrequesttoOxfordUniversity
Press,thepublisheroftheEuropeanHeartJournalandthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(Journals.Permissions@oup.com).
Downloaded
from

by
guest
on
22
January
2026

3998 ESCGuidelines
Document-Reviewers:MajaCikes(CPGReviewCoordinator)(Croatia),PaulusKirchhof(CPGReview
Coordinator)(Germany),MagdyAbdelhamid(Egypt),VictorAboyans(France),ElenaArbelo(Spain),
FernandoArribas(Spain),RiccardoAsteggiano(Italy),CristinaBasso(Italy),AxelBauer(Austria),
EmanueleBertaglia(Italy),TorBiering-Sørensen(Denmark),CarinaBlomström-Lundqvist(Sweden),
MichaelA.Borger(Germany),JelenaČelutkienė(Lithuania),BernardCosyns(Belgium),VolkmarFalk
(Germany),LaurentFauchier(France),BulentGorenek(Turkey),SigrunHalvorsen(Norway),RobertHatala
(Slovakia),HeinHeidbuchel(Belgium),StefanKaab(Germany),AleksandraKonradi(RussianFederation),
KonstantinosC.Koskinas(Switzerland),DipakKotecha(UnitedKingdom),UlfLandmesser(Germany),
BasilS.Lewis(Israel),AlesLinhart(CzechRepublic),Maja-LisaLøchen(Norway),LarsH.Lund(Sweden),
AndreasMetzner(Germany),RichardMindham(UnitedKingdom),JensCosedisNielsen(Denmark),
ToneM.Norekvål(Norway),MonicaPatten(Germany),EvaPrescott(Denmark),AminaRakisheva
(Kazakhstan),CarolAnnRemme(Netherlands),IvoRoca-Luque(Spain),AndreaSarkozy(Belgium),
DanielScherr(Austria),MartaSitges(Spain),RhianM.Touyz(Canada/UnitedKingdom),NicolasVanMieghem
(Netherlands),VedranVelagic(Croatia),SamiViskin(Israel),andPaulG.A.Volders(Netherlands)
Allexpertsinvolvedinthedevelopmentoftheseguidelineshavesubmitteddeclarationsofinterest.Thesehave
beencompiledinareportandpublishedinasupplementarydocumentsimultaneouslytotheguidelines.The
reportisalsoavailableontheESCwebsitewww.escardio.org/Guidelines
SeetheEuropeanHeartJournalonlineforsupplementarydatathatincludesbackgroundinformationand
detaileddiscussionofthedatathathaveprovidedthebasisoftheguidelines.
ClickheretoaccessthecorrespondingESCCardioMedchapters.
Keywords Guidelines (cid:129) Anti-arrhythmicdrugs (cid:129) Cardiacmagneticresonance (cid:129) Cardiomyopathies (cid:129) Catheterablation (cid:129)
Chroniccoronaryarterydisease (cid:129) Genetictesting (cid:129) Implantablecardioverterdefibrillator (cid:129) Prematureventricular
complex (cid:129) Primaryelectricaldisease (cid:129) Recommendations (cid:129) Riskcalculator (cid:129) Riskstratification (cid:129) Suddencardiac
death (cid:129) Suddendeath (cid:129) Ventriculararrhythmia (cid:129) Ventricularfibrillation (cid:129) Ventriculartachycardia
Table of contents 4.4.Riskcalculatorsforsuddencardiacdeathandreviewofthe
methodology................................................................................................ 4012
1.Preamble........................................................................................................ 4003 4.5.Awarenessandintervention:publicbasiclifesupport,and
2.Introduction ................................................................................................. 4005 accesstoautomatedexternaldefibrillators ................................... 4012
2.1.Whatisnew ........................................................................................ 4005 5.Evaluationandtreatment.Generalaspects.................................... 4014
3.Definitions..................................................................................................... 4011 5.1.Diagnostictools ................................................................................. 4014
3.1.Ventriculararrhythmiasubtypes ................................................ 4011 5.1.1.Historyandphysicalexamination...................................... 4014
3.2.Suddencardiacdeath....................................................................... 4011 5.1.2.Laboratorytesting.................................................................... 4014
3.3.Syncope ................................................................................................. 4011 5.1.3.Non-invasiveandinvasivetests .......................................... 4014
3.4.Specializedcentres............................................................................ 4011 5.1.3.1.Electrocardiogramandambulatory
3.5.Genetics................................................................................................. 4011 electrocardiographicmonitoring................................................ 4014
4.Epidemiologyofsuddencardiacdeath,publicawareness,and 5.1.3.2.Signal-averagedelectrocardiogram............................ 4014
riskstratification .............................................................................................. 4011 5.1.3.3.Exercisetesting .................................................................. 4014
4.1.Incidenceofsuddencardiacdeath............................................. 4011 5.1.3.4.Imaging................................................................................... 4014
4.2.Causesofsuddencardiacdeathindifferentagegroups . 4012 5.1.3.5.Provocativediagnostictests ......................................... 4015
4.3.Populationvs.individualriskprediction .................................. 4012 5.1.3.6.Electrophysiologicalstudy ............................................. 4015
Disclaimer:TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidenceavailableatthe
timeoftheirpublication.TheESCisnotresponsibleintheeventofanycontradiction,discrepancy,and/orambiguitybetweentheESCGuidelinesandanyotherofficialrecommendations
orguidelinesissuedbytherelevantpublichealthauthorities,inparticularinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofessionalsareencouragedtotakethe
ESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasinthedeterminationandtheimplementationofpreventive,diagnostic,ortherapeuticmedicalstrat-
egies;however,theESCGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalstomakeappropriateandaccuratedecisionsinconsid-
erationofeachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,thepatient’scaregiver.NordotheESCGuidelinesexempthealth
professionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsorguidelinesissuedbythecompetentpublichealthauthorities,inorderto
manageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations.Itisalsothehealthprofessional’sresponsibilityto
verifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
©TheEuropeanSocietyofCardiology2022.Allrightsreserved.Forpermissionspleasee-mail:Journals.Permissions@oup.com
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 3999
5.1.4.Genetictesting........................................................................... 4015 7.1.1.3.4.Managementofpatientswith
5.2. Diagnostic evaluation at first presentation with haemodynamicallytoleratedventriculartachycardiaand
ventricular arrhythmia in patients without known cardiac preservedandmildlyreducedejectionfraction ............. 4048
disease .................................................................................................... 4018 7.1.1.3.5.Managementofrecurrentventricular
5.2.1.Scenario1:Incidentalfindingofanon-sustained tachycardiainimplantablecardioverterdefibrillator
ventriculartachycardia........................................................................ 4018 carriers.............................................................................................. 4049
5.2.2.Scenario2:Firstpresentationofsustained 7.1.1.4.Coronaryanomalies......................................................... 4049
monomorphicventriculartachycardia......................................... 4018 7.1.2.Idiopathicprematureventricularcomplexes/
5.2.3.Scenario3:Suddencardiacarrestsurvivor ................... 4020 ventriculartachycardiaandprematureventricularcomplex-
5.2.4.Scenario4:Suddendeathvictim........................................ 4023 inducedcardiomyopathy ................................................................... 4050
5.2.5.Scenario5:Relativesofsuddenarrhythmicdeath 7.1.2.1.Idiopathicprematureventricularcomplexes/
syndromedecedents ........................................................................... 4024 ventriculartachycardia.................................................................... 4050
6.Therapiesforventriculararrhythmias.Generalaspects........... 4027 7.1.2.2.Prematureventricularcomplex-induced/-
6.1.Acutemanagement .......................................................................... 4027 aggravatedcardiomyopathy.......................................................... 4052
6.1.1.Treatmentofreversiblecauses .......................................... 4027 7.1.3.Cardiomyopathies .................................................................... 4054
6.1.2.Acutemanagementofsustainedmonomorphic 7.1.3.1.Dilatedcardiomyopathyandhypokineticnon-
ventriculartachycardia........................................................................ 4029 dilatedcardiomyopathy.................................................................. 4054
6.1.3.Managementofelectricalstormandincessant 7.1.3.1.1.Diagnosticevaluationandriskstratification.. 4054
ventriculartachycardia........................................................................ 4030 7.1.3.1.2.Primarypreventionofsuddencardiacdeath 4055
6.2.Long-termmanagement................................................................. 4034 7.1.3.1.3.Secondarypreventionofsuddencardiacdeath
6.2.1.Pharmacotherapy...................................................................... 4034 andmanagementofventriculararrhythmias ................... 4057
6.2.2.Devicetherapy........................................................................... 4038 7.1.3.2. Arrhythmogenic right ventricular
6.2.2.1.Implantablecardioverterdefibrillator....................... 4038 cardiomyopathy................................................................................. 4058
6.2.2.2.Addingcardiacresynchronizationtherapy............. 4040 7.1.3.2.1.Riskstratification....................................................... 4058
6.2.2.3.Wearablecardioverterdefibrillator.......................... 4040 7.1.3.2.2.Treatment.................................................................... 4060
6.2.3.Specialaspectsofdevicetherapy ...................................... 4041 7.1.3.3.Hypertrophiccardiomyopathy.................................... 4060
6.2.3.1.Optimizationofdeviceprogramming ...................... 4041 7.1.3.3.1.Riskstratificationandprimarypreventionof
6.2.3.2.Concomitanttreatmenttoavoidinappropriate suddencardiacdeath.................................................................. 4061
implantablecardioverterdefibrillatortherapy ..................... 4041 7.1.3.3.2.Treatmenttopreventventriculararrhythmia
6.2.3.3.Psychosocialimpactofimplantablecardioverter recurrence....................................................................................... 4062
defibrillatortreatment .................................................................... 4042 7.1.3.4.Leftventricularnon-compaction................................ 4063
6.2.3.4.Patientswithleftventricularassistdevices............ 4042 7.1.3.5.Restrictivecardiomyopathy.......................................... 4063
6.2.3.5.Complicationsofdevices............................................... 4042 7.1.3.6.Neuromusculardisorders ............................................. 4063
6.2.3.6.End-of-lifeissues................................................................ 4043 7.1.4.Inflammatorycardiacdiseases............................................. 4066
6.2.4.Interventionaltherapy ............................................................ 4043 7.1.4.1.Myocarditis........................................................................... 4066
6.2.4.1.Catheterablation .............................................................. 4043 7.1.4.2.Cardiacsarcoidosis........................................................... 4067
6.2.4.1.1.Patientswithstructuralheartdisease ............. 4043 7.1.4.3.Chagas’cardiomyopathy................................................ 4068
6.2.4.1.2.Patientswithoutapparentstructuralheart 7.1.5.Valvularheartdisease ............................................................. 4070
disease............................................................................................... 4044 7.1.6.Congenitalheartdisease........................................................ 4071
6.2.4.2.Autonomicmodulation .................................................. 4044 7.2.Primaryelectricaldisease............................................................... 4073
7.Diagnosticevaluation,management,andrisk 7.2.1.Idiopathicventricularfibrillation......................................... 4073
stratificationaccordingtoclinicalpresentationandknown(likely) 7.2.2.LongQTsyndrome(includingacquiredlongQT
disease.................................................................................................................. 4044 syndrome)................................................................................................ 4074
7.1.Specificstructuralheartdiseases................................................ 4044 7.2.3.Andersen–TawilsyndromeType1 .................................. 4079
7.1.1.Coronaryarterydisease........................................................ 4044 7.2.4.Brugadasyndrome ................................................................... 4079
7.1.1.1.Acutecoronarysyndromesandvasospasm.......... 4044 7.2.5.Earlyrepolarizationsyndromes.......................................... 4081
7.1.1.1.1.Acutecoronarysyndromes ................................. 4044 7.2.6.Catecholaminergicpolymorphicventricular
7.1.1.1.2.Vasospasm................................................................... 4045 tachycardia ............................................................................................... 4084
7.1.1.2.Earlyaftermyocardialinfarction................................. 4046 7.2.7.ShortQTsyndrome................................................................ 4086
7.1.1.3.Chroniccoronaryarterydisease................................ 4046 8.Specialaspectsinselectedpopulations............................................ 4088
7.1.1.3.1.Primarypreventionofsuddencardiacdeathin 8.1.Pregnantpatientsandperi-partumcardiomyopathy......... 4088
patientswithreducedejectionfraction ............................. 4046 8.1.1.Electrocardioversionandimplantablecardioverter
7.1.1.3.2.Primarypreventionofsuddencardiacdeathin defibrillatortherapyinpregnancy.................................................. 4088
patientswithpreservedormildlyreducedejection 8.1.2.Pharmacologicaltreatment................................................... 4088
fraction ............................................................................................. 4047 8.1.3.Catheterablation...................................................................... 4088
7.1.1.3.3. Secondary prevention of sudden cardiac 8.2.Hearttransplantation ...................................................................... 4089
death.................................................................................................. 4047 8.3.Suddencardiacdeathinathletes................................................ 4089
Downloaded
from

by
guest
on
22
January
2026

4000 ESCGuidelines
8.4.Wolff–Parkinson–Whitesyndrome .......................................... 4090 RecommendationTable14—Recommendationsforadding
8.5.Preventionofsuddencardiacdeathintheelderly............. 4090 cardiacresynchronizationtherapytoimplantablecardioverter
9.Keymessages............................................................................................... 4090 defibrillator ........................................................................................................ 4040
9.1.Generalaspects.................................................................................. 4090 RecommendationTable15—Recommendationsforwearable
9.2.Structuralheartdisease.................................................................. 4090 cardioverterdefibrillator.............................................................................. 4040
9.3.Primaryelectricaldisease............................................................... 4091 RecommendationTable16—Recommendationsfor
10.Gapsinevidence...................................................................................... 4091 optimizationofdeviceprogramming ..................................................... 4041
10.1.Generalaspects ............................................................................... 4091 RecommendationTable17—Recommendationsfor
10.2.Structuralheartdisease—general ........................................... 4091 concomitanttreatmenttoavoidinappropriateimplantable
10.3.Idiopathicprematureventricularcomplexes/ventricular cardioverterdefibrillatortherapy ............................................................ 4042
tachycardia .................................................................................................... 4091 RecommendationTable18—Recommendationsfor
10.4.Coronaryarterydisease.............................................................. 4091 psychosocialmanagementafterimplantablecardioverter
10.5.Cardiomyopathies .......................................................................... 4091 defibrillatorimplantation ............................................................................. 4042
10.6.Valvularheartdisease ................................................................... 4091 RecommendationTable19—Recommendationsforimplantable
10.7.Congenitalheartdisease.............................................................. 4091 cardioverterdefibrillatorimplantationinleftventricularassist
10.8.Primaryelectricaldisease ............................................................ 4091 devicerecipients.............................................................................................. 4042
11.‘Whattodo’and‘whatnottodo’messagesfromthe RecommendationTable20—Recommendationsforprevention
Guidelines........................................................................................................... 4092 ofimplantablecardioverterdefibrillatorcomplications ................. 4043
12.Qualityindicators.................................................................................... 4099 RecommendationTable21—Recommendationsforend-of-life
13.Supplementarydata................................................................................ 4099 issuesinimplantablecardioverterdefibrillatorcarriers ................. 4043
14.Dataavailabilitystatement................................................................... 4099 RecommendationTable22—Recommendationsfortreatment
15.Authorinformation................................................................................ 4099 ofventriculararrhythmiasinacutecoronarysyndromeand
16.Appendix..................................................................................................... 4100 vasospasm .......................................................................................................... 4046
17.References.................................................................................................. 4101 RecommendationTable23—Recommendationsforrisk
stratificationandtreatmentofventriculararrhythmiasearlyafter
myocardialinfarction..................................................................................... 4046
Tables of Recommendations RecommendationTable24—Recommendationsforrisk
stratification,suddencardiacdeathprevention,andtreatmentof
RecommendationTable1—Recommendationsforpublic ventriculararrhythmiasinchroniccoronaryarterydisease......... 4047
basiclifesupportandaccesstoautomatedexternal RecommendationTable25—Recommendationsforsudden
defibrillators............................................................................................ 4014 cardiacdeathpreventioninpatientswithcoronaryanomalies ....... 4050
RecommendationTable2—Recommendationsforgenetic RecommendationTable26—Recommendationsforthe
testing................................................................................................................... 4018 managementofpatientswithidiopathicprematureventricular
RecommendationTable3—Recommendationsforevaluation complexes/ventriculartachycardia .......................................................... 4052
ofpatientspresentingwithnewlydocumentedventricular RecommendationTable27—Recommendationsforthe
arrhythmia.......................................................................................................... 4018 managementofpatientswithprematureventricular
RecommendationTable4—Recommendationsforevaluationof complex-inducedorprematureventricularcomplex-aggravated
patientspresentingwithafirstepisodeofsustained cardiomyopathy............................................................................................................. 4053
monomorphicventriculartachycardia................................................... 4020 RecommendationTable28—Recommendationsforrisk
RecommendationTable5—Recommendationsforevaluationof stratification,suddencardiacdeathprevention,andtreatment
suddencardiacarrestsurvivors................................................................ 4022 ofventriculararrhythmiasindilatedcardiomyopathy/
RecommendationTable6—Recommendationsforevaluationof hypokineticnon-dilatedcardiomyopathy...................................... 4057
suddendeathvictims..................................................................................... 4023 RecommendationTable29—Recommendationsfordiagnostic,
RecommendationTable7—Recommendationsforevaluationof riskstratification,suddencardiacdeathprevention,and
relativesofsuddenarrhythmicdeathsyndromedecedents ........ 4027 treatmentofventriculararrhythmiasinarrhythmogenicright
RecommendationTable8—Recommendationsfortreatmentof ventricularcardiomyopathy........................................................................ 4060
reversibleconditions...................................................................................... 4029 RecommendationTable30—Recommendationsforrisk
RecommendationTable9—Recommendationsfortheacute stratification,suddencardiacdeathprevention,andtreatmentof
managementofsustainedventriculartachycardiaandelectrical ventriculararrhythmiasinhypertropiccardiomyopathy ............... 4062
storm.................................................................................................................... 4033 RecommendationTable31—Recommendationsforimplantable
RecommendationTable10—Recommendationsfortreatment cardioverterdefibrillatorimplantationinleftventricular
withheartfailuremedication..................................................................... 4034 non-compaction .............................................................................................. 4063
RecommendationTable11—Recommendationsforimplantable RecommendationTable32—Recommendationsforimplantable
cardioverterdefibrillatorimplantation(generalaspects) .............. 4040 cardioverterdefibrillatorimplantationinpatientswithcardiac
RecommendationTable12—Recommendationsforsecondary amyloidosis......................................................................................................... 4063
preventionofsuddencardiacdeath ....................................................... 4040 RecommendationTable33—Recommendationsforrisk
RecommendationTable13—Recommendationsfor stratification,suddencardiacdeathprevention,andtreatmentof
subcutaneousimplantablecardioverterdefibrillator....................... 4040 ventriculararrhythmiasinneuromusculardiseases ......................... 4065
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4001
RecommendationTable34—Recommendationsforsudden Table9Summaryoftherecommendationsforthetreatmentof
cardiacdeathpreventionandtreatmentofventricular patientswithfrequentidiopathicprematureventricular
arrhythmiasinmyocarditis.......................................................................... 4066 complexes/ventriculartachycardiaorprematureventricular
RecommendationTable35—Recommendationsforrisk complex-inducedcardiomyopathy.......................................................... 4051
stratification,suddencardiacdeathprevention,andtreatmentof Table10ModifiedlongQTsyndromediagnosticscore...................... 4076
ventriculararrhythmiasincardiacsarcoidosis.................................... 4067
RecommendationTable36—Recommendations for the List of fi gures
treatment of ventricular arrhythmias in Chagas’
cardiomyopathy ....................................................................................... 4070 Figure1Centralfigure.................................................................................. 4013
RecommendationTable37—Recommendationsforsudden Figure2Algorithmfortheevaluationofpatientspresentingwith
cardiacdeathpreventionandtreatmentofventricular anincidentalfindingofnon-sustainedventriculartachycardia .... 4019
arrhythmiasinvalvularheartdisease...................................................... 4070 Figure4Algorithmfortheevaluationofpatientspresentingwitha
RecommendationTable38—Recommendationsforrisk firstsustainedmonomorphicventriculartachycardiaepisode.... 4021
stratificationandprimarypreventionofsuddencardiacdeathin Figure3Typicalidiopathicventriculartachycardiamorphologies 4020
congenitalheartdisease ............................................................................... 4072 Figure5Bundlebranchre-entrantventriculartachycardia .......... 4022
RecommendationTable39—Recommendationsforsecondary Figure6PartOne.Algorithmfortheevaluationofsuddencardiac
preventionofsuddencardiacdeathandtreatmentofventricular arrestsurvivors ................................................................................................ 4024
arrhythmiaincongenitalheartdisease .................................................. 4072 Figure6PartTwo.Algorithmfortheevaluationofsuddencardiac
RecommendationTable40—Recommendationsforthe arrestsurvivors ................................................................................................ 4025
managementofpatientswithidiopathicventricularfibrillation.. 4073 Figure7Algorithmfortheevaluationofsuddendeathvictims . 4026
RecommendationTable41—Recommendationsforthe Figure8Algorithmfortheevaluationofrelativesofunexplained
managementofpatientswithlongQTsyndrome ........................... 4077 suddendeathdecedents .............................................................................. 4028
RecommendationTable42—Recommendationsfor Figure9Algorithmfortheacutemanagementofregularwide
managementofpatientswithAndersen–Tawilsyndrome........... 4079 QRScomplextachycardia........................................................................... 4029
RecommendationTable43—Recommendationsfor Figure10Repetitiverunsofventriculartachycardiainterrupted
managementofpatientswithBrugadasyndrome............................ 4080 byoccasionalsinusbeats ............................................................................. 4030
RecommendationTable44—Recommendationsforthe Figure11PartOne.Managementofpatientswithelectrical
managementofpatientswithearlyrepolarizationpattern/ stormorrepeatedimplantablecardioverterdefibrillator
syndrome............................................................................................................ 4083 discharges......................................................................................................... 4031
RecommendationTable45—Recommendationsforthe Figure11PartTwo.Managementofpatientswithelectrical
managementofpatientswithcatecholaminergicpolymorphic stormorrepeatedimplantablecardioverterdefibrillator
ventriculartachycardia.................................................................................. 4086 discharges ................................................................................................... 4032
RecommendationTable46—Recommendationsforthe Figure11PartThree.Managementofpatientswithelectrical
managementofpatientswithshortQTsyndrome......................... 4087 stormorrepeatedimplantablecardioverterdefibrillator
RecommendationTable47—Recommendationsforthe discharges ........................................................................................................... 4033
preventionofsuddencardiacdeathandmanagementof Figure12Algorithmforevaluationbeforeinitiationandfollow-up
ventriculararrhythmiaduringpregnancy.............................................. 4088 ofpatientsrequiringsodiumchannelblockingagents .................... 4038
RecommendationTable48—Recommendationsforthe Figure13Algorithmforevaluationbeforeinitiationandfollow-up
preventionofsuddencardiacdeathbeforeandafterheart ofpatientsrequiringdrugsassociatedwithQTprolongation .... 4039
transplantation ................................................................................................. 4089 Figure14Algorithmforthepreventionandmanagementof
RecommendationTable49—Recommendationsforrisk ventriculararrhythmiasinST-elevationmyocardialinfarction......... 4045
stratificationandpreventionofsuddencardiacdeathinathletes 4089 Figure15Algorithmforriskstratificationandprimaryprevention
RecommendationTable50—Recommendationsforimplantable ofsuddencardiacdeathinpatientswithchroniccoronaryartery
cardioverterdefibrillatorimplantationintheelderly...................... 4090 diseaseandreducedejectionfraction.................................................... 4048
Figure16Algorithmforthemanagementofsustained
List of tables monomorphicventriculartachycardiainpatientswithchronic
coronaryarterydisease................................................................................ 4049
Table1Classesofrecommendations.................................................... 4003 Figure17Algorithmforthemanagementofpatientswith
Table2Levelsofevidence.......................................................................... 4004 idiopathicprematureventricularcomplexes/ventricular
Table3Newsectionsandconcepts ...................................................... 4005 tachycardiaandnon-apparentstructuralheartdisease ................. 4051
Table4Newrecommendationsin2022 ............................................. 4005 Figure18Algorithmforthemanagementofpatientswith
Table5Changesinrecommendationssince2015........................... 4010 prematureventricularcomplex-induced/-aggravated
Table6Intravenousprovocativediagnostictests............................. 4016 cardiomyopathy............................................................................................... 4053
Table7Genetictestsandsuggestedwork-upofprobandsand Figure19Algorithmforriskstratificationandprimaryprevention
relativeswithprimaryelectricaldiseases.............................................. 4017 ofsuddencardiacdeathinpatientswithdilatedcardiomyopathy/
Table8Anti-arrhythmicdrugs(acuteandchronictreatment) .. 4035 hypokineticnon-dilatedcardiomyopathy ............................................. 4055
Downloaded
from

by
guest
on
22
January
2026

4002 ESCGuidelines
Figure20Typicalfeaturesofdilatedcardiomyopathyassociated BBR-VT Bundlebranchre-entrantventriculartachycardia
withlaminA/Cgenemutationwithventriculararrhythmias ...... 4056 BrS Brugadasyndrome
Figure21Typicalfeaturesofarrhythmogenicright CA Cardiacarrest
ventricular cardiomyopathy associated with ventricular cAMP Cyclicadenosinemonophosphate
arrhythmias................................................................................................ 4059 CAD Coronaryarterydisease
Figure22Typical features of hypertrophic cardiomyopathy CAG Coronaryangiogram
associated with sustained monomorphic ventricular CCB Calciumchannelblocker
tachycardia ................................................................................................. 4061 CHD Congenitalheartdisease
Figure23Algorithmforriskstratification,suddencardiacdeath
CIED Cardiacimplantableelectronicdevices
prevention,andtreatmentofventriculararrhythmiainmyotonic CMR Cardiacmagneticresonance
dystrophy.......................................................................................................................... 4064 CPR Cardiopulmonaryresuscitation
Figure24Algorithmforsuddencardiacdeathpreventionand CPVT Catecholaminergicpolymorphicventriculartachycardia
treatmentofventriculararrhythmiainpatientswithcardiac CRT Cardiacresynchronizationtherapy
sarcoidosis.......................................................................................................... 4068 CT/CTA Computedtomography/Computedtomography
Figure25Typicalfeaturesofcardiacsarcoidosisassociatedwith angiography
sustainedmonomorphicventriculartachycardia .............................. 4069 DCM Dilatedcardiomyopathy
Figure26Algorithmforthemanagementofsustainedventricular DNA Deoxyribonucleicacid
arrhythmiainpatientswithcongenitalheartdisease...................... 4071 ECG Electrocardiogram
Figure27Algorithmforthemanagementofpatientswith EF Ejectionfraction
idiopathicventricularfibrillation ............................................................... 4074 ERP Earlyrepolarizationpattern
Figure28Idiopathicventricularfibrillationtriggeredby
ERS Earlyrepolarizationsyndrome
short-coupledprematureventricularcomplexes ............................. 4075 FBI Fast,broad,irregular
Figure29LongQTsyndromeelectrocardiogramsand HCM Hypertrophiccardiomyopathy
torsade-de-pointesventriculartachycardia ......................................... 4076 HFrEF Heartfailurewithreducedejectionfraction
Figure30BriskstandingelectrocardiogramchangesandTwave HNDCM Hypokineticnon-dilatedcardiomyopathy
alternansinLongQTsyndromepatients............................................. 4077 HTX Hearttransplantation
Figure31Algorithmforthemanagementofpatientswithlong HV His–ventricularinterval
QTsyndrome................................................................................................... 4078 ICD Implantablecardioverterdefibrillator
Figure32Typicalexamplesof(A)Brugadatype1 ILR Implantablelooprecorder
electrocardiogram,and(B)earlyrepolarizationpattern IVF Idiopathicventricularfibrillation
electrocardiogram........................................................................................... 4080 LBBB Leftbundlebranchblock
Figure33PartOne.Algorithmforthemanagementofpatients LCSD Leftcardiacsympatheticdenervation
withBrugadapatternelectrocardiogram ............................................. 4082 LGE Lategadoliniumenhancement
Figure33PartTwo.Algorithmforthemanagementofpatients LMNA LaminA/C
withBrugadapatternelectrocardiogram ............................................. 4083 LQTS LongQTsyndrome
Figure34Managementofpatientswithearlyrepolarization LV Leftventricular
pattern/syndrome ........................................................................................... 4084 LVAD Leftventricularassistdevice
Figure35Managementofpatientswithcatecholaminergic LVEF Leftventricularejectionfraction
polymorphicventriculartachycardia ...................................................... 4085 LVH Leftventricularhypertrophy
Figure36Exercisetestofapatientwithcatecholaminergic LVNC Leftventricularnon-compaction
polymorphicventriculartachycardia ...................................................... 4086 LVOT Leftventricleoutflowtract
Figure37ShortQTsyndrome ................................................................. 4087 MI Myocardialinfarction
MRA Mineralocorticoidreceptorantagonist
MVP Mitralvalveprolapse
Abbreviations and acronyms MVT Monomorphicventriculartachycardia
NSVT Non-sustainedventriculartachycardia
AAD Anti-arrhythmicdrug NYHA NewYorkHeartAssociation
ACE-I Angiotensin-convertingenzymeinhibitor OHCA Out-of-hospitalcardiacarrest
ACS Acutecoronarysyndrome OMT Optimalmedicaltreatment
AED Automatedexternaldefibrillator PCI Percutaneouscoronaryintervention
AF Atrialfibrillation PCR Polymerasechainreaction
AH Atrial–Hisinterval PES Programmedelectricalstimulation
ALS Advancedlifesupport PET-CT Positronemissiontomographycomputed
ARB Angiotensinreceptorblocker tomography
ARNI Angiotensinreceptorneprilysininhibitor PPCM Peri-partumcardiomyopathy
ARVC Arrhythmogenicrightventricularcardiomyopathy PVC Prematureventricularcomplex
ATP Anti-tachycardiapacing PVT Polymorphicventriculartachycardia
AV Atrioventricular QI Qualityindicators
AVRT AVre-entrytachycardia RBBB Rightbundlebranchblock
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4003
RCM Restrictivecardiomyopathy Guidelines and their recommendations should facilitate decision
RCT Randomizedcontroltrial makingofhealthprofessionalsintheirdailypractice.However,guide-
RV Rightventricular
linesarenotasubstituteforthepatient’srelationshipwiththeirprac-
RVOT Rightventricleoutflowtract titioner.Thefinaldecisionsconcerninganindividualpatientmustbe
SADS Suddenarrhythmicdeathsyndrome madebytheresponsiblehealthprofessional(s),basedonwhatthey
SaECG Signal-averagedECG considertobethemostappropriateinthecircumstances.Thesede-
SCA Suddencardiacarrest cisions are made in consultation with the patient and caregiver as
SCD Suddencardiacdeath appropriate.
SD Suddendeath Guidelinesareintendedforusebyhealthprofessionals.Toensure
SGLT2 Sodium–glucoseco-transporter2 thatallusershaveaccesstothemostrecentrecommendations,the
SHD Structuralheartdisease ESCmakesitsguidelinesfreelyavailable.TheESCwarnsreadersthat
S-ICD Subcutaneous implantable cardioverter the technical language may be misinterpreted and declines any re-
defibrillator sponsibilityinthisrespect.
SMVT Sustainedmonomorphicventriculartachycardia Agreatnumberofguidelineshavebeenissuedinrecentyearsby
SPTV Sustainedpolymorphicventriculartachycardia theESC.Becauseoftheirimpactonclinicalpractice,qualitycriteria
SQTS ShortQTsyndrome forthedevelopmentofguidelineshavebeenestablishedtomakeall
STEMI STelevationmyocardialinfarction decisionstransparenttotheuser.Therecommendationsforformu-
SVT Supraventriculartachycardia latingandissuingESCGuidelinescanbefoundontheESCwebsite
TAVI Transcatheteraorticvalveimplantation ( The ESC Guidelines re-
TdP Torsadesdepointes
presenttheofficialpositionoftheESConagiventopicandareregu-
TOF TetralogyofFallot larlyupdated.
VA Ventriculararrhythmia InadditiontothepublicationofClinicalPracticeGuidelines,the
VF Ventricularfibrillation ESC carries out the EURObservational Research Programme of
VT Ventriculartachycardia international registries ofcardiovasculardiseases andinterventions
WCD Wearablecardioverterdefibrillator thatareessentialtoassessdiagnostic/therapeuticprocesses,useof
WPW Wolff–Parkinson–White resources,andadherencetoguidelines.Theseregistriesaimatpro-
viding a better understanding of medical practice in Europe and
aroundtheworld,basedonhigh-qualitydatacollectedduringrou-
1. Preamble tineclinicalpractice.
Furthermore, the ESC develops sets of quality indicators (QIs),
Guidelinessummarizeandevaluateavailableevidencewiththeaimof whicharetoolstoevaluatethelevelofimplementationoftheguide-
assisting health professionals in proposing the best management lines andmay be used by the ESC, hospitals,healthcare providers,
strategies for an individual patient with a given condition. and professionals to measure clinical practice, and in educational
Table1 Classesofrecommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
effcacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/effcacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
snoitadnemmocer
fo
sessalC
2202
CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4004 ESCGuidelines
Table2 Levelsofevidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
programmes,alongsidethekeymessagesfromtheguidelines,toim- EuropeanHeartJournal.Theguidelinesweredevelopedaftercareful
provequalityofcareandclinicaloutcomes. consideration of the scientific and medical knowledge and the evi-
TheMembersofthistaskforcewereselectedbytheESCtore- denceavailableatthetimeoftheirwriting.
present professionals involved with the medical care of patients ThetaskofdevelopingESCGuidelinesalsoincludesthecreation
withthispathology.Theselectionprocedureaimedtoensurethat of educational tools and implementation programmes for the re-
thereisarepresentativemixofmemberspredominantlyfromacross commendations, including condensed pocket guideline versions,
the whole of the ESC region and from relevant ESC Subspecialty summaryslides,summarycardsfornon-specialists,andanelectronic
Communities. Consideration was given to diversity and inclusion, version for digital applications (smartphones, etc.). These versions
notablywithrespecttogenderandcountryoforigin.Acriticalevalu- are abridged and thus, for more detailed information, the user
ationofdiagnosticandtherapeuticprocedureswasperformed,in- should always access the full-text version of the guidelines, which
cluding assessment of the risk–benefit ratio. The level of evidence is freely available via the ESC website and the European Heart
andthestrengthoftherecommendationofparticularmanagement Journal.TheNationalCardiacSocietiesoftheESCareencouraged
optionswereweighedandscoredaccordingtopredefinedscales,as to endorse, adopt, translate, and implement all ESC Guidelines.
outlinedbelow.ThetaskforcefollowedtheESCvotingprocedures. Implementationprogrammesareneededbecauseithasbeenshown
Allrecommendationssubjecttoavoteachievedatleast75%among that the outcome of disease may be favourably influenced by the
votingmembers. thoroughapplicationofclinicalrecommendations.
Theexpertsofthewritingandreviewingpanelsprovideddeclar- HealthprofessionalsareencouragedtotaketheESCGuidelines
ationofinterestformsforallrelationshipsthatmightbeperceivedas fully into account when exercising their clinical judgement, as well
realorpotentialsourcesofconflictsofinterest.Theirdeclarationsof as in the determination and the implementation of preventive,
interestwerereviewedaccordingtotheESCdeclarationofinterest diagnostic, or therapeutic medical strategies. However, the ESC
rulesandcanbefoundontheESCwebsite( Guidelinesdonotoverrideinanywaywhatsoevertheindividualre-
Guidelines)andhavebeencompiledinareportandpublishedina sponsibilityofhealthprofessionalstomakeappropriateandaccurate
supplementarydocumentsimultaneouslytotheguidelines. decisionsinconsiderationofeachpatient‘shealthconditionandin
Thisprocessensurestransparencyandpreventspotentialbiasesin consultationwiththatpatientorthepatient’scaregiverwhereap-
thedevelopmentandreviewprocesses.Anychangesindeclarationsof propriate and/or necessary. It is also the health professional’s re-
interestthatariseduringthewritingperiodwerenotifiedtotheESC sponsibility to verify the rules and regulations applicable in each
andupdated.Thetaskforcereceiveditsentirefinancialsupportfrom countrytodrugsanddevicesatthetimeofprescriptionand,where
theESCwithoutanyinvolvementfromthehealthcareindustry. appropriate,torespecttheethicalrulesoftheirprofession.
TheESCCPGCommitteesupervisesandcoordinatestheprepar- Off-labeluseofmedicationmaybepresentedinthisguidelineif
ationofnewguidelines.TheCommitteeisalsoresponsibleforthe sufficientlevelofevidenceshowsthatitcanbeconsideredmedically
approval processoftheseguidelines. TheESC Guidelines undergo appropriatetoagivenconditionandifpatientscouldbenefitfrom
extensivereviewbytheCPGCommitteeandexternalexperts,in- therecommendedtherapy.However,thefinaldecisionsconcerning
cludingamixofmembersfromacrossthewholeoftheESCregion anindividualpatientmustbemadebytheresponsiblehealthprofes-
and from relevant ESC Subspecialty Communities and National sionalgivingspecialconsiderationto:
Cardiac Societies. After appropriate revisions, the guidelines are
signedoffbyalltheexpertsinvolvedinthetaskforce.Thefinalized (1) thespecificsituationofthepatient.Inthisrespect,itisspecified
documentissignedoffbytheCPGCommitteeforpublicationinthe that,unlessotherwiseprovidedforbynationalregulations,off-
2202
CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4005
labeluseofmedicationshouldbelimitedtosituationswhereitis Table4 Newrecommendationsin2022
in the patient’s interest to do so, with regard to the quality,
safety,andefficacyofcare,andonlyafterthepatienthasbeen Recommendations Class
informedandhasprovidedconsent;
PublicbasiclifesupportandaccesstoAEDs
(2) country-specifichealthregulations,indicationsbygovernmental
Itisrecommendedthatpublic-accessdefibrillationbeavailable
drug regulatory agencies,and theethicalrules towhich health I
atsiteswherecardiacarrestismorelikelytooccur.a
professionalsaresubject,whereapplicable.
PromptCPRbybystandersisrecommendedatOHCA. I
Itisrecommendedtopromotecommunitytraininginbasiclife
2. Introduction I
supporttoincreasebystanderCPRrateandAEDuse.
Mobilephone-basedalertingofbasiclifesupport-trained
This document presents an update of the 2015 ESC Guidelines
bystandervolunteerstoassistnearbyOHCAvictimsshouldbe IIa
for the management of patients with ventricular arrhythmias (VA)
considered.
and the prevention of sudden cardiac death (SCD). New insights
intothe epidemiology of SCD,new evidence on genetics, imaging, TreatmentofVA.Generalaspects
andclinical findings for riskstratificationforVA and SCD,and ad- DCcardioversionisrecommendedasthefirst-linetreatment
vancesindiagnosticevaluationandtherapeuticstrategiesmadethis forpatientspresentingwithtoleratedSMVTprovidedthatthe I
revisionnecessary.Thecommitteewascomposedof25members anaesthetic/sedationriskislow.
including23expertphysicians,onemethodologist,andonepatient OptimalmedicaltreatmentincludingACE-I/ARB/ARNIs,
representative.ExpertswereselectedtocoverallareasofVAand MRAs,beta-blockers,andSGLT2inhibitorsisindicatedinall I
SCDaswellassubspecialtiesofcardiologywiththeassistanceofre- heartfailurepatientswithreducedEF.
latedESCworkinggroups. Implantationofacardioverterdefibrillatorisonly
All25membersofthetaskforcecommitteeapprovedtheguide- recommendedinpatientswhohaveanexpectationof I
line recommendations after an anonymous voting process. good-qualitysurvival.1year.
Ninety-nine peer reviewers reviewed the document. A systematic
Inpatientspresentingwithahaemodynamicallytolerated
literaturesurveywasconducted,afterinstructionsbythemethod- SMVTandknownorsuspectedSHD,intravenous IIa
ologistinthegroup,thatledtotheincorporationof1155references,
procainamideshouldbeconsidered.
ofwhich485wereselectedtosupporttherecommendationsand
Inpatientspresentingwithahaemodynamicallytolerated
furtherspecifiedinthetableofevidence(Supplementarydata).
SMVTintheabsenceofanestablisheddiagnosis,intravenous IIb
amiodaronemaybeconsidered.
2.1. What is new
InpatientswithSMVTorSPVT/VFtriggeredbyaPVCwith
The diagnostic and management parts of the guidelines have been similarmorphologyandanindicationforICD,catheterablation
adaptedtofacilitatetheiruseineverydayclinicaldecision-making. maybeconsideredwhenanICDisnotavailable, IIb
Thefirstgeneralparthasnewsectionsondiagnosticevaluation,
contraindicatedforconcurrentmedicalreasons,ordeclinedby
includingpharmacologicprovocativetests,genetictesting,andasys- thepatient.
tematic work-up of probands and relatives with primary electrical
TheWCDmaybeconsideredintheearlyphaseafterMIin
diseases.Comprehensiveflowchartsandrecommendationsforthe IIb
selectedpatients.
diagnosticevaluationatfirstpresentationwithaVAofpatientswith-
Coronaryarterydisease
out a previously known cardiac disease are provided for five fre-
InpatientswithCADandrecurrent,symptomaticSMVT,or
quently encountered clinical scenarios. Practical recommendations
foroptimizationofimplantablecardioverterdefibrillator(ICD)pro- ICDshocksforSMVTdespitechronicamiodaronetherapy, I
catheterablationisrecommendedinpreferencetoescalating grammingandalgorithmsformanagementofpatientsexperiencing
AADtherapy.
regularwidecomplextachycardiaandelectricalstormarepresented
(Table3). Cardiacstressimagingduringphysicalexerciseis
recommendedinadditiontocardiopulmonaryexercisetest
I
aftersurgeryinpatientswithanomalousaorticoriginofa
Table3 Newsectionsandconcepts
coronaryarterywithahistoryofabortedCA.
Newsectionsandconcepts Section InSCAsurvivorswithcoronaryarteryspasm,implantationof IIa
anICDshouldbeconsidered.
Provocativediagnostictests 5.1.3.5
ICDtherapyshouldbeconsideredinpatientswithCAD,
IIa
Genetictesting 5.1.4 NYHAclassI,andLVEF≤30%despite≥3monthsofOMT.
DiagnosticevaluationatfirstpresentationwithVAin 5.2
ICDimplantationshouldbeconsideredinpatientswithCAD,
patientswithoutknowncardiacdisease LVEF≤40%despite≥3monthsofOMTandNSVT,iftheyare IIa
Managementofpatientswithelectricalstorm 6.1.3
inducibleforSMVTbyPES.
Specialaspectsofdevicetherapy 6.2.3
Continued
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4006 ESCGuidelines
InpatientswithCADandhaemodynamicallywell-tolerated Genetictesting(includingatleastLMNA,PLN,RBM20,and
SMVTandLVEF≥40%,catheterablationinexperienced FLNCgenes)shouldbeconsideredforriskstratificationin
IIa
centresshouldbeconsideredasanalternativetoICDtherapy, patientswithapparentlysporadicDCM/HNDCM,who IIa
providedthatestablishedendpointshavebeenreached.b presentatyoungageorwithsignssuspiciousforaninherited
CatheterablationshouldbeconsideredinpatientswithCAD aetiology.
andrecurrent,symptomaticSMVT,orICDshocksforSMVT IIa ICDimplantationshouldbeconsideredinDCM/HNDCM
despitebeta-blockerorsotaloltreatment. patientswithanLVEF,50%and≥2riskfactors(syncope,LGE
IIa
IdiopathicPVC/VTandPVC-inducedcardiomyopathy onCMR,inducibleSMVTatPES,pathogenicmutationsin
LMNA,PLN,FLNC,andRBM20genes).
Catheterablationasfirst-linetreatmentisrecommendedfor
symptomaticidiopathicVT/PVCsfromtheRVOTortheleft I ICDimplantationshouldbeconsideredinpatientswithDCM/ IIa
HNDCMandhaemodynamicallytoleratedSMVT.
fascicles.
Inafirst-degreerelativeofapatientwithapparentlysporadic
Beta-blockersornon-dihydropyridineCCBsareindicatedin
symptomaticpatientswithidiopathicVT/PVCsfromanorigin I DCM/HNDCM,anECG,andanechocardiogrammaybe IIb
considered.
otherthantheRVOTortheleftfascicles.
Participationinhigh-intensityexerciseincludingcompetitive
InpatientswithPVCs/VTandapresentationnottypicalforan
idiopathicorigin,cCMRshouldbeconsidered,despiteanormal IIa sportsisnotrecommendedforindividualswithDCM/ III
HNDCMandaLMNAmutation.
echocardiogram.
Beta-blockers,non-dihydropyridineCCBsorflecainideshould ARVC
beconsideredwhencatheterablationisnotavailable,not InpatientswithsuspectedARVC,CMRisrecommended. I
IIa
desired,orisparticularlyriskyinsymptomaticpatientswith InpatientswithasuspectedordefinitediagnosisofARVC,
I
idiopathicVT/PVCsfromtheRVOTortheleftfascicles. geneticcounsellingandtestingarerecommended.
Catheterablationorflecainideshouldbeconsideredin ICDimplantationshouldbeconsideredinsymptomaticd
symptomaticpatientswithidiopathicVT/PVCsfromanorigin IIa patientswithdefiniteARVC,moderaterightorleftventricular IIa
otherthantheRVOTortheleftfascicles. dysfunction,andeitherNSVTorinducibilityofSMVTatPES.
InpatientswithanunexplainedreducedEFandaPVCburden InARVCpatientswithindicationforICDs,adevicewiththe
ofatleast10%,PVC-inducedcardiomyopathyshouldbe IIa capabilityofATPprogrammingforSMVTuptohighrates IIa
considered. shouldbeconsidered.
InpatientswithsuspectedPVC-inducedcardiomyopathy,CMR Avoidanceofhigh-intensityeexercisemaybeconsideredin
IIa
shouldbeconsidered. carriersofARVC-relatedpathogenicmutationsandno IIb
Innon-responderstoCRTwithfrequent,predominately phenotype.
monomorphicPVCslimitingoptimalbiventricularpacing Beta-blockertherapymaybeconsideredinallpatientswitha
IIa IIb
despitepharmacologicaltherapy,catheterablationorAADs definitediagnosisofARVC.
shouldbeconsidered. InpatientswithARVCandsymptomshighlysuspiciousforVA,
IIb
CatheterablationmaybeconsideredforidiopathicVT/PVCsin PESmaybeconsideredforriskstratification.
asymptomaticpatientswithrepeatedlymorethan20%of IIb
HCM
PVCsperdayatfollow-up.
CMRwithLGEisrecommendedinHCMpatientsfor
Amiodaroneasafirst-linetreatmentisnotrecommendedin I
III diagnosticwork-up.
patientswithidiopathicVTs/PVCs.
GeneticcounsellingandtestingarerecommendedinHCM
I DCM/HNDCM
patients.
Genetictesting(includingatleastLMNA,PLN,RBM20,and Inafirst-degreerelativeofapatientwithHCM,ECG,and
I
FLNCgenes)isrecommendedinpatientswithDCM/HNDCM echocardiogramarerecommended.
andAVconductiondelayat,50years,orwhohaveafamily I
ICDimplantationshouldbeconsideredinHCMpatientsaged
historyofDCM/HNDCMorSCDinafirst-degreerelative(at
16yearsormorewithanintermediate5-yearriskofSCD(≥4
age,50years).
to,6%)f,andwith(a)significantLGEatCMR(usually≥15%of
IIa
Inafirst-degreerelativeofaDCM/HNDCMpatient,anECG, LVmass);or(b)LVEF,50%;or(c)abnormalbloodpressure
andanechocardiogramarerecommendedif: responseduringexercisetestg;or(d)LVapicalaneurysm;or
(cid:129) theindexpatientwasdiagnosed,50yearsofageorhas
I (e)presenceofsarcomericpathogenicmutation.
clinicalfeaturessuggestiveofaninheritedcause,or Inchildren,16yearsofagewithHCMandanestimated
(cid:129) thereisafamilyhistoryofDCM/HNDCM,orpremature 5-yearriskofSD≥6%(basedonHCMRisk-Kidsscoreh),ICD IIa
unexpectedSD.
implantationshouldbeconsidered.
CMRwithLGEshouldbeconsideredinDCM/HNDCM
IIa InpatientswithHCMpresentingwithhaemodynamically
IIa
patientsforassessingtheaetiologyandtheriskofVA/SCD.
toleratedSMVT,ICDimplantationshouldbeconsidered.
Continued
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4007
InpatientswithHCMandrecurrent,symptomaticVA,or Inflammatorydiseases
recurrentsymptomaticICDtherapy,AADtreatmentshould IIa
Inpatientswithhaemodynamicallynot-toleratedsustainedVT
beconsidered. orVFduringtheacutephaseofmyocarditis,ICDimplantation IIa
Participationinhigh-intensityexercisemaybeconsideredfor
IIb beforehospitaldischargeshouldbeconsidered.
asymptomaticadultHCMpatientswithoutriskmarkers.
Inpost-myocarditispatientswithrecurrent,symptomaticVT,
IIa
ICDimplantationmaybeconsideredinHCMpatientsaged16
AADtreatmentshouldbeconsidered.
yearsormorewithalowestimated5-yearriskofSCD(,4%),f
IIb Catheterablation,performedinspecializedcentres,shouldbe
andwith(a)significantLGEatCMR(usually≥15%ofLVmass);
consideredinpost-myocarditispatientswithrecurrent,
or(b)LVEF,50%;or(c)LVapicalaneurysm. IIa
symptomaticSMVT,orICDshocksforSMVTinwhomAADs
Catheterablationinspecializedcentresmaybeconsideredin
areineffective,nottolerated,ornotdesired.
selectedpatientswithHCMandrecurrent,symptomatic
IIb InpatientswithhaemodynamicallytoleratedSMVToccurring
SMVT,orICDshocksforSMVT,inwhomAADsare inthechronicphaseofmyocarditis,ICDimplantationshould IIa
ineffective,contraindicated,ornottolerated.
beconsidered.
LVNCandRCM InpatientswithcardiacsarcoidosiswhohaveanLVEF.35%
InpatientswithanLVNCcardiomyopathyphenotypebasedon butsignificantLGEatCMRafterresolutionofacute IIa
CMRorechocardiography,implantationofanICDforprimary inflammation,ICDimplantationshouldbeconsidered.
IIa
preventionofSCDshouldbeconsideredtofollowDCM/ InpatientswithcardiacsarcoidosiswhohaveanLVEF35–50%
HNDCMrecommendations. andminorLGEatCMR,afterresolutionofacuteinflammation, IIa
AnICDshouldbeconsideredinpatientswithlight-chain PESforriskstratificationshouldbeconsidered.
amyloidosisortransthyretin-associatedcardiacamyloidosis IIa Inpatientswithcardiacsarcoidosis,LVEF35–50%,and
IIa
andhaemodynamicallynot-toleratedVT. inducibleSMVTatPES,ICDimplantationshouldbeconsidered.
Neuromusculardiseases Inpatientswithcardiacsarcoidosisandrecurrent,symptomatic
IIa
VA,AADtreatmentshouldbeconsidered.
Invasiveelectrophysiologicalevaluationisrecommendedin
patientswithmyotonicdystrophyandpalpitationsorsyncope I Amiodaroneshouldbeconsideredtoreducearrhythmia
suggestiveofVAorsurvivingaCA.
burdeninpatientswithChagas’cardiomyopathywhopresent IIa
ICDimplantationisrecommendedinpatientswithmyotonic withsymptomaticPVCsorVT.
I
dystrophyandSMVTorabortedCAnotcausedbyBBR-VT.
InpatientswithChagas’cardiomyopathyandrecurrent,
Invasiveelectrophysiologicalevaluationshouldbeconsidered symptomaticSMVT,orICDshocksforSMVTinwhomAADs IIa
inpatientswithmyotonicdystrophyandasuddenincreasein IIa areineffective,contraindicated,ornottolerated,catheter
ablationinspecializedcentresshouldbeconsidered.
thePRintervalorQRSduration.
Inpatientswithhaemodynamicallywell-toleratedSMVT
Invasiveelectrophysiologicalevaluationshouldbeconsidered
inpatientswithmyotonicdystrophyandaPRinterval≥240ms occurringinthechronicphaseofmyocarditis,preservedLV
orQRSduration≥120msorwhoareolderthan40yearsand IIa functionandalimitedscaramenabletoablation,catheter
IIb
ablationmaybeconsideredasanalternativetoICDtherapy,
havesupraventriculararrhythmias,orwhoareolderthan40
yearsandhavesignificantLGEonCMR afterdiscussionwiththepatientandprovidedthatestablished
endpointshavebeenreached.b
InmyotonicdystrophypatientswithoutAVconductiondelay
andasyncopehighlysuspiciousforVA,ICDimplantation IIa Catheterablation,inspecializedcentres,maybeconsideredin
cardiacsarcoidosisICDrecipientswithrecurrent,symptomatic shouldbeconsidered. IIb
SMVT,orICDshocksforSMVT,inwhomAADsare Inmyotonicdystrophypatientswithpalpitationshighly
suspiciousforVAandinductionofanon-BBR-VT,ICD IIa ineffective,contraindicated,ornottolerated.
implantationshouldbeconsidered. Congenitalheartdisease
Inpatientswithlimb-girdletype1BorEmery–Dreifuss InpatientswithCHDpresentingwithsustainedVAs,
musculardystrophiesandindicationforpacing,ICD IIa evaluationforresiduallesionsornewstructuralabnormalities I
implantationshouldbeconsidered. isrecommended.
ImplantationofanICDmaybeconsideredinpatientswith InselectedpatientswithCHD(includingatrialbafflerepairfor
Duchenne/BeckermusculardystrophyandsignificantLGEat IIb transpositionofthegreatarteries,Fontanoperation,and
CMR. Ebsteinanomaly)presentingwithCA,evaluationand IIa
ImplantationofanICDoverapermanentpacemakermaybe treatmentofSVTwithrapidventricularconductionshouldbe
consideredinmyotonicdystrophypatientswithadditionalrisk IIb considered.
factorsiforVAandSCD. InpatientswithrepairedTOFundergoingsurgicalor
Inpatientswithmyotonicdystrophy,serialelectrophysiological transcutaneouspulmonaryvalvereplacement,pre-operative
evaluationofAVconductionandarrhythmiainductionisnot cathetermappingandtransectionofVT-relatedanatomical IIb
III
recommendedwithoutarrhythmiasuspicionorprogressionof isthmusesbeforeorduringtheinterventionmaybe
ECGconductiondisorders. considered.
Continued Continued
Downloaded
from

by
guest
on
22
January
2026

4008 ESCGuidelines
InpatientswithrepairedTOFwithapreservedbiventricular Beta-blockersand/orflecainidewithorwithoutacetazolamide
functionandsymptomaticSMVT,catheterablationor shouldbeconsideredinpatientswithAndersen–Tawil IIa
IIb
concomitantsurgicalablationperformedinspecializedcentres syndrometotreatVA.
maybeconsideredasanalternativetoICDtherapy. AnILRshouldbeconsideredinpatientswithAndersen–Tawil
IIa
IdiopathicVF syndromeandunexplainedsyncope.
ICDimplantationmaybeconsideredinpatientswith
ItisrecommendedthatidiopathicVFisdiagnosedinaSCA
survivor,preferablywithdocumentationofVF,afterexclusion
Andersen–Tawilsyndromewhohaveahistoryofunexplained IIb
I
syncopeorsufferfromtoleratedsustainedVT.
ofanunderlyingstructural,channelopathic,metabolic,or
toxicologicalaetiology. Brugadasyndrome
Isoproterenolinfusion,verapamil,orquinidineforacute GenetictestingforSCN5Ageneisrecommendedforprobands
I
treatmentofanelectricalstormorrecurrentICDdischarges IIa withBrS.
shouldbeconsideredinidiopathicVF. BrSshouldbeconsideredinpatientswithnootherheart
Quinidineshouldbeconsideredforchronictherapyto diseaseandinducedtype1Brugadapatternwhohaveatleast
suppressanelectricalstormorrecurrentICDdischargesin IIa oneofthefollowing:
idiopathicVF. (cid:129) Arrhythmicsyncopeornocturnalagonalrespiration IIa
Clinicaltesting(history,ECG,andhighprecordialleadECG, (cid:129) AfamilyhistoryofBrS
exercisetest,echocardiogram)offirst-degreefamilymembers IIb (cid:129) AfamilyhistoryofSD(,45yearsold)withanegative
ofidiopathicVFpatientsmaybeconsidered. autopsyandcircumstancesuspiciousforBrS.
InidiopathicVFpatients,genetictestingofgenesrelatedto ImplantationofalooprecordershouldbeconsideredinBrS
IIb IIa
channelopathyandcardiomyopathymaybeconsidered. patientswithanunexplainedsyncope.
LongQTsyndrome BrSmaybeconsideredasadiagnosisinpatientswithnoother
IIb
heartdiseasewhoexhibitaninducedtype1BrugadaECG.
InpatientswithclinicallydiagnosedLQTS,genetictesting,and
I
PESmaybeconsideredinasymptomaticpatientswitha
geneticcounsellingarerecommended. IIb
spontaneoustypeIBrSECG.
Beta-blockers,ideallynon-selectivebeta-blockers(nadololor
Sodiumchannelblockertestisnotrecommendedinpatients
propranolol),arerecommendedinLQTSpatientswith III
I
documentedQTintervalprolongation,toreduceriskof withapriortypeIBrugadapattern.
arrhythmicevents. CatheterablationinasymptomaticBrSpatientsisnot III
MexiletineisindicatedinLQT3patientswithaprolongedQT recommended.
I
interval. Earlyrepolarizationsyndrome
InLQTS,itshouldbeconsideredtocalculatethearrhythmic ItisrecommendedthattheERPisdiagnosedasJ-pointelevation
I
riskbeforeinitiationoftherapybasedonthegenotypeandthe IIa of≥1mmintwoadjacentinferiorand/orlateralECGleads.
durationofQTcinterval. ItisrecommendedthattheERSisdiagnosedinapatient
I
ICDimplantationmaybeconsideredinasymptomaticLQTS resuscitatedfromunexplainedVF/PVTinthepresenceofERP.
patientswithhigh-riskprofile(accordingtothe1-2-3LQTS
IIb ICDimplantationisrecommendedinpatientswithadiagnosis I
Riskcalculator)inadditiontogenotype-specificmedical
ofERSwhohavesurvivedaCA.
therapies(mexiletineinLQT3patients). InaSCDvictimwithanegativeautopsyandmedicalchart
Routinediagnostictestingwithepinephrinechallengeisnot III review,andanante-mortemECGdemonstratingtheERP,the IIa
recommendedinLQTS. diagnosisofERSshouldbeconsidered.
Andersen–Tawilsyndrome First-degreerelativesofERSpatientsshouldbeconsideredfor
IIa
Genetictestingisrecommendedinpatientswithsuspected
clinicalevaluationforERPwithadditionalhigh-riskfeatures.j
I
Andersen–Tawilsyndrome. ILRshouldbeconsideredinindividualswithERPandatleast
IIa
ICDimplantationisrecommendedinpatientswithAndersen– oneriskfeaturekorarrhythmicsyncope.
TawilsyndromeafterabortedCAornot-toleratedsustained I IsoproterenolinfusionshouldbeconsideredforERSpatients
IIa
VT. withelectricalstorm.
Andersen–Tawilsyndromeshouldbeconsideredinpatients QuinidineinadditiontoanICDshouldbeconsideredfor
IIa
withoutSHDwhopresentwithatleasttwoofthefollowing: recurrentVFinERSpatients.
(cid:129) ProminentUwaveswithorwithoutprolongationoftheQT PVCablationshouldbeconsideredinERSpatientswith
interval recurrentVFepisodestriggeredbyasimilarPVC IIa
IIa
(cid:129) Bidirectionaland/orpolymorphicPVCs/VT non-responsivetomedicaltreatment.
(cid:129) Dysmorphicfeatures GenetictestinginERSpatientsmaybeconsidered.
IIb
(cid:129) Periodicparalysis
(cid:129) KCNJ2pathogeniclossoffunctionmutation. ICDimplantationorquinidinemaybeconsideredinindividuals
IIb
Continued withERPandarrhythmicsyncopeandadditionalriskfeatures.k
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4009
ICDimplantationorquinidinemaybeconsideredin Inselectedtransplantedpatientswithcardiacallograft
asymptomaticindividualswhodemonstrateahigh-riskERPjin IIb vasculopathyortreatedrejection,ICDimplantationmaybe IIb
thepresenceofafamilyhistoryofunexplainedjuvenileSD. considered.
Clinicalevaluationisnotrecommendedroutinelyin Inelderlypatientsinwhomabenefitfromthedefibrillatoris
III
asymptomaticsubjectswithERP. notexpectedduetothepatient’sageandcomorbidities,
IIb
ICDimplantationisnotrecommendedinasymptomatic omissionofICDimplantationforprimarypreventionmaybe
III
patientswithanisolatedERP. considered.
CPVT AAD,anti-arrhythmicdrug;ACE-Is,angiotensin-convertingenzymeinhibitors;AED,
automated external defibrillator; ARBs, angiotensin receptor blockers; ARNIs,
Genetictestingandgeneticcounsellingareindicatedinpatients
I angiotensin receptor neprilysin inhibitors; ARVC, arrhythmogenic right ventricular
withclinicalsuspicionorclinicaldiagnosisofCPVT. cardiomyopathy;ATP,anti-tachycardiapacing;AV,atrioventricular;BBR-VT,bundle
Beta-blockers,ideallynon-selective(nadololorpropranolol) branchre-entry;BrS,Brugadasyndrome;CA,cardiacarrest;CAD,coronaryartery
arerecommendedinallpatientswithaclinicaldiagnosis I disease;CCB,calciumchannelblocker;CHD,congenitalheartdisease;CMR,cardiac
magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic
ofCPVT. polymorphic ventricular tachycardia; CRT, cardiac resynchronization therapy; DC,
Epinephrineorisoproterenolchallengemaybeconsidered directcurrent;DCM,dilatedcardiomyopathy;ECG,electrocardiogram;EF,ejection
fraction;ERP,earlyrepolarizationpattern;ERS,earlyrepolarizationsyndrome;HCM,
forthediagnosisofCPVTwhenanexercisetestisnot IIb
hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy;
possible. ICD,implantablecardioverterdefibrillator;ILR,implantablelooprecorder;LGE,late
gadolinium enhancement; LMNA, lamin A/C; LQTS, long QT syndrome; LV, left
ShortQTsyndrome
ventricular; LVEF, left ventricular ejection fraction; LVNC, left ventricular
GenetictestingisindicatedinpatientsdiagnosedwithSQTS. I non-compaction; MI, myocardial infarction; MRAs, mineralocorticoid receptor
antagonists;NSVT,non-sustainedventriculartachycardia;NYHA,NewYorkHeart
SQTSshouldbeconsideredinthepresenceofaQTc
IIa Association; OHCA, out-of-hospital cardiac arrest; OMT, optimal medical therapy;
≤320ms. PES,programmedelectricalstimulation;PVC,prematureventricularcomplex;RCM,
SQTSshouldbeconsideredinthepresenceofaQTc≥320ms restrictive cardiomyopathy; RVOT, right ventricular outflow tract; SCA, sudden
IIa cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2,
and≤360msandarrhythmicsyncope.
sodium–glucose co-transporter 2; SHD, structural heart disease; SMVT, sustained
ILRshouldbeconsideredinyoungSQTSpatients. monomorphic ventricular tachycardia; SPVT, sustained polymorphic ventricular
IIa
tachycardia; SQTS, short QT syndrome; SVT, supraventricular tachycardia; TOF,
tetralogy of Fallot; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT,
ICDimplantationshouldbeconsideredinSQTSpatientswith ventriculartachycardia;WCD,wearablecardioverterdefibrillator.
IIa
arrhythmicsyncope.
aShoppingmalls,stadiums,publictransportstations,casinos.
bVTnon-inducibilityandeliminationofelectrogramsconsistentwithconductiondelay.
SQTSmaybeconsideredinthepresenceofa cIncludingbutnotlimitedtoolderage,rightbundlebranchblock(RBBB)morphology,
QTc≥320msand≤360msandafamilyhistoryofSD IIb SMVTconsistentwithre-entry.
atage,40years. dPresyncopeorpalpitationssuggestiveofVA.
eThe 2020 ESC Guidelines on sports cardiology and exercise in patients with
Quinidinemaybeconsideredin(a)SQTSpatientswhoqualify cardiovasculardisease.4
foranICDbutpresentacontraindicationtotheICDorrefuse fBasedontheHCMRiskSCD:
IIb gDefinedasafailuretoincreasesystolicpressurebyatleast20 mmHgfromresttopeak
it,and(b)asymptomaticSQTSpatientsandafamilyhistoryof
exercise,orafallof.20 mmHgfrompeakpressure.
SCD. hBasedontheHCMKidRiskscore:
IsoproterenolmaybeconsideredinSQTSpatientswithan
iFactorsfavouringICDimplantation:Age,5,6,11CTGexpansion,6–9,13,16SDorfamilyhistory
IIb ofSD,5ECGconductionabnormalities,16PRprolongation,13LBBB,5atrialarrhythmias,6,16
electricalstorm. non-sustainedVT,5LVdysfunction,17structuralabnormalitiesinCMR.14,15,18
Selectedpopulations
jERPhighriskfeatures:Jwaves.2mm,dynamicchangesinJpointandSTmorphology.
kHigh-riskERP:familyhistoryofunexplainedSD,40years,familyhistoryofERS.
Itisrecommendedthatathletesdiagnosedwitha
cardiovasculardiseaseassociatedwithSCDaremanaged I
accordingtocurrentguidelinesforsportseligibility.
The second part of the guidelines is structured according to
Continuationofbeta-blockersshouldbeconsideredduring IIa disease-specific management, providing a link to the updated
pregnancyinwomenwithARVC. ESCCardioMedchapterforadditionalcontent.Riskstratifi-
Oralmetoprolol,propranolol,orverapamilshouldbe
cation, SCD prevention, treatment of VA, and management of
consideredforlong-termmanagementofidiopathicsustained IIa
family members are addressed in a systematic fashion. Indications
VTduringpregnancy.
for cardiac magnetic resonance (CMR) imaging, genetic testing,
Catheterablationusingnon-fluoroscopicmappingsystems
and updated indications for catheter ablation of ventricular ar-
shouldbeconsidered,preferablyafterthefirsttrimester,in IIa rhythmias are presented. Flowcharts summarizing the workflow
womenwithhighlysymptomaticrecurrentSMVTrefractoryor fordiagnosticandtreatmentareprovidedforthediseaseentities.
whoareintoleranttoAADs. Thecolour-codingoftheflowchartsreflectstheclassofrecommen-
Continued dation according to this guideline and other ESC Guidelines.1–3
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4010 ESCGuidelines
Table5 Changesinrecommendationssince2015
CHD
InpatientsafterrepairofTOFwithoutarrhythmia
Class
symptoms,butwithacombinationofotherrisk
IIa IIb
2015 2022
factors,aelectrophysiologicevaluation,includingPES,
maybeconsidered.
Coronaryarterydisease InpatientswithCHDandrecurrent,symptomatic
InpatientswithsyncopeandpreviousSTEMI,PESis SMVT,orICDshocksforSMVTnotmanageableby
indicatedwhensyncoperemainsunexplainedafter IIa I medicaltherapyorICDreprogramming,catheter I IIa
non-invasiveevaluation. ablationperformedinspecializedcentresshouldbe
Intravenousamiodaronetreatmentshouldbe considered.
consideredforpatientswithrecurrentPVT/VF I IIa Primaryelectricaldiseaseandselectedpopulations
duringtheacutephaseofACS.
ICDimplantationisrecommendedinpatientswith
InpatientswithCADeligibleforICDimplantation, LQTSwhoaresymptomaticbwhilereceiving IIa I
catheterablationmaybeconsideredjustbefore(or IIa IIb beta-blockersandgenotype-specifictherapies.
immediatelyafter)ICDimplantationtodecrease
ICDimplantationshouldbeconsideredinpatients
subsequentVTburdenandICDshocks.
withCPVTwhoexperiencearrhythmicsyncopeand/
I IIa
PVC-inducedcardiomyopathy ordocumentedbidirectional/PVTwhileonthe
Inpatientswithacardiomyopathysuspectedtobe highesttoleratedbeta-blockerdoseandonflecainide.
causedbyfrequentandpredominatelymonomorphic IIa I Pre-participationcardiovascularevaluationof
I IIa
PVCs,catheterablationisrecommended. competitiveathletesshouldbeconsidered.
DCM/HNDCM CatheterablationoftriggeringPVCsand/orRVOT
epicardialsubstrateshouldbeconsideredinBrS
ICDimplantationshouldbeconsideredinpatients IIb IIa
patientswithrecurrentappropriateICDshocks
withDCM/HNDCM,symptomaticheartfailure
I IIa
(NYHAclassII–III)andLVEF≤35%after≥3months refractorytodrugtherapy.
ofOMT. LCSDshouldbeconsideredinpatientswithdiagnosis
ofCPVTwhenthecombinationofbeta-blockersand
Catheterablationinspecializedcentresshouldbe IIb IIa
flecainideattherapeuticdosageareeithernot
consideredinpatientswithDCM/HNDCMand
recurrent,symptomaticSMVT,orICDshocksfor IIb IIa effective,nottolerated,orcontraindicated.
SMVT,inwhomAADsareineffective, AAD,anti-arrhythmicdrug;ACS,acutecoronarysyndrome;ARVC,arrhythmogenic
contraindicated,ornottolerated. rightventricularcardiomyopathy;AV,atrioventricular;BrS,Brugadasyndrome;CA,
cardiacarrest;CAD,coronaryarterydisease;CHD,congenitalheartdisease;CPVT,
ARVC catecholaminergic polymorphic ventricular tachycardia; DCM, dilated
ICDimplantationshouldbeconsideredinpatients cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD,
IIb IIa implantable cardioverter defibrillator; LCSD, left cardiac sympathetic denervation;
withdefiniteARVCandanarrhythmicsyncope.
LQTS,longQTsyndrome;LV,leftventricle;LVEF,leftventricularejectionfraction;
ICDimplantationshouldbeconsideredinpatients NYHA, New York Heart Association; OMT, optimal medical treatment; PES,
withdefiniteARVCandsevereRVorLVsystolic IIb IIa programmed electrical stimulation; PVC, premature ventricular complex; PVT,
polymorphic ventricular tachycardia; RV, right ventricle; RVOT, right ventricular
dysfunction. outflow tract; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST
Inflammatorydiseases elevationmyocardialinfarction;TdP,torsadedepointes;TOF,tetralogyofFallot;VF,
ventricularfibrillation;VT,ventriculartachycardia.
Inpatientswithhaemodynamicallynot-tolerated aOtherriskfactorsincludemoderateRVorLVdysfunction,extensiveRVscarringon
SMVToccurringinthechronicphaseofmyocarditis, IIa I CMR,QRSduration≥180ms,andsevereQRSfragmentation.
bArrhythmicsyncopeorhaemodynamicallynot-toleratedVA.
ICDimplantationisrecommended.
ICDimplantationisrecommendedinpatientswith
IIb I
cardiacsarcoidosiswhohaveanLVEF≤35%. Anothernovelconceptofthisdocumentisthetableofevidence
ICDimplantationisrecommendedinpatientswith (see Supplementary data). The trials and studies that have been
cardiacsarcoidosiswho(1)havedocumented IIb I selected to support a recommendation are systematically de-
sustainedVT,or(2)abortedCA. scribedinthetableofevidenceaftercarefulreviewoftheavailable
Inpatientswithcardiacsarcoidosiswhohavean data and the applied methodology, prioritizing papers published
indicationforpermanentcardiacpacingrelatedto after 2015. Recommendations with level of evidence C that are
IIb IIa
high-degreeAVblock,ICDimplantationshouldbe notaccompaniedbyareferencearesupportedbythispanelofex-
considered,regardlessofLVEF. perts.Toassistphysiciansintheirdailyclinicalpractice,diagnostic
InpatientswithChagas’cardiomyopathyand and therapeutic procedures with promising usefulness, typically
symptomaticVTinwhomAADs(amiodaroneand
classifiedasclassIIb,butforwhichevidenceislimitedanddifficult
IIa IIb
beta-blockers)areineffectiveornottolerated,ICD to collect in the near future, the related recommendations are
implantationmaybeconsidered. notonlydescribedinthenarrativesbutarelistedinthetableof
recommendation.
Continued
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4011
fi
3. De nitions Sudden arrhythmic death syndrome (SADS): Unexplained sudden
death occurring in an individual older than 1 year with negative
3.1. Ventricular arrhythmia subtypes pathologicalandtoxicologicalassessment.Note:Synonymouswith
‘autopsy-negativesuddenunexplaineddeath’.
Prematureventricularcomplex(PVC):Prematureoccurrenceofanab-
normal QRS complex (duration typically ≥120ms, corresponding
3.3. Syncope
T-wave typically broad and in the opposite direction of the major
QRSdeflection,noprecedingP-wave). Unexplainedsyncope:Transientlossofconsciousnessduetocerebral
UnifocalormonomorphicPVCs:PVCswithasingleQRSmorphology. hypoperfusion, characterized by a rapidonset, short duration,and
Multifocal,multiform,orpolymorphicPVCs:PVCswithdifferentQRS spontaneouscompleterecovery,butunexplainedafterconventional
morphologies. workup.Work-upanddifferentialdiagnosisareprovidedinthe2018
Short-coupledPVC:APVCthatinterruptstheT-waveofthepre- ESCGuidelinesforthediagnosisandmanagementofsyncope.1
cedingconductedbeat. Arrhythmicsyncope:asabove,buthighlysuspiciousforintermittent
Ventricular tachycardia (VT): ≥3 consecutive beats with a rate bradycardia,rapidsupraventriculartachycardia(SVT),orVA.
.100b.p.m.originatingfromtheventricles,independentfromatrial
andatrioventricular(AV)nodalconduction. 3.4. Specialized centres
Non-sustained ventricular tachycardia (NSVT): Run of consecutive Multidisciplinaryteams:Amultidisciplinaryteamacrossspecialtiesis
ventricularbeatspersistingfor3beatsto30s. characterized by open communication, positive management and
Monomorphic ventricular tachycardia (MVT): Same QRS morph- leadership, appropriate resources, and a mix of skills.
ologyfrombeattobeat. Decision-makingshouldbesharedintheteam.
Polymorphicventriculartachycardia(PVT):ContinuallychangingQRS SpecializedcentreforcatheterablationofVA:Patientandprocedural
morphology. complexityvarywidely.Somepatientsrequireamoreexperienced
Sustained monomorphic/polymorphic ventricular tachycardia (SMVT/ operator and a centre with more capabilities, which is more likely
SPVT):ContinuousVTforatleast30s,orwhichrequiresaninterven- inpatientswithanon-ischaemicaetiology.Aspecializedcentrehas
tionfortermination. atleastoneoperatorwithappropriateexperienceininterventions
Bidirectionalventriculartachycardia:Beattobeatalternationofthe thatmayberequiredforasuccessfulprocedure(e.g.percutaneous
frontalQRSaxis(e.g.incatecholaminergicpolymorphicventricular epicardial access). The centre performs catheter ablation of VT in
tachycardia [CPVT], Andersen–Tawil, digoxin toxicity, acute structuralheartdisease(SHD)onaregularbasis.Inaddition,thecen-
myocarditis). tre has the required resources to manage medical conditions, co-
Torsadesdepointesventriculartachycardia(TdP):Subtypeofapoly- morbidities, and potential complications in patients undergoing
morphic VT in the context of QT prolongation with continually complexVAablation;thisincludesinterventionalcardiologyexpert-
changingQRScomplexesthatappeartospiralaroundthebaseline ise,acuteplacementofmechanicalcirculatoryassistdevices,andcar-
oftheelectrocardiogram(ECG)leadinasinusoidalpattern. diothoracic surgical back-up. Considering the variable availability
Ventricularfibrillation(VF):Achaoticrhythmwithundulationsthat
acrossEuropeancountries,itispreferabletotreatcomplexpatients
areirregularintimingandmorphology,withoutdiscreteQRScom- inthemostexperiencedcentrewithinreasonabledistance.
plexesonthesurfaceECG.
Electricalstorm:VAthatoccurs3ormoretimeswithin24h(sepa- 3.5. Genetics
rated by at least 5min), each requiring termination by an
Pathogenicvariantandlikelypathogenicvariant:TheAmericanCollege
intervention.
ofMedicalGeneticshasprovidedaframeworkfortheinterpretation
IncessantVT:ContinuoussustainedVTthatrecurspromptlydes-
ofdiseasecausationbygeneticvariantsstandardizedintoclasses.The
piterepeatedinterventionforterminationoverseveralhours.
geneticvariantsmostlikelytocauseanassociateddiseasearetermed
V,‘pathogenic’,andIV,‘likelypathogenic’.
Mutation:ThistermisusedinthisdocumenttomeanaClassIVor
3.2. Sudden cardiac death Vvariant.
Variant of uncertain significance: A change in a gene’s deoxyribo-
Suddencardiacarrest(SCA):Suddencessationofnormalcardiacactiv-
nucleicacid(DNA)sequencethathasanunknowneffectonaper-
itywithhaemodynamiccollapse.
son’shealth.
Suddencardiacdeath(SCD):Suddennaturaldeathpresumedtobe
ofcardiaccausethatoccurswithin1hofonsetofsymptomsinwit-
nessedcases,andwithin24hoflastbeingseenalivewhenitisunwit- 4. Epidemiology of sudden cardiac
nessed.SCDinautopsiedcasesisdefinedasthenaturalunexpected
death, public awareness, and risk
deathofunknownorcardiaccause.
fi
strati cation
Suddenunexplaineddeath:Unexplainedsuddendeathoccurringin
anindividualolderthan1year.
Sudden infant death syndrome (SIDS): Unexplained sudden death 4.1. Incidence of sudden cardiac death
occurringinanindividualyoungerthan1yearwithnegativepatho- SCD accounts for approximately 50% of all cardiovascular deaths,
logical and toxicological assessment and negative forensic examin-
withupto50%beingthefirstmanifestationofcardiacdisease.19–24
ationofthecircumstancesofdeath. Ideally, cases suspicious of SCD should be identified from multiple
Downloaded
from

by
guest
on
22
January
2026

4012 ESCGuidelines
sourcesandundergoautopsy,whichisrequiredtoreliablyexclude fromthegeneralpopulationatriskofSCDastheirfirstcardiacevent.
non-cardiaccausesofsuddendeath(SD). Models for novel SCD risk stratification in the general population
TheincidenceofSCDincreasesmarkedlywithage.Withavery
haverecentlybeenproposed.71–73Therearenocleardatasupport-
lowincidenceduringinfancyandchildhood(1per100000person- ingthebenefitofmassscreeningprogramsinthegeneralpopulation
years),25–27theincidenceisapproximately50per100000person- forpreventingSCD.74–76
years in middle-aged individuals (in the fifth to sixth decades of Fordecades,investigatorshaveenvisionedabroadrangeof‘indi-
life).28–30Intheeighthdecadeoflife,itreachesanannualincidence cators’forSCD,especiallyoccurringinthesettingofCAD.Several
ofatleast200per100000person-years.20Atanyage,maleshave non-invasivemarkersofriskhavebeenproposed(includinglatepo-
higher SCD rates compared with females, even after adjustment tentials,heartratevariability,periodicrepolarizationdynamics,and
for risk factors of coronary artery disease (CAD).24,31–33 Ethnic baroreflex sensitivity).77 Despite the promising outcomes of initial
background also seems to have large effects.34,35 It is estimated studies,however,these‘predictors’havenotyetinfluencedclinical
that 10–20% of all deaths in Europe are SCD.36,37 Approximately practice.Leftventricularejectionfraction(LVEF)isonlyused,often
300000 people in Europe have out-of-hospital cardiac arrest incombinationwithNewYorkHeartAssociation(NYHA)class,for
(OHCA)treatedbyemergencymedicalsystemseveryyear.38,39 primary prevention indication of an ICD in the setting of chronic
IntheWesternworld,theepidemiologyofSCDiscloselyrelated CADanddilatedcardiomyopathy(DCM).Riskstratificationschemes
to CAD, which is responsible for up to 75–80% of SCD cases.40 andcalculatorshavebeendevelopedforinheritablearrhythmogenic
WhiletheprevalenceofCADhasnotdecreased,therehasbeena diseases,suchashypertrophiccardiomyopathy(HCM),arrhythmo-
significantdeclineinmortalityduetoCAD.Reportsshowthatthe genic right ventricular cardiomyopathy (ARVC), and lamin A/C
incidenceofSCDisdeclining,40–42buttheriskofSCDasapropor- (LMNA)cardiomyopathy.78–82
tionoftheoverallcardiovasculardeathsmayhaveincreased.43,44 Whatisconsideredlow,intermediate,orhighriskwilldependon
Although regular physical activity benefits cardiovascular health, thetypeofevent(e.g.fatalornot)andtheriskofaneventinthe
sport, particularly when practiced vigorously, has been shown to background population. For instance, mortality depends on age,
beassociatedwithSCDduringorshortlyafterexerciseinselected sex,andotherriskfactorsincludingcomorbidities.Thesituationis
populations.45–51Reportshavesuggestedthatthemajorityofsports- furthercomplicatedwhenconsideringaspecifictypeofdeath,e.g.
related SCD occurs in a recreational52,53 rather than competitive SCD. Then non-SCD deaths are competing events (or competing
setting, especially among middle-aged male participants, suggesting risks)toSCDinthesensethattheiroccurrencepreventstheobser-
thatCADisthemostcommonunderlyingcause.46,54,55 vationofSCD,andmaymakeinterventionstopreventSCD,suchas
anICD,oflimitedbenefit.
4.2. Causes of sudden cardiac death in
4.4. Risk calculators for sudden cardiac
different age groups
death and review of the methodology
CardiacdiseasesassociatedwithSCDvarydependingontheindivi-
dual’sage.Intheyoungthereisapredominanceofprimaryelectric AnumberofriskcalculatorsforSCDhavebeenproposedforadult
diseasesandcardiomyopathies,aswellasmyocarditis,andcoronary
andpaediatricpopulations.80,81,83–85Thefieldofpredictionmodelling
anomalies.25,27,56–61 However,halfofSCDcasesduringthefourth hasevolvedoverthepastdecades,establishingstandardsforthede-
decade are related to CAD, especially acute coronary syndrome velopment,validation(internalandexternal),andreportingofpre-
(ACS).62,63 diction models inSCD.86,87 Inaddition to discrimination measures
In older populations, chronic structural diseases predominate suchasthec-index,measuresofcalibrationsuchasthecalibration
(CAD either through acute coronary events or chronic coronary slopehaverecentlyreceivedmoreattentionbecauseitisnotonly
stenoses,valvularheartdiseases,andheartfailure),whilepotentially importanttodistinguishpatientswithhigherrisksfromthosewith
inheritedelectricaldiseasesorstructuralnon-ischaemicdiseasesmay
lowerrisksbutalsotoobtainarobustquantificationoftheriskitself
cause more than 50% of SCD in individuals under the age of 50 fromtheriskcalculators.88Typicalshortcomingsinthedevelopment
years.27 andvalidationofriskcalculatorsinclude,butarenotlimitedto,the
Agedistributionatpresentationwithventriculararrhythmiasand useofhistoricsamplesnotrepresentativeofcontemporarypatient
suddencardiacdeath,dominantarrhythmiasubtypes,triggers,genet- cohorts,missingvalues,compositeoutcomeswithcompositeevents
icfactors,andgenderassociatedwithincreasedriskforventricular ofdifferentclinicalimportance,lackofexternalvalidation,andmiss-
arrhythmias in selected primary electrical and structural heart dis- ingcalibration.Inthisdocumentdifferentcut-offfor5yearsriskof
easesarepresentedinFigure1. SCD/VAisusedforindicationofICD.Eachcut-offwaschosenby
theoriginalauthorsandthetaskforcegroupconsideringthecom-
4.3. Population vs. individual risk petingrisk,theoutcomemeasured(SCDvsVA)andtherobustness
ofeachriskcalculator.
prediction
Inthegeneralpopulation(individualswithoutknownheartdisease),
4.5. Awareness and intervention: public
themosteffectiveapproachforpreventingSCDresidesinquantifi-
basic life support, and access to
cationoftheindividualriskofdevelopingCADbasedonriskscore
charts.64,65 Several studies have provided evidence that there is a automated external defibrillators
geneticpredispositiontodiesuddenlyduringacuteischaemia.66–70 SurvivalrateremainsstrikinglylowafterOHCA,89–95althoughmajor
Thegoalwouldbetoidentifytherelativelysmall,high-risksubgroups regionaldisparitieshavebeendescribed.96Earlyimplementationof
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4013
Genetic risks and triggers Age at Dominant subtype
for VA/SCD VA/SCD of VA (%)
10 20 30 40 50 60 70 80 0 50 100
PPVT
CPVT
MMVT
PPVT
LQT
MMVT
PPVT
BrS
MMVT
PPVT
ACS
MMVT
Sarcoid PPVT
MMVT
PPVT
HCM
MMVT
PPVT
DCM
MMVT
PPVT
ARVC
MMVT
PPVT
rTOF MMVT
chronic PPVT
CAD MMVT
Figure1Centralfigure.GeneticriskforVA/SCD,typicaltriggersforVA/SCD,ageatpresentationwithVA/SCD,sexpredominance,andtypicalVA
(PVT/VFvs.MVT)indifferentdiseasesassociatedwithVA/SCD.ACS,acutecoronarysyndrome;ARVC,arrhythmogenicrightventricularcardiomyop-
athy;BrS,Brugadasyndrome;CAD,coronaryarterydisease;CPVT,catecholaminergicpolymorphicventriculartachycardia;DCM,dilatedcardiomyop-
athy; HCM, hypertrophic cardiomyopathy; LQT, long QT syndrome; MVT, monomorphic ventricular tachycardia; PVT, polymorphic ventricular
tachycardia;rTOF,repairedtetralogyofFallot;SCD,suddencardiacdeath;VA,ventriculararrhythmia;VF,ventricularfibrillation.
resuscitative interventions, especially prior to emergency medical increased availability of public access defibrillators and community
systemarrival,hasbeenidentifiedaskeyelementstoimprovesur- training in basic life support,89–95 preferably initiated in childhood
vival.95,97 Bystander cardiopulmonary resuscitation (CPR) and use andrepetitive.98–100Finally,dispatchofbasiclifesupport-trainedvo-
of public automated external defibrillators (AEDs) have demon- lunteers,throughspecificmobileappsnetworks,hasbeenshownto
strated improvement of neurological and functional outcome as increasetherateofbystander-initiatedCPR,andasaresult,greatly
well as survival of OHCA patients. Data support the need for reducestheresuscitation-freeintervalandimprovestheoutcomeof
Downloaded
from

by
guest
on
22
January
2026

4014 ESCGuidelines
OHCA victims.101–103 Education of public officials and community b-type-natriuretic peptide as a method to select the need for an
membersregardingtheimportanceofincreasingratesofbystander ICD.110,111
CPRandpromotingtheuseofearlydefibrillationbylayandprofes-
sionalrescuersiscriticaltoincreasingsurvivalrates. 5.1.3.Non-invasiveandinvasivetests
5.1.3.1.Electrocardiogramandambulatoryelectrocardiographic
monitoring2
RecommendationTable1—Recommendationsfor The12-leadECGisanimportanttoolforthediagnosisofunderlying
publicbasiclifesupportandaccesstoautomatedex- disease, for risk stratification in selected populations, and for the
ternaldefibrillators
diagnosisoftheVAsubtype,ifcaptured.Documentationofarrhyth-
miasrelatedtosymptomsisclinicallypivotalbutmaybechallenging
Recommendations Classa Levelb
withsporadicevents.ThetypeofECG-monitoringdeviceandthere-
Itisrecommendedthatpublicaccessdefibrillation cordingtimeshouldthereforematchthefrequencyofclinicalevents.
beavailableatsiteswherecardiacarrestismore I B Monitoringoveraperiodof24–48h(typically‘Holterrecording’)is
likelytooccur.c,90–92 appropriatefordailyarrhythmias,112whileintermittentmonitoring
PromptCPRbybystandersisrecommendedat over a longer period, with patient-activated ECG recorders (or
I B
OHCA.93–95 mobile-health/smartphones), should be preferred for infrequent
events.113Implantablelooprecorders(ILR)canbeusefulindiagnos-
Itisrecommendedtopromotecommunity
traininginbasiclifesupporttoincreasebystander I B ing arrhythmias in patients with potentially life-threatening symp-
CPRrateandAEDuse.93,97,104
toms,suchasunexplainedsyncope.114
Mobilephone-basedalertingofbasiclife
support-trainedbystandervolunteersto 5.1.3.2.Signal-averagedelectrocardiogram
IIa B
assistnearbyOHCAvictimsshouldbe Signal-averaged electrocardiogram (SaECG) can detect very low
considered.101–103,105 amplitudesignals(‘latepotentials’)intheterminalQRSsegment115
usingthreetime-domainmeasurements:QRSduration,low-amplitude
AED,automatedexternaldefibrillator;CPR,cardiopulmonaryresuscitation;OHCA,
(,40µV)signaldurationandrootmeansquarevoltageofterminal
out-of-hospitalcardiacarrest.
aClassofrecommendation. 40msQRS.112AbnormalitiesintheSaECGcanalsobeassessedby
bLevelofevidence. frequency-domainanalysis.112SaECGcancontributetothediagno-
cShoppingcentres,stadiums,publictransportstations,casinos.
sisofARVC.116
5.1.3.3.Exercisetesting
5. Evaluation and treatment.
Exercisetestingisusefulforthediagnosisandforevaluatingresponse
General aspects totherapyinpatientswithsuspected/provenadrenergic-dependent
rhythmdisturbances,suchasexercise-inducedidiopathicMVT,PVT,
5.1. Diagnostic tools
orbidirectionalVTinCPVT.117,118The4-minuterecoveryQTcafter
exercisetestingcancontributetothediagnosisLQTS.119
5.1.1.Historyandphysicalexamination
Historyshouldfocuson‘redflags’,includingfeaturesofarrhythmic
5.1.3.4.Imaging
syncope,e.g.absenceofvagalprodrome,andfamilyhistoryofpre-
matureorSCDincluding,e.g.drowningorcaraccidentinlongQT Imagingiscrucialtoassesscardiacfunctionanddetectcardiomy-
syndrome(LQTS),andCPVT.1,106Subtlefeaturestosuggestinher- opathies( ESCCardioMedchapter10).120Anegativeimaging
itedcausesincludeafamilyhistoryofepilepsy,suddeninfantdeath study supports primary electrical disease in a patient with VA.
syndrome,deafness(LQTS),heartfailure,orpacemakerimplantation
Echocardiographyisareadilyavailableandfirst-linediagnosticandrisk
at,50yearsold.Featuresofdiseasesrelatedtopro-arrhythmiccon- stratificationtoolforvalvediseases,CADandDCM,HCM,ARVC,121
ditionsincludemid-systolicclickinmitralvalveprolapse(MVP)and andleftventricularnon-compaction(LVNC).Echocardiographicstrain-
outflowtractmurmurswithValsalvainHCM.Specificskinfeatures rate imaging allows differentiation between active and passive move-
mayberelevant,e.g.Lupuspernio,erythemanodosuminsarcoidosis, ment ofmyocardialsegmentsand early detection ofmyocardialdys-
angiokeratomainFabry’sdisease,xanthelasma/xanthoma,andpalmo- function. Wall motion abnormalities can indicate previous infarcts,
plantarkeratosisinARVC. cardiomyopathies, or inflammatory disease. Global longitudinal strain
isarobustmeasureofleftventricular(LV)functionandcandetectsub-
tlechangesinLVfunctionwhileLVEFisstillpreserved.122Strainimaging
5.1.2.Laboratorytesting canassessmechanicaldispersionreflectinginhomogeneouscontraction
Natriuretic peptides (b-type-natriuretic peptide, or N-terminal
thatcouldbeassociatedwithincreasedriskofVA.122–125
pro-b-type-natriureticpeptide)mayhavearoleintheidentification CMRcurrentlyprovidesthemostaccurateandreproduciblemeas-
ofindividualsatincreasedriskofSCDinthegeneralpopulation107,108 urement of atrial, biventricular global and regional systolic function,
orinpatientswithCAD.109Thereisnotsufficientevidencetouse and can detect myocardial oedema, fibrosis, infiltration, and
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4015
perfusion defects ( ESC CardioMed chapter 11.4).126 CMR is Withadvancesinhigh-densitymapping,voltagemapping,conduc-
moresensitivethanechocardiographytodiagnoseARVC,127isdiag- tion/repolarisation metrics, and electrogram fractionation can
nosticinLVNC,andcandetectapicalaneurysmsinHCM.Fibrosis be employed to identify ablation targets, or to diagnose
detection by late gadolinium enhancement (LGE) contributes to cardiomyopathic disease. Endocardial mapping may be helpful in
VAriskstratificationinHCM,128DCM,129andpotentiallyinmitral thedifferentiationofARVCfrombenignoutflowtractVTandfor
valveprolapsearrhythmicsyndrome.130,131Novelmyocardialmap- targeting biopsy in suspected myocarditis, ARVC, and sarcoidosis
pingtechniquescandetectdiffusefibrosisandcansuggesttheaeti- cases.158–162
ology of left ventricular hypertrophy (LVH) for specific therapy
guiding,e.g.Fabrydiseaseandamyloidosis.Theprognosticvaluere- 5.1.4.Genetictesting
mainstobeevaluated. Massiveparallelornext-generationsequencinghasledtoincreasing
Cardiacimagingbycomputedtomography(CT)hastheadvantage availabilityofgenetictestingatreducedcost.Mostdiagnosticcardiac
ofahighspatialresolution( ESCCardioMedchapter12.1).132 genetictestingemployslargegenepanelsdeterminedbyassociations
ECG synchronization, additional breath-hold sequences, and beta- with disease generated by prior research, i.e. candidate genes.163
blocker to lower the heart rate improve the quality. Radiation Many previous gene associations have, however, been challenged
exposure is in the range of an invasive coronary angiogram fortheirdiagnosticutility.Therefore,itisnotrecommendedtoin-
(CAG). Coronary computed tomography angiography (CTA) is clude questionable genes in routine diagnostic
panels.164–168
the preferred method to rule out coronary artery stenosis Genome-wideassociationstudieshaveidentifiedthatcommongen-
in patients with low probability of CAD.133,134 The quality of eticvariationsinglenucleotidepolymorphismscancauseormodify
almostallimagemodalitiesisinfluencedbythepresenceoffrequent phenotypes in BrS, LQTS, HCM, and DCM. Polygenic risk scores,
PVCs. measuresderivedfromthecumulativeeffectsofthesesinglenucleo-
tidepolymorphisms,maythereforeplayaroleindiagnosisandprog-
nosticationintheseconditionsinthefuture.168–173
5.1.3.5.Provocativediagnostictests
Sequencing produces digital data that require subsequent bio-
ThesearesummarizedinTable6.Commontestsperformedareso-
informatic analysis, permitting accurate ascertainment of most
diumchannelblockertestingforBrugadasyndrome(BrS)andadeno-
DNA alterations affecting the coding frame of each gene.174 The
sine test to exclude latent pre-excitation.135,136 Epinephrine
mostcommonfindingsaresinglenucleotidevariantscausingsimple
challenge may be useful in CPVT when exercise cannot be per-
aminoacidsubstitutions(missense),prematureterminations,orspli-
formed. Epinephrine test is not recommended for LQTS due to
cingabnormalities.Insertionsand/ordeletionsarerarer.Theclinical
the high false positive rate and utility of exercise testing.137
importance of most non-coding variants is still to be
CoronaryvasospasmasacauseofVFintheabsenceofobstructive
determined.174,175
coronary diseases/cardiomyopathy can be tested with incremental
Aframeworkfortheinterpretationofdiseasecausationbygenetic
intracoronarydosesofacetylcholine/ergonovine.
variantshasstandardizedadjudicationintofiveclasses:V‘pathogen-
ic’;IV‘likelypathogenic’;III‘variantofuncertainsignificance’;II‘likely
5.1.3.6.Electrophysiologicalstudy benign’;andI‘benign’.Acombinationofevidenceisemployed:gene–
Electrophysiologicalstudiesincludingmeasurementofbaselineinter- diseaseassociation;presenceofavariantinhealthyand/ordiseased
vals(e.g.atrial–Hisinterval[AH]andHis–ventricularinterval[HV]), populations;insilicodata;invitroandinvivofunctionaldata;andfamily
programmed electrical stimulation (PES), and electroanatomical segregationdata.176
mapping can be used for diagnostic purposes and to guide ther- Amutation(ClassIVorVvariant)canbeusedimmediatelyeither
apy.145–150TheyieldofPESvarieswiththeunderlyingcardiaccondi- for confirmation of diagnosis in probands (the first affected family
tion and its severity, the presence or absence of spontaneous VT, member),orforinitialdiagnosisofrelativesandmayhelptoguide
concomitantdrugtherapy,stimulationprotocol,andsite(s)ofstimu- therapyand/orprognosis.PeriodicreassessmentofallclassIVand
lation.Typicalprotocolsincludestimulationfrom2rightventricular IIIvariantsisindicated.176
(RV)siteswith2–3basicdrivecyclelengths,introductionof3extra- Pre-implantationgenetictestingisanearlyformofpre-natalgen-
stimuli,andisoprenalineadministration.148,151,152 etic diagnosis. Genetic diagnoses of in vitro fertilized embryos are
Inthecurrentera,PESismainlyemployedtoconfirmthediagnosis identifiedbybiopsies,therebyallowingtransferofgeneticallynormal
ofVTandinducemappableVAswithnon-inducibilitybeinganabla- embryosintotheuterus.Ifthetechniqueisavailable,itisimportant
tionendpoint.PatientswithheartfailureandLVEF≤35%generally toprovideinformationtopatientswithmonogenicheartdiseasesin
willhaveanindicationforanICD;therefore,VT/VFinductionbefore child-bearingage.Thelegislationforpre-implantationgenetictesting
implantation is not necessary. In patients with SHD and mildly re- variesindifferentcountriesandstrategiesdiffer.
ducedorpreservedLVEFwhopresentwithunexplainedsyncope,in- Geneticandclinicaltestingshouldbeundertakenonlybymultidis-
ductionofSMVTwithPEScanbehelpfultoidentifytheunderlying ciplinaryteamsincludingprofessionalswithskillstocounselonthe
causeandtopredictsubsequentevents.146,153PVT/VFinductionin implicationsandtheuncertaintyofresultsandexperiencedcardiol-
SHDisingeneralconsideredasanon-specificfinding.154–156
ogists able to direct testing to thecorrect
phenotype.135,177–179
A
In primary electrical diseases, PES is not of prognostic value, al- negative result does not exclude a diagnosis and should not be
though there is some evidence to consider its use in BrS.127 used for this purpose. A framework for genetic and other clinical
Invasive electrophysiological evaluation can have important clinical diagnostic tests for primary electrical diseases based on evidence
implicationsinpatientswithmyotonicdystrophy.157 whereavailablehasbeenprovidedinTable7.
Downloaded
from

by
guest
on
22
January
2026

4016 ESCGuidelines
stsetcitsongaidevitacovorpsuonevartnI
6elbaT
feR
noitacoL
noitavresbO
,tsetpotsotairetirC
snoitacidniartnoC
tsetevitisoP
slocotorP
noitacidnI
citsongaiD
semit
dnagnillesnuoc
noisufni/esoD
tset
tnemeganam
noitarud/etar
931,831,631
robalhtaC
evitagenfinim03
,GCESrB1epyT,FV/TV
.FH,GCESrBIepyT
.GCE1epytSrB
nim01–5revogk/gm1
SrBfoyrotsihylimaF
enilamjA
gnitsettneitaptuo
evitisopfih4;tset
gninediwSRQ,sCVP
foecnedivefinoituacerP
esodmumixam(
.SDASro
llufhtiwnoitacol
.tset
.%051.
redisnoc(esaesidnoitcudnoc
gk/gm1ro)gm001
ACdetaticsuseR
noitaticsuser
viretsinimda,FV/TVfI
.)eriwgnicapyraropmet
.nim/gm01ta
.DHStuohtiw
.tnempiuqe
muidosvi,enilanerposi
dradnatsnidroceR
.etanobracib
laidrocerphgihdna .nim03revosdael
041
.enilamjasaemaS
;tsetevitagenfih4
.enilamjasaemaS
.enilamjasaemaS
.enilamjasaemaS
nim01revogk/gm2
.enilamjasaemaS
ediniacelF
.tsetevitisopfih42
esodmumixam(
.)gm051
dradnatsnidroceR laidrocerphgihdna .nim03revosdael
141
.enilamjasaemaS
.nim03
≥erusserpdoolbcilotsyS
.sm084≥noitagnolorpcTQ
TVPfostaeb3≥
.nim01tseR
dnaTVPC
enirhpenipE
,gHmm
002
lanoitceridibro
/gk/gµ520.0tatratS
ACdetaticsuser
,TVProTVdeniatsus-non
.TV
nim01rofnim
tuohtiwrohtiw
evaw-T,nim/sCVP01.
yllaitneuqesesaercni
esicrexenehwDHS
tneitapro,snanretla
/gµ2.0dna1.0,50.0ot
.elbisaeftontset
.ecnarelotni
.spetsnim5ninim/gk
foyrotsihylimaF
retfatsisrepsmotpmysfI
.SDAS
vi,noitaunitnocsid gm5–5.2lolorpotem
.nim1revo
241
.balhtaC
lamroN
roferiwyraropmeT
,%05.sisonetsniamtfeL
yretrayranoroC
yranorocartnI
fonoicipsuS
enilohclytecA
erudecorp-tsop
.gnicappu-kcab
lessev-2,esaesidlessev-3
dezilausivmsaps
dna02:ACR:noitcejni
yranoroc
.emitlanoitavresbo
.kcohscinegoidracfoksiR
,noisulccolatothtiwesaesid
gnirud
,05,02:ACL.gµ05
.msapsosav
,eruliaflaner,FHVI/IIIAHYN
.erudecorp
.s02revogµ001dna
.amhtsalaihcnorbereves
slavretninim-3. .snoitcejnineewteb gµ05foesodlamixaM gµ001dnaACRehtni .ACLehtni
deunitnoC
Downloaded
from

by
guest
on
22 January
2026

ESCGuidelines 4017
2202CSE© 2202CSE©
341
.balhtaC
saemaS
dluohseriwyraropmeT
,%05.sisonetsniamtfeL
saemaS
yranorocartnI
saemaS
enivonogrE
.enilohclyteca
pu-kcabrofdecalpeb
lessev-2,esaesidlessev-3
enilohclyteca
:noitcejniesiwpets
.enilohclyteca
.gnicap
,noisulccolatothtiwesaesid
)gm06–02(ACR
.kcohscinegoidracfoksiR
.eruliaflaner,FHV/IIIAHYN
revo)gm06–02(ACL
.nim5–2fodoirepa
441
.enilamjasaemaS
.nim5
:stceffeediS
,esaesidedonsunis,amhtsA
fonoitacfiitnedI
sesulobgm81,21,6
tnetaledulcxE
enisonedA
,msapsohcnorB
.enisonedaotygrella
yrossecca
esodmumixamotpu
.noitaticxe-erp
,FA,elotsysa,aidracydarb
.yawhtap
VAlitnurogm42
:tsinogatnA.eruzies
rokcolb
.enillyhpoeht
.srucconoitaticxe-erp
traeHkroYweN,AHYN;yretrayranoroctfel,ACL;eruliaftraeh,FH;margoidracortcele,GCE;aidracyhcatralucirtnevcihpromylopcigrenimalohcetac,TVPC;tserracaidrac,AC;emordnysadagurB,SrB;ralucirtnevoirta,VA;noitallirbfilairta,FA ralucirtnev,TV;noitallirbfiralucirtnev,FV;esaesidtraehlarutcurts,DHS;emordnyshtaedcimhtyhrraneddus,SDAS;yretrayranorocthgir,ACR;aidracyhcatralucirtnevcihpromylop,TVP;sexelpmocralucirtneverutamerp,sCVP;noitaicossA
.aidracyhcat
sesaesidlacirtceleyramirphtiwsevitalerdnasdnaborpfopu-krowdetseggusdnastsetciteneG
7elbaT
SRE
FVcihtapoidI
TVPC
SrB
STQL
bIIssalC
bIIssalC
aIssalC
IssalC
aIssalC
tsetciteneG
GCE
3oiranecs,3.2.5noitceSeeS
tsetesicrexE
GCEdaellaidrocerphgihdnaGCE
GCE
sisongaidrofenotsrenroC
lacinilclaitinI
dnaborP
ctsetevitacovorpsrekcolblennahcmuidoS
tsetesicrexE
tset
retloH
edulcxE
bypoconehpedulcxE
deriuqcaedulcxE
sessecorp/stsetrehtO
yhpargoidracohcE
DHS/bypoconehp
STQL
ksirfolevelnotnednepedsraey3–1
pu-wolloF
GCE
laidrocerphgihdnaGCE
GCE
sraey01tatrats:sGCEdaellaidrocerphgihdnaGCE
GCE
lacinilC
sevitaleR
margoidracohcE
sGCEdael
tsetesicrexE
61.trats:ctsetevitacovorpsrekcolblennahcmuidoS
tsetesicrexE
gnineercs
tsetesicrexE
htribmorF
181,081detacidniyllacinilcsselnusraey
)elbisaefnehw(
281margoidracohcE
htribmorF
ksirfolevelnotnednepedsraey3–1
ro/dnaepytonehpevitisoP
pu-wolloF
tnairavV/VIssalC
egrahcsiD
ondnaepytonehpevitageN
tnairavV/VIssalC
.noitallirbfiralucirtnev,FV;emordnysTQgnol,STQL;emordnysnoitaziraloperylrae,SRE;margoidracortcele,GCE;aidracyhcatralucirtnevcihpromylopcigrenimalohcetac,TVPC;emordnysadagurB,SrB
.gnitsetciteneglatanoengnidulcnIa
.yllatnemnorivnedecudorpsitubesaesidcitenegafoscitsiretcarahcsahypoconehpAb
.nrettapadagurB1epytdetnemucodafoesacnitoNc
Downloaded
from

by
guest
on
22
January
2026

4018 ESCGuidelines
Recommendation Table 2 — Recommendations for (usually,300ms,average245+28,inoneseries)mayidentifypa-
genetictesting tientsathigherriskofSCD.186,187Resting12-leadECGisafirst-line
evaluationandmayshowsignsofSHDorprimaryelectricaldiseases
Recommendations Classa Levelb ( ESCCardioMedchapter8.6).188Echocardiographyisthefirst-
Genetictestingisrecommendedwhenacondition lineimagingmodalitythatprovidesimportantinformationaboutcar-
isdiagnosedinalivingordeceasedindividualwith diacfunctionandpotentialSHD( ESCCardioMed10.3,10.10,
I B
alikelygeneticbasisandariskofVAand
10.12).120,189,190Holtermonitoringisusefultoassessthefrequency
SCD.56,183 ofNSVTandrelatedPVCs( ESCCardioMedchapter8.9).191In
Whenaputativecausativevariantisfirstidentified, addition,anatleast3-leadHolter(V1,twoinferiorleads)maygivea
evaluationforpathogenicityisrecommended I C first estimate if NSVT/PVC are unifocal or multifocal and of the
usinganinternationallyacceptedframework.176 NSVTsite(s)oforigin.ThelatterisimportantiftheNSVThasnot
beenpreviouslydocumentedona12-leadECG.192
WhenaClassIVorClassVvarianthasbeen
identifiedinalivingordeceasedindividualwitha An exercise test can be helpful to capture the 12-lead ECG of
conditionthatcarriesariskofVAandSCD, I C NSVT and to identify exercise-induced arrhythmias. Increasing ar-
genetictestingoffirst-degreeandsymptomatic rhythmiaswithexercise, notsuggestiveofidiopathicorigin,should
raisesuspicionofSHDandmaynecessitateadvicetorefrainfrom
relativesandobligatecarriersisrecommended.
physicalexerciseuntildiagnosisandinitiationofappropriatetreat-
Itisrecommendedthatgenetictestingand
ment.UnderlyingsignificantCADshouldberuledoutaccordingto
counsellingonitspotentialconsequencesshould
I C thepatient’spre-testprobability.
beundertakenbyanexpertmultidisciplinary
CMRshouldbeconsideredwhencardiomyopathiesorinflamma-
team.179
tory diseases are suspected on initial evaluation ( ESC
ItisrecommendedthatClassIII(variantsof
CardioMedchapter10.4).193Inaddition,CMRcanidentifyareasof
uncertainsignificance)andClassIVvariantsshould
I C fibrosisassubstratesofNSVT.129
beevaluatedforsegregationinfamilieswhere
possible,andthevariantre-evaluatedperiodically.
Itisnotrecommendedtoundertakegenetic
testinginindexpatientswithinsufficientevidence III C Recommendation Table 3 — Recommendations for
evaluation of patients presenting with newly docu-
ofageneticdisease.
mentedventriculararrhythmia
SCD,suddencardiacdeath;VA,ventriculararrhythmia.
aClassofrecommendation. Recommendations Classa Levelb
bLevelofevidence.
InpatientswithnewlydocumentedVA(frequent
PVCs,NSVT,SMVT),abaseline12-leadECG,
recordingoftheVAon12-leadECG,whenever I C
5.2. Diagnostic evaluation at first
possible,andanechocardiogramare
presentation with ventricular recommendedasfirst-lineevaluation.
arrhythmia in patients without known InpatientswithnewlydocumentedVA(frequent
cardiac disease PVCs,NSVT,SMVT)andsuspicionofSHDother IIa B
VAand(aborted)SCDarecommonfirstmanifestationsofaprevi- thanCADafterinitialevaluation,aCMRshouldbe
considered.194,195
ously not known cardiac condition. A comprehensive diagnostic
evaluationisprovidedforfivefrequentlyencounteredscenarios.
InpatientswithanincidentalfindingofaNSVT,
IIa C
a≥24hHolterECGshouldbeconsidered.
5.2.1.Scenario1:Incidentalfindingofa CAD, coronary artery disease; CMR, cardiac magnetic resonance; ECG,
electrocardiogram; NSVT, non-sustained ventricular tachycardia, PVCs, premature
non-sustainedventriculartachycardia
ventricular contractions; SHD, structural heart disease; SMVT, sustained
Analgorithmfortheevaluationofpatientspresentingwithaninci- monomorphicventriculartachycardia;VA,ventriculararrhythmia.
dentalfindingofNSVTispresentedinFigure2. aClassofrecommendation.
IncidentalNSVTisacommonfindingduringroutinecardiological
bLevelofevidence.
evaluation(e.g.fornon-cardiacdiseases,pre-initiationofoncological
treatments, pre-participation in sports) and monitoring before in-
duction of anaesthesia/sedation for non-cardiac procedures.184 5.2.2.Scenario2:Firstpresentationofsustained
Patients with incidentally found NSVT require further evaluation. monomorphicventriculartachycardia
Arecentsyncopesuspiciousforcardiacoriginisahigh-risksymptom An algorithm for the evaluation of patients presenting with a first
and may prompt admission to hospital.1,185 The morphology of SMVTepisodeispresentedinFigure4.
NSVT (polymorphic or monomorphic) is important to assess. The majority of patients presenting with SMVT have
TypicalMVTmorphologies(Figure3)cansuggestanidiopathicorigin underlying SHD. SMVT in SHD is mainly due to scar-related
withfavourableprognosis.Incontrast,short-coupledPVCinitiating re-entry and only occasionally due to re-entry involving a
non-sustainedPVTormonomorphicNSVTwithshortcyclelength diseased conduction system or due to focal sources.
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4019
Patient with incidental finding of NSVT
NSVT evaluation Personalhistory
Family history Laboratory
(Cycle length,,morphologyyy, (Cardiovascularrrisk factors,
(SCD,, primary electrical (Electrolytes,
exercise induced) symptoms,, co-morbidities,
disease,, cardiomyopathy) (NTTT-)proBNPPP,TSH/T4)
(Class I) medicaaation)
Ambulatory Arrhythmic syncope or fast monomorphic NSVT Consider
N Y
evaluation or short coupled PVC fffollowed by polymorphic NSVT admission
12-lead ECG Echocardiogram ≥24 h Holter
(Class I) (Class I) (Class IIa)
Suggestive of Suggestive/Diagnostic of
Suggestive of SHDb
idiopathic origina primary electrical diseasec
NSVT/PVC burden >10% Exclude
CADd
CMR
(Class IIa)
N Y
Go to section Furtherevaluaaation according Go to section
Dischargee
Idiopathic PVC/VT tomostlikkkely diagnosis Primary electrical disease
Figure2Algorithmfortheevaluationofpatientspresentingwithanincidentalfindingofnon-sustainedventriculartachycardia. CAD,coronaryartery
disease;CMR,cardiacmagneticresonance;ECG,electrocardiogram;N,No;NSVT,non-sustainedventriculartachycardia;PVC,prematureventricularcom-
plex;SCD,suddencardiacdeath;SHD,structuralheartdisease;Y,Yes.aECGmorphologysuggestiveofRVOTorfascicularorigin,negativefamilyhistory,
normal12-leadECG,andechocardiogram.be.g.atrioventricularconductionabnormalities,Qwaves,broadQRScomplex,ST/Twavesdeviations,abnormally
highorlowvoltages.Ventriculardysfunction/dilatation/hypertrophy/wallthinning,wallmotionabnormalities,multitopicPVCs/NSVTs/increasingventricular
arrhythmia(VA)burdenwithexercise.ce.g.Brugadapattern,long/shortQT,polymorphic/bidirectionalVAwithexercise.dDiagnostictesttoexcludeCAD
accordingtopatientprofileandsymptoms.eConsiderre-evaluationincaseofnewsymptomsorchangesinpatientclinicalcondition.
The diagnosis of the underlying aetiology and identification of conduction impairment, e.g. in DCM, myotonic dystrophy, and
patients with idiopathic VT is important. Initial evaluation in- post-cardiac valve surgery (Figure 5).
cludes a comprehensive clinical and family history, 12-lead IfinitialevaluationraisessuspicionofunderlyingCAD,aCAGcan
ECG, and echocardiography. Recording of the 12-lead VT ECG excludesignificantCAD.IfECGandechocardiographyaresuggestive
is indicated as it provides important information on the VT foracardiomyopathy,CMRprovidesimportantdiagnosticinforma-
site of origin. Specific VT morphologies (e.g. right ventricular tiononscardistributionandtissuecharacteristics(Section5.1.3.4).
outflow tract [RVOT] or fascicular origin) (Figure 3) in the ab- When non-invasive evaluation is inconclusive, electroanatomical
senceofa familyhistoryfor cardiomyopathies and without evi- mappingandPESmaybeconsideredforthedifferentialdiagnosisbe-
dence for SHD are suggestive for idiopathic VTs.196 Atypical tweenidiopathicVTandearlyARVC.197Electroanatomicalmapping-
ECGmorphologiesanduncommonclinicalpresentationsshould guidedbiopsycanbeofvaluetoprovideatissuediagnosisforARVC
raise suspicions for underlying SHD even if baseline ECG and andinflammatorydiseaseswithafocaldistribution(e.g.cardiacsar-
echocardiogram are normal. In this scenario, additional evalu- coidosis).198,199 In cases of suspected inflammatory diseases, posi-
ation with CMR should be considered.194 Bundle branch re- tron emission tomography CT (PET-CT), autoimmune serology,
entrant ventricular tachycardia (BBR-VT), resembling bundle and biopsies of affected tissue are part of the diagnostic
branch block configuration on the ECG, is a feature of evaluation.200,201
Downloaded
from

by
guest
on
22
January
2026

4020 ESCGuidelines
RVOT VT (LBBB-like, inferior axis, V4 transition)
LV fascicular VT (RBBB- like, superior axis, QRS 130 ms)
Figure3Typicalidiopathicventriculartachycardiamorphologies.LBBB,leftbundlebranchblock;LV,leftventricle;RBBB,rightbundlebranchblock;
RVOT,rightventricularoutflowtract;VT,ventriculartachycardia.
Recommendation Table 4 — Recommendations for 5.2.3.Scenario3:Suddencardiacarrestsurvivor
evaluationof patients presentingwith afirst episode Analgorithmfortheevaluationofsuddencardiacarrestsurvivorsis
ofsustainedmonomorphicventriculartachycardia presentedinFigure6.
UrgentCAGisrecommendedforpatientspresentingwithSTele-
Recommendations Classa Levelb vationmyocardialinfarction(STEMI).203–206Despitedisparatefindings
InpatientspresentingwithafirstSMVTepisode, of pooled data
analyses,207–211
three randomized controlled trials
electrophysiologicalstudy,electroanatomical
(RCTs)havefoundnosignificantbenefitforearlyCAGincardiacar-
IIb C
mapping,andmapping-guidedbiopsiesmaybe rest (CA) without ST-elevation. In case of electrical instability after
consideredforaetiologicalevaluation.197–199,202 CA,suspiciousforongoingischaemia,thispanelfounda CAGindi-
cated.BrainandchestCTscanmayacutelyidentifynon-cardiaccauses
SMVT,sustainedmonomorphicventriculartachycardia. ofabortedSD,212aswellasbloodtestresultsforpertinenttoxico-
aClassofrecommendation.
bLevelofevidence.
logicalanalysis.213–215Retentionandstorageofsuitablebloodsamples
willallowsubsequentdiagnosticevaluation,includingDNAanalysis.213
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4021
Patient with first SMVT episode
VT 12-lead ECG Personal history
Family history Laboratory
(Cycle length,, morphologyyy, (Cardiovascularrisk factors,
(SCD,, primary electrical (Electrolytes,
exercise induced) symptoms,, co-morbidities,
disease,, cardiomyopathy) (NTTT-)proBNPPP,TSH/T4)
(Class I) medicaaation)
12-lead ECG Echocardiogram
(ClassI) (ClassI)
Suggestive of idiopathic origina Suggestive of CADb Suggestive of SHD other thanCADc
Go to sectionIdiopathic PVC/VT CAG NoCAD
Exclude
CAD
CADd
CMR
Go to sectionCCCAD (Class IIa)
Suggestive ofARRRVCe Suggestive of other cardiomyopathyf Suggestive of inflammatory diseaseg
N YY PETTT-CT
Cardiac/tissue biopsy
Autoimmuneserology
Mapping-guided biopsy
(if regionalventricular
involvement)
(Class IIb)
negative positive
EP study andRRRV
electro-anatomicalmapping Further evaluation Go to section
Go to section
(± mapping-guided biopsy) according to most likkkely Inflammatory
ARVC
(Class IIb) diagnosis carrrdiac diseases
Figure4Algorithmfortheevaluationofpatientspresentingwithafirstsustainedmonomorphicventriculartachycardiaepisode.ARVC,arrhythmo-
genicRVcardiomyopathy;CAD,coronaryarterydisease;CAG,coronaryangiography;CMR,cardiacmagneticresonance;ECG,electrocardiogram;EP,
electrophysiological;LV,leftventricular;N,No;PET-CT,positronemissiontomographyandcomputedtomography;PVC,prematureventricularcom-
plex;RV,rightventricular;SCD,suddencardiacdeath;SHD,structuralheartdisease;SMVT,sustainedmonomorphicventriculartachycardia;VT,ven-
triculartachycardia;Y,Yes.aECGmorphologysuggestiveofRVoutflow tractorfascicularorigin,negativefamilyhistory,normal12-leadECG,and
echocardiogram.be.g.Qwaves,QRSfragmentation,ST/Tabnormalities,wallmotionabnormalitiesincoronaryterritories.ce.g.atrioventricular(AV)
conductionabnormalities,Qwaves,broadQRScomplex,T-waveinversion,abnormallyhighorlowvoltages.Ventriculardysfunction/dilatation/hyper-
trophy/wall thinning/wall motion abnormalities/diffuse hypokinesia. dDiagnostic test to exclude CAD according to patient profile and symptoms.
eAccordingtorevisedtaskforcecriteria.116fe.g.AVconductionabnormalities,abnormallyhighorlowvoltages,broadQRS,ST/Twavedeviations,LV
dilatationanddysfunction,lategadoliniumenhancementwithnon-ischaemicdistribution.ge.g.AVconductionabnormalities,broadQRS,ST/Tdeviations,
multifocalPVCs,inflammatoryhyperaemiaandoedema,fibrosis,LVandRVsystolicdysfunction,pericardialeffusion.
Downloaded
from

by
guest
on
22
January
2026

4022 ESCGuidelines
ECG during sinus rhythm ECG during BBR-VT
I I
II II
III III
aVR aVR
aVL aVL
aVF aVF
V1 V1
V2 V2
V3 V3
V4 V4
V5 V5
V6 V6
Figure5Bundlebranchre-entrantventriculartachycardia.BBR-VT,bundlebranchre-entrantventriculartachycardia;ECG,electrocardiogram.
Any ECG tracing from emergency services, as well as recordings into the mechanism of CA and to offer therapeutic options in
frominterrogationofcardiovascularimplantableelectronicdevices some
patients.244–248
Genetic testing may identify a molecular
(CIEDs)canalsocontributetodiagnosis.216–219Theresting12-lead
causeofSCAbyidentifyingpathogenicmutationsingenesasso-
ECG(includinghighprecordiallead)220isfundamentalandshould ciatedwithspecificphenotypes.213,249,250
be repeated regularly during recovery. Continuous heart rhythm
monitoring is recommended until definite treatment.221,222
Echocardiographymayallowearlydiagnosistoidentifyanystructural Recommendation Table 5 — Recommendations for
abnormality.222,223 Coronary imaging will be important to exclude
evaluationofsuddencardiacarrestsurvivors
CAD, dissection, or anomalies.62,224 Coronary optical coherence
tomography and/or intravascular ultrasound may be helpful to Recommendations Classa Levelb
characterize stenosis/plaque stability and underlying mechanism of
stenosis.225CMRhasrepeatedlybeenshowntoprovidesignificantin- Diagnosticevaluation
crementaldiagnosticvalue,inparticularforconcealedcardiomyop- TheinvestigationofaSCAsurvivorwithout
athy.131,226–228 Primary electrical diseases may be uncovered by obviousextra-cardiaccauseisrecommendedto I B
provocative manoeuvres such as sodium channel blocker chal-
beoverseenbyamultidisciplinaryteam.177,251–256
lenge,136,229–231 lying to standing ECGs,232,233 adenosine chal- InelectricallyunstablepatientsafterSCA,with
lenge,144,234 epinephrine challenge,141,152,235–239 ergonovine/ suspicionofongoingmyocardialischaemia,a I C
acetylcholine,222,240 mental stress,241,242 and exercise coronaryangiogramisindicated.
testing.116,117,119,232,243 Electrophysiological study and electroa- Continued
natomicmappingmaybeusefultoprovidepatient-specificinsights
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4023
InSCAsurvivors,brain/chestCTscanshouldbe suspectedtobeinherited,withareportedcombineddiagnosticyield
consideredwhenpatientcharacteristics,ECG,and
ofgeneticandclinicalevaluationof18–53%.252,266,271Post-mortem
IIa C
echocardiographyarenotconsistentwithacardiac genetictestingonthedeceased,targetedtothecauseofdeath,iden-
cause.212,257
tifiedmutationsinaroundone-thirdofcases.56,266,269
InSCAsurvivors,collectionofbloodsamplesat
presentationisrecommendedforpotential I B
Recommendation Table 6 — Recommendations for
toxicologyandgenetictesting.56,214
evaluationofsuddendeathvictims
RetrievalofrecordingsfromCIEDsandwearable
monitorsisrecommendedforallSCA I B Recommendations Classa Levelb
survivors.217,218
InvestigationofunexpectedSD,especiallyincase
InSCAsurvivors,repeated12-leadECGsduring
ofsuspicionofinheriteddisease,shouldbemadea I B
stablerhythm(includinghighprecordiallead I B publichealthpriority.20,25,56
ECG),aswellascontinuouscardiacmonitoring,
IncasesofSD,itisrecommendedtocollecta
arerecommended.220,222
detaileddescriptionofcircumstancesofdeath,
Echocardiographyisrecommendedforevaluationof I B
I C symptomspriortodeath,thefamilyhistory,and
cardiacstructureandfunctioninallSCAsurvivors.
toreviewpriormedicalfiles.25,56
CoronaryimagingandCMRwithLGEare
Acomprehensiveautopsyisrecommended,
recommendedforevaluationofcardiacstructure
I B ideally,inallcasesofunexpectedSD,andalwaysin I B
andfunctioninallSCAsurvivorswithoutaclear
those,50yearsofage.183,264,265,267,269,270
underlyingcause.62,222,223,226
IncasesofSCD,itisrecommendedtoretain
Sodiumchannelblockertestandexercisetesting
samplessuitableforDNAextractionandconsulta
isrecommendedinSCAsurvivorswithoutaclear I B
cardiacpathologistwhenaninheritedcauseis I B
underlyingcause.117,222,258–260
suspectedorthecauseofdeath
InSCAsurvivors,ergonovine,acetylcholine,or
unexplained.264,265
hyperventilationtestingmaybeconsideredforthe IIb B
ToxicologyscreensarerecommendedinSDcases
diagnosisofcoronaryvasospasm.240,261 I B
withuncertaincauseofdeath.267,268
CIEDs,cardiacinsertableelectronicdevices;CMR,cardiacmagneticresonance;CT, ForSCDwherethecauseisknownorsuspected
computedtomography;ECG,electrocardiogram;LGE,lategadoliniumenhancement; tobeheritable,genetictestingtargetedtothe I B
SCA,suddencardiacarrest.
aClassofrecommendation. causeisrecommended.56,266,269
bLevelofevidence.
FollowingSADS,post-mortemgenetictesting
targetedtoprimaryelectricaldiseaseis
5.2.4.Scenario4:Suddendeathvictim recommendedwhenthedecedentisyoung(,50) I B
AnalgorithmfortheevaluationofSDvictimsispresentedinFigure7. and/orthecircumstancesand/orfamilyhistory
Potential genetic cardiac disease can be identified in 25–49% of supportaprimaryelectricaldisease.56,183,223
casesofSCDintheyoung(,50yearsofage).Thismayalsoaffect
Whenanautopsydiagnosespossibleheritable
relativesofthedeceased.25,56,59Tofindthecauseofdeath,itisim-
cardiacdisease,itisrecommendedtorefer
I B
portanttocollect allavailable dataonprior symptoms,comorbid- first-degreerelativesforcardiacassessmentina
ities,andfamilyhistory.25,56,215,262,263 specializedclinic.271,272
ThemainroleofautopsyinSDistoestablishthecauseofdeath. Innon-autopsiedcasesofSDwhereinherited
An expert cardiac pathologist alters the initial diagnosis in 41% of cardiacdiseaseissuspected,itisrecommendedto
cases, highlighting the need for expert
evaluation.263–265
Inherited referfirst-degreerelativesforcardiacassessment
I B
cardiac diseases identified at autopsy include cardiomyopathies inaspecializedclinic.223,253,273
(HCM,DCM,ARVC)andprematureCAD.25,27,56,266Atoxicology
FollowingSADS,post-mortemgenetictestingin
screen can reveal drug overdose or polypharmacy in 31–56% of thedecedentforadditionalgenesmaybe IIb C
youngSDcases.267,268Inautopsy-negativecaseswithnegativetoxi-
considered.
cology,thetermsuddenarrhythmicdeathsyndrome(SADS)maybe
FollowingSADS,hypothesis-freepost-mortem
applied and primary electrical diseases are potential
genetictestingusingexomeorgenome III B
causes.56,183,223,253RetainingtissueforDNAextractionisimportant
sequencingisnotrecommended.274,275
forpost-mortemgeneticanalysis,wheretheyieldcanbeashighas
oneoutofthree.183,269,270 DNA,deoxyribonucleicacid;SADS,suddenarrhythmicdeathsyndrome;SCD,sudden
Clinicalevaluationoffirst-degreerelativesisimportantifthecause cardiacdeath;SD,suddendeath.
aClassofrecommendation.
of death after autopsy is unknown (Section 5.2.5, scenario 5) or bLevelofevidence.
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4024 ESCGuidelines
5.2.5.Scenario5:Relativesofsuddenarrhythmic depending on population and clinical investigative proto-
deathsyndromedecedents cols.276 Aetiologies included LQTS, BrS, CPVT, and other dis-
An algorithm for the evaluation of relatives of SADS decedents is orders, such as cardiomyopathy.276 All study protocols relied
presentedinFigure8. upon a similar initial approach of evaluating the decedent’s
Studies evaluating families of SADS decedents have identi- pathological reports, medical history, and circumstances of
fied underlying genetic heart disease in relatives that is pre- death,andthenofferingclinicalevaluationtorelativeswithamin-
sumed to be the cause of death in the absence of other imum of personal history, family history, physical examination,
findings. The overall diagnostic yield ranged from 18 to 53%, ECG and exercise test, and echocardiography.223,252,253,277–282
SCA survivor
12-lead ECG (Class I)
UrgentCAGa (Class I) Y STEMI N Electrical instability
suspiciousfffor ongoing
Y myocardial ischaemia
N
Evaluation of patient
characteristics and
circumstances of SCA
Acute culprit lesion N (Class I)
Echocardiogram
Y
(Class I)
Further evaluation according
to STEMI guidelines
Suspiciousfffor extracardiac cause
Y
Brain and chest CT scan (Class IIa)
N
Extracardiac cause identified Y Non-cardiac
N
Collect blood samplefffor toxicology
and genetic testing (Class I)
Review/Repeat ECG (Class I)
PreexcitedAF
Preexcitation or suggestive of
Y or probable primary
primary electrical disease
electrical diseaseb,,c
N
Figure6PartOne.Algorithmfortheevaluationofsuddencardiacarrestsurvivors.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4025
N
Echocardiogram suggestiveof CAD/
Y
cardiomyopathy/valvular heart disease/other SHD
N
Cardiac CT/CAG (if previously not perffformed)
Further evaluation (Class I)
according to most
likkkely diagnosis.
CAD/Coronary
If SMVTTT,go to CAD/coronary anomaly Y
anomaly
scenario 2:
PPPatient withfffirst N
SMVT episoded
CMR
(Class I)
Y LGE on CMR
N
High lead and repeated 12-lead ECGs
(Class I)
Primary
Primary electrical disease Y
electrical disease
N
Sodium channel blockkker test (Class I)
Exercise test (Class I)
Primary electrical disease Y
N
N Suspicion of vasospasme
Y
TTTestfffor coronary vasospam
(Class IIb)
Positive Y VVVasospasm
N
IdiopathicVF
Figure6PartTwo.Algorithmfortheevaluationofsuddencardiacarrestsurvivors.AF,atrialfibrillation;CAD,coronaryarterydisease;CAG,cor-
onaryangiogram;CMR,cardiacmagneticresonance;CT,computedtomography;ECG,electrocardiogram;LGE,lategadoliniumenhancement;N,No;
SCA,suddencardiacarrest;SHD,structuralheartdisease;SMVT,sustainedmonomorphicventriculartachycardia;STEMI,STelevationmyocardialin-
farction;VF,ventricularfibrillation;Y,Yes.aThe2017ESCGuidelinesforthemanagementofacutemyocardialinfarctioninpatientspresentingwith
ST-segment elevation.3 bRule out SHD according to patient age and characteristics; QT duration needs to be reassessed several days after arrest.
cConsidercardiacCT/CAGdependingonpatientcharacteristicsandclinicalcontext.dLeftventricularfunctiononechocardiogramneedstobereassessed
severaldaysafterarresttoexcludestunningascauseofsystolicdysfunction.eIncaseofhighclinicalsuspicion(typicalsymptomsandtransientSTelevation
duringmonitoring),itcanbeconsideredtotestforcoronaryvasospasmearlier.
Downloaded
from

by
guest
on
22
January
2026

4026 ESCGuidelines
Sudden death victim
Collect detailed description about:
Circumstances of death
Symptoms and prior history of deceased
Family history
(Class I)
Comprehensive autopsya
(Class I)
Saaave bloodfffor potential toxicology testing
(Class I)
Non-cardiac cause of SD SCD of suspected inherited causeb SCDofnon-inheritedcause
Saaave tissue fffor potential genetic testing
(Class I)
Cause diagnosed Negative autopsy
TTTargeted genetic testing TTToxicology testing
(Class I) (Class I)
Refffer first-degreerelatives Cause of death not due
Drug overdose
fffor cardiac assessment to drug overdose
(Class I)
Sudden arrhythmic death syndrome
(SADS)
SADS decedent
age <50years or circumstances or
family history suggestive
of heritabledisease
Refffer first-degreerelatives
fffor cardiac assessment
(Class I)
Post-mortem genetic testing
with genetic counsellingc
(Class I)
Go toScenario 5:
Relatives of unexplained SD decedent
Figure7Algorithmfortheevaluationofsuddendeathvictims.SADS,suddenarrhythmicdeathsyndrome;SCD,suddencardiacdeath;SD,sudden
death.aAutopsyisrecommended,ideallyinallcasesofunexpectedSDandalwaysinthoseunder50years.Autopsyshouldincludefullmacroscopic
examinationandhistopathologyofallorgans.Theheartshouldideallybeexaminedbyanexpertcardiacpathologist.SamplessuitableforDNAextraction
shouldberetainedwheninheritedcausesorunexplaineddeatharesuspected.bBasedonallcircumstances,thisincludesnegativeautopsies,autopsieswith
uncertainfindings,non-ischaemiccardiomyopathies,coronaryarterydiseasewherefamilialhypercholesterolaemiaissuspectedandthoracicaorticdis-
sections.cAfterinformedconsentofrelatives.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4027
Where they diverged was the frequency of usage of additional AmbulatorycardiacrhythmmonitoringandCMR
testssuchashigh-leadECGs,Holtermonitoring,signal-averaged maybeconsideredinrelativesofSADS IIb C
ECG, CMR, and provocativetesting.135Sodiumchannel blocker decedents.223,253,277,281
drug challenge and high-lead ECGs systematically performed in
Pharmacologicaltestingincludingepinephrine
SADS relatives provided a yield of 28% BrS diagnoses in one
challenge(ifexercisetestingisimpractical)and
study281; however, there are concerns about false positives.139 sodiumchannelblockerchallengemaybe IIb B
Furthermore, epinephrine challenge has not been studied sys- consideredinfirst-degreerelativesofSADS
tematically in SADS families but, in the opinion of this panel, decedentswithnormalbaselinetesting.223,281
may be of utility in CPVT-suspected patients who are unable
InSADSfamilieswithoutadiagnosisafterclinical
to exercise.137
evaluation,follow-upisnotrecommendedfor
Recent data indicated at least a 13% genetic yield in SADS asymptomaticadultswhocanbedischargedwith III C
cases.135,178,183,276,283Routinefollow-upoffamilieswithoutadiag-
advicetoreturniftheydevelopsymptomsorif
nosisyieldslittleinnewdiagnoses,284althoughchildrenofdecedents
thefamilyhistorychanges.181,284
maybefollowedforage-penetrantdiseaseuntiladulthood.181
Ifanautopsyisambiguous,orifanautopsywasnotundertakenin BrS,Brugadasyndrome;CMR,cardiacmagneticresonance;ECG,electrocardiogram;
SADS,suddenarrhythmicdeathsyndrome.
ayoungSCDcasewithfamilyorpersonalhistorysuspiciousforin-
aClassofrecommendation.
heritedheartdisease,thentheyieldoffamilialevaluationwassimilar bLevelofevidence.
tothatinclearSADScases.223,253,271
6. Therapies for ventricular
Recommendation Table 7 — Recommendations for arrhythmias. General aspects
evaluation of relatives of sudden arrhythmic death
syndromedecedents
6.1. Acute management
Recommendations Classa Levelb 6.1.1.Treatmentofreversiblecauses
Reversiblecausesmayaccountforupto50%ofSCA.285,286However,
FamilialevaluationofSADSdecedentsis mostofthetimeitisdifficulttodeterminetheexactunderlyingcauseof
recommended:
SCAandwhetheritisreversible.Acomprehensiveevaluationofpa-
(cid:129) forfirst-degreerelatives
tients with SCA is mandatoryif the underlying cardiacdisease isun-
(cid:129) forrelativeswhomustcarryamutationbased
knownordiseaseprogressionissuspected(Section5.2.3,scenario3).
onanalysisofthefamilyhistory
I B Electrolyteimbalances,suchashypokalaemia,maytriggerVA,andara-
(cid:129) forrelativeswithsuspicioussymptoms pidriseinextracellularpotassiummayleadtoasystole.287–289Otherfac-
(cid:129) whenthedecedent’sageis,50years,orif
torssuchasbradycardia,ischaemia,coronaryspasm,thrombosis,fever,
thereisothercircumstantialdataorfamily
acutestarvation,anddietingmaycontributetotheoccurrenceofVA.
historytosuggestheritable 290–292Acutecorrectionofthesereversiblefactorsisrecommended.
disease.223,252,253,277,281
Drug-induced arrhythmias should be suspected in patients being
FamilialevaluationofSADSdecedentsis
treatedwithagentsknowntoaltertheelectricalpropertiesoftheheart
recommendedtoincludegenetictestingwhen
I B (e.g.inducingQRSand/orQTprolongation)orcausingelectrolyteab-
post-mortemgenetictestinginaSADSdecedent
normalities(e.g.thiazideandloopdiuretics).Whendrug-inducedar-
detectsapathogenicmutation.183,253,277,281
rhythmiasarepresumed,anyoffendingdrugneedstobewithdrawn
BaselinefamilialevaluationofSADSdecedentsis
and substances that are known to prolong QT (e.g. sotalol) should
recommendedtoincludetakingamedicalhistory beavoided.293,294Hypomagnesaemiaand/orhypokalaemiamaybeas-
andperformingphysicalexamination,standardand I B
sociatedwithTorsadesdepointes(TdP).Intravenousmagnesiumisan
highprecordialleadECG,echocardiography,and effectivetherapyforTdPevenintheabsenceofhypomagnesaemia.295
exercisetesting.223,252,253,277,281
InrefractorycasesofrecurrentTdPinthesettingofacquiredlongQT,
InSADSfamilieswithoutadiagnosisafterclinical thearrhythmiacanbesuppressedbyincreasingtheunderlyingheart
evaluation,follow-upisrecommendedfor I C rateusingisoproterenol(isoprenaline)ortransvenouspacing.
childrenofdecedentsuntiltheyreach PatientswhosurviveSCAinthecontextofapresumedreversible
adulthood.181,284 causemayhaveahighmortalityrate.286Inarecentlargeobservational
Pharmacologicaltestingwithasodiumchannel study296onsurvivorsofSCAattributedtoareversibleandcorrectable
blockershouldbeconsideredinrelativesofSADS cause,subsequentICDimplantationwasassociatedwithlowerall-cause
decedentswhoare16yearsorolderwhen IIa B mortality except for aborted CA occurring in the presence of acute
baselinetestingand/orprobandfindingsincrease myocardialinfarction(MI).Thus,theneedforprophylacticICDimplant-
thesuspicionofBrS.277,281 ationshouldbeconsideredbasedontheunderlyingcardiacdiseaseand
Continued anindividualevaluationofthefutureriskoflife-threateningVA.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4028 ESCGuidelines
Relatives of unexplained sudden death decedent
Non-autopsied SADS decedent SADS decedent
sudden death decedent Genetic testing negative Pathogenic mutation identified
withyoung age,, family history of or not perffformed
SCD or circumstances (age <50years or circumstances or
suggestive of heritable heart disease family history suggestive
of heritable disease)
Familialevaluation in
Familialevaluation in
first-degree relatives,
first-degreerelatives,
or relatives with suspicious
obligate carriers or relatives
symptoms
with suspicious symptoms
(Class I)
according to condition
(Class I)
Medical history Genetic counselling and
Physical examination cascade testing fffor relatives
Standard and high (Class I)
precordial lead ECG
Echocardiography
Exercise testing
(Class I)
Diagnosis Y
N
Ambulatory cardiac rhythm
monitoring and CMR
(Class IIb)
Clinical and/or
Diagnosis Y
genetic diagnosis
N
Sodium channel Manage relatives
blockkker testa according to condition
(Class IIa)
Epinephrine testb
(Class IIb)
Diagnosis Y
N
Follow-upfffor children
of decedent
Discharge asymptomatic adultsc
(Class I)
Figure8Algorithmfortheevaluationofrelativesofunexplainedsuddendeathdecedents.CMR,cardiacmagneticresonance;ECG,electrocardiogram;
N,No;SADS,suddenarrhythmicdeathsyndrome;SCD,suddencardiacdeath;Y,Yes.aOver16yearsold+anysuspicionsforBrugadasyndromeon
testsordecedentcircumstancesofdeath.bIfexerciseisnotfeasible.cRe-evaluateifchangeinfamilyhistoryornewsymptoms.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4029
Recommendation Table 8 — Recommendations for 6.1.2.Acutemanagementofsustained
treatmentofreversibleconditions monomorphicventriculartachycardia
PatientspresentingwithSMVTshouldbetreatedaccordingtosymp-
Recommendations Classa Levelb
tomsandaetiology(Figure9).Patientspresentingwithhaemodynam-
Withdrawalofoffendingagentsisrecommended ic instability require immediate synchronized cardioversion. If
wheneverdrug-inducedVAsare I B synchronization is not possible, an unsynchronized shock should
suspected.293,294,297 be used. Cardioversion is not indicated in patients with repetitive
Investigationforreversiblecauses(e.g.electrolyte NSVTs(Figure10).Documentationofanyhaemodynamicallytoler-
imbalances,ischaemia,hypoxaemia,fever)cis I C ated wide QRS tachycardia on 12-lead ECG is important.
recommendedinpatientswithVA.292,298 Administrationofadenosine300orvagalmanoeuvreswithcontinuous
recording of 12-lead ECG should be considered if supraventricular
Despiteapossiblecorrectablecauseforthe
tachycardia(SVT)islikely.Intravenousadenosinemayalsoterminate
presentingVA,theneedforICDimplantation
shouldbeconsideredbasedonanindividual IIa C specific VT subtypes. Such a response supports cyclic adenosine
monophosphate(cAMP)-mediatedtriggeredactivityasanunderlying
evaluationoftheriskofsubsequentVA/
SCD.286,296,299 VT mechanism.301 Pre-excited atrial fibrillation (AF) can be recog-
nizedbythe‘FBI’(fast,broad,irregular)ECGpattern.Itmaymimic
ICD,implantablecardioverterdefibrillator;SCD,suddencardiacdeath;VA,ventricular
VT,andintravenousadministrationofdrugsthatslowAVconduction,
arrhythmia.
aClassofrecommendation. such as adenosine, beta-blockers, and amiodarone, should be
bLevelofevidence. avoided.302PromptterminationofSMVTisrecommendedevenfor
cListnotexhaustive.
toleratedSMVT,asrapidhaemodynamicaldeteriorationmayoccur.
Acute management of a patient with regular wide QRS complex tachycardia
Cardioversion/defibrillation/ALS Haemodynamically History, physical examination,
N Y
(Class I) tolerated 12-lead ECG
Known or suspicion Adenosine or vagal
of structural manoeuvres if SVT likelya
heart disease (Class IIa)
N
Y
IdiopathicVT
Known Known Other type
fascicularVT outflow tractVT or uncertain
Anaesthetic risk Anaesthetic risk
for cardioversionb for cardioversionb
N Y N Y
Verapamil Beta-blockers Procainamide Procainamide
(Class I) (Class I) (Class IIa) (Class IIa)
Flecainide Amiodarone
Ajmaline (Class IIb)
Sotalol
Amiodaronec
(Class IIb)
Cardioversion (Class I)
Figure9AlgorithmfortheacutemanagementofregularwideQRScomplextachycardia.ALS,advancedlifesupport;ECG,electrocardiogram;N,No;
SVT,supraventriculartachycardia;VT,ventriculartachycardia;Y,Yes.aBesidesSVT,adenosinemayalsoterminateidiopathicVT,whichthenindicates
triggeredactivityasthemechanismunderlyingthearrhythmia.bBenefitofcardioversionshouldbeweighedagainstrisksrelatedtoanaesthesia/sedation.
cConsideringlimitedavailabilityoftheotheranti-arrhythmicdrugs.
2202CSE© Downloaded
from

by
guest
on
22
January
2026

4030 ESCGuidelines
Repetitive runs of VT
mm:ss
00:00
00:30
01:00
01:30
02:00
02:30
03:00
03:30
04:00
04:30
05:00
05:30
06:00
06:30
07:00
07:30
08:00
08:30
09:00
Figure10Repetitiverunsofventriculartachycardiainterruptedbyoccasionalsinusbeats.VT,ventriculartachycardia.
Termination can be achieved with electrical cardioversion, anti- overdrivepacingmayterminatethoseVTswithacyclelengthunder
arrhythmicmedications,orpacingtechniques.Allanti-arrhythmic theprogrammedICDdetectionrate.IncaseofaknownidiopathicVT
drugs(AADs)mayleadtohypotension,buttheindividualriskof (Figure4),treatmentwithbeta-blockers(forRVOTVT)306orverap-
anaesthesia/sedationrequired forcardioversionalsoneedstobe amil (for fascicular VT)307 is recommended for acute conversion.
considered.Forpharmacologicalterminationofahaemodynamic- AlthoughverapamilmayterminateothertypesofidiopathicVT,307
allytoleratedVTofunknownaetiology,intravenousprocainamide importantadverseeffectssuchasseverehypotensionmayoccur.
oramiodaronecanbeused.InthePROCAMIOtrial,303procaina- IftheVTaetiologyisuncertain,intravenousadministrationofver-
midetherapywasassociatedwithahigherproportionoftachycar- apamilisnotrecommended.308,309Acomprehensiveevaluationof
dia termination and fewer major cardiac adverse events than patients presenting with SMVT is mandatory if the underlying
amiodarone.Intravenousprocainamideshouldnotbeusedinpa- cardiac disease is unknown or disease progression is suspected
tientswithsevereheartfailure,acuteMI,andend-stagerenaldisease. (Section5.2.2,scenario2).
AdministrationofotherAADs(ajmaline,sotalol,andflecainide)304,305
maybeconsideredinpatientswithoutsignificantheartdisease,but 6.1.3.Managementofelectricalstormandincessant
the risk of adverse events should be carefully weighed. Availability ventriculartachycardia
ofAADshastobetakenintoaccount,e.g.procainamideisnotavail- AnelectricalstormiscommoninICDpatientsandhasbeendefined
able in many European countries. In patients with an ICD, manual as three or more episodes of sustained VA occurring within 24h,
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4031
requiring either anti-tachycardia pacing (ATP) or cardioversion/ multipleshocks.FrequentICDshockscanalsobeinappropriatelyde-
defibrillation, with each event separated by at least 5min.310–312 livered(Figure11).
Patients who experience an electrical storm are prone to psycho- IncasesofinappropriateICDshocks(e.g.duetoSVTsorleadde-
logicaldisorders,heartfailuredecompensation,andincreasedmor- fects)orunnecessaryICDtherapy(e.g.forNSVTorforrepetitiveVTs
tality.313,314 The severity of an electrical storm can range from thatterminateandrestartspontaneously),disablingofICDtherapiesis
recurrentasymptomaticVTepisodes terminatedbyATPto alife- recommended.Ifanelectrophysiologyspecialistorprogrammerisnot
threateningelectricalinstabilitywithVAthatrecursfrequentlyafter available,theICDcanbedisabledbyplacingamagnetoverthedevice.
Patient with electrical storm or repeated ICD discharges
STEP 1
Rhythm
assessment/ICD ICD Disable ICD by
interrogation Inappropriate therapy due programming magnet placement Treatment
if programmer ofAF/SVTa
toAF/SVT/lead oversensing optimizationa
not available (Class I)
(Class I)
(Class I)
Inappropriate
or unnecessary Y
therapies
Disable ICD by
ICD
magnet placement
N Recurrent non-sustained programming
if programmer
VA episodes optimizationa
not available
(Class I)
Electrical (Class I)
storm
STEP 2
Assessment of ALS including external
haemodynamic cardioversion/defibrillation
status N (Class I)
Haemodynamically Sedation (for comfort)
Y
stable (Class I)
STEP 3
Assessment of VA type
VA type
PolymorphicVA MonomorphicVA
Figure11PartOne.Managementofpatientswithelectricalstormorrepeatedimplantablecardioverterdefibrillatordischarges.
Downloaded
from

by
guest
on
22
January
2026

4032 ESCGuidelines
Incaseofhaemodynamicinstabilityatinitialevaluation,institution suppression in two smaller studies.319,320 Administration of other
ofadvancedlifesupport(ALS)isrecommended.315Reversiblecon- AADssuchasprocainamide,321lidocaine,322orquinidine296,297de-
ditionscontributingtoinitiationandperpetuationofVAneedtobe pendsonthespecificsituation,typeofVA,andunderlyingaetiology.
corrected(seeSection6.1.1).Furthermanagementdependsonthe Whenelectricalstormremainsintractable,withmultipleshocksina
type of VA and the underlying aetiology.312,316 A multifaceted ap- few hours, despite available anti-arrhythmic therapies, deep sed-
proachisoftenrequiredformanagement,consistingofICDrepro- ation/intubationshouldbeconsidered,alongwithmechanicalventi-
gramming when appropriate, AAD therapy, sedation, catheter lation.325Ifbeta-blockertreatmentisinsufficientornottoleratedto
ablation,autonomicmodulation,andmechanicalcirculatorysupport. decreasesympathetictone,selectedpatientsmaybenefitfromauto-
Elevated sympathetic tone needs to be addressed. For patients nomicmodulation,i.e.percutaneousganglionicstellateblockade,326
withrecurrentICDshocks,sedationisindicatedtoalleviatepsycho- thoracic epidural anaesthesia,327 or left cardiac sympathetic
logicaldistressanddecreasepro-arrhythmogenicsympathetictone. denervation.328
Initial treatment with beta-blockers, preferably non-selective beta- The most common arrhythmia underlying electrical storm is
blockers like propranolol, which was superior to metoprolol in SMVT associated with SHD that is amenable to catheter abla-
one study,317 combined with amiodarone318 is most commonly tion.313,329 Successful ablation was associated with a significant re-
used. In patients with recurrent haemodynamically not-tolerated duction in VT and electrical storm recurrence and improved
VTs resistant to amiodarone, landiolol (ultra-short-acting long-termsurvivalinretrospectiveanalyses.330,331Inpatientswithin-
β1-selective blocker) was found to be effective for arrhythmia cessantslowMVT,catheterablationispreferredoverAADtherapy,
Polymorphic VA
Underlying aetiology
Acute External Polymorphic Acquired Primary
ischaemia precipitating VA triggered long QT electrical
factors by unifocal disease
PVC
Brugada, ERS Idiopathic VF Long QT, CPVT
Go to Treatment Catheter Remove Isoproterenol Isoproterenol Beta-blocker
flowchart according to ablation precipitating (Class IIa) (Class IIa) (Class I)
STEMI underlying (Class IIa) factors
(Figure 14) condition (Class I) Quinidine Quinidine Pacingd
(Class I) Quinidineb (Class IIa) (Class IIa) (Class I)
(Class IIb)
Mg++/K+ i.v.
Catheter Verapamil Mg++/K+ i.v.
(Class I)
ablation (Class IIa) (Class I)
Isoproterenol (Class IIa) Catheter AAD
(Class I)
ablation of according
Pacing PVC triggers to underlying
(Class I) (Class IIa) disease
(Class IIa)
Autonomic
modulation
(Class IIa)
Recurrent VA
Deep sedation/ intubation
(Class IIa)
Mechanicalcirculatory support
(ClassIIb)
Figure11PartTwo.Managementofpatientswithelectricalstormorrepeatedimplantablecardioverterdefibrillatordischarges.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4033
MonomorphicVA
VA burdenc
High Low
ICD programming optimizationa ICD programming optimizationa
(Class I) (Class I)
Beta-blocker/sedation
(Class I)
On amiodarone or
Amiodarone i.v. amiodarone not desirable N
(Class I)
AAD according to
underlying disease
and cardiac function
Y
Recurrent VA
Recurrent VA
Catheter ablation Catheter ablation
(Class I) (Class I)
Deep sedation/intubation
(Class IIa)
Autonomic modulation
(Class IIb)
Mechanical circulatory support
(Class IIb)
Overdrive pacinge
Figure 11 Part Three. Management of patients with electrical storm or repeated implantable cardioverter defibrillator discharges. AAD, anti-
arrhythmicdrug;AF,atrialfibrillation,ALS,Advancedlifesupport;CPVT,catecholaminergicpolymorphicventriculartachycardia;ERS,earlyrepolarization
syndrome;ICD,implantablecardioverterdefibrillator;N,No;PVC,prematureventricularcomplex;STEMI,ST-elevationmyocardialinfarction;SVT,su-
praventriculartachycardia;VA,ventriculararrhythmia;VF,ventricularfibrillation;Y,Yes.aSpecialaspectsofdevicetherapysection.bNodataoneffectof
quinidineonPVC-triggeredpolymorphicVAsinpatientswithcardiomyopathies.cHighVAburdenreferstoaclinicalscenarioofveryfrequentVAepi-
sodesrequiringICDshocks,whenonlyshortperiodsofstablerhythmcanbeachieved.LowVAburdenreferstoaclinicalscenarioofrepeatedATPs/ICD
shocksfollowedbystablerhythm.dIfbradycardiaorpost-extrasystolicpausesfacilitateinitiationofPVT/VF.eOverdrivepacing(bypacingwithaslightly
higherratethanthebaselinerhythm)canbeusefultotemporarilysuppressslowrecurrent/incessantVT.
which may only further slow VT. Catheter ablation should also Recommendation Table 9 — Recommendations for
be considered in patients with recurrent symptomatic episodes theacutemanagementofsustainedventriculartachy-
of PVT or VF triggered by a similar
PVC.221,332–334
Institution
cardiaandelectricalstorm
of mechanical circulatory support may be considered for
Recommendations Classa Levelb
haemodynamic stabilization, when conventional therapy fails,
andtoprovidecirculatorysupportduringablation.335Inarecent AcutemanagementofsustainedVT
meta-analysis336 including 2465 patients, a substantially lower
DCcardioversionisrecommendedasthe
mortalitywasobservedwithprophylacticmechanicalcirculatory first-linetreatmentforpatientswith I B
supporttreatmentamongpatientssufferingfromelectricalstorm haemodynamicallynot-toleratedSMVT.303,339
orhigh-riskPAINESDscore.337Incontrast,rescueuseofmech-
DCcardioversionisrecommendedasthe
anical circulatory support during ablation was associated with a first-linetreatmentforpatientspresentingwith
highmortalityrate.338Inpatientswithelectricalstormduetore- I C
toleratedSMVTprovidedthattheanaesthetic/
current PVT/VF, the underlying aetiology determines further
sedationriskislow.
management(Figure11).
Continued
Downloaded
from

by
guest
on
22
January
2026

4034 ESCGuidelines
Inpatientspresentingwithahaemodynamically Autonomicmodulationmaybeconsideredin
toleratedidiopathicVT,treatmentwith patientswithelectricalstormrefractorytodrug
I C IIb C
intravenousbeta-blocker(RVOTVT)or treatmentandinwhomcatheterablationis
verapamil(fascicularVT)isrecommended.306,307 ineffectiveornotpossible.326,328,340
Inpatientspresentingwitharegular Institutionofmechanicalcirculatorysupportmay
haemodynamicallytoleratedwideQRScomplex beconsideredinthemanagementof
IIb C
tachycardiasuspectedforSVT,administrationof IIa C drug-refractoryelectricalstormandcardiogenic
adenosineorvagalmanoeuvresshouldbe shock.335
considered.300
AAD,anti-arrhythmicdrug;CAD,coronaryarterydisease;DC,directcurrent;LQT,
Inpatientspresentingwithahaemodynamically longQT;PVC,prematureventricularcomplex;PVT,polymorphicVT;RVOT,right
toleratedSMVTandknownorsuspectedSHD, ventricular outflow tract; SHD, structural heart disease; SMVT, sustained
IIa B
monomorphic ventricular tachycardia; SVT, supraventricular tachycardia; TdP,
intravenousprocainamideshouldbe
Torsadesdepointes;VF,ventricularfibrillation;VT,ventriculartachycardia.
considered.303 aClassofrecommendation.
Inpatientspresentingwithahaemodynamically
bLevelofevidence.
toleratedSMVTintheabsenceofanestablished
IIb B
diagnosis,intravenousamiodaronemaybe
considered.303 6.2. Long-term management
Inpatientspresentingwithahaemodynamically
6.2.1.Pharmacotherapy
toleratedSMVTintheabsenceofsignificantSHD,
IIb C Optimalmedicaltreatmentoftheunderlyingcardiacdisease,including
flecainide,ajmaline,orsotalolmaybe
themaximaltolerateddosesofheartfailuremedication,ismandatory.341
considered.304,305
In patients with heart failure with reduced ejection fraction
Intravenousverapamilisnotrecommendedin
(HfrEF), the 2021 ESC Guidelines for the diagnosis and treatment
broadQRScomplextachycardiaofunknown III B
of acute and chronic heart failure recommend angiotensin-
mechanism.308,309
converting enzyme inhibitor (ACE-I)/angiotensin receptor blocker
Managementofelectricalstorm (ARB)/angiotensinreceptorneprilysininhibitors(ARNIs),mineralo-
Mildtomoderatesedationisrecommendedin
corticoidreceptorantagonists(MRAs),beta-blockers,andsodium–
patientswithelectricalstormtoalleviate glucose co-transporter 2 (SGLT2) inhibitors to reduce mortality
I C
psychologicaldistressandreducesympathetic
duetoheartfailureandSCD.342
tone.
Antiarrhythmictherapywithbeta-blockers
(non-selectivepreferred)incombinationwith
RecommendationTable10—Recommendationsfor
intravenousamiodaroneisrecommendedin I B
treatmentwithheartfailuremedication
patientswithSHDandelectricalstormunless
contraindicated.317,318 Recommendations Classa Levelb
Intravenousmagnesiumwithsupplementationof
OptimalmedicaltreatmentincludingACE-I/ARB/ potassiumisrecommendedinpatientswith I C
ARNIs,MRAs,beta-blockers,andSGLT2
TdP.295 I A
inhibitorsisindicatedinallheartfailurepatients
Isoproterenolortransvenouspacingtoincrease withreducedEF.343–347
heartrateisrecommendedinpatientswith
acquiredLQTsyndromeandrecurrentTdP I C ACE-I,angiotensin-convertingenzymeinhibitor;ARB,angiotensinreceptorblocker;
ARNIs, angiotensin receptor neprilysin inhibitor; EF, ejection fraction; MRA,
despitecorrectionofprecipitatingconditionsand
mineralocorticoidreceptorantagonists;SGLT2,sodium–glucoseco-transporter2.
magnesium. aClassofrecommendation.
Catheterablationisrecommendedinpatients
bLevelofevidence.
presentingwithincessantVTorelectricalstorm I B
duetoSMVTrefractorytoAADs.330,331
Deepsedation/intubationshouldbeconsideredin
AADshaveanimportantroleasadjunctivetherapyinthemanage-
patientswithanintractableelectricalstorm IIa C
ment of VA, especially in symptomatic patients (Table 8). Until now,
refractorytodrugtreatment.325
noAADexceptforbeta-blockershasdemonstratedreductioninall-
Catheterablationshouldbeconsideredinpatients causemortality.Eachdrughasasignificantpotentialforcausingadverse
withrecurrentepisodesofPVT/VFtriggeredbya
IIa C events,includingpro-arrhythmia.Forexample,numerousAADs,as
similarPVC,non-responsivetomedicaltreatment
wellasalargenumberofdrugswithothertherapeuticindications,
orcoronaryrevascularization.221,332,333
can prolong the QT interval ( and
Quinidinemaybeconsideredinpatientswith
provokeTdP,havenegativechronotropiceffects,maydeteriorate
CADandelectricalstormduetorecurrentPVT IIb C
heart failure, and cause bradycardia. Several drugs increase the
whenotherAADtherapyfails.323,324
risk of VA in patients with BrS (
Continued
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4035
Table8 Anti-arrhythmicdrugs(acuteandchronictreatment)
Anti-arrhythmic EffectsonECG Indications Oraldoseper Sideeffects Contraindications,
drug (specific day precautions,other
indication) (i.v.dose) considerations
Amiodarone Decreasessinus PVC,VT,VF 200–400mg Cardiac: Precautions:
nodefrequency, Loadingdose: Bradycardia,TdP Sinusnodedysfunction,
prolongsQT 600–1200mg/ (infrequent) severeAVconduction
intervala 24h8–10days. Extracardiac: disturbances,
(Loadingdose: Photosensitivity,corneal hyperthyroidism
5mg/kgin deposits,hypothyroidism, Otherconsiderations:
20min–2h,2–3 hyperthyroidism, Canbeusedinpatientswith
timesin24h,then pulmonarytoxicity, heartfailure.Increasesthe
600–1200mg/ hepatotoxicity, riskofmyopathywhenused
24h8–10days) polyneuropathy,skin withstatins
discoloration
Adenosine TransitoryAVblock Regularwide Nooraluse Chestpain,flushing, Contraindications:
complex (6–18mgbolus) bronchoconstriction Severeasthma,pre-excited
tachycardiaof AF
unknownorigin Otherconsiderations:
(outflowtract Antagonist:theophylline
VT)
Ajmaline ProlongsQRS VT Nooraluse Cardiac: Contraindications:
durationandQT (unmaskingBrS (1mg/kgover VF(rareinsuspectedBrS), BrSECGtypeI,QT
intervala ECG) 5–10min occasionalTdP,negative prolongation
(maximumdose inotrope
100mg)or Extracardiac:
1mg/kgat Cholestaticjaundice,
10mg/min) headache,nausea,
thrombocytopenia
Beta-blocker Decreasessinus PVC,VT Various Cardiac: Contraindications:
nodefrequency, (LQTS,CPVT) (various) Bradycardia,AVblock, Severesinusnode
prolongsPRinterval, hypotension,negative dysfunction,severeAV
shortensQTinterval inotrope conductiondisturbances,
Extracardiac: decompensatedheartfailure,
Fatigue,bronchospasm, coronaryvasospasm,severe
sexualdisturbances, asthma,BrS
depression,cold
extremities
Landiolol Seebeta-blocker VT,electrical Nooraluse Seebeta-blocker Contraindications:
(Ultra-shortacting storm 100µg/kgbolusin Seebeta-blocker.
β1-selectiveblocker) 1min,infusion Bradycardia,hypotension
10–40µg/kg/min Otherconsiderations:
(max80µg/kg/ Limitedexperiencewithits
min;max24h usebeyond24h
totaldose
57.6mg/kg/day)
Nadolol Seebeta-blocker PVC,VT 40–120mg Seebeta-blocker Contraindications:
(Non-selective (LQTS,CPVT) Seebeta-blocker
β1β2blocker) Otherconsiderations:
Plasmahalf-life20–24h
Propranolol Seebeta-blocker PVC,VT 80–320mg Seebeta-blocker Contraindications:
(Non-selectiveβ1β2 (electricalstorm, (160mg/24h) Seebeta-blocker
blocker) LQTS,CPVT)
Disopyramide Increasessinusnode PVC,VT 250–750mg Cardiac: Contraindications:
frequencyand Negativeinotrope,AV Severesinusnode
prolongsPRinterval, block,pro-arrhythmia dysfunction,severeAV
QRSduration,and (MVT,occasionalTdP) conductiondisturbances,
QTintervala severeintraventricular
Continued
Downloaded
from

by
guest
on
22
January
2026

4036 ESCGuidelines
Extracardiac: conductiondisturbances,
Anticholinergiceffects priorMI,significantSHD,
hypotension
Otherconsiderations:
ReducesLVoutflowtract
obstructionandsymptomsin
HCM
Flecainide ProlongsPRinterval, PVC,VT 200–400mg Cardiac: Contraindications:
QRSduration,and (unmaskingBrS (1–2mg/kgover Pro-arrhythmia(MVT, PriorMI,significantSHD,BrS,
QTintervala ECGb) 10min) occasionalTdP),negative severesinusnode
inotrope,sinus dysfunction,severeAVor
bradycardia,AVblock,1:1 intraventricularconduction
AVconductionduring disturbances,inheritedLQTS
flutter (otherthanLQTS3),severe
Extracardiac: kidneydisease(CrCl
Centralnervoussystem ,35mL/min/1.73m2)
effects(e.g.drowsiness, Otherconsiderations:
diplopia,headache) DiscontinueifQRSwidening
.25%orbundlebranch
block
Isoproterenol Increasessinusnode (Electricalstorm Nooraluse Cardiac: Contraindications:
frequency,shortens inBrS,idiopathic (0.5–10µg/min) Sinustachycardia, ACS,LQTS
QTinterval VF,andERS,TdP, vasodilation Otherconsiderations:
beta-blocker Extracardiac: Shortplasmahalftime
overdose; Headache,sweating, (2min)
acquiredLQTS) tremor
Lidocaine Nosignificanteffects (VT/VF Nooraluse Cardiac: Precautions:
associatedwith (50–200mgbolus, Sinoatrialarrest Reduceddosewithreduced
ACS) then2–4mg/min) Extracardiac: liverbloodflow(e.g.shock,
Centralnervoussystem β-blockade,severeheart
effects(e.g.drowsiness, failure)
dizziness) Otherconsiderations:
Moreeffectivewithhigh
potassiumlevel.Few
haemodynamicsideeffects
Mexiletine Nosignificanteffects PVC,VT 600–1200mg Cardiac: Contraindications:
(LQT3) Loadingdose: Sinusbradycardiainsinus Sinusnodedysfunction,
400mginitially nodedysfunction, severeAVconduction
followedby hypotension disturbances,severeheart
600mginthefirst Extracardiac: failure
24h Centralnervoussystem
effects(e.g.tremor,
dysarthria,dizziness),
gastrointestinalcomplaints
Procainamide ProlongsPRinterval, VT (100mgbolus, Cardiac: Contraindications:
QRSduration,and canberepeated Sinusbradycardia, Severesinusnode
QTintervala after5minifno hypotension,TdP dysfunction,severeAV
effect,max500– Extracardiac: conductiondisturbances,
750mg[max Rash,myalgia,vasculitis, severeintraventricular
50mg/min].Then, systemiclupus, conductiondisturbances,
2–6mg/min) agranulocytosis severeLVdysfunction
hypotension,BrS
Propafenone ProlongsPRinterval, PVC,VT 450–900mg Cardiac: Contraindications:
QRSduration,and Sinusbradycardia,AV PriorMI,significantSHD,BrS,
QTintervala block,negativeinotrope, severesinusnodedysfunction,
pro-arrhythmia(MVT, severeAVorintraventricular
occasionalTdP) conductiondisturbances,
Extracardiac: LQTS,significantrenalorliver
Gastrointestinal disease
disturbances,headache, Otherconsiderations:
drymouth DiscontinueifQRSwidening
.25%orbundlebranchblock
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4037
Quinidine Increasessinusnode (VFc,BrS,SQTS) 600–1600mg Cardiac: Contraindications:
frequencyand Loadingdose: Hypotension,TdPd Severesinusnode
prolongsPRinterval, Start200mg Extracardiac: dysfunction,severeAVor
QRSduration,and every3huntil Gastrointestinal intraventricularconduction
QTintervala effect,max.3gin disturbances,auditoryand disturbances,previousMI,
first24h visualdisturbances, significantSHD,hypotension,
confusion,leukopenia, LQTS
haemolyticanaemia,
thrombocytopenia,
anaphylaxis
Ranolazine Decreasessinus VT 750–2000mg Cardiac: Contraindications:
nodefrequency, (LQTS3) Sinusbradycardia, Severesinusnode
prolongsQT hypotension dysfunction,severeheart
intervala Extracardiac: failure,LQTS(otherthan
Dizziness,nausea, LQTS3)
constipation, Precautions:
gastrointestinal Concomitanttreatments
disturbance,headache, associatedwithQTinterval
rash prolongation
Sotalol Decreasessinus VT 160–640mg Seebeta-blockers,TdPd Contraindications:
nodefrequency, (0.5–1.5mg/kgin (.2%ofpatients,close Severesinusnode
prolongsQT 10min.If monitoringofQTinterval dysfunction,severeAV
intervala necessary,canbe andCrCl) conductiondisturbances,
repeatedafter severeheartfailurewith
6h) reducedLVEF,significant
LVH,CrCl,30ml/min,
coronaryvasospasm,LQTS
Precautions:
Concomitanttreatments
associatedwithQTinterval
prolongation,hypokalaemia
Otherconsiderations:
Potassiumchannelblocker
effectsrequirehigherdose
thanbeta-blockereffects
Verapamil ProlongsPRinterval (LVfascicular 120–480mg Cardiac: Contraindications:
tachycardia) (5–10mginslow Sinusbradycardiainsinus Heartfailurewithreduced
bolus.Ifnecessary, nodedysfunction,AV LVEF,severesinusnode
canberepeatedin block,negativeinotrope, dysfunction,andsevereAV
30min) hypotension conductiondisturbances,VT
Extracardiac: ofunknownorigin,ACS,
Gastrointestinal WPWsyndrome
disturbances,peripheral Otherconsiderations:
oedema,flushing Increasetheriskofmyopathy
whenusedwithstatins
ACS,acutecoronarysyndrome;AF,atrialfibrillation;AV,atrioventricular;BrS,Brugadasyndrome;CPVT,catecholaminergicpolymorphicventriculartachycardia;CrCl,creatinine
clearance;ECG,electrocardiogram;ERS,earlyrepolarizationsyndrome;HCM,hypertrophiccardiomyopathy;LQTS,longQTsyndrome;LV,leftventricular;LVEF,leftventricular
ejectionfraction;LVH,leftventricularhypertrophy;MI,myocardialinfarction;MVT,monomorphicventriculartachycardia;PVC,prematureventricularcomplex;SHD,structural
heartdisease;SQTS,shortQTsyndrome;TdP,torsadesdepointes;VF,ventricularfibrillation;VT,ventriculartachycardia;WPW,Wolff–Parkinson–White.
aPrecautionwithconcomitantconditionsordrugsthatprolongQTinterval.ShouldbediscontinuedifQTc.500ms.SeeFigure13Algorithmforevaluationbeforeinitiationand
follow-upofpatientsrequiringdrugsassociatedwithQTprolongation.
bIfajmalinenotavailable.
cSubacuteMI,multifocalectopicPurkinje-relatedprematurecontractions,ERS,idiopathicVF.
dProarrhythmicsideeffectsrequirestrongindicationinpatientswithoutICD.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4038 ESCGuidelines
Patient requiring sodium channel blocking agents
Contraindications:
Assessment of patient
riskprofilebeforeinitiation Brugada syndromea
PriorMI(flecainide)b
Severe LV dysfunction
Severevalvularheartdisease
Known cardiac disease
Severe bradycardia, BBB,>firstdegreeAVblock
or
ECG abnormalities Y
or Precaution:
Abnormal echocardiogram Any degree of LV dysfunction
LV hypertrophy
N Anysignificantvalvularheartdisease
FirstdegreeAVblock
Initiatetreatmentc Prolonged QT interval (disopyramide, quinidine)
Initiatetreatmentonindividualdecision(risk/benefit)d
ECG 1–2 weeks after initiation
or increase in dosagee
ΔQRS > 25%f or
Considertochangetodffierentdrug
Abnormal exercise test?
(new BBB,ΔQRS >25% Y Consider to reduce dose
Considertomeasuredrugserumlevel
or QRS >130 ms)
N
Continue treatment
Inform patient about
warning symptoms (syncope)
Periodic ECG for QRS width evaluation
Control changes in renal and hepatic function
Be aware of potential drug interactions
Figure12Algorithmforevaluationbeforeinitiationandfollow-upofpatientsrequiringsodiumchannelblockingagents.AV,atrioventricular;BBB,bun-
dlebranchblock;ECG,electrocardiogram;LV,leftventricular;MI,myocardialinfarction;N,No;Y,Yes.a
cCo-administrationofdrugswithAVnodalblockingeffectinpatientswithatrialfibrillationoratrialflutter.dInimplantablecardioverterdefibrillatorcarriers,a
higherriskofdrug-inducedpro-arrhythmiamightbeaccepted.eAccordingtothe2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillation.348
fAΔQRS.25%isnotanabsolutecut-offvaluebutdependentonQRSwidthbeforedruginitiationandindividualizedpatientrisk–benefitconsiderations.
Modificationofriskfactors,whenpossible,isimportantforpreventionof Therefore, the use of an ICD for secondary prevention of SCD
pro-arrhythmia. In patients who require a potentially arrhythmia- thatoccurredintheabsenceofreversiblecausesiswidelyaccepted.
inducingdrug,regularECGandothertestsaccordingtothepatient’s Several randomized controlled trials353–356 have established the
profileandAADcharacteristicsarerecommended(Figures12and13). roleoftheICDforprimarypreventionofSCDinheartfailurepa-
tientswithanLVEF≤35%.Thereportedmortalityreductionhasre-
6.2.2.Devicetherapy cently been supported by two large contemporary prospective
6.2.2.1.Implantablecardioverterdefibrillator registries enrolling more than 5000 patients.357,358 In the
ICDisanintegralpartoftreatingpatientssurvivingaCAduetoaVA EU-CERT-ICDtrial,primarypreventionICDimplantationwasasso-
orthosedeemedtobeathighriskthereof.Drawbacksarethehigh ciatedwitha27%lowermortalitywithsimilarresultsinCADand
up-frontdevicecosts,device-associatedcomplications,andtherela- DCM.357 Results of the DANISH trial, however, indicate that the
tivelyhighnumber-to-treatneededtopreventoneSCDinprimary mortality benefit may be less clear in contemporary patients with
prevention. non-ischaemicheartfailure(seeSection7.1.3.1).359
A patient-level meta-analysis of the three early ICD
trials349–351
Inthework-upforICDtherapy,itisofparamountimportanceto
comparing ICD to medical therapy for secondary prevention of considerthepatient’slifeexpectancy,qualityoflife,andcomorbidities,
SCD demonstrated a 28% mortality reduction (HR 0.72; 95% CI andtoreassessanddiscusstheseissueswiththepatientatthetimeof
0.6–0.87;P=0.0006)almostentirelyduetoreductionofarrhythmic generatorchange.Thereisevidencethatpatientswithend-stagerenal
death(HR0.5;95%CI0.37–0.67;P,0.0001)intheICDgroup.352 disease,withdiabetes,andelderlypatientsbenefitlessornotatallfrom
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4039
Patientrequiring a drug associated with QT prolongationa
Assessment of patient
risk profilebefffore initiation
Long QT syndrome or
Y Contraindicated:: Do not initiate treatment
baseline QTc >500 msb
N
Hypokalaemia/hypomagnesaemia/
Renal failure/liver failure/
LLLV hypertrophy/ Y Start drug if strong indication with closefffollow-up
Heart failure/
Additional QT prolonging drug
N
Initiate treatment
ECG at baseline,, after 1 daaay and after1–2
weeks of initiation or increase in dosagec
Consider to change to difffffferent drug
QTc >500 ms Y If strong indication,, consider to reduce dose
Consider to assess drug serum level
Continue treatment
Inffform patient about warning symptoms (syncope)
N
Control changes inrenal and hepatic function
Be aaaware of potential drug interactions
Figure13Algorithmforevaluationbeforeinitiationandfollow-upofpatientsrequiringdrugsassociatedwithQTprolongation.ECG,electrocardio-
gram;LV,leftventricular;N,No;Y,Yes.a
tothe2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillation.348
aprimarypreventionICD.357,360–362Womenhavebeenunderrepre-
Complications of ICD therapy include inappropriate therapies,
sentedinallprimarypreventiontrialsanddatasuggestthattheymay leadfractures,anddevice-relatedinfections.Asubcutaneousimplan-
benefitless.361In general,the SCD riskneedstobeweighed against tablecardioverterdefibrillator(S-ICD)hasbeenintroducedtoad-
theindividual’scompetingriskofanon-arrhythmicdeath.363,364 dress problems related to transvenous leads. S-ICD has no
Inthecontextofpatient-centredmedicine,physiciansandhealth- intravascular lead and therefore cannot deliver ATP. In the
careprofessionalsshouldengageICDcandidatesandrecipientsina PRAETORIANtrial,849patientswithanICDbutnopacingindica-
jointdecisionprocess.Communicationofrelevantinformation,en- tionwererandomizedtoanS-ICDoratransvenousICD.366Overa
suringagoodunderstandingofthebenefits,risks,andpotentialcon- meanfollow-upof49months,non-inferioritywasshownforthepri-
sequencesofdifferentoptions,toenablethepatienttopartakein mary endpoint of device-related complications and inappropriate
decision-makingismandatory.Thisshareddecision-makingprocess shocks. The rate of inappropriate shocks was 9.7% in the S-ICD
shoulddiscussthedifferentscenariosincludingprimaryprevention group and 7.3% in the ICD group (HR 1.43; 95% CI 0.89–2.30)
ICD implantation, consideration of ICD generator replacement, andtherateofdevicerelatedcomplicationswas5.9%intheS-ICD
andend-of-lifecare.Importantly,theperceptionof‘goodqualityof and 9.8% in the ICD group (HR 0.69; 95% CI 0.44–1.09). There
life’ depends on numerous factors that are weighed differently by wasalsonodifferenceinthesecondaryendpointofdeathandappro-
people with different cultural, religious, and socioeconomic back- priate shocks, but the trial had not been powered to show non-
grounds. Although clinical prediction scores, such as the inferiorityforthissecondaryendpoint.Ofnote,morethan80%of
MADIT-ICDbenefitscore,365mayprovidehelpfuladditionalinfor- theincludedpatientswereinNYHAclassIandIIandtheincluded
mation,clinicaldecision-makingshouldnotonlyrelyonsuchscores. patientswereyoungerthaninpriorICDtrials.
Downloaded
from

by
guest
on
22
January
2026

4040 ESCGuidelines
RecommendationTable11—Recommendationsfor 6.2.2.2.Addingcardiacresynchronizationtherapy2
implantable cardioverter defibrillator implantation Cardiacresynchronizationtherapy(CRT)doesreducemortalityin
(generalaspects) heart failure,367 and careful evaluation of the potential benefit of
CRTinpatientswithICDindicationbeforeimplantationismanda-
Recommendations Classa Levelb
tory.2 The role of the addition of a defibrillator is less well estab-
Implantationofacardioverterdefibrillatorisonly lished.368,369 The ongoing randomized controlled RESET-CRT trial
recommendedinpatientswhohavean I C aimstodeterminetheimpactofCRT-defibrillatoronoverallmortal-
expectationofgoodqualitysurvival.1year. ityandSCDinheartfailurepatientswithaCRTindication.
ItisnotrecommendedtoimplantanICDin
patientswithincessantVAsuntiltheVAis III C
RecommendationTable14—Recommendationsfor
controlled.
addingcardiacresynchronizationtherapytoimplanta-
ICD,implantablecardioverterdefibrillator;VA,ventriculararrhythmia.
blecardioverterdefibrillator
aClassofrecommendation.
bLevelofevidence. Recommendations Classa Levelb
WhenanICDisindicated,itisrecommendedto
evaluatewhetherthepatientcouldbenefitfrom I C
RecommendationTable12—Recommendationsfor CRT-defibrillator.367
secondarypreventionofsuddencardiacdeath*
CRT,cardiacresynchronizationtherapy;ICD,implantablecardioverterdefibrillator.
aClassofrecommendation.
Recommendations Classa Levelb bLevelofevidence.
ICDimplantationisrecommendedinpatients
withdocumentedVForhaemodynamically 6.2.2.3.Wearablecardioverterdefibrillator
I A
not-toleratedVTintheabsenceofreversible Thewearablecardioverterdefibrillator(WCD)isanexternaldefib-
causes.349–352
rillatorthathasbeenshowntosuccessfullydetectandtreatVTand
InpatientswithVT/VF,anindicationforICD,and VF.370Itisthereforesuitableforpatientswhoareatriskbuttempor-
nocontraindicationforamiodarone,amiodarone arilynotcandidatesforanICDowing,forexample,toextractionof
maybeconsideredwhenanICDisnotavailable, IIb C an infected device and subsequent antibiotic treatment.371 An un-
contraindicatedforconcurrentmedicalreasons, solvedproblemistheprotectionofpatientsintheearlyphase(40
ordeclinedbythepatient. days)afteranMI.TheVESTtrialenrolled2302patientswithacute
InpatientswithSMVTorSPVT/VFtriggeredbya MIandanLVEF≤35%andrandomizedthemearlyina2:1fashion
PVCwithsimilarmorphologyandanindication toreceiveaWCDornotunderguideline-directedoptimalmedical
forICD,catheterablationmaybeconsidered treatment(OMT).372Afterafollow-upof90daystherewasnodif-
IIb C
whenanICDisnotavailable,contraindicatedfor ferenceintheprimaryendpointofarrhythmicdeath(1.6vs.2.4%;RR
concurrentmedicalreasons,ordeclinedbythe 0.67;95%CI0.37–1.21;P=0.18).Concernwasraisedregardingthe
patient. lowmedianweartimeof18h(IQR3.8–22.7).Themedianweartime
washigher(23.4h,IQR22.2–23.8)inarecentmulticentreregistry
ICD, implantable cardioverter defibrillator; PVC, premature ventricular complex;
afterstructuredpatienteducation.371However,basedontheavail-
SMVT,sustainedmonomorphicVT;SPVT,sustainedpolymorphicVT;VF,ventricular
fibrillation;VT,ventriculartachycardia. able data, the task force does not recommend routine use of the
*Forprimarypreventionandspecificaspectsofsecondaryprevention,gotoSection7.
WCDintheearlypost-MIphase.Nevertheless,theuseofthedevice
aClassofrecommendation.
bLevelofevidence. maybeconsideredinselectedpost-MIpatientsdeemedtobeathigh
riskforSCD.
DataonthebenefitoftheWCDforprimarypreventionofSCDin
otherclinical situations(e.g.acutemyocarditis, primary prevention
RecommendationTable13—Recommendationsfor indication during pregnancy) are sparse and no recommendations
subcutaneousimplantablecardioverterdefibrillator canbecurrentlymade.
Recommendations Classa Levelb
RecommendationTable15—Recommendationsfor
Subcutaneousdefibrillatorshouldbeconsidered wearablecardioverterdefibrillator
asanalternativetotransvenousdefibrillatorin
patientswithanindicationforanICDwhenpacing IIa B Recommendations Classa Levelb
therapyforbradycardia,cardiac
TheWCDshouldbeconsideredforadultpatients
resynchronization,orATPisnotneeded.366
withasecondarypreventionICDindication,who
IIa C
ATP,anti-tachycardiapacing;ICD,implantablecardioverterdefibrillator. aretemporarilynotcandidatesforICD
aClassofrecommendation. implantation.
bLevelofevidence.
Continued
2202CSE©
2202CSE©
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4041
TheWCDmaybeconsideredintheearlyphase Insingle-ordual-chamberICDpatients
IIb B
afterMIinselectedpatients.371,372 withoutbradycardiapacingindications,
I A
itisrecommendedtominimizeventricular
ICD,implantablecardioverterdefibrillator;WCD,wearablecardioverterdefibrillator.
aClassofrecommendation.
pacing.378–380
bLevelofevidence. Programmingofprolongeddetectionsettingsis
indicated(durationcriteriaofatleast6–12sor30 I A
6.2.3.Specialaspectsofdevicetherapy intervals).373,382,383
6.2.3.1.Optimizationofdeviceprogramming
Itisrecommendedtoprogramtheslowest
OptimizationofICDprogrammingisessentialtominimizethebur- tachycardiatherapyzonelimit≥188b.p.m.in I A
denofICDtherapyandtoimprovepatientoutcome.373–375Detailed
primarypreventionICDpatients.382,383
recommendations are available in expert consensus papers.376,377
InpatientswithSHD,programmingofatleastone
Bradycardia mode should be customized to prevent unnecessary
ATPtherapyisrecommendedinall I A
RVpacing,thusreducingheartfailurehospitalizationsandall-cause
tachyarrhythmiaszones.375,384,391
mortality378–380 ( ESC CardioMed chapter 43.21).381 A tachy-
ItisrecommendedtoprogramalgorithmsforSVT
cardiadetectionprogrammingstrategyincorporatingprolongedset-
vs.VTdiscriminationfortachycardiaswithrates I B
tingsandhighratethresholds(≥188b.p.m.AdvanceIIItrial,382≥200
upto230b.p.m.383–385
MADIT-RIT383)reducesICDtherapiesandall-causemortalitywith-
outincreasingtheriskofsyncope.373,382,383Theevidenceisstronger Itisrecommendedtoactivateleadfailure I B
alerts.397–399
for primary prevention compared to secondary prevention indica-
tions382 ( ESC CardioMed chapter 43.21).381 Consistent use Remotemonitoringisrecommendedtoreduce I B
theincidenceofinappropriateshocks.395
ofSVT/VTdiscriminatorseveninratesupto230b.p.m.isrecom-
mendedinICDrecipientswithoutcompleteheartblocktoreduce
ProgrammingofburstATPasfirstattemptis
I B
inappropriatetherapies.383–385Properatrialsensingisaprerequisite recommendedoverrampATP.392
for activation of dual-chamber discriminators376 ( ESC ForS-ICDs,adualdetectionzoneconfiguration
CardioMedchapter43.21).381Ingeneral,amulti-zonedetectionpro- isrecommendedwithactivationofdiscrimination
I B
grammingisfavouredtoenabletailoreduseofdetectionandtherapy algorithminthelowerconditionalshock
settingsatdifferenttachycardiarates.383,386Asingle-zoneprogram- zone.388–390
mingwithahighcut-offratemaybeconsideredinpatientswitha ForroutineICDprogramming,activationofmore
highlikelihoodofVFonly(e.g.primaryelectricaldiseases).387Insub- thanonetachycardiadetectionzoneshouldbe IIa B
cutaneous ICDs, a dual-zone configuration should be adopted. considered.383,386
Standardized programming including a lower ‘conditional shock’
ATP, anti-tachycardia pacing; ICD, implantable cardioverter defibrillator; SHD,
zone with activated discrimination algorithms and a higher ‘shock structuralheartdisease;S-ICD,subcutaneousICD;SVT,supraventriculartachycardia;
zone’basedonratecriteriaonlyhasbeenshowntoreduceinappro- VT,ventriculartachycardia.
priate shock rates without compromising patient
safety.388–390 aClassofrecommendation.
bLevelofevidence.
SystematicuseofATPbeforeshockdelivery,alsoforveryfastven-
triculartachyarrhythmias,hasbeenshowntoreduceshocktherapy
withoutincreaseinarrhythmicsyncope.375,384,391BurstATPispre-
6.2.3.2.Concomitanttreatmenttoavoidinappropriate
ferredoverrampduetoincreasedefficacyinfirsttachycardiater-
implantablecardioverterdefibrillatortherapy
mination.392 Incorporation of remote monitoring into follow-up
Apartfromoptimizationofdeviceprogramming,pharmacological
practiceofICDrecipientsshouldbepromotedtooptimizesurveil-
and/or invasive management may prevent inappropriate ICD
lanceof device integrity, to enableprompt detectionand manage-
therapy. Beta-blockers (carvedilol superior to metoprolol in
ment of actionable events, and to prevent occurrence of
MADIT-CRT) should be titrated to the maximal tolerated dose
inappropriate
shocks393–396
( ESC CardioMed chapter 43.
inheartfailurepatientstoreducetheriskofinappropriatether-
21).381 The proposed recommendations for optimal device pro- apy.400Inpatientswithinappropriatetherapiesduetorecurrent
gramming are applicable to the majority of ICD recipients. SVT,catheterablationshouldbefirst-linetreatment,givenitshigh
Customizationmaybeneededinindividualpatients. successandlowcomplicationrate.302,401–403IncaseofAF-related
inappropriate therapies, unresponsive to optimized pharmaco-
RecommendationTable16—Recommendationsfor
logical rate control treatment, individualized treatment strategy
optimizationofdeviceprogramming
(rate vs. rhythm) dependent on patient characteristics is sug-
gested.348InpatientswithearlyAF,adoptionofarhythmcontrol
Recommendations Classa Levelb
strategyimprovedpatientoutcomeintheEAST-AFNET4trial.404
OptimizationofICDprogrammingisindicatedto In CRT-defibrillator patients, AV node ablation has been asso-
avoidinappropriateandunnecessarytherapies I A ciatedwithreducedinappropriateICDshocksandlowerhospital-
andtoreducemortality.373–375 ization rates compared to drug treatment405 ( ESC
Continued CardioMedchapter41.14).406
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4042 ESCGuidelines
RecommendationTable17—Recommendationsfor 6.2.3.4.Patientswithleftventricularassistdevices
concomitant treatment to avoid inappropriate im- VAsarecommonamong leftventricularassistdevice(LVAD)car-
plantablecardioverterdefibrillatortherapy
riers.425–428VAsareusuallywell-tolerated,asLVADsmaintain
ad-
equate cardiac output and prevent circulatory collapse.429
Recommendations Classa Levelb
However,sustaineduntreatedVAsmayleadtocirculatorycollapse
CatheterablationisrecommendedforICD even inthe presence ofan LVAD, especiallyearly after device im-
patientswithrecurrentSVTresultingin I C plantation and in patients with higher pulmonary vascular resist-
inappropriateICDtherapies.401,402 ance.430VAspre-andpost-LVADimplantationareassociatedwith
Pharmacologicaltreatmentorcatheterablationis an increased risk of cardiovascular and all-cause mortality, while
recommendedinpatientswithAF-related
ICDcansignificantlyreducesustainedVA.425,426,431–434Thesedata
I C
inappropriateICDtherapiesdespiteoptimalICD supportICDimplantationforsecondarypreventioninLVADrecipi-
programming.401,405,407 entswithsymptomaticVA.
Observationalstudiesinpatientswithprevious-generation,pulsa-
AF,atrialfibrillation;ICD,implantablecardioverterdefibrillator;SVT,supraventricular
tile LVADs reported a longer survival with
ICD435–437
( ESC
tachycardia.
aClassofrecommendation. CardioMedchapter37.32).438
bLevelofevidence. Recent registries enrolling continuous-flow LVAD carriers have
questionedICDmortalityreduction,butavailabledataareinconsist-
ent.425,426,428,439,440AnanalysisoftheINTERMACSregistry,enrol-
6.2.3.3.Psychosocialimpactofimplantablecardioverter ling the largest continuous-flow LVAD cohort, showed that ICD
defibrillatortreatment presence was not associated with prolonged survival.428 The lack
Almost 20% of ICD recipients suffer from anxiety and depression
ofdocumentedsurvivalbenefitamongcontinuous-flowLVADcar-
thatareassociatedwithincreasedmortality.408–411InICDpatients, riers,inconjunctionwiththelikelihoodofVAtoleranceandtheas-
psychologicaldistressismainlycausedbytheconcernofpotentially sociatedrisksofICDplacementinthesepatients(riskofinfection,
receiving ICD shocks rather than by having experienced an ICD deviceinteraction),favoursanindividualizedapproach.
shock.412,413 Thus, assessment of ICD concerns is recommended
in all ICD patients before ICD shocks occur. Systematic screening RecommendationTable19—Recommendationsfor
ofICDpatientsforpsychologicaldistressisfeasiblewiththeuseof implantablecardioverterdefibrillatorimplantationin
specificquestionnaires.413–416 leftventricularassistdevicerecipients
A significant proportion of ICD patients with clinically relevant
symptoms of anxiety and depression remains undertreated.417 Recommendations Classa Levelb
CommunicationwithallICDrecipientsisneededtoclarifymiscon- ICDimplantationshouldbeconsideredinLVAD
IIa B
ceptionsaboutthedevicefunction,todiscussconcernsaboutsexual recipientswithsymptomaticsustainedVAs.425,431
functioning,drivingrestrictions,andtorecommendanactionplanin
caseofshocktherapy.418,419Referraltomentalhealthprofessionals
ICD,implantablecardioverterdefibrillator;LVAD,leftventricularassistdevices;VA,
ventriculararrhythmia.
maybeneededforspecificinterventions.418,420Cognitivebehaviour- aClassofrecommendation.
al therapy intervention may also be provided by trained cardiac bLevelofevidence.
nurses to alleviate anxiety.421 Web-based interventions may also
prove useful in improving psychosocial well-being in ICD patients
6.2.3.5.Complicationsofdevices
withincreasedpsychosocialdistress.422
PreventionofICDcomplicationsisimportanttoreduceassociated
morbidity,mortality,andfinancialburden.Duringimplantationofde-
RecommendationTable18—Recommendationsfor
vices, antibiotic prophylaxis, peri-procedural patient preparation,
psychosocial management after implantable cardio-
andappropriatesurgicaltechniqueshouldbeimplementedtopre-
verterdefibrillatorimplantation
vent device infections and formation of pocket
haematoma.441–443
Recommendations Classa Levelb Cephalic or axillary vein access is preferred over the subclavian
vein route to reduce the risk of pneumothorax and lead fail-
Assessmentofpsychologicalstatusand ure.444–446
Proper selection of ICD systems is important.
treatmentofdistressisrecommendedinICD I C
Single-chamberICDsarerecommendedinprimarypreventionpa-
patients.421–423
tientswithoutatrialorAVsequentialpacingindications.Thisreduces
Communicationbetweenpatientandphysician/ peri-proceduralcomplicationsandgeneratorreplacementsascom-
healthcareprofessionalisrecommendedto paredtodual-chamberICDs.Thisapproachdoesnotincreasethe
addressICD-relatedconcernsandtodiscuss I C risk of inappropriate shocks if optimal device programming is
quality-of-lifeissuesbeforeICDimplantationand used.447–450Routineuseofsingle-coildefibrillatorleadsisfavoured
duringdiseaseprogression.412,424
duetoreducedriskofcomplicationsduringleadremovalwithoutas-
ICD,implantablecardioverterdefibrillator.
sociateddifferencesinshockefficacy.451,452Useofdual-coilleadscan
aClassofrecommendation. beconsideredinclinicalsettingswhereahigherdefibrillatorthresh-
bLevelofevidence. oldissuspected,e.g.HCM,right-sidedimplantations.453,454
2202CSE©
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4043
RecommendationTable20—Recommendationsfor SHD.466–468However,ICDsdonotpreventVA,andmanyofthese
prevention of implantable cardioverter defibrillator patientswillexperiencesymptomaticVT/VFrecurrencesresultingin
complications
syncope or ICD shocks and may require additional treat-
ment.330,383,419,469–471
Recommendations Classa Levelb
InpatientswithSHD,thechoiceofanti-arrhythmicagentsismost-
Single-chamberICDisrecommendedover lylimitedtobeta-blockers,sotalol,andamiodaronetohelpcontrol
dual-chamberICDinprimarypreventionpatients VT/VF recurrences, and this treatment is frequently hampered by
withoutcurrentorexpectedindicationforatrial I A sideeffects.318,472
orAVsequentialpacingduetoalowerriskof Owingtoadvancesmadeoverthelastthreedecades,catheter
device-relatedcomplications.447,448,450 ablation has become increasingly important for the management
Theuseofsingle-coilleadsoverdual-coilICD ofscar-relatedVTs.473Sincetheearly1990s,catheterablationof
leadsshouldbeconsideredduetolower
BBR-VThasbeenverysuccessful474–477andisconsideredasfirst-
IIa C complicationrateduringtransvenouslead line therapy466,467 (Figure 5). Subsequently, catheter ablation has
extraction.451 been shown to be very effective in controlling incessant VTs or
electrical storms330,331 and in reducing subsequent VT burden.
AV,atrioventricular;ICD,implantablecardioverterdefibrillator.
aClassofrecommendation. ManyobservationalstudieshaveshownapositiveeffectofVTab-
bLevelofevidence. lationonclinicaloutcomeintermsofVTrecurrences.478–483Inpa-
tientswithCAD,threerandomizedtrials471,484,485havereported
that catheter ablation, compared to conventional treatment, de-
6.2.3.6.End-of-lifeissues
creasesthelikelihoodofsubsequentICDshocksandpreventsre-
PatientswithactiveICDsexperienceaconsiderablerateofshocksin
currentVTepisodes.
thelastphaseoflife.455Interminallyillpatientsandattheendoflife,
Thecriticalpartofre-entrantVTcircuits,referredtoasthe‘pro-
healthcareprofessionalscanfacilitateadecisionbythepatientand
tectedVTisthmus’,istheprimarytargetforablation,460,486butitis
the patient’s family by explaining in a sensitive and understandable
very challenging to unmask in haemodynamically not-tolerated
manner the benefits and burdens of continued ICD therapy.456
VT.487,488Duetothehighlikelihoodofmultiplere-entrycircuitsin
PatientsshouldbeinformedabouttheoptionsofICDdeactivation.
a scar and difficulties in identifying critical isthmuses, the ablation
Ingeneral,deactivationofanti-bradycardiatherapyisdiscouragedto
strategy has gradually evolved over the years towards more ex-
avoidquality-of-lifeimpairment,andinsomecountriesdeactivation tendedablationofthearrhythmogenicsubstrate.489–492Specialat-
in pacemaker-dependent patients may be prohibited by law.457
tention should be paid to cases of PVT/VF initiated by similar
Deactivation should be discussed before device implantation and
PVCs,wherethetriggeringPVC(oftenrelatedtothePurkinjenet-
whenthereissignificantdeteriorationofthepatient’shealthstatus.
work)shouldbetargetedforablation.221,332,333,493
Despiteanincreasingtrendtoaddressandperformdevicedeactiva-
TheelectrophysiologicalcharacteristicsofVTcircuitsdependon
tion after careful consideration, current rates are still low and im-
the underlying SHD. Thus, post-infarct VTs are mainly related to
provedpatientcareisneeded.458,459
anendocardialVTcircuit(amenabletoendocardialablation),while
the location of re-entrant VT circuits is more variable in patients
RecommendationTable21—Recommendationsfor withcardiomyopathies.494–496Here,intramuraland/orepicardialin-
end-of-lifeissuesinimplantablecardioverterdefibril- volvementaremorecommon.Thissignificantlycontributestothe
latorcarriers differenceintheclinicaloutcomesofVTablationinrelationtothe
underlyingheartdiseasewithabetteroutcomeinCADascompared
Recommendations Classa Levelb tonon-ischaemicaetiologies.497–499
Informeddiscussionwithpatientandfamilyabout Effectiveablationrequiresdurableablationlesionstoarrhythmo-
ICDdeactivationoptionsandshared genictissue.Insomecases,suchasintramuralVTs,difficultiesremain
decision-makingisindicatedpriortoimplantation I C inachievingthisobjectivewithcurrentcatheters,regardlessofthe
andincaseofsignificanthealthstatus approach (endocardial/epicardial).500 To improve the formation of
deterioration.458 myocardiallesions,newcatheter-basedtechniquesarebeingevalu-
ated (e.g. bipolar/needle ablation, transcoronary alcohol abla-
I aC CD las, sim op fl ra en ct oab mle mc ea nr dd aio tiv oe nr .terdefibrillator. tion),501–506 as well as radiotherapy ablation507,508 or surgical
bLevelofevidence. ablation,509whicharecurrentlybailouttreatments.
WhenplanningVTablation,itisimportanttocollectallavailable
informationaboutthearrhythmogenicsubstrate,especiallytoiden-
6.2.4.Interventionaltherapy tifyscars(usingCMRorCTscan),510–514andtohelpdeterminethe
6.2.4.1.Catheterablation exitsiteofVAswiththe12-leadECGdocumentationofclinicalVTs
6.2.4.1.1. Patientswith structuralheart disease. Inpatientswith orPVCsthatinducePVT/VF.
SHD, SMVTs are primarily due to a scar-related re-entrant The mean long-term success rate of VT ablation varies from
mechanism.460–465
30% to 70%, depending on the underlying
SHD.481,515–518
Because of a higher risk of SCD, an ICD implantation is usually Peri-proceduralcomplications,inparticularstroke,cardiactampon-
recommended in patients with sustained VAs associated with
ade,ordeath,mayoccur.519–522
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4044 ESCGuidelines
6.2.4.1.2. Patients without apparent structural heart disease. STEMI and non-STEMI.69,546 In addition, an early repolarization
‘Idiopathic VTs’ is the term for VTs that are not associated with pattern has been associated with increased risk of VAs and
SHD or a genetic arrhythmic syndrome. Most idiopathic VTs are SCD in ACS.547
mediatedbytriggeredactivity,butare-entrantmechanism(involving
the LV Purkinje network) explains verapamil-sensitive fascicular Prevention of ventricular arrhythmias in ST elevation myocardial
VTs.523 Three important key features distinguish idiopathic VTs infarction
fromVTsassociatedwithSHD.First,idiopathicVTsmostlyoriginate Urgentreperfusionisthemostimportanttherapy,292,548asacute
fromasinglesiteandspecificregionoftheheart(namelytherightor ischaemia triggers arrhythmias. Beta-blocker treatment is also
left ventricular outflow tracts,524,525 along the valve annuli,526–528 recommendedtopreventVA.3,549Inarecentrandomizedtrialofpa-
papillarymuscle,529ortheLVPurkinjenetwork).523Second,node- tients with STEMI, early intravenous metoprolol before percutan-
tectablescarisfoundinidiopathicVTs.530Finally,idiopathicVTshave eous coronary intervention reduced the incidence of arrhythmias
a benign prognosis so that ICD implantation is generally not intheacutephaseandwasnotassociatedwithanincreaseinadverse
recommended.466 events.550ProphylactictreatmentwithAADshasnotprovenbene-
TheearliestsiteofactivationduringVTistheablationtargetfor ficial,andmayevenbeharmful.322Correctionofelectrolyteimbal-
focalsources,whileabnormalPurkinjetissue(withdiastolicactivity ancesisstronglyrecommended.289
duringVT)istheablationtargetofleftfascicularVTs.531,532
Catheter ablation is curative in most idiopathic VT patients and Managementofsustainedventriculartachycardiaandventricular
peri-proceduralcomplicationsarerare.533–537 fibrillationinacutecoronarysyndrome
Electrical cardioversion or defibrillation is the intervention of
choicetoacutelyterminateVAsinACSpatients(Figure14).205,339
6.2.4.2.Autonomicmodulation
RecurrentsustainedVT,especiallywhenpolymorphic,orrecurrent
Theroleoftheautonomicnervoussysteminpromotingarrhythmias
haslongbeenrecognized,leadingtotheconceptofCoumel’striangle VF can indicate incomplete reperfusion or recurrence of acute is-
chaemia.Inthiscase,immediatecoronaryangiographyisindicated.3
ofarrhythmogenesis.538
ForrecurrentPVTdegeneratingintoVF,beta-blockersarerecom-
Sympathetic activation has been demonstrated as playing a key
mended.551,552Inaddition,deepsedationmaybehelpfultoreduce
roleininducingVAsinsomeentities,suchascongenitalLQTSand
episodesofVTorVF.553Intravenousamiodaroneshouldbeconsid-
CPVT,539,540andleftcardiacsympatheticdenervationwasshown
eredtoacutelysuppressrecurrenthaemodynamicallyrelevantVAs,
tobeassociatedwithadecreaseinthefrequencyofarrhythmo-
genic syncope in congenital LQTS.541,542 The efficacy of cardiac althoughthereisapaucityofcontrolledstudiesforamiodaronedur-
ingSTEMI554andtheevidenceinthissettingismainlyextrapolated
sympathetic blockade by different approaches (thoracic epidural
fromstudiesofOHCA.555Iftreatmentwithbeta-blockersandamio-
anaesthesia,percutaneousstellateganglionanaesthesia,orsurgical
daroneisnoteffective,lidocainemaybeconsidered.322Theuseof
stellate ganglion resection) in reducing the arrhythmia burden in
otherAADsinACSisnotrecommended.549,556Inhaemodynamic-
refractoryVT/VFhasbeenrecognizedinseveralsmallobservation-
allyunstablepatientswithrefractoryVA,mechanicalcirculatorysup-
alstudies.326,328,340Furtherstudiesareneededtoassesswhichpa-
tients may benefit from a modulation of the autonomic nervous port may be considered.336,557 For VA in the context of relative
bradycardia or pause-related, pacing may be effective to prevent
systemtobettercontrolVT/VF.
re-initiation.
7. Diagnostic evaluation, Theprognosticsignificanceofearlyventriculararrhythmias
Early VAs are defined as VT/VF occurring within 48h after a
management, and risk
STEMI. In the contemporary percutaneous coronary intervention
fi strati cation according to clinical (PCI)-basedrevascularizationera,almostallVAoccurwithinthefirst
presentation and known (likely)
24h.558EarlyVAhavebeenassociatedwithanuptosix-foldincrease
inin-hospitalmortality,whereaslong-termprognosisseemsnotto
disease
besignificantlyaffected.543,559,560Inaprospectivecohortstudy,pa-
tientswithVFduringtheacuteSTEMIphasehadlowandverysimilar
7.1. Specific structural heart diseases
incidence of late SCD as compared with VF-free patients during
7.1.1.Coronaryarterydisease 5-year observation.560 Of note, early monomorphic VT was asso-
7.1.1.1.Acutecoronarysyndromesandvasospasm ciatedwithsignificantlyhigherincidenceofadequateICDinterven-
7.1.1.1.1. Acute coronary syndromes. SCD is a major cause of tions compared with early VF, and was an independent predictor
mortality in ACS, mostly caused by sustained VAs, in particular ofdeathduringlong-termfollow-up.561Thus,theprognosticsignifi-
VF. The majority of studies have reported on patients with canceofVTandVFoccurringintheacutephaseofMImaybediffer-
STEMI. Of patients with STEMI, 4–12% develop VA within the ent.TheimpactofVAoccurringlateafterreperfusion(.48h)on
first 48h after the onset of symptoms.69,543,544 Pre-reperfusion lateSCDislessclear.
VAs are more common than reperfusion-induced or post- Podoleckietal.559recentlydemonstratedthatlong-termall-cause
reperfusion arrhythmias in STEMI.545 Haemodynamic instability, mortalityafterSTEMIwaspredictedbyVAoccurringlateafterre-
cardiogenic shock, LVEF,40%, and the sum of ST-segment de- perfusion (.48h after reperfusion), while early reperfusion VAs
viations in all leads are independent predictors of VA both in didnotaffect5-yearoutcome.Furtherstudiesarerequiredtoclarify
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4045
Prevention and treatment of VAs in the acute phase of STEMI
Beta-blocker i.v.priortoPCI,ifnot contraindicateda,b
(ClassIIa)
Urgent CAG and revascularizationa
(Class I)
VA
Further revascularization if appropriatea
(Class I)
Repletion of K+, Mg2+ a
(Class I)
Beta-blocker i.v.b
(Class I)
Sedation (for comfort)c
(Class I)
Recurrent VA
Amiodarone i.v.
(Class IIa)
Lidocaine i.v.
(Class IIb)
Deep sedation/intubationc
(Class IIb)
Recurrent VA
Catheter ablationd
(Class IIa)
Overdrive pacinga
(Class IIa)
Autonomic modulationc
(Class IIb)
Mechanical circulatory supportc
(Class IIb)
Figure14AlgorithmforthepreventionandmanagementofventriculararrhythmiasinST-elevationmyocardialinfarction.CAG,coronaryangiogram;PCI,
percutaneouscoronaryintervention;STEMI,ST-elevationmyocardialinfarction;VA,ventriculararrhythmias.aThe2017ESCGuidelinesforthemanagementof
acutemyocardialinfarctioninpatientspresentingwithST-segmentelevation.3bIntravenousbeta-blockersmustbeavoidedinpatientswithhypotension,acute
heartfailure,AVblockorseverebradycardia.cFlowchartforthemanagementofelectricalstorm.dIfsimilarPVCtriggersrecurrentpolymorphicVA.
theimpactofVAoccurring.48hafterSTEMIonlateSCDincon- 7.1.1.1.2.Vasospasm. Coronaryarteryspasmsmighthaveanim-
temporarypatientsundergoingacutePCI. portant role in the pathogenesis of VA. The long-term prognosis
Downloaded
from

by
guest
on
22
January
2026

4046 ESCGuidelines
RecommendationTable22—Recommendationsfor far in randomized studies. The PROTECT-ICD randomized trial
treatmentofventriculararrhythmiasinacutecoron- (NCT03588286) is currently examining whether PES may guide
arysyndromeandvasospasm
the decision on ICD implantation in patients with reduced EF in
the early phase after STEMI.
Recommendations Classa Levelb
Reverse remodelling following an MI is associated with signifi-
TreatmentofVAsinACS cantly lower rates of death, SCA, and other adverse clinical out-
comes.573,574 Therefore, assessment of the indication for
Intravenousbeta-blockertreatmentisindicated
forpatientswithrecurrentPVT/VFduringSTEMI I B prophylactic ICD implantation, usually performed by repeat echo-
unlesscontraindicated.551,552 cardiography, should take place in the post-remodelling phase of
the MI after the first 6 weeks in patients with a pre-discharge
Intravenousamiodaronetreatmentshouldbe
LVEF ≤40%. Reassessment of the LVEF before 6 weeks following
consideredforpatientswithrecurrentPVT/VF IIa C
MI may not discriminate between myocardial stunning and
duringtheacutephaseofACS.552,554,555
remodelling.
Intravenouslidocainemaybeconsideredforthe
In the early post-MI phase, electrical storm and/or recurrent
treatmentofrecurrentPVT/VFnotrespondingto
IIb C episodes of PVT or VF are immediately life-threatening condi-
beta-blockersoramiodarone,orifamiodaroneis
tions. In this setting, it is important to exclude ischaemia as
contraindicatedduringtheacutephaseofACS.554
the triggering factor for the arrhythmias. If medical treatment
ProphylactictreatmentwithAADs(otherthan III B is not sufficient to suppress the arrhythmic episodes, catheter
beta-blockers)isnotrecommendedinACS.322
ablationispotentiallyeffectiveparticularlyiftheepisodesarefo-
Vasospasm callytriggeredbysimilarPVCs.332,575IfPVTrecursdespitebeta-
InSCAsurvivorswithcoronaryartery blocker and amiodarone treatment, suppression by quinidine
spasm,implantationofanICDshouldbe IIa C therapy has been reported.323
considered.562–564
AAD,anti-arrhythmicdrug;ACS,acutecoronarysyndrome;ICD,implantablecardioverter
defibrillator;PVT,polymorphicventriculartachycardia;SCA,suddencardiacarrest;
STEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF,
RecommendationTable23—Recommendationsfor
ventricularfibrillation. risk stratification and treatment of ventricular ar-
aClassofrecommendation. rhythmiasearlyaftermyocardialinfarction
bLevelofevidence.
Recommendations Classa Levelb
Riskstratification
of patients with variant angina who survive a CA is worse than in Early(beforedischarge)assessmentofLVEFis
I B
other patients with variant angina.562,563 In a recent multicentre recommendedinallpatientswithacuteMI.567,568
European survey,564 patients with life-threatening VAs secondary Inpatientswithpre-dischargeLVEF≤40%,
tocoronaryvasospasmwereathighriskforrecurrence,especially re-evaluationofLVEF6–12weeksafterMIis
wheninsufficientmedicaltherapywasadministered.Whilecalcium I C
recommendedtoassessthepotentialneedfor
channelblockers(CCB)arecapableofsuppressingepisodes,beta- primarypreventionICDimplantation.568,573,574
blockersmaytriggerVAs.Asmedicalinterventionandmultiplevaso-
TreatmentofVAs
dilatordrugsmaynotbesufficientlyprotective,placementofanICD
Catheterablationshouldbeconsideredinpatients
shouldstillbeconsideredinSCAsurvivorswithvariantangina.
withrecurrentepisodesofPVT/VFtriggeredbya
similarPVCnon-responsivetomedicaltreatment IIa C
7.1.1.2.Earlyaftermyocardialinfarction
orcoronaryrevascularizationinthesubacute
The first weeks after a STEMI carry the highest risk both for all- phaseofMI.332
cause death and for SCD, particularly in patients with reduced
LVEF.565,566 For this reason, early assessment of LVEF, i.e. before
ICD,implantablecardioverterdefibrillator;LVEF,leftventricularejectionfraction;MI,
myocardial infarction; PVC, premature ventricular complex; PVT, polymorphic
discharge, is recommended.567,568 Early routine prophylactic ICD ventriculartachycardia;VA,ventriculararrhythmia;VF,ventricularfibrillation.
implantation in the first 40 days after MI did not reduce mortality aClassofrecommendation.
bLevelofevidence.
in post-MI patients with reduced LVEF in two randomized trials
(DINAMIT and IRIS),569,570 and is therefore not recommended.
Early assessment by further non-invasive tests, apart from LVEF
measurement, has also not proven to be useful for risk stratifica- 7.1.1.3.Chroniccoronaryarterydisease
tionwithregardtoSCD.571Limitedevidencesuggeststhatinvasive 7.1.1.3.1.Primarypreventionofsuddencardiacdeathinpatients
riskstratificationbyPESintheearlypost-MIphasemaybehelpful with reduced ejection fraction. Forty days after STEMI, approxi-
for identification of high-risk patients with reduced LVEF.572 mately 5% of patients will have an LVEF ≤35%.576 These patients
However, the utility of this approach has not been confirmed so are at risk for SCD. Therefore, in patients with LVEF ≤35% and
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4047
heart failure symptoms NYHA class II and III, primary preventive Theadditionoforalamiodaroneor
ICD implantation is recommended.356 ICD implantation should beta-blockerreplacementbysotalolshouldbe
alsobeconsideredforasymptomaticpatientswithanEF≤30%.354
consideredinpatientswithCADwith
IIa B
In this population, mortality reduction by an ICD has been recurrent,symptomaticSMVT,orICDshocks
demonstrated in four
RCTs.353–356
In patients with CAD, a forSMVTwhileonbeta-blocker
reduced LVEF (≤40%), and asymptomatic NSVT, inducibility by treatment.318,581
PES identifies patients who benefit from an ICD, independent
InpatientswithCADandhaemodynamically
fromNYHAclass.355
well-toleratedSMVTandLVEF≥40%,catheter
Sincethepublicationoftheaforementionedtrials,earlyrevascu- ablationinexperiencedcentresshouldbeconsidered IIa C
larization strategies and modern heart failure medication have re-
asanalternativetoICDtherapy,providedthat
ducedtheoverallriskofSCDinheartfailurepatients.577Although
establishedendpointshavebeenreached.c,480,580
total mortality has been reduced, the relative reduction by the
ICDimplantationshouldbeconsideredinpatients
ICD is a consistent 27%, which has been corroborated in two
withahaemodynamicallytoleratedSMVTandan
recent large prospective registry studies enrolling 2327 European LVEF≥40%ifVTablationfails,isnotavailable,oris IIa C
patients between 2014 and 2018 (EU-CERT-ICD)357 and 2610
notdesired.
Swedish patients enrolled between 2000 and 2016 (SwedeHF
Catheterablationshouldbeconsideredinpatients
registry).358
withCADandrecurrent,symptomaticSMVT,or
IIa C
ICDshocksforSMVTdespitebeta-blockersor
sotaloltreatment.471
InpatientswithCADeligibleforICDimplantation,
RecommendationTable24—Recommendationsfor catheterablationmaybeconsideredjustbefore(or IIb B
risk stratification, sudden cardiac death prevention, immediatelyafter)ICDimplantationtodecrease
and treatment of ventricular arrhythmias in chronic subsequentVTburdenandICDshocks.484,485,582,583
coronaryarterydisease
AAD, anti-arrhythmic drug; CAD, coronary artery disease; ICD, implantable
cardioverter defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial
Recommendations Classa Levelb
infarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart
Association;OMT,optimalmedicaltherapy;PES,programmedelectricalstimulation;
RiskstratificationandprimarypreventionofSCD
SCD,suddencardiacdeath;SMVT,sustainedmonomorphicventriculartachycardia;
STEMI,STelevationmyocardialinfarction;VA,ventriculararrhythmia;VF,ventricular
InpatientswithsyncopeandpreviousSTEMI,PES
fibrillation;VT,ventriculartachycardia.
isindicatedwhensyncoperemainsunexplained I C aClassofrecommendation.
afternon-invasiveevaluation.146,584 bLevelofevidence.
cVTnon-inducibilityandeliminationofelectrogramsconsistentwithconductiondelay.
ICDtherapyisrecommendedinpatients
withCAD,symptomaticheartfailure(NYHA
I A
classII–III),andLVEF≤35%despite≥3months
ofOMT.354,356 7.1.1.3.2.Primarypreventionofsuddencardiacdeathinpatientswith
preservedormildlyreducedejectionfraction. Therearenodatasup-
ICDtherapyshouldbeconsideredinpatientswith
CAD,NYHAclassI,andLVEF≤30%despite≥3 IIa B porting primary prophylactic ICD implantation in post-infarct pa-
monthsofOMT.354 tients with preserved or mildly reduced LVEF. These patients are
heterogeneouswithregardtotheirpotentialarrhythmicsubstrate,
ICDimplantationshouldbeconsideredinpatients
and efforts are under way to identify those with the highest risk
withCAD,LVEF≤40%despite≥3monthsof
IIa B forSCD.PESisrecommendedinpost-infarctpatientsinwhomsyn-
OMT,andNSVT,iftheyareinducibleforSMVTby
coperemainsunexplainedafternon-invasiveevaluationtoguidepa-
PES.355
tientmanagement(Figure15).146
InpatientswithCAD,prophylactictreatment
InthePRESERVE-EFstudy,41of575post-infarctpatientswithan withAADsotherthanbeta-blockersisnot III A
LVEF≥40%andonenon-invasiveECGriskfactormorethan40days
recommended.556,578,579
post-MIwereinducibleforVT/VFduringPESandreceivedanICD.151
SecondarypreventionofSCDandtreatmentofVAs
Duringthe32-monthfollow-upperiod,noSCDoccurredand9of
ICDimplantationisrecommendedinpatients 37 ICD patients received an appropriate ICD therapy. However,
withoutongoingischaemiawithdocumentedVF theroleofappropriateICDtreatmentassurrogateforSCDinpa-
I A
orhaemodynamicallynot-toleratedVToccurring tients with preserved LVEF is unknown, and randomized trials are
laterthan48hafterMI.349–351
needed.ProphylactictreatmentwithAADsotherthanbeta-blockers
InpatientswithCADandrecurrent,symptomatic isnotindicatedregardlessoftheLVEF.556,578,579
SMVT,orICDshocksforSMVTdespitechronic
amiodaronetherapy,catheterablationis I B
recommendedinpreferencetoescalatingAAD 7.1.1.3.3. Secondary prevention of sudden cardiac death. The
therapy.471 three pivotal secondary prevention ICD trials enrolled 1866 pa-
Continued tients between 1990 and
1997.349–351
A patient-level
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4048 ESCGuidelines
Patient with chronic CAD
LLLVEF evaluation 6–12weeks after acute MI
in patients with LLLVEF ≤40% at discharge
(Class I)
LLLVEF36–40% LLLVEF ≤35%
N NSVT or NYHA class ≥II Y
unexplained syncope
ICD
Follow-up Y N (Class I)
PES
N LLLVEF ≤30% Y
(ClassI)
No SMVT inducible
SMVT inducible
and unexplained syncope
ILR implantationa ICD implantation ICD implantation
(Class I) (Class IIa) (Class IIa)
Figure15Algorithmforriskstratificationandprimarypreventionofsuddencardiacdeathinpatientswithchroniccoronaryarterydiseaseandreduced
ejectionfraction.CAD,coronaryarterydisease;ICD,implantablecardioverterdefibrillator;ILR,implantablelooprecorder;LVEF,leftventricularejection
fraction;MI,myocardialinfarction;N,No;NSVT,non-sustainedventriculartachycardia;NYHA,NewYorkHeartAssociation;PES,programmedelectrical
stimulation;SMVT,sustainedmonomorphicventriculartachycardia;Y,Yes.aThe2018ESCGuidelinesforthediagnosisandmanagementofsyncope.1
meta-analysisdemonstrateda28%mortalityreduction(HR0.72; 90%oftheclinicaland58%ofallinducibleVTs.Subsequently,42%of
95% CI 0.60–0.87; P=0.0006) almost entirely due to reduction thepatientsreceivedanICD.Afterameanfollow-upof3.8years,
of arrhythmic death (HR 0.50; 95% CI 0.37–0.67; P,0.0001) in 42% of the patients died irrespective of the presence or absence
the ICD group.352 This translates to an extension of survival of ofanICD(P=0.47).
4.4 months over a mean follow-up of 6 years by the ICD. Alargermulticentreretrospectivestudylookedat166patients
Around 80% of the study population suffered from CAD. withanLVEF.30%presentingwithwell-toleratedSMVT,which
Patientswithwell-toleratedSMVTwereexcludedfromsecondary were treated by catheter ablation only, and compared the out-
preventiontrials(Figure16). come to a control group of 378 patients implanted with an
ICD.480Ofthe166patientsundergoingablationasfirst therapy,
7.1.1.3.4.Managementofpatientswithhaemodynamicallytoler- 55% suffered from CAD. The mean LVEF was 50%, and after a
ated ventricular tachycardia and preserved and mildly reduced meanfollow-upof32months,overallmortalitydidnotdifferbe-
ejectionfraction. Withthebetterunderstandingofthemechanisms tweenthegroups(12%).
ofVTafterMI,aswellasimprovedablationandimagingtechnologies, ThesedatasuggestthateitherICDimplantationorablationinex-
catheterablationhasbecomeanoptionforthetreatmentofhaemo- periencedcentresshouldbeconsideredinpatientswithapreserved
dynamicallywell-toleratedVTinselectedpost-MIpatientswithpre- or mildly reduced EF presenting with haemodynamically tolerated
servedormildlyreducedEF,evenwithoutICDback-up.Onesmall SMVT. Of note, although ICDs have been commonlyimplanted in
monocentric retrospective trial studied patients with CAD, LVEF thispopulation,thesecondarypreventiveICDtrialsfailedtoshow
.40%, and haemodynamically tolerated VT who underwent cath- a survival benefit in patients with an LVEF ≥35%.352 Although
eterablationasfirst-linetherapy.580Theinvestigatorscouldabolish SMVT is rarely caused by ischaemia and revascularization alone
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4049
SMVT in a patient with chronic CAD
First presentation SMVT in ICD carriersa
≥40% LLLVEF <40% Electrical storm Symptomatic SMVT
Go to flowchart
Haemodynamically
N electrical storm On amiodarone
tolerated
(Figure 11)
Y Y N
Catheter ablation ICD implantation Catheter ablation Catheter ablation
(Class IIa) (Class I) (Class I) (Class IIa)
ICD implantationb Catheter ablation Sotalolc
(Class IIa) (Class IIb) (Class IIa)
Amiodaroneb Amiodarone
(Class IIa) (Class IIa)
Figure16Algorithmforthemanagementofsustainedmonomorphicventriculartachycardiainpatientswithchroniccoronaryarterydisease.CAD,
coronaryarterydisease;ICD,implantablecardioverterdefibrillator;LVEF,leftventricularejectionfraction;N,No;SMVT,sustainedmonomorphicven-
triculartachycardia;Y,Yes.aIncessantventriculartachycardiainmonitorzone:considercatheterablation.bIfcatheterablationisnotavailable,notsuc-
cessfulornotdesiredbythepatient.cToreduceICDshocks.
doesnotpreventVTrecurrence,exclusionortreatmentofsignifi- However, in patients who present with a first VT episode and in
cantCADbeforecatheterablationisreasonable. whomanICDisindicated,catheterablationperformedimmediately
beforeorshortlyafterICDimplantationmaybeconsideredtode-
creasesubsequentVTandICDshocks.484,485,583
7.1.1.3.5.Managementofrecurrentventriculartachycardiainim-
plantablecardioverterdefibrillatorcarriers.
Frequent,symptomat-
ic VT in ICD recipients should be treated medically with either 7.1.1.4.Coronaryanomalies
amiodaroneorsotalol.318,581InpatientswithCADinwhomSMVT Anomalous aortic origin of a coronary artery, either the left or
recurswhileonamiodaronetreatment,catheterablationisrecom- theright,arisingfromtheoppositesinusofValsalva,isassociated
mendedoverescalationofAADtherapy.IntheVANISHtrial,the withanincreasedriskofSCD,especiallyinindividuals,35years
compositeendpointofdeath,VTstorm,andappropriateICDther- duringorfollowingvigorousexercise.585Anomalousaorticorigin
apywasreachedsignificantlylessoftenintheablationgroupascom- of the left coronary artery is less common but more malignant
pared to the escalated amiodarone-therapy group over a mean than anomalous aortic origin of the right coronary artery. Other
follow-up of 28 months (59% vs. 68.5%; HR 0.72; 95% CI 0.53– risk factors for SCD are interarterial course between the aorta
0.98; P=0.04).471 The ongoing VANISH2 trial (ClinicalTrials.gov and pulmonary artery, slit-like shaped orifice, high orifice, acute-
Identifier:NCT02830360)addressesthequestionofwhethercath- angle take-off, and intramural course and its length.585,586
eter ablation as first-line treatment is superior to AAD therapy in Indicationsforsurgicalintervention,especiallyinasymptomaticpa-
post-MIpatientswithSMVT. tients,arebasedontheevaluationofhigh-riskanatomybyCTAand
PreventiveVTablationafterafirstdocumentedSMVT,whichwas theassessmentofexercise-inducedischaemiausingadvancedim-
followedbyICDimplantation,reducedneithermortalitynorhospi-
agingmodalities.586–588Cardiacstressimagingisalsoindicatedto
talizationsforarrhythmiaorworseningheartfailurewhencompared evaluateexercise-inducedischaemiaaftersurgicalintervention,es-
to a deferred ablation strategy only after the third ICD shock.582 peciallyinpatientswithanabortedCA.588
Downloaded
from

by
guest
on
22
January
2026

4050 ESCGuidelines
RecommendationTable25—Recommendationsfor Several drugs have been used to treat idiopathic PVCs/VT.
suddencardiacdeathpreventioninpatientswithcoron- Recommendations are based on small or non-controlled series.
aryanomalies
Beta-blockersandCCBsarethemost-studieddrugsandbothhave
beenshowntobe effectiveatarrhythmiasuppression.304Theevi-
Recommendations Classa Levelb
dence for flecainide is scarce.592 In case of a higher burden of
Diagnosticevaluation PVCswithhigherheartrateorduringexercise,beta-blockersshould
bepreferred.593Ifthereisnotsuchacorrelation,theuseofflecainide
Cardiacstressimagingduringphysicalexerciseis
orCCBdrugshavebeenassociatedwithmoreeffectivePVCsup-
recommendedinadditiontocardiopulmonary
exercisetestinpatientswithanomalousaortic I C pression. Beta-blockers should also be selected when a focal trig-
geredactivitymechanismissuspected.CCBshouldbethedrugof
originofacoronaryarterywithaninterarterial
coursetoconfirm/excludemyocardialischaemia.587 choice for fascicular PVC/VT. Although data are lacking, beta-
blockersorCCBsareconsideredfirstchoiceforPVCswithanorigin
Cardiacstressimagingduringphysicalexerciseis outsidetheRVOTortheleftfasciclesbecauseflecainidemayhave
recommendedinadditiontocardiopulmonary
proarrhythmic side effects. Amiodarone is associated with severe
exercisetestaftersurgeryinpatientswith I C
systemictoxicityandshouldbeusedonlyifablationorotherdrugs
anomalousaorticoriginofacoronaryarterywith
failorcannotbeused.594Asummaryoftherecommendationsforthe
ahistoryofabortedCA.
treatment of idiopathic PVCs/VT and PVC-induced or aggravated
Treatment
cardiomyopathywithAADsisprovidedinTable9.
Surgeryisrecommendedinpatientswith AhighsuccessrateofcatheterablationofidiopathicPVCs/VThas
anomalousaorticoriginofacoronaryarterywith I C been reported with rare complications, particularly for the RVOT
CA,syncopesuspectedtobeduetoVAs,orangina and fascicular types.535 In a randomized study including patients
whenothercauseshavebeenexcluded.585,586,588
with RVOT PVCs, ablation was superior to AAD therapy for
Surgeryshouldbeconsideredinasymptomatic arrhythmia suppression with no differences in complications.595
patientswithanomalousaorticoriginofa Ablation is therefore recommended as the first-line therapy for
coronaryarteryandevidenceofmyocardial RVOTandfascicularPVCs/VT.Theavailableinformationforother
IIa C
ischaemiaorabnormalaorticoriginoftheleft formsofidiopathicPVCs/VTislimitedandmostlyrestrictedtothe
coronaryarterywithhigh-risk acutesuccessofablation,which,ingeneral,islowerandassociated
anatomy.c,585,586,588 withmorerecurrencesthanforRVOTandfascicularPVCs/VT.540
Inaddition,accesstoandablationatspecificlocations(e.g.sinusof
CA,cardiacarrest;VA,ventriculararrhythmia.
aClassofrecommendation. Valsalva,LVsummit)mayincreasetheriskforproceduralcomplica-
bLevelofevidence. tions. Therefore, when the 12-lead ECG is highly suspicious of a
cHigh-riskanatomyisdefinedasinterarterialcourse,slit-likeshapedorifice,highorifice,
PVC/VTsourceoutsidetheRVOTorleftfascicles,thelevelofrec-
acute-angletake-off,andintramuralcourseanditslength.
ommendationforablationislower.
Ingeneral,treatmentofchildrenshouldbesimilartothatofadults.
However,ablationshouldbedeferredinyoungandsmallchildrendue
totheriskofcomplicationsandtherelativelylargersizeoftheablation
7.1.2.Idiopathicprematureventricularcomplexes/
lesionascomparedtothechild’sheart.596,597Verapamilisnotrecom-
ventriculartachycardiaandprematureventricular
mendedasthefirst-linetherapyinchildren,1yearoldbecauseithas
complex-inducedcardiomyopathy
beenassociatedwithhypotensioninsomecasereports.542Ofnote,all
7.1.2.1.Idiopathicprematureventricularcomplexes/ventricular reportedpatientshadeitherheartfailure,overdosingofverapamil,or
tachycardia otherconcurrentAADsatthetimeverapamilwasgiven.598
PVCs/VT in patients without SHD are defined as idiopathic Patients may present with asymptomatic frequent PVCs/VTs.
(Figure 17). In patients with presumed idiopathic PVCs/VT based
Onlyaminorityofpatientswith.1000PVCsperdaywilldevelop
on a negative history and normal physical examination, 12-lead ventricular dysfunction after 5 years follow-up.599 A PVC burden
ECGandtransthoracicechocardiographyareimportantfirstdiag- of10%seemstobetheminimalthresholdfordevelopmentofLV
nostic steps to exclude underlying SHD. Twenty-four-hour ECG dysfunction, with higher risk when the PVC burden is
HoltermonitoringisusuallyperformedtodeterminethePVCburden.
.20%.535,600,601RegularassessmentofLVEFinthissettingisthere-
MultiformPVCsatprolongedECGmonitoringandsubtlechangeson
foreindicated.Todate,therearenodatasupportingthebenefitof
ECGorechocardiographyneedtoberecognized.589CMRshouldbe arrhythmia treatment for asymptomatic patients with preserved
performedwheneverECGandechocardiographyareinconclusiveto ventricularfunction.Inaddition,PVCburdenoftendecreasesspon-
ruleoutSHD,ortheclinicalpresentationraisessuspicionforSHD.590,591 taneously over time, particularly in children.599,602 In selected pa-
PatientsneedtobetreatedwhenPVCs/VTaresymptomaticor tients, e.g. patients who do not want to be followed, catheter
associatedwithdeteriorationofcardiacfunction.Theclinicalcourse
ablationmaybeconsidered.InpatientswithPVCburden,10%,re-
andresponsestodifferenttreatmentshavebeenmostlystudiedin evaluationmaybeappropriateincaseofdevelopmentofnewsymp-
thoseoriginatingfromtheRVOTortheleftfascicles. tomsorchangeinpatientcondition.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4051
Patient with PVCs / MonomorphicVT and non-apparent SHDa
ECG,, Holter,, and echocardiogram
Assessment
Inconclusive or atypical presentationb
CMR (Class IIa)
Assessment
Structural abnormal heart Structural normal heart
Go to flowchart
PVC-induced
SHD or PVC-induced cardiomyopathy Idiopathic PVC/VT
carrrdiomyopathy
(Figure 18)
Dischargee N Symptomsc
N Y
>10% PVCs N >20% PVCs RRRVOOOT / Fascicular PVC/VTd
Y Y Y N
Regular Regular Catheter ablation Beta-blockkkerr orCCB
fffollow-upLLLVEF fffollow-up LLLVEF (Class I) (Class I)
(Class I) (Class I)
Beta-blockkkers, Flecainide
CCB or (Class IIa)
Catheter ablation
Flecainide Catheter ablation
(Class IIb)
(Class IIa) (Class IIa)
Figure17Algorithmforthemanagementofpatientswithidiopathicprematureventricularcomplexes/ventriculartachycardiaandnon-apparentstruc-
turalheartdisease.CCB,calciumchannelblocker;CMR,cardiacmagneticresonance;ECG,electrocardiogram;LVEF,leftventricularejectionfraction;N,No;
PVC,prematureventricularcomplex;RVOT,rightventricularoutflowtract;SHD,structuralheartdisease;VT,ventriculartachycardia;Y,Yes.aNon-apparent
SHDisdefinedbylackofsignificantabnormalitiesinphysicalexamination,basalECG,andechocardiogram.bAtypicalpresentation:e.g.olderage,rightbundle
branchblockmorphology,sustainedmonomorphicVTconsistentwithre-entry.cSymptomsshouldberelevantandrelatedtoPVC/VT.dOriginsuspectedby
ECGorconfirmedduringelectrophysiologicalevaluation.eConsiderre-evaluationincaseofnewsymptomsorchangesinpatientclinicalcondition.
Table9 Summaryoftherecommendationsforthetreatmentofpatientswithfrequentidiopathicprematureven-
tricularcomplexes/ventriculartachycardiaorprematureventricularcomplex-inducedcardiomyopathy
Ablation Beta-blocker CCB Flecainide Amiodarone
RVOT/fascicularPVC/VT:
ClassI ClassIIa ClassIIa ClassIIa ClassIII
Symptomatic,normalLVfunction
PVC/VTotherthanRVOT/fascicular:
ClassIIa ClassI ClassI ClassIIa ClassIII
Symptomatic,normalLVfunction
RVOT/fascicularPVC/VT:
ClassI ClassIIa ClassIIIa ClassIIab ClassIIa
LVdysfunction
PVC/VTotherthanRVOT/fascicular:
ClassI ClassIIa ClassIIIa ClassIIab ClassIIa
LVdysfunction
PVC:
ClassIIb ClassIII
Burden.20%,asymptomatic,normalLVfunction
CCB,calciumchannelblocker;LV,leftventricular;PVC,prematureventricularcomplex;RVOT,rightventricularoutflowtract;VT,ventriculartachycardia.
aIntravenouscalciumchannelblockers.
bInselectedpatients(onlymoderateLVdysfunction).
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4052 ESCGuidelines
RecommendationTable26—Recommendationsfor 7.1.2.2.Prematureventricularcomplex-induced/-aggravated
the management of patients with idiopathic prema- cardiomyopathy
tureventricularcomplexes/ventriculartachycardia
The importance of PVC-induced cardiomyopathy as a second-
ary and reversible cause of LV dysfunction in patients without
Recommendations Classa Levelb
SHD has been recognized.607,608 The patient’s medical and
Generalrecommendations family history, 12-lead ECG, Holter-ECG, and echocardiog-
raphy form the cornerstones of the evaluation of patients
Regularassessmentofventricularfunctionof
patientswithPVCburden.10%andnormal I C with suspected PVC-induced cardiomyopathy (Figure 18).
ventricularfunctionisindicated.602,603 PVC burden has been shown to be the strongest independent
predictor of PVC-induced cardiomyopathy in several stud-
InpatientswithPVCs/VTanda
ies.600,609–611 Day-by-day fluctuations of PVC burden have
presentationnottypicalforanidiopathic
IIa C been reported in patients undergoing 14-day monitoring, but
origin,cCMRshouldbeconsidered,
mostdata arebasedon 24-h registrations.611A PVCburdenof
despiteanormalechocardiogram.195
at least 10% appears to be the minimal threshold for develop-
Treatment
mentofPVC-inducedcardiomyopathy,andtheriskincreasesfur-
Catheterablationasfirst-linetreatmentis ther with a PVC burden .20%.600,611 In patients with a PVC
recommendedforsymptomaticidiopathicVT/
I B
burden,10%,othercardiomyopathyaetiologiesshouldbesus-
PVCsfromtheRVOTortheleft pected and further diagnostic work-up undertaken. In such pa-
fascicles.d,535,595,596,604 tients, Holter-ECG should be repeated to assessfluctuations in
Beta-blockersornon-dihydropyridineCCBsare PVC burden. Factors predicting adverse LV remodelling in pa-
indicatedinsymptomaticpatientswithidiopathic tients with frequent PVCs include superior PVC axis, epicardial
I C
VT/PVCsfromanoriginotherthantheRVOTor origin, NSVT, shorter coupling interval, and male gen-
theleftfascicles.304,593 der.535,611–613
Beta-blockers,non-dihydropyridineCCBs,or FrequentPVCscanalsoaggravateLVdysfunctioninpatientswith
flecainideshouldbeconsideredwhencatheter SHD. In such cases, LV dysfunction can either be a direct conse-
ablationisnotavailable,desired,orisparticularly quenceofPVCsasinPVC-inducedcardiomyopathy,orduetothe
IIa B
riskyinsymptomaticpatientswithidiopathicVT/ limiting effect of PVCs on optimal biventricular pacing in CRT pa-
PVCsfromtheRVOTortheleft tients. Parameters such as smaller LV end diastolic diameter and
fascicles.304,592,593 shorter intrinsic QRS duration might help to distinguish
Catheterablationorflecainideshouldbe PVC-induced cardiomyopathy from PVC-aggravated cardiomyop-
consideredinsymptomaticpatientswith athy.614 CMR should be considered for patients suspected to have
IIa C
idiopathicVT/PVCsfromanoriginotherthanthe PVC-inducedcardiomyopathytoexcludesubtleformsofSHD.590,615
RVOTortheleftfascicles.535,604,605 InapatientwithfrequentPVCs,thepresenceofLGEsuggestsSHD
Catheterablationmaybeconsideredfor with frequent PVCs rather than PVC-induced cardiomyopathy, in
idiopathicVT/PVCsinasymptomaticpatientswith whichLGEismostlyabsent.GiventhatPVCswithaRBBBmorphology
IIb B
repeatedlymorethan20%ofPVCsperdayat
havebeenreportedtoshowastrongerassociationwithLGE,616those
follow-up.535,600,601 patientsshouldbeparticularlyconsideredforCMR.
CatheterablationofidiopathicVT/PVCsisnot ThediagnosisofPVC-inducedcardiomyopathyvs.PVC-aggravated
recommendedinchildren,5yearsofageor cardiomyopathycanbeconfirmedonlyafterLVEFimprovement/nor-
,10kgweightexceptwhenpreviousmedical III C malization(reverseremodelling)followingsuppressionofthePVCs.
therapyfailsorwhenVTisnothaemodynamically
CatheterablationofthePVCsisveryefficient,withreportedsuc-
tolerated.597 cess rates of 75–90%, and is considered first-line treatment for
Amiodaroneasafirst-linetreatmentisnot PVC-induced
cardiomyopathy.535,600,609,610,612,617–620
Factors af-
recommendedinpatientswithidiopathicVTs/ III C fectingacuteablationsuccessandclinicaloutcomeincludethesite
PVCs.594
oforiginofPVCs(highestforoutflowtractPVCs),thenumberof
Verapamilisnotrecommendedinchildren,1year
PVCmorphologies,andtheabsenceofLGEonCMR.535,610,614Inpa-
tientswithSHD,catheterablationoffrequentmonomorphicPVCs
ofagewithPVC/VT,particularlyiftheyhavesignsof III C
hasalsobeenshowntoimproveLVEFinpatientswithbothCADand
heartfailureorconcurrentuseofotherAADs.606
cardiomyopathieswithandwithoutCRT.609,617,621–623Similarly,the
AAD, anti-arrhythmic drug; CCB, calcium channel blocker; CMR, cardiac magnetic use of anti-arrhythmic medications for PVC suppression has been
resonance;PVC,prematureventricularcomplex;RVOT,rightventricularoutflowtract;
showntoimproveLVEF.InoneRCT,amiodaroneresultedinabet-
SMVT,sustainedmonomorphicventriculartachycardia;VT,ventriculartachycardia.
aClassofrecommendation. terPVCsuppressionandahigherLVEFimprovementcomparedto
bLevelofevidence. placebo.624 Sodium channel blockers can also effectively suppress
cIncludingbutnotlimitedtoolderage,rightbundlebranchblock(RBBB)morphology,
PVCs.625 In one study, flecainide reduced the PVC burden from
SMVTconsistentwithre-entry.
dLevelofevidenceCforVT/PVCsfromleftfascicles. 36% to 10% and resulted in LVEF increase from 37% to 49%.626
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4053
Patient withPVC-Burden >10% and mildlyreducedor reduced LLLVEF
N Known SHD Y
(suspicious)CAD, Further evaluation LLLV dysfunction
valvular heart diseaseor Y according to explained by underlying
inflammatory heart disease most likkkely diagnosis heart disease
N N Y
CMR
Follow-up
(Class IIa)
N LGE Y
Suspected PVC induced SHD aggraaavatedby
cardiomyopathy frequent PVC’s
Catheter ablation Catheter ablation
(Class I) (Class IIa)
AAD Amiodarone
(Class IIa) (Class IIa)
Figure18Algorithmforthemanagementofpatientswithprematureventricularcomplex-induced/-aggravatedcardiomyopathy.AAD,anti-arrhythmic
drug;CAD,coronaryarterydisease;CMR,cardiacmagneticresonance;LGE,lategadoliniumenhancement;LV,leftventricular;LVEF,leftventricularejec-
tionfraction;N,No;PVC,prematureventricularcomplex;SHD,structuralheartdisease;Y,Yes.
While flecainide have a more favourable adverse effect profile re- RecommendationTable27—Recommendationsfor
garding organ toxicity, increased mortality has previously been themanagementofpatientswithprematureventricular
showninpatientswithMI.556Forselectedpatientswithsuspected complex-induced or premature ventricular complex-
aggravatedcardiomyopathy
PVC-inducedcardiomyopathyandPVC-aggravatedcardiomyopathy,
flecainide can still be considered, particularly if an ICD is in place
Recommendation Classa Levelb
(Table9).
A raremonogeneticcauseofPVC-inducedcardiomyopathy,re- Diagnosticevaluation
ferredtoasmultifocalectopicPurkinje-relatedprematurecontrac-
InpatientswithanunexplainedreducedEFanda
tions,has been reported.It is characterized by a DCM phenotype
PVCburdenofatleast10%,PVC-induced IIa C
andthepresenceofnumerousPVCswithRBBBand/orleftbundle cardiomyopathyshouldbeconsidered.600,609,610
branchblock(LBBB)morphologiesandanincreasedriskofSCD.627
InpatientswithsuspectedPVC-induced
PathogenicmutationsintheSCN5Ageneleadtoagainoffunction
cardiomyopathy,CMRshouldbe IIa B
ofthesodiumchannelresponsibleforhyperexcitabilityofthefasci-
considered.590,615
cularPurkinjesystem.627,628Limiteddatasuggestthatpatientswith
Treatment
multifocalectopicPurkinje-relatedprematurecontractionsdonot
respondtobeta-blockersbutmightbenefitfromtherapywithfle- Inpatientswithacardiomyopathysuspectedtobe
cainide,quinidine,oramiodarone.627–631 causedbyfrequentandpredominately
I C
monomorphicPVCs,catheterablationis
recommended.535,600,609,612,617,618,620
Continued
Downloaded
from

by
guest
on
22
January
2026

4054 ESCGuidelines
Inpatientswithacardiomyopathysuspectedtobe Pathogenic mutations are identified in 25–55% of DCM pa-
causedbyfrequentandpredominately tients,634,639,640 most often with autosomal dominant inherit-
monomorphicPVCs,treatmentwithAADscshould IIa C ance. Truncated mutations in the titin gene (TTN) are most
beconsideredifcatheterablationisnotdesired, frequently found, followed by LMNA, sarcomeric, and desmo-
suspectedtobehigh-risk,orunsuccessful.624,626 somal mutations. Mutations in genes such as LMNA, PLN,
RBM20, and FLNC are associated with a higher risk of VA and
InpatientswithSHDinwhompredominately
SCD.641–645CarriersofdesmosomalandLMNAvariantsexperi-
monomorphicfrequentPVCsaresuspectedtobe
contributingtothecardiomyopathy,AAD IIa B encedthehighestrateofVA/SCD,whichwasindependentofthe
LVEFinoneseries.645
(amiodarone)treatmentorcatheterablation
shouldbeconsidered.617,621,622,624 TheyieldofgenetictestingisparticularlyhighinDCMpatientswith
familialformsofDCMorSCDinafirst-degreerelativeatyoungerage.
Innon-responderstoCRTwithfrequent,
AninheritedDCMisalsomorelikelyinpatientswhopresentatyoung
predominatelymonomorphicPVCslimiting
ageorwithsignssuspiciousforaspecificaetiology(e.g.prolongedAV
optimalbiventricularpacingdespite IIa C
conductionforLMNA)(Figure20).634,639,640,646First-degreerelatives
pharmacologicaltherapy,catheterablationor
of DCM/HNDCM patients should undergo clinical diagnostic evalu-
AADsshouldbeconsidered.623
ation,especiallyifaninheritedcauseissuspected.
AAD, anti-arrhythmic drug; CMR, cardiac magnetic resonance; CRT, cardiac Discrimination between high- and low-risk patients for SCD
r de es fiy bn rc ilh lar to on ri ;zat Lio Vn
,
lt eh ftera vp ey n; trE icF u, lare ;jec Pt Vio Cn
,
f pra rc et mio an t; ureICD ve, ni tm ricp ula lan rtab cl oe mc pa lerd xi ;ov Se Hrt Der
,
remains challenging. Beyond LVEF and NYHA
class,357,359,635,647–650
structuralheartdisease.
recentdatasuggestthatbothgeneticandCMRfindingscancontrib-
aClassofrecommendation. ute to risk stratification. A meta-analysis of 29 studies combining
bLevelofevidence.
2948 patients studied the role of CMR in patients with DCM.129
cFlecainideonlyinselectedpatients(ICDrecipients,onlymoderateLVdysfunction).
LGE was significantly associated with the arrhythmic endpoint,
evenwhenincludingonlystudiesthatperformedmultivariateanalysis
7.1.3.Cardiomyopathies (HR 6.7; P,0.001). Interestingly, the association between LGE and
7.1.3.1.Dilatedcardiomyopathyandhypokineticnon-dilated the arrhythmic endpoint remained significant among patients with
cardiomyopathy
meanLVEF.35%.Similarly,arecentstudyof1020consecutivepa-
tientswithDCMandCMRobservedthatLGEandLVEFwereboth
DCMischaracterizedbyLVdilatationandsystolicdysfunctionunex-
plainedbyCADorabnormalloadingconditions.632Thetruepreva- risk markersfor all-cause mortality and cardiacdeath, but only LGE
lenceisdifficulttoestimate.Olderstudiesreportedaprevalenceof1 was significantly associated with SCD risk.651
in2700individuals.633
SCDriskstratificationhasbeenrefinedinthesubgroupofpatients
withLMNAmutations,whichrepresent5–10%ofallDCMpatients.
Historic data in adults with DCM showed a 1-year mortality of
20–25%anda50%survivalat5years.634RecenttrialsofDCMpa- LMNAmutationsareassociatedwithearlyatrialandventricularar-
rhythmias, premature conduction disease, a high risk of SCD, and
tients with systolic heart failure and OMT report 5-year mortality
ratesintherangeof21–28%.356,359SCDoccursinupto12%ofpa- progression to end-stage heart failure.80,642,652,653 In a multicentre
tientswithDCMandstillaccountsfor25–35%ofalldeaths.359,634,635
registryof269LMNAmutationcarriers,NSVT,LVEF,45%atfirst
evaluation,malesex,andnon-missensemutationswereidentifiedas
In children, the annual incidence of DCM is 0.57 cases per
100000.636Theprognosisinchildrenispoor,witha5-yearincidence independentriskfactorsforVA.652VAoccurredonlyinpersonswith
atleasttwooftheseriskfactors.Theriskstratificationwassubse-
of heart transplantation or heart failure-related death of 40%.
quently externally validated.653 Another study,which involved 589
However,incontrasttoadults,theincidenceofSCDinpaediatric
DCMpatientsismuchlower,witha5-yearincidenceof2.4–3%as
LMNAmutationcarriers,identifiedAVblockasanadditionalpredict-
or.Recentlyariskcalculatorhasbeendeveloped(
reported in two large paediatric cardiomyopathy registries from
theUnitedStatesandAustralia.637,638 vta.fr/)topredicttheriskoflife-threateningVA (C-indexof0.776
CausesofDCMcanbegeneticoracquired.639Geneticpredisposition [95% CI: 0.711–0.842]).80 In patients with a 5-year estimated risk
≥10% and a manifest cardiac phenotype (NSVT, LVEF , 50%, or
mayalsointeractwithextrinsicfactorssuchasinperi-partum,alcoholic,
orchemotherapy-relatedcardiomyopathies.639Thephenotype,par- AVconductiondelay),aprimarypreventionICDimplantationshould
beconsideredtoavoidpotentialover-implantationinmutationcarriers
ticularlyofgeneticaetiologies,canchangeovertimeand/ormaynot
withoutacardiacphenotype.InLMNAmutationcarrierswithaDCM
meetstandarddiseasecriteriaatthetimeofdiseasemanifestation.As
phenotype,high-intensityexercisehasbeenassociatedwithahighrisk
aconsequence,anewcategoryofahypokineticnon-dilatedcardio-
myopathy(HNDCM)hasbeenproposed.639
ofSCDandimpairedLVEFandisthereforenotrecommended.654,655
AriskscoreforVApredictionhasbeenrecentlyproposedforpa-
tientswithDCMorARVCrelatedtothep.Arg14delmutationinthe
7.1.3.1.1. Diagnostic evaluation and risk stratification. An algo- PLNgene.656Validationstudiesareneededbeforeitcanberecom-
rithm for risk stratification and primary prevention of SCD in pa- mendedforclinicaluse.
tientswithDCM/HNDCMispresentedinFigure19. BeyondgeneticsandCMR,additionalSCDpredictorshavebeen
Careful diagnostic work-up, including genetic testing and CMR, suggested,oftenderivedfromsmallcohortswithnoorfewreplica-
should be considered to identify the underlying cause for tionstudies.Anunexplainedsyncoperequiresfurtherevaluationand
aetiology-orientedriskstratificationandtreatment.341,639 PES may determine the underlying cause. The risk for arrhythmic
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4055
Patient with DCM/HNDCM
CMR (Class IIa)
Go to specific sections
Suspicious of cause requiring specific treatment Y for specific aetiology-directed management,
especially for inflammatory diseases
N
Family history of DCM/HNDCM or
family history of SCD (<50 y, first-degree relative) or
AV block <50 y
N Y
5-year risk ofVA ≥10%
Genetic testing Pathogenic and LVEF <50%
(Class IIa) (Class I) mutation LMNA or NSVT
orAV conduction delay
N Y
≤35% LVEF 36–50%
Annual ICD implantation
reevaluation (Class IIa)
ICD implantation ≥2 risk factorsa
(Class IIa)
N Y
ICD implantation
N Unexplained syncope
(Class IIa)
Y
Follow-up
ILRb (Class I) PES (Class IIa)
N SMVT inducible
Y
ICD implantation
(Class IIa)
Figure19Algorithmforriskstratificationandprimarypreventionofsuddencardiacdeathinpatientswithdilatedcardiomyopathy/hypokineticnon-
dilatedcardiomyopathy.AV,atrioventricular;CMR,cardiacmagneticresonance;DCM,dilatedcardiomyopathy;HNDCM,hypokineticnon-dilatedcar-
diomyopathy;ICD,implantablecardioverterdefibrillator;ILR,implantablelooprecorder;LMNA:laminA/Cgene;LVEF,leftventricularejectionfraction;
N,No;NSVT,non-sustainedventriculartachycardia;PES,programmedelectricalstimulation;SCD,suddencardiacdeath;SMVT,sustainedmonomorphic
ventriculartachycardia;VA,ventriculararrhythmias;Y,Yes.aRiskfactors:unexplainedsyncope,pathogenicvariantsinPLN,FLNC,orRBM20,LGEon
CMR,inducibleSMVTatPES.bThe2018ESCGuidelinesforthediagnosisandmanagementofsyncope.1
eventsinDCMpatientswithalowLVEFandanunexplainedsyncope Guidelines for the diagnosis and treatment of acute and chronic
wassimilartothosewithpriorCA657andhigh,independentfrom heartfailureismandatory.342Re-evaluationofcardiacfunctionand
theoutcomeofPES.148However,datainDCMpatientswithamildly clinicalstatusafter3months’OMTisrequiredbeforeprimarypre-
reducedEFsuggestanincrementalvalueofPES.AmongDCMpa- ventionICDimplantation.LVfunctionismorelikelytoimprovein
tientswithanEF≥40%andanunexplainedsyncope,whounderwent DCMcausedbymyocarditisorTTNmutations.
ICD implantation after a positive PES, 80% had appropriate ICD The efficacy of primary prevention ICDs in DCM patients with
therapy during follow-up. No SCD or symptomatic VA occurred HFrEFhasbeenaddressedinsixRCTs.635
innon-induciblepatients.146 Five studies were published between 2002 and 2005 (CAT,
AMIOVIRT, DEFINITE, COMPANION, and SCD-HeFT). The
7.1.3.1.2.Primarypreventionofsuddencardiacdeath. Inpatients first three were smaller studies enrolling only DCM patients,
with DCM/HNDCM, OMT according to current 2021 ESC whereas SCD-HeFT and COMPANION were larger and
Downloaded
from

by
guest
on
22
January
2026

4056 ESCGuidelines
ECG sinus rhythm – Small amplitude P waves and first degreeAV block
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
ECGVT – RBBB-like, inferior axis (LV summit origin)
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
CMR – Mid-wall septal LGE
4-chamber Short axis
Figure20TypicalfeaturesofdilatedcardiomyopathyassociatedwithlaminA/Cgenemutationwithventriculararrhythmias.AV,atrioventricular;CMR,
cardiacmagneticresonance;ECG,electrocardiogram;LGE,lategadoliniumenhancement;LV,leftventricle;RBBB,rightbundlebranchblock;VT,ven-
triculartachycardia.
includedpatientswithCADandDCM.TheCOMPANIONstudy randomized to ICD therapy (HR 0.87; 95% CI 0.68–1.12; P=0.28)
differed from the others as it compared CRT-defibrillator, wasobserved,despiteasignificantreductioninSCDintheICDgroup
CRT-pacemaker, and OMT. A meta-analysis of the five trials (HR0.50;95%CI0.31–0.82;P=0.005).Potentialexplanationsarethe
(1854 patientswithDCM)demonstrated a 31% reduction inall- lowSCDrateinthetrial(4.3%intheICDgroupand8.2%inthecontrol
cause mortality with ICD relative to medical therapy (RR 0.69 group),theexcellentmedicaltreatment(.90%ofpatientsonACEin-
[95% CI 0.55, 0.87], P,0.002).658 This effect persisted when hibitorsandbeta-blockers,.50%onMRA),andthehighprevalence
COMPANION was excluded. (58%)ofCRT.Ameta-analysisofallsixprimarypreventiontrialsstillde-
Morerecently,theDANISHtrialenrolled1116symptomaticpatients monstratedareduction,althoughlower,inoverallmortalitywithICD
(NYHAclassIIorIII)withnon-ischaemicsystolicheartfailure(LVEF≤ therapy(RR0.76;95%CI0.65–0.91;P=0.002).635Inasensitivityana-
35%).PatientswererandomizedtoICDornoICDafterOMT.359No lysis,thebenefitofICDtherapywasmaintainedaftertheremovalofany
reduction in the primary endpoint of all-cause death for patients singlestudyfromthepooledanalysis.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4057
TheresultsoftheDANISHtrialemphasizetheneedforfurther ethanol ablation, bipolar ablation, surgical ablation) may be re-
refiningtheindicationforprimarypreventionICDsincontempor- quired in patients with pathogenic mutations (LMNA gene) and
aryDCMpatients.Ageandcomorbidityneedtobeconsidered.635 in those with deep intramural, anteroseptal substrate loca-
IntheDANISHtrial,ICDimplantationwasassociatedwithasignifi- tions.499,665,666Consideringthecomplexityoftheablationpro-
cantlylowerrateofdeathinyoungerpatients.359Afurtheranalysis cedure, DCM patients should therefore be treated only in
of the DANISH data647 showed an association between reduced specializedcentres.
all-cause mortality and ICDs in patients ≤70 years of age (HR,
0.70; 95% CI 0.51–0.96; P=0.03), but not in patients .70 years
ofage. Recommendation Table 28 — Recommendations
Prospective studies evaluating the benefit of ICDs in DCM/
forriskstratification,suddencardiacdeathpreven-
tion, and treatment of ventricular arrhythmias in
HNDCM patients with intermediate LV dysfunction, but with
dilated cardiomyopathy/hypokinetic non-dilated
riskfactorsthathavebeenassociatedwithVAandSCD(including cardiomyopathy
LGEonCMR,pathogenicmutationsinPLN,FLNC,RBM20,unex-
plained syncope, and inducibility of SMVT), are lack- Recommendation Classa Levelb
ing.129,641,643,644,659–662
Given the limitation of LVEF as the only
Diagnosticevaluationandgeneralrecommendations
risk marker in DCM/HNDCM, this panel of experts shares the
opinionthatinthepresenceofacombinationofriskmarkersan Genetictesting(includingatleastLMNA,PLN,
ICDshouldbeconsidered. RBM20,andFLNCgenes)isrecommendedin
patientswithDCM/HNDCMandAVconduction
I B
7.1.3.1.3. Secondary prevention of sudden cardiac death and delayat,50years,orwhohaveafamilyhistoryof
managementofventriculararrhythmias. Threerandomizedtrials DCM/HNDCMorSCDinafirst-degreerelative
(AVID,CASH,andCIDS)havecomparedICDtherapyandmedical
(atage,50years).641–645
treatmentforsecondarypreventioninpatientsafterabortedCAor CMRwithLGEshouldbeconsideredinDCM/
not-toleratedVT.349,351,352Thethreetrialsenrolledatotalof1963 HNDCMpatientsforassessingtheaetiologyand IIa B
patients,ofwhomonly292(14.8%)hadnon-ischaemicaetiologies.A theriskofVA/SCD.129,651,667
significantreductionindeathfromanycauseinpatientswithICDs Genetictesting(includingatleastLMNA,PLN,
wasdemonstrated,whichwasalmostentirelyduetoa50%reduc- RBM20,andFLNCgenes)shouldbeconsideredfor
tioninarrhythmicdeath.352Inthesubgroupofpatientswithcardio- riskstratificationinpatientswithapparently
IIa C
myopathies there was a similar but non-significant trend in the sporadicDCM/HNDCM,whopresentatyoung
reduction of death.352 RCTs have excluded patients with haemo- age,orwithsignssuspiciousforaninherited
dynamicallytoleratedVT.InDCMpatientstheVTsubstrateisless aetiology.641–645
well defined, and disease progression needs to be considered. Participationinhigh-intensityexerciseincluding
Therefore,despitethelackofdata,thispanelofexpertssharesthe competitivesportsisnotrecommendedfor
III C
opinion that an ICD should also be considered in DCM patients individualswithDCM/HNDCMandaLMNA
withhaemodynamicallytoleratedVT. mutation.655
Optimization of ICD programming (see Section 6.2.3.1) can re- RiskstratificationandprimarypreventionofSCD
duceICDshocksdeliveredinresponsetoVT,butadditionaltherapy
ICDimplantationshouldbeconsideredinpatients
toreducesymptomaticVAepisodesisoftenrequired.IntheOPTIC
withDCM/HNDCM,symptomaticheartfailure
trial, 412 patients with ICD implantation within 21 days of VT/VF IIa A
(NYHAclassII–III),andLVEF≤35%after≥3
wererandomizedtoamiodaroneplusbeta-blockers,sotalolalone,
monthsofOMT.357,359,635,650
orbeta-blockeralone.ICDshockratesafteroneyearwere10.3%,
24.3%, and 38.5%, respectively. The higher efficacy of amiodarone ICDimplantationshouldbeconsideredinDCM/
HNDCMpatientswithapathogenicmutationin
plusbeta-blockerscomparedtosotalolneedstobeweighedagainst
LMNAgene,iftheestimated5-yearriskof
thehigherrateofmedication-relatedadverseeventsonanindividual IIa B
life-threateningVAis≥10%candinthepresence
basis.318 Although only limited data are available, sodium channel
blockersmaycontrolVTinSHDandmaybebeneficialinICDreci-
ofNSVTorLVEF,50%orAVconduction
delay.80,652,653
pientswithoutadvancedheartfailure.ThemajorityofSMVTisdue
ICDimplantationshouldbeconsideredinDCM/
toscar-relatedre-entry,whichcanbetargetedbycatheterablation.
HNDCMpatientswithaLVEF,50%and≥2risk
AcuteablationoutcomehasbeenreportedtobesimilarforCAD
and DCM.497,663 However, VT recurrence rates are usually higher factors(syncope,LGEonCMR,inducibleSMVTat IIa C
PES,pathogenicmutationsinLMNA,dPLN,FLNC,
inDCMpatients (VT-freesurvival40.5%inDCMvs.57%inCAD
at1year).497Aftermultipleproceduresin36%ofthepatients,long- andRBM20genes).
termfreedomofVTcouldbeachievedin69%ofcasesinaretro- InDCM/HNDMpatients,electrophysiological
spective, single-centre cohort of 282 patients treated between evaluationshouldbeconsideredwhensyncope IIa C
1999and2014.664 remainsunexplainedafternon-invasive
Epicardialablationisneededin27–30%oftheprocedures.497,664 evaluation.661,668
Outcomeisparticularlypoor,andbailoutstrategies(transcoronary Continued
Downloaded
from

by
guest
on
22
January
2026

4058 ESCGuidelines
ARVC is characterized by a predominant RV involvement. The
SecondarypreventionofSCDandtreatmentofVAs
2010 revised international diagnostic task force criteria are based
ICDimplantationisrecommendedinpatients
onamultiparametricstrategy116(Figure21).Tissuecharacterization
withDCM/HNDCM,whosurviveSCAduetoVT/
I B byCMRwasnotincluded.However,RVfattyinfiltrationandLVLGE
VForexperiencehaemodynamically
arefrequentlyobserved(in29–53%and35.5–45%ofprobands,re-
not-toleratedSMVT.349,351,352
spectively)andmaybepresentbeforepatientsmeetmajortaskforce
Catheterablationinspecializedcentresshouldbe
imaging
criteria.676–678
Both wall motion alterations and pre-/
consideredinpatientswithDCM/HNDCMand
post-contrast signal abnormalities have been suggested to en-
recurrent,symptomaticSMVTorICDshocksfor IIa C hancethediagnosticaccuracyofCMRforARVC.679Theidentifi-
SMVT,inwhomAADsareineffective,
cation of biventricular and left-dominant involvement in ARVC
contraindicated,ornottolerated.481,497,664,669
patients680,681hasrecentlyledtotheproposedterm‘arrhythmo-
Theadditionoforalamiodaroneorreplacementof geniccardiomyopathy’.682
beta-blockersbysotalolshouldbeconsideredin
Restrictionfromhigh-intensityexerciseisregardedasapreventive
patientswithDCM/HNDCMandanICDwho
IIa B toolinclinicallyaffectedARVCpatientstoreducetheriskofVAsand
experiencerecurrent,symptomaticVAdespite diseaseprogression.683–685Whethersportrestrictionisbeneficialin
optimaldeviceprogrammingandbeta-blocker
allmutationcarrierswithoutdiseaseexpressionhasnotbeenevalu-
treatment.318
ated in prospective cohorts, but avoidance of competitive, high-
ICDimplantationshouldbeconsideredinpatients intensityexerciseseemstobereasonable.686,687SCDandVAoccur
withDCM/HNDCMandhaemodynamically IIa C disproportionately during exercise in affected patients, and
toleratedSMVT. high-dose isoproterenol infusion may provoke PVT in .90% of
ManagementofrelativesofapatientorSCDvictimwith ARVC patients,supporting therole ofsympathetic stimulation for
DCM/HNDCM arrhythmogeneity.152,688,689 Whether beta-blockers can prevent
Inafirst-degreerelativeofaDCM/HNDCM spontaneousVAis,however,unclear.Limiteddatasuggestapoten-
patient,anECGandanechocardiogramare
tialbeneficialroleofatenolol.690
recommendedif:
(cid:129)theindexpatientwasdiagnosed,50yearsofageor I C
7.1.3.2.1.Riskstratification.
InARVCpatientsnotimplantedwith
hasclinicalfeaturessuggestiveofaninheritedcause,or
ICDs, CA occurs in 4.6–6.1%, while 23% of patients experience a
(cid:129)thereisfamilyhistoryofDCM/HNDCM,or
non-fatal SMVT during an average follow-up of 8–11 years.691–694
prematureunexpectedSD.646
WhetheraSMVTisacutelylife-threateningdependsontheVTcycle
Inafirst-degreerelativeofapatientwith
length,cardiacfunction,andthecircumstancesunderwhichVToc-
apparentlysporadicDCM/HNDCM,anECGand IIb C curs.Amongdefinite/probableARVCpatientsconsideredathighrisk
anechocardiogrammaybeconsidered.646
forVA,23–48%willexperienceappropriateICDinterventionduring
AAD,anti-arrhythmicdrug;AV,atrioventricular;CMR,cardiacmagneticresonance;DCM,
ameanfollow-upof4.7years.In16–19%ofcases,ICDintervention
dilated cardiomyopathy; ECG, electrocardiogram; HNDCM, hypokinetic non-dilated istriggeredbyfastVT≥250b.p.m.orVF,whichisconsideredassur-
cardiomyopathy; ICD, implantable cardioverter defibrillator; LGE, late gadolinium
rogate for a life-threatening
event.695–698
In a large cohort of 864
enhancement; LVEF, leftventricular ejection fraction; NSVT, non-sustainedventricular
tachycardia;NYHA,NewYorkHeartAssociation;OMT,optimalmedicaltherapy;PES, ARVCpatients(38.8%withapriorVA),43%hadVT/VFduringame-
programmed electrical stimulation; SCA, sudden cardiac arrest; SCD, sudden cardiac dian follow-up of 5.75 years, but only 10.8% a potentially life-
death; SD, sudden death; SMVT,sustained monomorphic ventricular tachycardia; VA,
ventriculararrhythmia;VF,ventricularfibrillation;VT,ventriculartachycardia. threateningevent.Thus,in3outof4ARVCpatients,ICDtherapy
aClassofrecommendation. isappropriatebutmaynotbeconsideredacutelylife-saving.Thisis
bLevelofevidence. relevant because risk prediction algorithms and models are based
cBasedontheriskcalculator
dSeespecificrecommendationsforLMNA. on combinedarrhythmic endpoints, which are often equated with
ICD indications to prevent SCD. This is particularly important for
7.1.3.2.Arrhythmogenicrightventricularcardiomyopathy the young ARVC patients with a lifetime risk of ICD-related
ARVCisaninheriteddiseasecharacterizedbyfibrofattymyocardial complications.695,699
replacement.670Theprevalencerangesfrom1:1000to1:5000indi- RandomizedstudiesofICDtherapyforsecondarypreventionare
viduals,withmalepredominanceamongprobands.671Patientswith lacking,butthehighratesofappropriateICDtherapytriggeredby
SCD/VF at first presentation are typically younger (median age 23 fastVT/VFepisodesinpatientsimplantedafterCAorhaemodynam-
[range 13–57]) compared to those who present with a SMVT ically poorly tolerated VT strongly suggest a survival benefit from
(medianage36years[range14–78]).672 ICD.700Inpatientswhopresentwithahaemodynamicallytolerated
ARVC is caused by pathogenic mutations in desmosomal genes
VT,thesurvivalbenefitfromICDislessclear.691,700–702Identification
andlesscommonlyinnon-desmosomalgenes.Genetictestingisin- ofARVCpatientsatriskforSCDisdifficult,andtheevidencesup-
dicatedandidentificationofamutation(inupto73%ofprobands)is porting risk factors for life-threatening VAs is limited. Arrhythmic
a major criterion for the diagnosis.116,671 In 4–16% compound/ syncopewasapredictorforsubsequenteventsinmostseriesofpa-
digenicmutationsarefound,whichhavebeenassociatedwithanin- tients with definitive ARVC (pooled HR 3.67; CI 2.75–
creasedriskofVAatyoungerage.672,673Thediseasepenetrancein 4.9)81,696,701,703and,inthesepatients,anICDshouldbeconsidered.
first-degree relatives is 28–58%,674,675 supporting regular clinical RVandLVdysfunctionhavebeenassociatedwithahigherarrhyth-
evaluationofrelatives. mic risk.675,704 Cut-off values are difficult to determine but, in
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4059
ECG sinus rhythm – NegativeT wavesV1-V4, terminal QRS duration >55 ms
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
ECGVT – LBBB-like, superior axis (basal RV origin)
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
CMR – Dilated RV with basal aneurysm
4-chamber 3-chamber Short axis
Figure21Typicalfeaturesofarrhythmogenicrightventricular cardiomyopathy associated with ventricular arrhythmias. CMR, cardiac magnetic
resonance; ECG, electrocardiogram; LBBB, left bundle branch block; RV, right ventricle; VT, ventricular tachycardia.
patientswithsevereRVdysfunction(RVfractionalareachange≤17% although supporting dataare lacking, thispanel ofexperts supports
or RV ejection fraction ≤35%), an ICD should be considered. thatanICDshouldbeconsidered706insymptomaticARVCpatients
Likewise, ARVC patients with significant LV involvement (LVEF withmoderateRV(,40%)and/orLVdysfunction(,45%)andwho
≤ 35%) should be treated according to the current DCM recom- haveeitherNSVTorhaveSMVTinducibleatPES.Aninternallyvali-
mendation regarding ICD implantation. There are conflicting data dated risk model has recently been developed from 528 patients
on the independent predictive value of NSVT for subsequent sus- withdefiniteARVCandnopriorVA,includingage,sex,arrhythmic
tainedarrhythmicevents.695,696,701Likewise,theroleofPESinrisk syncope, NSVT, PVC burden, leads with T-wave inversion and RV
stratification, particularly in asymptomatic patients, is not well de- ejectionfraction,topredictanysustainedVA(c-index0.77).81Inadd-
fined.695,696,705Inoneseriesincludingmainlysymptomaticpatients, ition,apredictionmodelforspecificallylife-threateningVAhasbeen
bothNSVTandapositivePESindependentlypredictedarrhythmic promoted based on 864 ARVC patients, with predictors including
events,whileothersreportalowdiagnosticaccuracy.696Riskpredic- male sex, age, 24h PVC count, and leads with T-wave inversion
tion based on a single parameter does not consider the potential (c-index0.74).702However,validationstudiesareneededbeforethese
combined effect and interactions between factors. Therefore, riskmodelscanberecommendedforclinicaluse.
Downloaded
from

by
guest
on
22
January
2026

4060 ESCGuidelines
7.1.3.2.2.Treatment. Upto97.4%ofallVAepisodesinARVCICD
eitherNSVTorinducibilityofSMVTat
recipientsareSMVT.TheveryhighterminationratebyATP(92%of
PES.695,696,701,703,705
allepisodes)independentfromVTcyclelengthstronglysupportsde-
InpatientswithARVCandsymptomshighly
vices with the capability for ATP.698 S-ICDs reduce lead-related
suspiciousforVA,PESmaybeconsideredforrisk IIb C
complicationsandhavebeenproventoeffectivelyshockterminate
stratification.695,705
VA in small cohorts of ARVC patients during short-term
follow-up.707 SecondarypreventionofSCDandtreatmentofVAs
Additional treatment to supress VA is often required. Although ICDimplantationisrecommendedinARVC
not confirmed by clinical data, beta-blockers are recommended as patientswithhaemodynamicallynot-toleratedVT I C
first-linetherapyinsymptomaticpatients. orVF.700
DataonAADstopreventVTrecurrencearelimitedtosmallob- InpatientswithARVCandnon-sustainedor
servationalstudiesandregistries.Ingeneral,AADtherapyhaslimited sustainedVAs,beta-blockertherapyis I C
efficacy. Although sotalol was effective to prevent inducibility of recommended.
VT,708 it did not supress clinically relevant arrhythmias.690,708 InpatientswithARVCandrecurrent,
Treatmentwithamiodaroneorclass1drugswasassociatedwitha symptomaticSMVTorICDshocksforSMVT
trendtolowerVTrecurrenceascomparedwithsotalol.709Theadd- despitebeta-blockers,catheterablationin IIa C
itionofflecainidetobeta-blockers/sotalolwasbeneficialinasmallco-
specializedcentresshouldbe
hort.710 Catheterablationprovides an alternative. Endocardialand considered.482,709,714
adjuvantepicardialsubstrateablation,ifneeded,hasbeenassociated InARVCpatientswithindicationforICDs,a
withpromisingVT-freesurvival.Potentialproceduralrisks,drugside devicewiththecapabilityofATPprogrammingfor IIa B
effects, and the patient’s preference need to be taken into SMVTuptohighratesshouldbeconsidered.698
consideration.482
ICDimplantationshouldbeconsideredinARVC
patientswithahaemodynamicallytolerated IIa C
SMVT.692
RecommendationTable29—Recommendationsfor
diagnostic, risk stratification, sudden cardiac death InpatientswithARVCandrecurrent,
prevention,andtreatmentofventriculararrhythmias symptomaticVTdespitebeta-blockers,AAD IIa C
inarrhythmogenicrightventricularcardiomyopathy treatmentshouldbeconsidered.709,710
ManagementofrelativesofapatientwithARVC
Recommendations Classa Levelb
Inafirst-degreerelativeofapatientwithARVC,
I C
Diagnosticevaluationandgeneralrecommendations ECGandechocardiogramarerecommended.675
InpatientswithsuspectedARVC,CMRis
I B AAD,anti-arrhythmicdrug;ARVC,arrhythmogenicrightventricularcardiomyopathy;
recommended.676–678
ATP, anti-tachycardia pacing; CMR, cardiac magnetic resonance; ECG,
Inpatientswithasuspectedordefinitediagnosis electrocardiogram; ICD, implantable cardioverter defibrillator; LV, left ventricle;
NSVT,non-sustainedventriculartachycardia;PES,programmedelectricalstimulation;
ofARVC,geneticcounsellingandtestingare I B RV, right ventricle; SCD, sudden cardiac death; SMVT, sustained monomorphic
recommended.672,673 ventriculartachycardia;VA,ventriculararrhythmia;VT,ventriculartachycardia.
aClassofrecommendation.
Avoidanceofhigh-intensityexerciseis bLevelofevidence.
recommendedinpatientswithadefinitediagnosis I B cThe 2020 ESC Guidelines on sports cardiology and exercise in patients with
ofARVC.683–685 cardiovasculardisease.4
dPresyncopeorpalpitationssuggestiveofVA.
Avoidanceofhigh-intensitycexercisemaybe
consideredincarriersofARVC-related IIb C
pathogenicmutationsandnophenotype.683,687
7.1.3.3.Hypertrophiccardiomyopathy
Beta-blockertherapymaybeconsideredinall
IIb C
patientswithadefinitediagnosisofARVC. HCMischaracterizedbyincreasedLVwallthicknessnotexplained
byabnormalloadingconditions(suchashypertensionorvalvulardis-
RiskstratificationandprimarypreventionofSCD
ease).128,715Becausethenaturalhistoryandmanagementdiffersac-
ICDimplantationshouldbeconsideredinpatients
cordingtotheunderlyingaetiologyofLVH,diagnosticwork-upisof
withdefiniteARVCandanarrhythmic IIa B
paramountimportance(seeSection7.1.3.5)andincludesCMRand
syncope.696,701,711–713
genetic
testing.716–725
HCM is usually caused by a mutation with
ICDimplantationshouldbeconsideredinpatients autosomal dominant inheritance, supporting cardiac screening in
withdefiniteARVCandsevereRVorLVsystolic IIa C first-degreerelatives,inparallelwithgenetictestingintheindexpa-
dysfunction.675,691 tient.Asarcomericgenemutationisidentifiedin30–60%,mostfre-
ICDimplantationshouldbeconsideredin quently in patients who are younger at diagnosis or with a family
symptomaticdpatientswithdefiniteARVC, IIa C historyofHCM.646,722
moderaterightorleftventriculardysfunction,and TheestimatedprevalenceofHCMinadultsis1in500.726Inchil-
Continued dren,theprevalenceismuchlower.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4061
AnnualmortalityrelatedtoHCMis1–2%inmoststudieswith exerciseinHCMpatientswithoutriskmarkersmaynotbeasso-
contemporary management strategies,128,715 and may be as low ciatedwithVA.733,734
as 0.5%.727 The annual rate of SCD or appropriate ICD therapy
is about 0.8% but is largely dependent on age and risk pro- 7.1.3.3.1.Riskstratificationandprimarypreventionofsuddencar-
file.85,728–730
HCM patients are at risk for heart failure, AF, and diacdeath. Inprimaryprevention,thechallengeremainstoidentify
stroke.128,715 Most HCM-related deaths at age ≤60 years occur the relatively small group of patients with the highest risk of SCD.
suddenly, whileolder patients die moreoften of strokeor heart NSVTisidentifiedoncontinuous(24/48h)ambulatoryECGmonitor-
failure.731SCDisoftenrelatedtoVA,whichcanbeaconsequence ing in 20–25% of patients.128,715 Its prevalence increases with age
of ischaemia, left ventricle outflow tract (LVOT) obstruction, or andcorrelateswithLVwallthicknessandLGEonCMR.716–721,735
supraventriculararrhythmias.SCDmayalsobetriggeredbyexer- TheprognosticvalueofNSVTforSCDismoreimportantinyoung
cise, and participation in competitive sport has been discour- patients (,30 years).735 The relation between the duration, fre-
aged.732 However, recent data suggest that even vigorous quency, or rate of NSVT and HCM prognosis remains unclear.735
ECG sinus rhythm – NegativeT wavesV2-V6 and inferior leads
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
ECGVT – RBBB-like, superior axis (apical LV origin)
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
CMR – Apical aneurysm with LGE
4-chamber 2-chamber
Figure22Typical features of hypertrophic cardiomyopathy associated with sustained monomorphic ventricular tachycardia. CMR, cardiac
magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; RBBB, right bundle branch block; VT,
ventricular tachycardia.
Downloaded
from

by
guest
on
22
January
2026

4062 ESCGuidelines
DocumentedNSVTduringexercisetestisveryrare,butwasasso- RecommendationTable30—Recommendationsfor
ciatedwithahigherriskofSCD.732Additionalriskfactorshavebeen risk stratification, sudden cardiac death prevention,
identifiedanda5-yearSCDriskstratificationscorebasedonseven andtreatmentofventriculararrhythmiasinhypertro-
piccardiomyopathy
factors(age,LVwallthickness,LAsize,LVOTgradient,NSVT,un-
explainedsyncope,andfamilyhistoryofSCD)hasbeendeveloped85
Recommendation Classa Levelb
(HCMRisk-SCD:
ternallyvalidated.85,728,729Thecalculatorisnotintendedforusein Diagnosticevaluationandgeneralrecommendations
eliteathletes,orinindividualswithmetabolicorinfiltrativediseases,
CMRwithLGEisrecommendedinHCMpatients
I B
oraftermyectomyoralcoholseptalablation.85 fordiagnosticwork-up.716–718
Additional factors not captured by the Risk-SCD model should
Geneticcounsellingandtestingarerecommended
I B
also be consideredinpatients with intermediate orlow calculated inHCMpatients.721–725
risk, including LV systolic dysfunction, apical aneurysm, extensive
Participationinhigh-intensityexercisemaybe
LGEonCMR,andpresenceofsingleormultiplesarcomericmuta- consideredforasymptomaticadultHCMpatients IIb C
tions (Figure 22).716,717,722,736–739 Extensive LGE on CMR defined withoutriskmarkers.733
as ≥15% of LV mass has been suggested as good predictor of
RiskstratificationandprimarypreventionofSCD
SCDinadults.However,thresholdsmaybedifficulttousebecause
LGE quantification is dependent on CMR acquisition, type, and Itisrecommendedthatthe5-yearriskofSCDis
amountofcontrast.
assessedatfirstevaluationandat1–3-year
I C
Periodic reassessment is mandatory as part of the longitudinal intervals,orwhenthereisachangeinclinical
evaluationofpatients.VAinducedbyPESisconsiderednon-specific, status.
althoughconflictingresultshavebeenreported.740,741 ICDimplantationshouldbeconsideredinpatients
Inchildrenfewdataonprimarypreventionwereavailableuntilthe aged16yearsormorewithanestimated5-year IIa B
recentdevelopmentofscoresandrelatedriskcalculators.83,84The riskofSD≥6%.c,85,728,729
HCM Risk-Kids score84 has been developed and externally vali- ICDimplantationshouldbeconsideredinHCM
dated742specificallyinchildrenwithHCM(1–16yearsofage)and patientsaged16yearsormorewithan
includesunexplainedsyncope,maximalLVwallthickness,largeleft intermediate5-yearriskofSCD(≥4to,6%)c
atrialdiameter,lowLVOTgradient,andNSVT( andwith(a)significantLGEatCMR(usually≥15%
IIa B
org).Incontrasttoadults,includingageandfamilyhistoryofSCD ofLVmass);or(b)LVEF,50%;or(c)abnormal
didnotimprovetheperformanceofthepaediatricmodel.Patients bloodpressureresponseduringexercisetestd;or
withpriorVForsustainedVT,knowninbornerrorsofmetabolism, (d)LVapicalaneurysm;or(e)presenceof
andsyndromiccausesofHCMwereexcluded.Thepredictivevalue
sarcomericpathogenicmutation.716,717,722,736–739
of LGE in children is less defined, although preliminary data were Inchildrenlessthan16yearsofagewithHCMand
reported.743 anestimated5-yearriskofSD≥6%(basedon
IIa B
HCMRisk-Kidsscoree),ICDimplantationshould
beconsidered.84,742
7.1.3.3.2. Treatment to prevent ventricular arrhythmia recur- ICDimplantationmaybeconsideredinHCM
rence. PatientssurvivingaCAduetoVT/VForhaemodynamically patientsaged16yearsormorewithanestimated IIb B
not-toleratedVTremainathighriskforfuturelife-threateningVA, 5-yearriskofSCDof≥4to,6%.c,85,728,729
andwillbenefitfromICDtherapy.128,744–746
ICDimplantationmaybeconsideredinHCM
There are no RCTs in HCM or cohort studies supporting a patientsaged16yearsormorewithalow
significant role of drugs to prevent SCD.128,715,747 Amiodarone estimated5-yearriskofSCD(,4%)candwith(a)
IIb B
mayreduceVAbutwithconflictingresultsregardingSCDpreven- significantLGEatCMR(usually≥15%ofLVmass);
tion.747,748Disopyramideandbeta-blockersareefficienttocontrol or(b)LVEF,50%;or(c)LVapical
symptoms and LVOT obstruction, but there is no evidence that aneurysm.716,717,722,736–739
theyreducetheriskofSCD.128,715Similarly,surgicalmyectomyor
SecondarypreventionofSCDandtreatmentofVAs
alcoholablationarenotrecommendedwiththeaimtoreducerisk
ICDimplantationisrecommendedinHCM
ofSCDinpatientswithLVOTobstruction.128,715FollowingICDim-
patientswithhaemodynamicallynot-toleratedVT I B
plantationforprimaryorsecondaryprevention,themostcommon
orVF.744–746
documentedVAsubtypeisSMVT,andATPissuccessfulin69–76.5%
of all episodes.749–751 Although data on drug efficacy are lacking, InpatientswithHCMpresentingwith
haemodynamicallytoleratedSMVT,ICD IIa C
AADs(beta-blockers,amiodarone,sotalol,sodiumchannelblockers)
implantationshouldbeconsidered.
should be considered in HCM patients with symptomatic VA.
InpatientswithHCMandrecurrent,symptomatic
CatheterablationmayalsobeconsideredinhighlyselectedHCMpa-
VA,orrecurrentICDtherapy,AADtreatment IIa C
tientswithSMVT,inwhomAADsareineffective,contraindicatedor
shouldbeconsidered.
not tolerated, as outcome after ablation is inferior compared to
othernon-ischaemicaetiologies.752–754 Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4063
Catheterablationinspecializedcentresmaybe Heartfailureisoneoftheleadingsymptomsinprimaryandsecond-
consideredinselectedpatientswithHCMand
aryRCM.760
recurrent,symptomaticSMVTorICDshocksfor IIb C In Fabry disease the majority of the reported cardiovascular
SMVT,inwhomAADareineffective, deathshavebeencategorizedasSCDinarecentsystematicreview
contraindicated,ornottolerated.753,754 of 13 studies including 4185 patients.761 Higher age, male gender,
LVH,LGE,andNSVThavebeenidentifiedaspotentialriskfactors
ManagementofrelativesofapatientwithHCM
associated with SCD events. However, SCD rates were reported
Inafirst-degreerelativeofapatientwithHCM,
I C inonly11ofthestudies,including623patients.Theretrospective,
ECGandechocardiogramarerecommended.
observational nature of most of these small, single-centre studies
AAD, anti-arrhythmic drug; CMR, cardiac magnetic resonance; ECG, and the low absolute number of cardiovascular deaths (36/623)
electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable andSCD(30/623)donotcurrentlyallowguidanceforprimarypre-
cardioverterdefibrillator;LGE,lategadoliniumenhancement;LV,leftventricle;LVEF,
ventionICDimplantation.761
left ventricular ejection fraction; SCD, sudden cardiac death; SD, sudden death;
SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; Amyloidosiscanbecausedbydifferentmisfoldedprecursorpro-
VF,ventricularfibrillation;VT,ventriculartachycardia.
teinsleadingtodepositsintissueandorgans.Cardiacamyloidosisis
aClassofrecommendation.
mainlyrelatedtolight-chainamyloidortransthyretinamyloid.The
bLevelofevidence.
cBasedontheHCMRisk-SCD: lattercanbesubdividedintowild-type,alsocalledsenileamyloid,
dDefinedasafailuretoincreasesystolicpressurebyatleast20mmHgfromresttopeak
moreoftencomplicatedbyAVconductiondelayandatrialarrhyth-
exercise,orafallof.20mmHgfrompeakpressure.
mias, and amyloid due to pathogenic mutations in the TTR gene. eBasedontheHCMkidriskscore:
Diseasemanifestationdependsonthemutation.Despiteadvances
inthetreatmentofamyloidlight-chainamyloidosis,outcomeisstill
7.1.3.4.Leftventricularnon-compaction poor in patients with manifest cardiac involvement.762 Causes of
LVNCcomprisesaheterogeneousgroupofdiseases.Thediagnosisis death are progressive heart failure, autonomic dysfunction, and
challenging,andvariousdiagnosticcriteriahavebeenproposed.The electromechanicaldissociation.762,763Thebenefitofprimarypre-
yieldofgenetictestsinindexpatientsislow.755
ventionICDimplantationinpatientswithcardiacamyloidosisisun-
The morphologicalphenotypeofnon-compactionbasedon im- certain. Currently, an ICD should be considered in patients with
agingparametersmayalsoappearinahealthypopulation.756
haemodynamically not-tolerated VT after careful discussion of
Ameta-analysisincluding2501LVNCpatientsrevealedariskof the competing risks of non-arrhythmic death and non-cardiac
cardiovascularmortalitysimilartothatofDCMpatients,withnore- death.
lationtotheextentoftrabeculation.757CMR-baseddetectionoffo-
cal fibrosis using LGE in LVNC with preserved ejection was
associatedwithseriouscardiacevents(aborteddeath,ICDtherapy,
RecommendationTable32—Recommendationsfor
implantablecardioverterdefibrillatorimplantationin
hearttransplantation[HTX]/LVAD)inanothermeta-analysisinclud-
patientswithcardiacamyloidosis
ing574patients(OR6.1;CI2.1–17.5;P,0.001).758Acombination
ofCMRcriteriawithsystematicgenotypingmayovercomecurrent
Recommendations Classa Levelb
uncertaintiesregardingriskstratification.759
AnICDshouldbeconsideredinpatientswith
RecommendationTable31—Recommendationsfor light-chainamyloidosisortransthyretin-associated IIa C
implantablecardioverterdefibrillatorimplantationin cardiacamyloidosisandhaemodynamically
leftventricularnon-compaction not-toleratedVT.
ICD,implantablecardioverterdefibrillator;VT,ventriculartachycardia.
Recommendations Classa Levelb aClassofrecommendation.
bLevelofevidence.
InpatientswithaLVNCcardiomyopathy
phenotypebasedonCMRorechocardiography,
implantationofanICDforprimarypreventionof IIa C 7.1.3.6.Neuromusculardisorders
SCDshouldbeconsideredtofollowDCM/ Analgorithmforriskstratification,SCDprevention,andtreatment
HNDCMrecommendations. ofVAsinmyotonicdystrophyispresentedinFigure23.
Arrhythmias are common and often the first manifestation of
CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HNDCM,
hypokineticnon-dilatedcardiomyopathy;ICD,implantablecardioverterdefibrillator;
neuromusculardisorders.764Myotonicdystrophyisthemostcommon
LVNC,leftventricularnon-compaction;SCD,suddencardiacdeath. muscular dystrophy in the adult population (prevalence 1 in 8000).
aClassofrecommendation.
Myotonicdystrophyistheconsequenceoftrinucleotiderepeatexpan-
bLevelofevidence.
sionintheendofDMPKgene,whichresultsinmis-splicingofSCN5A
andcardiacconductionsystemdelaysandarrhythmia.Duchennedys-
7.1.3.5.Restrictivecardiomyopathy trophyalsohasahighincidence(1in3500malebirths).Asmostpa-
Thephenotypeofrestrictivecardiomyopathy(RCM)israreandcan tientsdiebeforetheageof20,itisrarelyseeninadulthood.Other
betheconsequenceofdifferentaetiologies,includinginfiltrativedis- neuromusculardisorders, such asBecker (1in100000 male births)
orders (e.g. amyloidosis) and storage disease (e.g. Andersen–Fabry andfacioscapulohumeral(1in100000)dystrophies,arelesscommon.
disease), the identification of which is crucial for guiding therapy. Mostofthesedisordersareassociatedwithconductionandrhythm
2202CSE©
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4064 ESCGuidelines
Patient with myotonic dystrophy
Syncope or Aborted
Asymptomatic VT
palpitationsa cardiac arrest
Pacemakkker/ICDc
Spontaneous Spontaneous EPevaluation
YY implantation YY N
AAAV blockb AAAV blockb (Class I)
(Class I)
N
PR≥240 ms or EP evaluationd
QRS >120 ms or (Class IIa)
>40 y and atrial
arrhythmias or YY Pacemakkker/ICDc
>40 y and LGE implantation
on CMR (Class IIb)
N YY
Follow-up PR/QRS
(ClassI) sudden increase
N
Asymptomatic/ HV ≥70 ms BBR-VT Aborted cardiac Syncopea or
palpitations arrest/VT and
or subnodal palpitations
and negative non-BBRVT or
AAAV block and non-BBRVT
EPevaluation noVT induction
Catheter ablation
(Class I)
Pacemakkker/ICDc
Follow-up ICDimplantation ICD implantation implantation
(Class I) (Class I) (Class IIa) (Class I)
Figure23Algorithmforriskstratification,suddencardiacdeathprevention,andtreatmentofventriculararrhythmiainmyotonicdystrophy.AV,atrioven-
tricular; BBR-VT, bundle branch re-entrant ventricular tachycardia; CMR, cardiac magnetic resonance; EP, invasive electrophysiological evaluation; HV,
His-to-ventricleinterval;ICD,implantablecardioverterdefibrillation;LGE,lategadoliniumenhancement;N,No;VT,ventriculartachycardia,Y,Yes.aSyncope
orpalpitationshighlysuspiciousofarrhythmicorigin.bSpontaneousAVblock:thirdoradvancedsecond-degreeAVblock.cFactorsfavouringICDimplantation:
age,5,6,11CTGexpansion,6–9,13,16suddendeath(SD)orfamilyhistoryofSD,5ECGconductionabnormalities,16PRprolongation,13leftbundlebranchblock,5atrial
arrhythmias,6,16non-sustainedVT,5LVdysfunction,17significantLGEinCMR.14,15,18dFurthermanagementaccordingtooutcomeofEPevaluation.
disturbances,somelife-threatening,andwithmechanismsamenableto unless a cause, such as AV block, has been clinically documen-
specificanti-arrhythmictherapy.17Anti-arrhythmictherapyshouldbe ted.153 Sudden increase of PR interval and QRS duration have
considered,as muscular function and life expectancy are often only been associated with AV block and SCD in myotonic dystrophy
moderatelylimited.765Itisgenerallyrecommendedtotreatpatients despitetheabsenceofsymptoms,andelectrophysiologicalevalu-
withneuromusculardiseases who havesurvived a CAorhaveVAs ationshouldbeconsidered.766,767AnHVinterval≥70msshould
orventriculardysfunctioninthesamewayaspatientswithoutextra- prompt pacemaker implantation regardless of symptoms.
cardiac manifestations. However, the benefit of ICD implantation Induction of BBR-VT in a symptomatic patient strongly supports
should be balanced with the overall prognosis in some subtypes, BBR-VT ( ESC CardioMed chapter 42.5)768 as an underlying
suchasDuchennedystrophy. causeofsymptoms,andablationoftherightbundlebranchisre-
Symptoms may be the result of bradycardia or tachyarrhyth- commended.153Followingbundlebranchablation,theriskofAV
mias and invasive electrophysiological evaluation is warranted block at follow-up is considered particularly high due to
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4065
progressiveHis–Purkinjedisease,andapacemakershouldbeim-
ICDimplantationisrecommendedinpatients
planted. Prolonged PR or QRS intervals,13,16,80 concurrent atrial withmyotonicdystrophyandSMVToraborted I C
arrhythmias,6,16,80 and LGE at CMR14,15,18 in patients older than CAnotcausedbyBBR-VT.766
40 years have all been associated with AV block and SCD at
Invasiveelectrophysiologicalevaluationshouldbe
follow-up in myotonic dystrophy. Accordingly, pacemaker im-
consideredinpatientswithmyotonicdystrophy
IIa B
plantation may be considered even in the absence of symptoms.
andasuddenincreaseinthePRintervalorQRS
Although data are lacking, implantation of an ICD rather than a duration.766,767
pacemaker may be preferred in myotonic dystrophy patients,
Invasiveelectrophysiologicalevaluationshouldbe
with additional risk factors for VA and SCD (Figure 23).
consideredinpatientswithmyotonicdystrophy
Permanent pacemaker implantation may also be considered in andaPRinterval≥240msorQRSduration
patients with Kearns–Sayre syndrome, Emery–Dreiffus, or ≥120msorwhoareolderthan40yearsandhave IIa B
limb–girdlemusculardystrophywithanydegreeofAVblockbe-
supraventriculararrhythmiascorwhoareolder
cause of the substantial risk of rapid progression to total block. than40yearsandhavesignificantLGEon
Inpatientswithlimb–girdletype1BorEmery–Dreifussmuscular
CMR.c,5,14,16,766
dystrophies who have an indication for pacing or significant LGE
InmyotonicdystrophypatientswithoutAV
on CMR, ICD implantation should be considered.769
conductiondelayandasyncopehighlysuspicious
ImplantationofanICDratherthanapacemakermaybealsocon- IIa C
forVA,ICDimplantationshouldbe
sideredinpatientswithDuchenne/Becker,whenthereissignificant
considered.766
LGE on CMR.770,771 However, the general prognosis of these dis-
Inmyotonicdystrophypatientswithpalpitations
easesshouldbetakenintoconsideration.Inpatientswhohavesur-
highlysuspiciousforVAandinductionofa
vivedaCAduetoaSMVT,implantationofanICDisrecommended IIa C
non-BBR-VT,ICDimplantationshouldbe
whenotherthanBBR-VTs(e.g.scar-relatedVTs)areinducibleorif
considered.766
VTisnotinducible.Myotonicdystrophypatientswithasyncopelike-
Inpatientswithlimb–girdletype1BorEmery–
lyduetoaVA,evenifnotinducible,andthosewithpalpitationsand
Dreifussmusculardystrophiesandindicationfor IIa C
induction of a non-BBR-VT are considered at risk for arrhythmic
pacing,ICDimplantationshouldbeconsidered.769
SCD,andICDsshouldbeconsidered.
ImplantationofanICDmaybeconsideredin
Duetotheprogressivenature,annualfollow-upwithanECGis
patientswithDuchenne/Beckermuscular IIb C
recommended,evenintheconcealedphaseofthediseasewhenpa-
tientsareasymptomaticandtheECGisnormal.6,13Duetoslowpro-
dystrophyandsignificantLGEatCMR.770,771
gressionandthefactthatsignificantchangesareoftenreflectedon ImplantationofanICDoverapermanent
the surface ECG, serial electrophysiological evaluation to assess pacemakermaybeconsideredinmyotonic IIb C
AVconductionandarrhythmiainductionisnotrecommendedinpa-
dystrophypatientswithadditionalriskfactorsdfor
tientswithoutarrhythmiasuspicionorprogressionofECGconduc- VAsandSCD.
tiondisorders.767,772 Inmyotonicdystrophypatients,serial
electrophysiologicalevaluationofAVconduction
RecommendationTable33—Recommendationsfor andarrhythmiainductionisnotrecommended III C
risk stratification, sudden cardiac death prevention, withoutarrhythmiasuspicionorprogressionof
and treatment of ventricular arrhythmias in neuro- ECGconductiondisorders.772
musculardiseases
ManagementofVA
Recommendations Classa Levelb InsymptomaticpatientswithBBR-VT,catheter I C
ablationisrecommended.e,153,474,475,477
Generalrecommendations Inpatientswithmyotonicdystrophyundergoing
Annualfollow-upwithatleasta12-leadECGis ablationforBBR-VT,pacemaker/ICD I C
recommendedinpatientswithmuscular implantationisrecommended.153
I C
dystrophies,evenintheconcealedphaseofthe
AV,atrioventricular;BBR-VT,bundlebranchre-entrantventriculartachycardia;CA,
disease.6,13
cardiac arrest; CMR, cardiac magnetic resonance; ECG, electrocardiogram; ICD,
Itisrecommendedthatpatientswith implantable cardioverter defibrillator; LBBB, left bundle branch block; LGE, late
gadoliniumenhancement;LV,leftventricular;SCD,suddencardiacdeath;SD,sudden
neuromusculardisorderswhohaveVAsor
death; SHD, structural heart disease; SMVT, sustained monomorphic ventricular
ventriculardysfunctionaretreatedinthesame I C tachycardia;VA,ventriculararrhythmia;VT,ventriculartachycardia.
wayforarrhythmiaaspatientswithout aClassofrecommendation.
neuromusculardisorders.17,765
bLevelofevidence.
cLevelofevidenceC.
Riskstratification,primaryandsecondarypreventionofSCD dFactorsfavouringICDimplantation:Age,5,6,11CTGexpansion,6–9,13,16SDorfamily
history of SD,5 ECG conduction abnormalities,16 PR prolongation,13 LBBB,5 atrial
Invasiveelectrophysiologicalevaluationis arrhythmias,6,16 non-sustained VT,5 LV dysfunction,17 structural abnormalities in
recommendedinpatientswithmyotonic CMR.14,15,18
I C
eIn other cardiac conditions (e.g. aortic valve replacement) with BBR-VT, catheter
dystrophyandpalpitationsorsyncopesuggestive
ablationisalsorecommended.
ofVAorsurvivingaCA.153
Continued
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4066 ESCGuidelines
7.1.4.Inflammatorycardiacdiseases DCM.795 Development of DCM has been observed in 21% of pa-
Cardiac inflammation has been associated with altered myocardial tients with acute myocarditis over a mean follow-up period of 3
electricalpropertiesandarrhythmias,andhasbeenreportedinvari- years.796 The exact proportion of chronic DCM consecutive to
ouscardiomyopathiessuchas,obviously,myocarditis,butalsoinher- theprogressionofacutemyocarditisremainsunknown,butmyocar-
itedcardiomyopathiesorafterMI.773,774 ditishasbeenidentifiedasthecauseofDCMinupto12%ofcasesin
Inflammatorycardiomyopathiesarecharacterizedbymyocardial alargeretrospectivestudy.797InpatientswithSMVTofunclearaeti-
inflammation(i.e.myocarditis)astheprimarycauseofcardiacdam- ology,myocarditisshouldbesuspectedespeciallywhenCMRreveals
age,whereassecondarymyocardialinflammationsarecausedbyan subepicardialand/orintramuralabnormalfibroticmyocardialtissue.
initialmyocardialpathology.775,776 ThepresenceofLGEatCMRhasalsobeenassociatedwiththelate
Myocarditis,sarcoidosis,andChagas’diseaseareamongthemajor occurrenceofVAsinpatientswithendomyocardialbiopsy-proven
entitieswithininflammatorycardiomyopathies. viralmyocarditis.798–800
The management of documented VAs in chronic myocarditis is
7.1.4.1.Myocarditis similar to that of patients with DCM, including ICD implantation
Thediagnosisofmyocarditiscanbechallenging.Thereisnopathog- and the use of AADs. Catheter ablation can be effective to treat
nomonicclinicalpresentationofthisdisease,777withcardiacmanifes- SMVT, the arrhythmogenic substrate of which is often found on
tations ranging from subtle symptoms to severe heart failure, the epicardium of the lateral/basal left
ventricle.752,801–803
In one
complete AV block, and SCD.778 In young people, it is estimated publication,802 non-inducibility of VT after catheter ablation led to
that2–12%ofSCDarerelatedtomyocarditis.779–781
avoidanceofICDimplantationinone-thirdofpatients,withsubse-
Myocarditisisdiagnosedonendomyocardialbiopsybyestablished quentlynoVTrecurrenceduringfollow-up.
histological, immunological, and immunohistochemical criteria, as
well as polymerase chain reaction (PCR) to detect viral gen-
RecommendationTable34—Recommendationsfor
omes.782,783Thisimpliesthatendomyocardialbiopsy,althoughnot
sudden cardiac death prevention and treatment of
widely used, is the diagnostic gold standard for myocarditis.778,784
ventriculararrhythmiasinmyocarditis
In current practice, the diagnosis of myocarditis relies on clinical
presentation,elevatedtroponinlevel,ECGchanges,evidenceofLV Recommendations Classa Levelb
dysfunction, absence of significant CAD or valvular heart disease,
andsuggestivefindingsonCMRorPET-CT. Generalrecommendations
Inthecontextofsuspectedorconfirmedacutemyocarditis,pa- Inconfirmedorclinicallysuspectedacute
tients with a life-threatening presentation (fulminant myocarditis, myocarditis,itisrecommendedthatpatientswho
I C
sustainedVAs,orcompleteAVblock)aretobereferredtoaspecia- presentwithlife-threateningVAsarereferredtoa
lized centre.785,786 A specialized centre must have the capacity to specializedcentre.786,804
perform cardiac catheterization, endomyocardial biopsies, use SecondarypreventionofSCDandtreatmentofVA
mechanicalcirculatorysupportdevices,andmanagecomplexVAs.
Inpatientswithhaemodynamicallynot-tolerated
SustainedVAsmayoccurinacutemyocarditis.Inalargeseriesof
SMVToccurringinthechronicphaseof
patients,786in-hospitalVForCAwasreportedin2.5%ofcases.In I C
myocarditis,anICDimplantationis
anotherseriesofacutemyocarditisinchildren,787sustainedtachyar-
recommended.794,805
rhythmiaswerereportedin11.5%ofpatients,withVAsaccounting
Inpatientswithhaemodynamicallynot-tolerated
for most cases (79.5%). Tachyarrhythmias were associated with a
sustainedVTorVFduringtheacutephaseof
2.3-foldincreasedriskofdeath.787Giantcellmyocarditis,although IIa C
myocarditis,ICDimplantationbeforehospital
rare, has a higher risk of life-threatening VAs, which are seen in
dischargeshouldbeconsidered.788,794,806
14% of giant cell myocarditis patients on initial presentation, and
AADsshouldbeconsidered(preferably
thendevelopasrefractoryarrhythmiasinmorethanhalfofthepa-
amiodaroneandbeta-blockers)inpatientswith
tientsduringthecourseofthedisease.788,789 IIa C
symptomaticnon-sustainedorsustainedVAs
Themanagementofacutemyocarditisdependsonclinicalpresen-
duringtheacutephaseofmyocarditis.
tation,viralPCRfrommyocardialbiopsies,andhistologicalfindings.
Inpost-myocarditispatientswithrecurrent,
Inpatientswithsuspectedmyocarditiswhopresentwithmildheart
symptomaticVT,AADtreatmentshouldbe IIa C
failure,itisrecommendedtoavoidexerciseandusebeta-blockers
considered.
andACEinhibitors.790PatientswithVAsorAVblockmustbeadmit-
Catheterablation,performedinspecialized
tedtothehospitalandcontinuouslymonitored.
Treatmentofarrhythmiasinpatientswithinflammatoryheartdis- centres,shouldbeconsideredinpost-myocarditis
patientswithrecurrent,symptomaticSMVTor IIa C
ease does not differ from generally accepted clinical principles.
ICDshocksforSMVTinwhomAADsare
Symptomatic VAs may require AADs such as amiodarone and/or
beta-blockers.791–793Ofnote,inaretrospectiveobservationalstudy, ineffective,nottolerated,ornotdesired.752,801,802
Inpatientswithhaemodynamicallytolerated
patients with sustained VAs duringthe acute phase ofmyocarditis
(LVEF53+10%)hadahighrisk(45%at3years)ofVT/VFrecur- SMVToccurringinthechronicphaseof
IIa C
rencesduringfollow-up.794 myocarditis,ICDimplantationshouldbe
considered.
Myocarditis may resolve without sequelae, recur, or become
chronic. Thus, myocarditis is often considered a precursor of Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4067
Inpatientswithhaemodynamicallywell-tolerated whatever the LVEF, ICD should also be considered in patients with
SMVToccurringinthechronicphaseof
anindicationforpermanentcardiacpacingorthepresenceofsignificant
myocarditis,preservedLVfunctionandalimited
scaratCMR.833,834Indeed,asshownintworecentmeta-analyses,821,832
scaramenabletoablation,catheterablationmay IIb C theoccurrenceofVAishigherinpatientswithcompleteAVblock(OR
beconsideredasanalternativetoICDtherapy,
=2.19;P,0.01),andthepresenceofscaratCMRisassociatedwitha
afterdiscussionwiththepatientandprovidedthat higherriskofthecompositeendpointofventriculararrhythmicevents
establishedendpointshavebeenreached.c
andmortality(OR=10.74;P,0.00001).Awidelyaccepteddefinition
ofsignificantLGEisnotavailable.LGEin≥9/29segments(17LVand12
AAD, anti-arrhythmic drug; ICD, implantable cardioverter defibrillator; LV, left RVsegments)andLGEaffecting≥22%oftheLVmasshavebeenasso-
ventricular;SCD, suddencardiacdeath; SMVT, sustained monomorphicventricular
tachycardia; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular ciatedwitharrhythmicendpoints.820,827,835
tachycardia. Corticosteroid therapy is a mainstay of cardiac sarcoidosis
aClassofrecommendation.
treatment,buttheeffectofthistreatmentontheoccurrenceof
bLevelofevidence.
cVTnon-inducibilityandeliminationofelectrogramsconsistentwithconductiondelay.
VAshasonlybeenascertainedfromobservationalstudies.836–838
Obviously,baseduponpathophysiologyofthedisease,inflamma-
tionplaysaroleinthedevelopmentofventricularscarinpatients
withcardiacsarcoidosis.However,sofarthereisnoevidencethat
VAsaredirectlytriggered byactiveinflammationitself.Indeed,a
7.1.4.2.Cardiacsarcoidosis
scar-relatedintramuralorepicardialsubstrate(withapredilection
Sarcoidosisisamultisysteminflammatorydiseaseofunknowncause,
inperi-valvularregions)explainsmostVTsinpatientswithcardiac
withageneticpredisposition,807characterizedbytheaccumulation
sarcoidosis.839 The VT substrate was more likely located in seg-
of T lymphocytes, mononuclear phagocytes, and non-caseating
mentswith scar transmurality at CMR and a lower degree of in-
granulomasleadingtotissuescarring.808Althoughlunginvolvement
flammation on PET-scan.840 Catheter ablation may help to
ismostfrequent,anyorgancanbeaffected.Itisestimatedthat5%of
prevent VT,839,841,842 in particular if AAD treatment fails,837 but
patients with sarcoidosis have symptoms indicative of cardiac in-
VTrecurrencesarestillfrequent,752,839inparticularifcatheterab-
volvement. However, using advanced cardiac imaging modalities
lationisperformedduringactiveinflammation,withAADscontin-
(CMR/PET-CT), subclinical cardiac sarcoidosis is increasingly diag-
uedinmanypatients.839,843
nosed.808–811
Thediagnosisofcardiacsarcoidosisischallenging.Itcanmimicthe
ARVCphenotypeintheeventofapredominantRVinvolvement810
ortheheartistheonlyorganaffectedbysarcoidosis(so-called‘iso-
RecommendationTable35—Recommendationsfor
lated cardiac sarcoidosis’).812 Cardiac electroanatomical voltage risk stratification, sudden cardiac death prevention,
mappingmayhelpinthedifferentialdiagnosisbetweenisolatedcar- and treatment of ventricular arrhythmias in cardiac
diacsarcoidosisandARVC.813Thethreeusualcardiacmanifestations sarcoidosis
ofcardiacsarcoidosisareLVdysfunction,AVconductionabnormal-
Recommendations Classa Levelb
ities, and VAs. Complete AV block develops primarily during the
acute inflammatory phase as opposed to sustained VT, which fre- RiskstratificationandprimarypreventionofSCD
quentlydevelopsintheadvancedstageofthedisease(Figure24).814
ICDimplantationisrecommendedinpatients
In addition to isolated cardiac sarcoidosis,812 three independent
withcardiacsarcoidosiswhohaveaLVEF I B
factorshave been found associated with an adverse outcome and, ≤35%.812,828–830,832
particularly,theriskofVAs:(i)anLVEF,35%812;(ii)documentation
Inpatientswithcardiacsarcoidosiswhohavean
ofhigh-degreeAVblock815,816;and(iii)presenceofRVorLVscarring
atCMR(Figure25).817–821However,VAsandSCDmayoccurinpa- indicationforpermanentcardiacpacingrelatedto IIa C
tientswithamildlyreducedornormalLVEF.PES,822–825PET-CT,826 high-degreeAVblock,ICDimplantationshouldbe
considered,regardlessofLVEF.816
andLGE-CMRhelpstratifytheriskofVAsinsuchpatients.827Ina
Inpatientswithcardiacsarcoidosiswhohave
series of 120 patients with biopsy-proven extracardiac sarcoidosis
aLVEF.35%butsignificantLGEatCMR
and preserved LV/RV systolic function, VT inducibility at PES was
afterresolutionofacuteinflammation, IIa B
low (6%) but associated with the composite endpoint of VAs and
ICDimplantationshouldbe
SCD,whichoccurredin3patients,allwithabnormalPETorCMR
(P=0.009).825Inacohortof66asymptomaticpatientswithbiopsy-
considered.817–819,821,833,834
Inpatientswithcardiacsarcoidosiswhohavea
proven extracardiac sarcoidosis and abnormal PET-CTor CMR, 8
LVEF35–50%andminorLGEatCMR,after
(11%)wereinducibleatPESand6of8hadVAordiedduringfollow- IIa C
up, compared to 1 of 68 non-inducible patients (P,0.0001). Of
resolutionofacuteinflammation,PESforrisk
stratificationshouldbeconsidered.
note,induciblepatientshadalowerLVEFatPES,whichfurtherde-
terioratedat2-yearfollow-up.823 Inpatientswithcardiacsarcoidosis,LVEF35–50%
ThebenefitofICDs,bothforprimaryandsecondaryprevention,has andinducibleSMVTatPES,ICDimplantation IIa C
beenreported.828–832DatasupporttheuseofICDsforprimarypre- shouldbeconsidered.823–825
vention of SCD in patients with LVEF ≤35%.812,830 In addition, Continued
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4068 ESCGuidelines
7.1.4.3.Chagas’cardiomyopathy
SecondarypreventionofSCDandtreatmentofVAs
Chagas’ disease, a myocardial disease caused by the parasite
ICDimplantationisrecommendedinpatients
Trypanosomacruzi,isthemostcommoncauseofnon-ischaemiccar-
withcardiacsarcoidosiswho(1)have
I B diomyopathyinLatinAmerica.Aftertheincubationperiod,thevast
documentedsustainedVT,or(2)aborted
majorityofinfectedpersonshaveminorornosymptoms,andvery
CA.812,828–830,832
few(,1%)developacutemyocarditis.845However,peoplearein-
Inpatientswithcardiacsarcoidosisandrecurrent, fected for life, and years to decades after the initial infection 20–
symptomaticVA,AADtreatmentshouldbe IIa C
30% of them will develop cardiomyopathy,846 which can lead to
considered.
heart failure, heart block and atrial and ventricular arrhythmias.
Catheterablation,inspecializedcentres,maybe
SCD, particularly due to VF, is the most common cause of death
consideredincardiacsarcoidosisICD-recipients inpatientswithChagas’cardiomyopathy.847,848Ariskscoredevel-
withrecurrent,symptomaticSMVTorICD IIb C opedbyRassietal.849aswellasthepresenceofmyocardialfibrosis
shocksforSMVT,inwhomAADsareineffective, atLGE-CMR850areusefulinassessingtheriskofdeathinChagas’dis-
contraindicated,ornottolerated.839,841,842
easepatients.However,whethersuchriskstratificationcantranslate
AAD, anti-arrhythmic drug;AV, atrio-ventricular; CA,cardiac arrest; CMR, cardiac
intoclinicalbenefitthroughICDtreatmentneedstobeassessedin
magneticresonance;ICD,implantablecardioverterdefibrillator;LGE,lategadolinium prospective trials, also considering the high annual mortality in
enhancement; LVEF, left ventricular ejection fraction; PES, programmed electrical ChagaspatientswithICDs.851
stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic VT; AV,
ventriculararrhythmia;VT,ventriculartachycardia. AlthoughICDimplantationmayseemreasonableforthesecond-
aClassofrecommendation. ary prevention of SCD in patients with Chagas’ cardiomyopathy,
bLevelofevidence. there are controversial studies851–856 about the benefits and risks
Patients with cardiac sarcoidosis
Aborted cardiac arrest or ICD implantation
sustainedVT or LLLVEF ≤35% Y (Class I)
N
Indication fffor permanent
Y
cardiac pacing
N
Significant LGEa Y
N
LLLVEF 35-50%
N and minor LGE
Y
PES
(Class IIa)
ICD implantation
Follow-up N SMVT inducible Y
(Class IIa)
Amiodarone
(Class IIa)
Symptomatic recurrentVVVA
Catheter ablation
(Class IIb)
Figure24Algorithmforsuddencardiacdeathpreventionandtreatmentofventriculararrhythmiainpatientswithcardiacsarcoidosis.ICD,implantable
cardioverterdefibrillator;LGE,lategadoliniumenhancement;LVEF,leftventricularejectionfraction;N,No;PES,programmedelectricalstimulation;
SMVT,sustainedmonomorphicventriculartachycardia;VA,ventriculararrhythmia;VT,ventriculartachycardia;Y,Yes.aLGEaffecting≥9/22segments
or≥22%oftheLVmasshasbeenassociatedwitharrhythmicendpoints.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4069
ECG sinus rhythm – Prominent R’wave inV1-V3a
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
ECGVT – LBBB-like, inferior axis (RVOT origin)
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
CMR PET-CT
Basal LV and RV free wall LGE Lateral and basal-septal LV increased 18FDG uptake
Figure25Typicalfeaturesofcardiacsarcoidosisassociatedwithsustainedmonomorphicventriculartachycardia.CMR,cardiacmagneticresonance;
ECG,electrocardiogram;LBBB,leftbundlebranchblock;LGE,lategadoliniumenhancement;LV,leftventricle;PET-CT,positronemissiontomography
CT;RV,rightventricle;RVOT,rightventricularoutflowtract;VT,ventriculartachycardia.aNotetheprominentR′inV1toV3,apatternfrequentlyfound
incardiacsarcoidosiswithRVinvolvement.844
ofICDimplantationinthesepatients.Indeed,ameta-analysisofob- and a high 9.0% annual mortality rate in 1041 ICD patients with
servationalstudiesfoundnobenefitofICD(n=483)vs.amiodarone Chagas’disease.851
(n=115) for the secondary prevention of SCD in patients with Amiodarone857andcatheterablation858–860havebeensuccessful-
Chagas’diseaseasall-causeannualmortalityrateswerecomparable lyusedtocontrolrecurrentVAsinsomepatients.Aswithvarious
in both groups (9.7% and 9.6%, respectively).856 Another forms ofmyocarditis, thearrhythmogenic substrateis often found
meta-analysisfounda4.7%annualincidenceofinappropriateshocks attheepicardiuminChagas’cardiomyopathy.
Downloaded
from

by
guest
on
22
January
2026

4070 ESCGuidelines
Recommendation Table 36 — Recommendations the LVEF remained ≤35% did not show survival benefit from
for the treatment of ventricular arrhythmias in ICDimplantation,probablyrelatedtothehighcompetingriskof
Chagas’ cardiomyopathy
death from heart failure and relevant comorbidities in this
population.869,870
Recommendations Classa Levelb
InpatientspresentingwithSMVTafteraorticvalvereplacement,
Amiodaroneshouldbeconsideredtoreduce PES is indicated because of the high probability of BBR-VT as the
arrhythmiaburdeninpatientswithChagas’ underlying mechanism—an arrhythmia that is potentially curable
IIa C
cardiomyopathywhopresentwithsymptomatic withcatheterablation.871,872
PVCsorVT.857 SCDhasbeenreportedtooccurin0.2–0.4%ofpatientswithMVP
InpatientswithChagas’cardiomyopathyand peryear.873,874However,thetotalnumberofpatientsdyingsudden-
recurrent,symptomaticSMVTorICDshocksfor lywiththisconditionismostlikelyunderestimated,consideringthat
SMVTinwhomAADsareineffective,
itisacommonvalvevariantwithanestimatedprevalenceof2–3%in
IIa C contraindicated,ornottolerated,catheter thegeneralpopulation.875
ablationinspecializedcentresshouldbe Using rigorous criteria for morphologic diagnosis (i.e. myxoma-
considered.859,860 tous mitral valve) at post-mortem, MVP has been associated with
InpatientswithChagas’cardiomyopathyand 7%ofallcasesofjuvenileSCDintheRegistryoftheVenetoregion
symptomaticVTinwhomAADs(amiodarone of Italy.228 Recent pathological and clinical studies on SCD victims
andbeta-blockers)areineffectiveornot IIb C with MVP orpatients with MVP andmajor VAs have providedin-
tolerated,ICDimplantationmaybe sights into the potential VA
substrate.130,228,876–880
In particular,
considered.851,854–856 myocardialfibrosisaffectingboth theinfero-basalLVfreewalland
the papillary muscles has been recognized in pathological and
AAD, anti-arrhythmic drug; ICD, implantable cardioverter defibrillator; PVCs, LGE-CMR studies.228 The scarring process has been related to
premature ventricular complexes; SMVT, sustained monomorphic ventricular
tachycardia;VT,ventriculartachycardia. mechanicalstretchsecondarytotheexcessivemobilityofthemitral
valveapparatusduetomitralvalvulardisjunctionandposteriorsys-
toliccurling.876ThisindicatesapromisingroleofCMRforarrhyth-
mic risk stratification beyond traditional electrophysiological
7.1.5.Valvularheartdisease markers.
Valvular heart diseases predispose to SCD both in the pre- Proposedcriteriaforan‘arrhythmicMVPsyndrome’thathave
operativeperiodandaftervalvularsurgery.Inoldcohortsofsymp- been associated with an increased risk for SCD include: young
tomatic,non-operatedpatientswithsevereaorticstenosisorse- adults (most often women), QTc prolongation and/or negative
vere mitral regurgitation, the incidence of SCD was 50–60%. In T-waveininferiorECGleads,mitralannulardisjunction,bi-leaflet
these studies, the rate of SCD secondary to VA was not involvement on echocardiography, frequent PVCs, or non-
specified.861,862 sustained PVT on Holter monitoring and/or exercise test-
RatesofSCDinpatientswithprostheticvalvesrangefrom15% ing.130,228,876–880 Reduced LVEF and/or myocardial fibrosis on
to30%,withanestimatedannualriskof0.2–0.9%.863Inalargeser- CMR may add to the risk profile. These data are mainly derived
iesof1533patientswhounderwentaorticormitralvalvereplace- fromsmallretrospectiveseriesofSCDsurvivorsandpost-mortem
ment, 6% of deaths were caused by arrhythmias.864 A recent studies.Therefore,identificationofthesmallsubgroupofpatients
reportof3726patientsundergoingtranscatheteraorticvalveim- atriskofSCDremainschallenging.228,874Robustdatatosupport
plantation(TAVI)showed5.6%SCDduring22monthsoffollow- recommendations for risk stratification of SCD in patients with
up, emphasizing the remaining SCD risk also after valve MVParenotavailable.
replacement.865
Smallobservationalstudieshaveshownthatpatientswithresidual
LVdysfunctionaftervalvularsurgerywhoundergoICDimplantation
haveappropriatetherapyandmortalityratessimilartopatientswith
ischaemic or dilated cardiomyopathy.866–868 ICD implantation in RecommendationTable37—Recommendationsfor
these patients should therefore follow DCM/HNDCM sudden cardiac death prevention and treatment of
ventriculararrhythmiasinvalvularheartdisease
recommendations.
InpatientsafterTAVI,SCDhasbeenassociatedwiththepres-
Recommendations Classa Levelb
ence of new-onset conduction disturbances (LBBB, QRS .
160ms)andreducedLVEF≤40%.865SCD inthesepatientsmay PESwithstandbycatheterablationis
betheconsequenceofadvancedAVblock,andpermanentpacing recommendedinpatientswithaorticvalvedisease
indicationshouldfollowthe2021ESCGuidelinesoncardiacpacing andSMVTtoidentifyandablateBBR-VT, I C
andcardiacresynchronizationtherapy.2TheroleofICDimplant- especiallyifitoccursfollowingavalve
ationforpreventionofSCDafterTAVIislessclear.Tworecent intervention.871,872,881
retrospective analyses including a total of 203 patients in whom Continued
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4071
Inpatientswithvalvularheartdiseaseand combinationofsurgicalincisions,myocardialscarandresidualornew
persistentLVdysfunctionaftersurgical anatomicalabnormalitiesformthesubstrateforVAs(Figure26).
correction,(ifpossible)itisrecommendedthat I C RiskstratificationforSCDinCHDpatientsandnodocumented
ICDimplantationforprimarypreventionfollows sustained VA remains difficult due to a mixed patient population,
DCM/HNDCMrecommendations.868 theabsenceofRCTs,andrelativelysmallobservationalstudies.Inpa-
tientswithbiventricularphysiologyandasystemicLV,thestandard
BBR-VT, bundle branch re-entrant ventricular tachycardia; DCM, dilated criterionofanLVEF≤35%isusedforpatientselectionforprimary
cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD,
implantablecardioverterdefibrillator;LV,leftventricular;PES,programmedelectrical prevention ICD implantation.885,886 For patients with unexplained
stimulation;SMVT,sustainedmonomorphicventriculartachycardia. syncope,severearrhythmiasymptomssuchaspalpitationsorpre-
aClassofrecommendation.
syncopeandNSVT,PESshouldbeconsidered.887Inasymptomatic
bLevelofevidence.
patients with tetralogy of Fallot (TOF) but other indicators for a
VAsubstrate,electrophysiologicalevaluationmayrefineriskstratifi-
7.1.6.Congenitalheartdisease cation.888ThesurgicaleraandthetechniquesusedaffecttheVAsub-
Advancesinsurgicalrepairandmedicaltreatmenthaveimprovedthe strateandoccurrenceofVAsandshouldbeconsidered.Theuseofa
long-term prognosis of children born with congenital heart disease transannularpatchrepairinTOFpatients,forexample,wasfoundto
(CHD).Morethan90%nowsurvivetoadulthood,882andconsequently beassociatedwithalowerriskforVA.889Thebenefitofprimarypre-
theprevalenceofadultCHDhassteadilyincreased.883Withfewerpa-
ventionICDtherapyinpatientswithsingleorsystemicRVsisless
tientsdyingfromperi-operativeeventsandearlyheartfailure,SCDhas wellestablishedandrequiresconsiderationofdisease-andpatient-
becomealeadingcauseofdeathinadultswithrepairedCHD.884The specificfactors.890,891
Sustained VA in a patient with CHD
Evaluation ofresidual or new
anatomical abnormalities
(Class I)
Residual or new abnormalities
Y
requiring intervention
Pre-operative catheter mapping
and ablation before or during
the interventiona
(Class IIa)
N
Catheter or surgical intervention for
correctable lesions ± ICD
Simple or moderate CHD and
preserved biventricular function and Y
haemodynamically tolerated VT
Catheter ablationa
(Class I)
N
Recurrent symptomatic
ICD implantation
SMVT/ICD therapy despite N Successful ablation
(Class I)
medical treatmentb
Y
Catheter ablation Withhold of ICD
TOF Others implantationa
(Class I) (Class IIa) (Class IIb)
Figure26Algorithmforthemanagementofsustainedventriculararrhythmiainpatientswithcongenitalheartdisease.CHD,congenitalheartdisease;
ICD,implantablecardioverterdefibrillator;N,No;TOF,tetralogyofFallot;VA,ventriculararrhythmia;VT,ventriculartachycardia;Y,Yes.aDataderived
frompatientswithTOFandrelatedlesions.bInTOF,anti-arrhythmicdrugfailureisnotrequired.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4072 ESCGuidelines
InCHDpatientswithsustainedVAorCAsurvivors,acompre- InpatientswithCHDwithpresumedarrhythmic
hensiveevaluationofincitingfactors,includingcardiacimaging(par- syncopeandwitheitheratleastmoderate
IIa C
ticularly CMR) and haemodynamic assessment, is important ventriculardysfunctionorinducibleSMVTonPES,
(Figure26).892Ifpre-existingornewanatomicalabnormalitiesrequir- ICDimplantationshouldbeconsidered.887,889,902
ing intervention are detected, the treatment plan should consider
Inpatientswithadvancedsingleventricleor
pre-orintra-operativemappingandtransectionoftheVTsubstrate,
systemicRVdysfunctionwithadditionalrisk
because accessibility might be impaired post-operatively.888,893,894 factors,cICDimplantationmaybe IIb C
Pre-operative evaluation and intervention are especially important considered.890,891
inTOFpatientsundergoingsurgicalpulmonaryre-valving.Inselected
TetralogyofFallot
patientswithCHD(includingthosewithatrialbafflerepairfortrans-
InpatientsafterrepairofTOFwitharrhythmia
positionofthegreatarteries,FontanoperationandEbsteinanom-
symptomsandNSVT,electrophysiologic
aly), evaluation and treatment of SVT (such as intra-atrial IIa C
evaluationincludingPESshouldbe
re-entrant tachycardias or AV re-entrant tachycardias) with rapid
ventricularconductionshouldalsobeconsidered.890,895,896
considered.889,903–905
Intheabsenceofidentifiablereversiblefactors,ICDimplantation InpatientsafterrepairofTOFwitharrhythmia
for secondary prevention of SCD is recommended.349,350 While symptomsandapositivePES,oracombinationof IIa C
transvenous ICD systems have been most frequently used and
otherriskfactorsdandapositivePES,ICD
havetheadvantageofanti-tachycardiaandanti-bradycardiapacing, implantationshouldbeconsidered.
subcutaneousICDsmaybeanalternativeinselectedpatientswith InpatientsafterrepairofTOFwithoutarrhythmia
limitedvenousaccesstotheventricleorwithintracardiacshunts. symptoms,butwithacombinationofotherrisk
IIb C
InCHDpatients,MVTmostoftenarisesfromre-entranttachy- factors,delectrophysiologicevaluation,including
cardiasusinganatomicalisthmusesboundedbyvalves,patchmater- PES,maybeconsidered.
ial, and surgical incisions. Early mapping and ablation studies, InpatientswithrepairedTOFundergoingsurgical
particularlyinTOFpatients,identifiedcriticalanatomicalisthmuses ortranscutaneouspulmonaryvalvereplacement,
of reproducible anatomical location.897,898 Following this concept, pre-operativecathetermappingandtransection IIb C
those anatomical isthmuses can be reconstructed and transected ofVT-relatedanatomicalisthmusesbeforeor
insinusrhythmduringcatheterablationproceduresusingelectroa- duringtheinterventionmaybeconsidered.894
natomical mapping systems, achieving acute success rates of
AV,atrioventricular;CHD,congenitalheartdisease;CMR,cardiacmagneticresonance;
80%.888,899–901Theuseofconductionblockacrossanatomicalisth-
EF,ejectionfraction;ICD,implantablecardioverterdefibrillator;LV,leftvalve;NSVT,
musesasaproceduralendpoint,inadditiontonon-inducibilityofVT, non-sustained monomorphic ventricular tachycarda; NYHA, New York Heart
has further improved long-term ablation outcomes.888,899 Association;OMT,optimalmedicaltreatment;PES,programmedelectricalstimulation;
RV, right ventricular; SCD, sudden cardiac death; SMVT, sustained monomorphic
Accordingly, catheter ablation is recommended in particular in ventriculartachycarda;TOF,tetralogyofFallot;VT,ventriculartachycardia.
TOF patients with recurrent SMVT. Due to the complexity of aClassofrecommendation.
bLevelofevidence.
CHDpatientsaswellastheVTsubstrate,thoseproceduresshould
cDataaresparseandriskfactorsmaybelesion-specific,includingnon-sustainedVT,
beperformedincentreswithexpertiseincatheterablationofCHD NYHAII/III,severeAVvalveregurgitation,andwideQRS≥140ms(transpositionof
patients.CatheterablationmaybeconsideredinlieuofICDimplant- thegreatarteries).
dOtherriskfactorsincludemoderateRVorLVdysfunction,extensiveRVscarringon
ationinselectedTOFpatientswithSMVTandpreservedbiventricu-
CMR,906,907QRSduration≥180ms886,908andsevereQRSfragmentation.909,910
lar function, provided the combined procedural endpoint of
non-inducibilityandconductionblockacrosstheanatomicalisthmus
canbereached.888,899
RecommendationTable39—Recommendationsfor
secondary prevention of sudden cardiac death and
treatment of ventricular arrhythmia in congenital
RecommendationTable38—Recommendationsfor heartdisease
risk stratification and primary prevention of sudden
cardiacdeathincongenitalheartdisease Recommendations Classa Levelb
Recommendations Classa Levelb SecondarypreventionofSCDandtreatmentofVA
AllCHDpatients
RiskstratificationandprimarypreventionofSCD
InpatientswithCHDpresentingwithsustained
AllCHDpatients VAs,evaluationforresiduallesionsornew I B
InadultswithCHDwithbiventricularphysiology structuralabnormalitiesisrecommended.892,893
andaleftsystemicventriclepresentingwith InpatientswithCHDwithnottoleratedVT/
symptomaticheartfailure(NYHAII/III)andEF I C abortedCAduetoVF,ICDimplantationis
I C
≤35%despite≥3monthsofOMT,ICD
indicatedafterexclusionofreversible
implantationisindicated.885,886 causes.349,350
Continued Continued
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4073
InpatientswithCHDandrecurrent,symptomatic Isoproterenol,verapamil,orquinidinehavebeenemployedforacute
SMVTorICDshocksforSMVTnotmanageable treatment of recurrent ICD discharges or electrical
bymedicaltherapyorICDreprogramming, IIa C
storm.912,913,918,922–926Inseveralsmallstudies,quinidinewashighly
catheterablationperformedinspecializedcentres effectiveinreducingorevenpreventingarrhythmiainducibilitydur-
shouldbeconsidered.c899–901 ing programmed stimulation.923,924,926 Moreover, a retrospective
studyin46patientsshowedareductionofmeanICDshocksfrom
InselectedpatientswithCHD(includingatrial
bafflerepairfortranspositionofthegreatarteries, 7.5 per patient over 2.9 years to 0.9 shocks per patient over 3.7
years,withadecreaseinventricularstormsfrom36to3afterquini-
FontanoperationandEbsteinanomaly)
IIa C dineinitiation.922InpatientswithrecurrentepisodesofVFtriggered
presentingwithCA,evaluationandtreatmentof
byasimilarPVCunresponsivetomedicaltreatment,catheterabla-
SVTwithrapidventricularconductionshouldbe
considered.890,895 tionhas shown success(Figure
28).186,221,333,493,927–930PVCs
most
commonlyoriginatefromthePurkinjesystemandcanbeeliminated
TetralogyofFallot
with a high acute success rate of
87–100%.186,221,333,493,927–930
InpatientswithrepairedTOFwhopresentwith
Detailed electroanatomic mapping may also reveal localized struc-
SMVTorrecurrent,symptomaticappropriate turalalterations(62.5%inonestudy).248
ICDtherapyforSMVT,catheterablation I C
performedinspecializedcentresis
RecommendationTable40—Recommendationsfor
recommended.899–901
themanagementofpatientswithidiopathicventricu-
InpatientswithrepairedTOFwithSMVTwhoare larfibrillation
undergoingsurgicalortranscutaneouspulmonary
valvereplacement,pre-operativecatheter Recommendations Classa Levelb
IIa C
mappingandtransectionofVT-relatedanatomical
Diagnosticevaluation
isthmusesbeforeorduringtheintervention
shouldbeconsidered.888,893,894 ItisrecommendedthatidiopathicVFisdiagnosed
inaSCAsurvivor,preferablywithdocumentation
InpatientswithrepairedTOFwithapreserved
ofVF,afterexclusionofanunderlyingstructural, I B
biventricularfunctionandsymptomaticSMVT,
channelopathic,metabolic,ortoxicological catheterablationorconcomitantsurgicalablation IIb C
aetiology.222,911
performedinspecializedcentresmaybe
consideredasanalternativetoICDtherapy.899,901 Clinicaltesting(history,ECGandhighprecordial
leadECG,exercisetest,echocardiogram)of
IIb B
CA, cardiac arrest; CHD, congenital heart disease; ICD, implantable cardioverter first-degreefamilymembersofidiopathicVF
defibrillator;SCD,suddencardiacdeath;SMVT,sustainedmonomorphicventricular
patientsmaybeconsidered.222,278,916
tachycardia; SVT, supraventricular tachycardia; TOF, tetralogy of Fallot; VA,
ventriculararrhythmia;VF,ventricularfibrillation;VT,ventriculartachycardia. InidiopathicVFpatients,genetictestingofgenes
aClassofrecommendation.
relatedtochannelopathyandcardiomyopathy IIb B
bLevelofevidence.
cSpecificrecommendationsforTOF(ClassI-B). maybeconsidered.249,278,914,915
SecondarypreventionofSCDandtreatmentofVA
ICDimplantationisrecommendedinidiopathic
7.2. Primary electrical disease VF.352,917–919 I B
7.2.1.Idiopathicventricularfibrillation
Isoproterenolinfusion,verapamil,orquinidinefor
The diagnosis of idiopathic ventricular fibrillation (IVF) is made in acutetreatmentofanelectricalstormor
IIa C
SCA survivors, preferably with documented VF, after exclusion of recurrentICDdischargesshouldbeconsideredin
structural, channelopathic, metabolic, or toxicological aetiolo- idiopathicVF.912,913,918,922–924,926
gies.135,222,911–913Diagnostictestsincludebloodchemistry,ECG(in-
Quinidineshouldbeconsideredforchronic
cluding high lead), cardiac CT/coronary angiography, telemetry/ therapytosuppressanelectricalstormor IIa B
Holter,exercisestresstest,echocardiogram,sodium-channelblock- recurrentICDdischargesinidiopathicVF.923,924
ertestingandCMR(seeSection5.2.3,scenario3).135,222,911Genetic
Catheterablationbyexperienced
testingforchannelopathyandcardiomyopathygenesmaybeconsid-
electrophysiologistsshouldbeconsideredin
eredwithamutationyieldof3–17%.249,914,915Clinicalevaluationof idiopathicVFpatientswithrecurrentepisodesof IIa C
first-degreefamilymembersmaybeconsidered,butthediagnostic
VFtriggeredbyasimilarPVCnon-responsiveto
yieldislow.Inparticularthesignificanceofdetectedearlyrepolariza-
medicaltreatment.927–930
tionpattern(ERP)inasymptomaticrelativesisuncertain.182,916
InIVFpatients,ICDimplantationreducestheriskofarrhythmic
ECG,electrocardiogram;ICD,implantablecardioverterdefibrillator;PVC,premature
death by up to 68% compared to
amiodarone352,917–921 v ve en nt tr ri ic cu ul la ar rac ro rm hyp thle mx; iaS ;C VFA ,, vs eu nd trd ie cun lac ra fird bi ra ilc lata ir or ne .st; SCD, sudden cardiac death; VA,
(Figure 27). In observational studies with a mean follow-up of 5–6 aClassofrecommendation.
years,21.0–29.6%ofIVFpatientsexperiencedanarrhythmicrecur- bLevelofevidence.
rence, corresponding to an annual ICD shock rate of 3.6–5.7%,
whereas 4.5–17.5% experienced inappropriate shocks.919–921
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4074 ESCGuidelines
Patient with idiopathic ventricular fibrillation
ICD implantation
(Class I)
Genetic counselling and testing
(Class IIb)
Recurrent ICD shocks
Acute treatment:
Isoproterenol
VVVerapamil
Quinidine
(Class IIa)
Chronic treatment:
Quinidine
(Class IIa)
Recurrent ICD shocks
Catheter ablation of PVC triggers
(Class IIa)
Figure27Algorithmforthemanagementofpatientswithidiopathicventricularfibrillation.ICD,implantablecardioverterdefibrillator;PVC,premature
ventricularcomplex.
7.2.2.LongQTsyndrome(includingacquiredlong (a) Andersen–TawilSyndrome(LQT7),increasinglyconsidered
QTsyndrome) itsownentity.933,934
LQTSischaracterizedbyaprolongedQTintervalandVAsmainly (b) Timothy Syndrome (LQT8), characterized by prolonged
triggeredbyadrenergicactivation.Themeanageatpresentationis QT,syndactyly,cardiacmalformations,autismspectrumdis-
14years.TheannualrateofSCDinasymptomaticpatientswithun- orderanddysmorphism.935
treatedLQTShasbeenestimatedtobelessthan0.5%,82whileitin- (3) Autosomal-recessive LQTS (Jervell and Lange–Nielsen
creasestoaround5%inthosewithhistoryofsyncope.931 Syndrome),combiningextremeQTprolongationwithcongeni-
Rare variants in 17 genes932 have been associated with LQTS. taldeafness.936
However, the causality for several of the identified genes has been
questioned.166TheundisputedgenesarethosecausingLQT1,LQT2
This panel of experts has confirmed the diagnostic criteria pro-
and LQTS3: KCNQ1, KCNH2 and SCN5A, respectively, with gene-
specific triggers being exercise (LQTS1), emotional stress (LQTS2)
posedinthepreviousversionoftheguidelines:aQTc≥480msor
andsleep(LQTS3).Geneticscreeningidentifiesamutationin75%of a LQTS risk score .3937 (Table 10) for clinical diagnosis (Figures
29 and 30). In the presence of arrhythmic syncope or CA, a QTc
LQTScasesandthreemaingenesaccountfor90%ofpositivelygeno-
typedcases.178ThesubtypesofLQTSmaybegroupedasfollows:
≥460msissufficienttoconsideradiagnosisofLQTS.Achallenge
fortheclinicianisestablishingthedurationoftheQTintervalinpa-
(1) Autosomal-dominant LQTS (prevalence: 1 in 2500) without tientswithbroadQRScomplexes(e.g.inthepresenceofventricular
extra-cardiacmanifestation. pacingorventricularconductiondefects).Inthissetting,aformula
(2) Autosomal-dominant LQTS with extra-cardiac manifestation, has been proposed that adjusts QT by QRS duration.938 While
comprising: measuring the QT, the patient moving briskly from recumbent to
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4075
ECG sinus rhythm – short-coupled PVCs
Telemetry tracings – short-coupled PVC inducingVF
Figure28Idiopathicventricularfibrillationtriggeredbyshort-coupledprematureventricularcomplexes.ECG,electrocardiogram;PVC,premature
ventricularcomplex;VF,ventricularfibrillation.
orthostaticpositionmaybehelpfulforthediagnosisofLQTS.232,939 have greater efficacy in reducing arrhythmic risk.940,944–946
Epinephrinechallengeisnotrecommendedasa routinediagnostic Clinical, electrocardiographic and genetic parameters should be
tool,asreproducibilityismodest.137Patientswithaclinicaldiagnosis considered for the individual risk estimation.82 Recently, risk
ofLQTSarerecommendedtoundergogeneticcounsellingandtest- stratification based on QT interval duration and genotype has
inginspecializedcentrestoreceivegenotype-specificmanagement been integrated in a LQTS calculator (the 1-2-3 LQTS Risk
andpermitidentificationofrelativesatrisk.Relativeswithamutation calculator).947
but without QT prolongation still receive a diagnosis of LQTS, as Theutilityofgenetictestingisexemplifiedbytheneedtoavoid
they are at risk of experiencing VA, although less frequently than genotype-specificrisksandbytheuseofmexiletineasagenotype-
phenotype-positivepatients.940 specifictreatmentforLQT3,whichreducesthelengthofQTinterval
All LQTS patients receive advice on avoidance of hypokal- andthenumberofarrhythmicevents.948Itshouldbenotedthatdif-
aemia, QT-prolonging medications and genotype-specific trig- ferentmutationsinSCN5Ashowdifferentresponsestomexiletine.
gers.941–943 Beta-blockers are also recommended in all LQTS Forexample,selectedmutationsidentifiedinpatientsnotrespond-
patients. Non-selective beta-blockers nadolol and propranolol ing to mexiletine showed a distinctive electrophysiological profile
Downloaded
from

by
guest
on
22
January
2026

4076 ESCGuidelines
Table 10 Modified long QT syndrome diagnostic Giventheuncertainroleofbeta-blockersinLQT3,therearenoin-
score243
dications on whether mexiletine should be administered as a
stand-alone therapy or in combination with beta-blockers.
Findings Points
Considering that some mutations may not respond to mexiletine,
ECG QTc ≥480ms 3.5 itisadvisabletoperformoraltestingtoverifythattheQTcshortens
=460–479ms 2 40msbeforeprescribingchronictreatment.948
=450–459ms(inmales) 1 SurvivorsofaCAhaveahighriskofrecurrences,evenonbeta-
blockers (14% within 5 years on therapy), supporting the use of
≥480msduring4thminute 1
ICDinCAsurvivors.952Moreover,ICDimplantationisindicated
ofrecoveryfromexercise
when a patient experiences syncope and/or VA despite optimal
stresstest
pharmacological therapy, as syncopal events are associated with
Torsadedepointes 2
increased risk of CA.953,954 Women with LQTS, particularly
Twavealternans 1
LQT2,haveanincreasedriskofarrhythmiabothduringpregnancy
NotchedTwavein3leads 1 and especially first year post-partum.955 Silent carriers of muta-
Lowheartrateforage 0.5
tionspresentalow,butnotnegligible,riskofcardiacevents,and
Clinicalhistory Syncope Withstress 2 the use of beta-blockers should be considered in this group of
Withoutstress 1 patients.956
Familyhistory Familymember(s)withdefiniteLQTS 1 Leftcardiacsympatheticdenervation(LCSD)isrecommendedfor
UnexplainedSCDatage,30yearsin 0.5 symptomaticpatientsdespitebeta-blockerswhenICDiscontraindi-
first-degreefamily catedordeclined,orforanICDcarrierwhoexperiencesmultiple
Geneticfinding Pathogenicmutation 3.5 shocks while on beta-blockers. This is supported by the evidence
that LCSD, especially when performed with a video-assisted tech-
ECG,electrocardiogram;LQTS,longQTsyndrome;SCD,suddencardiacdeath.
DiagnosisofLQTSwithascore.3. nique, is safe and effective,957 well-tolerated by patients958 and
doesnothaveanegativeimpactoncardiovascularperformance.959
whenstudiedinvitro.949,950Additionally,inthecaseofmutationsthat However,becausecomplicationsdooccurandhalfofthepatients
cause overlapping syndromes, mexiletine does not induce ST seg- experiencebreakthrougheventsaftertheprocedure,LCSDisnot
ment elevation, while flecainide has been reported to do so.951 an alternative to ICD for high-risk patients.960 Prophylactic ICD
A
LQT1
LQT2
LQT3
B
I V1
II V2
III V3
aVR V4
aVL V5
aVF V6
Figure29LongQTsyndromeelectrocardiogramsandtorsade-de-pointesventriculartachycardia.(A)ECGcharacteristicsinthethreemajorLQTS
phenotypes.(B)ExampleofTorsade-de-pointesinamalepatientwithaSCN5A(c.1238C.A,p.A413E)mutation.LQT,LongQT.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4077
A Brisk StandingTest
Recumbent Standing
B T wave alternans
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
Figure30BriskstandingelectrocardiogramchangesandTwavealternansinLongQTsyndromepatients.(A)ECGchangesduringbriskstandingtestin
amaleLQTSpatientwithKCNH2(p.S818L)mutation,increasedheartrateisassociatedwithlessadaptationofQTinterval.(B)Twavealternansinamale
patientwithCACNA1C(p.G406R)mutation.
therapy in addition to OMT may be considered in asymptomatic
LQTS patients identified with high-risk according to the 1-2-3 Routinediagnostictestingwithepinephrine III C
LQTS Risk calculator.947 PES is not useful for risk stratification in challengeisnotrecommendedinLQTS.137
LQTS.961 GeneralrecommendationstopreventSCD
Figure31illustratesthealgorithmforthemanagementofpatients
ThefollowingisrecommendedinLQTS:
withlongQTsyndrome. (cid:129) AvoidQT-prolongingdrugs.c
(cid:129) Avoidandcorrectelectrolyteabnormalities. I C
RecommendationTable41—Recommendationsfor
(cid:129) Avoidgenotype-specifictriggersfor
themanagementofpatientswithlongQTsyndrome
arrhythmias.943
Beta-blockers,ideallynon-selectivebeta-blockers
Recommendations Classa Levelb (nadololorpropranolol),arerecommendedin
LQTSpatientswithdocumentedQTinterval I B
Diagnosis
prolongation,toreduceriskofarrhythmic
ItisrecommendedthatLQTSisdiagnosedwith events.940,945,946
eitherQTc≥480msinrepeated12-leadECGs
I C MexiletineisindicatedinLQT3patientswitha
I C
withorwithoutsymptomsorLQTSdiagnostic prolongedQTinterval.948
score.3.
Beta-blockersshouldbeconsideredinpatients
InpatientswithclinicallydiagnosedLQTS,genetic I C withapathogenicmutationandanormalQTc IIa B
testingandgeneticcounsellingarerecommended. interval.82
ItisrecommendedthatLQTSisdiagnosedinthe
Riskstratification,preventionofSCDandtreatmentofVA
presenceofapathogenicmutation,irrespectiveof I C
ICDimplantationinadditiontobeta-blockersis
theQTduration.
recommendedinLQTSpatientswith I B
TheLQTSdiagnosisshouldbeconsideredinthe
presenceofaQTc≥460msand,480msin
CA.952,953,962,963
repeated12-leadECGsinpatientswithan IIa C ICDimplantationisrecommendedinpatients
withLQTSwhoaresymptomaticdwhilereceiving I C
arrhythmicsyncopeintheabsenceofsecondary
causesforQTprolongation.952,962,963
beta-blockersandgenotype-specifictherapies.
Continued
Continued
Downloaded
from

by
guest
on
22
January
2026

4078 ESCGuidelines
LCSDisindicatedinpatientswithsymptomaticd ICDimplantationmaybeconsideredin
LQTSwhen:(a)ICDtherapyiscontraindicatedor asymptomaticLQTSpatientswithhigh-risk
declined;(b)patientisonbeta-blockersand I C profile(accordingtothe1-2-3LQTSRisk
IIb B
genotype-specificdrugswithanICDandexperiences calculator)inadditiontogenotype-specific
multipleshocksorsyncopeduetoVA.541,957–959 medicaltherapies(mexiletineinLQT3
EitherICDimplantationorLCSDshouldbe patients).82,940,947,948
consideredinpatientswithsymptomaticdLQTS, Invasiveelectrophysiologicstudyisnot
III C
whenbeta-blockersandgenotype-specific IIa C recommendedinLQTS.961
therapiesarenottoleratedorcontraindicatedat
CA,cardiacarrest;ECG,electrocardiogram;ICD,implantablecardioverterdefibrillator;
thetherapeuticdose. LCSD,leftcardiacsympatheticdenervation;LQTS,longQTsyndrome;SCD,sudden
InLQTS,itshouldbeconsideredtocalculatethe cardiacdeath;VA,ventriculararrhythmia.
arrhythmicriskbeforeinitiationoftherapybasedon IIa C
aClassofrecommendation.
bLevelofevidence.
thegenotypeandthedurationofQTcinterval.940 c
dArrhythmicsyncopeorhaemodynamicallynon-toleratedVA.
Continued
Patient with long QT syndrome
Asymptomatic patient
Asymptomaticpatient with
Syncope prior to with or without pathogenic
Aborted cardiac arrest pathogenicmutation
medical treatment mutation and
without QT prolongation
QT prolongation
General recommendationsa (Class I)
Beta-blockkkersb (Class I) Beta-blockkkersb (Class IIa)
SCN5A mutation (LQT3):: Mexiletine (Class I)
If LQT1,, LQT2 or LQT3,
assess arrhythmic risk
Arrhythmic syncope or
with genotype and QTc
YY non-toleratedVVVA
(1-2-3-LQTS-Risk
under medical therapppy
risk(cid:2)calculator)
(Class IIb)
N
Medical therapppy High risk fffeatures,
N contraindicated, based on genotype N Follow-up
or not tolerated and QTc
Follow-up YY YY
ICD implantation
LCSD
(Class IIb)
(Class IIa)
ICD implantation
(Class IIa)
ICD contraindicated,
ICD implantation LCSD
declined or
(ClassI) (Class I)
recurrent ICD shocks
Figure31AlgorithmforthemanagementofpatientswithlongQTsyndrome.ICD,implantablecardioverterdefibrillator;LCSD,leftcardiacsympa-
theticdenervation;LQT,longQT;N,No;VA,ventriculararrhythmia;Y,Yes.aGeneralrecommendations:avoidanceofQT-prolongingdrugs(
crediblemeds.org),correctionofelectrolyteabnormalities(hypokalaemia,hypomagnesaemia,andhypocalcaemia),avoidanceofgenotype-specifictriggers
forarrhythmias(strenuousswimminginLQT1,exposuretoloudnoisesinLQT2).bPreferredbeta-blockers:nadololandpropranolol.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4079
7.2.3.Andersen–TawilsyndromeType1 7.2.4.Brugadasyndrome
Andersen–TawilsyndromeType1,alsoclassifiedasLQT7,isararedis- Thetype1BrugadaECGpatternischaracterizedbyJpointelevation
ease(1:1000000)characterizedbythreemainsymptoms:frequentVA of.2mVwithcovedSTelevationandTwaveinversioninatleast
(e.g.bidirectionalVT),dysmorphologiesandperiodicparalysis.964–967
onerightprecordialECGlead,V1orV2,positionedinthesecond,
Theinwardrectifiercurrent(I )decreasedbyKCNJ2lossoffunction third or fourth intercostal spaces (Figure 32). It may occur either
K1
mutation968causes an increase inU waveamplitude rather than QT spontaneously or be induced by exposure to sodium channel-
prolongation.964,967–970SyncopeordocumentedVTisassociatedwith
blocking drugs or
fever.135,231,973–978
It is mandatory to exclude
life-threateningVA,andastudyfounda5-yearprobabilityof7.9% other conditions that may explain the type 1 pattern, so-called
oflife-threateningVA.967Inpatientswithsustainedhaemodynamic- phenocopies.979
ally not-tolerated VT or CA, an ICD is recommended.964,967 BrS is diagnosed in patients without other heart disease and a
Flecainide and/or beta-blockers seem to reduce VA,964,970,971 spontaneous type 1 pattern, regardless of symptoms, due to its
whereas amiodarone may be proarrhythmic and should only be rarity in the general population and association with
usedwithanICD.967Inpatientswithsyncopedespitemedicalther- risk.231,979,980The type1 pattern mayalsobeinduced byadmin-
apy,anICDorILRshouldbediscussed.967 istrationofasodiumchannel-blockingdrugasadiagnostictestin
patientssuspectedtohaveconcealedBrSbutwithoutaspontan-
eous type 1
ECG.135,136,231,387,973,978,981–985
However, provoca-
tion with drug or fever is less specific than previously thought,
RecommendationTable42—Recommendationsfor
with 2–4% prevalence in healthy subjects and higher prevalence
management of patients with Andersen–Tawil
in patients with AV nodal reentry tachycardia or an accessory
syndrome
pathwayinonestudy.977,978,986Intheopinionofthispanelofex-
Recommendations Classa Levelb perts, an induced type 1 ECG pattern therefore requires other
clinical features, such as documented PVT/VF, arrhythmic syn-
Diagnosis cope, or relevant family history.
Genetictestingisrecommendedinpatientswith TheyieldofgenetictestinginBrSpatientsisapproximately20%,
I C
suspectedAndersen–Tawilsyndrome.964,967 with the SCN5A gene the only gene with evidence of association
Andersen–Tawilsyndromeshouldbeconsidered for clinical testing purposes.164,980 Phenotype and genotype mis-
inpatientswithoutSHDwhopresentwithatleast matchisseeninSCN5Afamilies,whichisexplainedbyvariableeffects
twoofthefollowing: of mutation severity and a polygenic risk score derived from
(cid:129) ProminentUwaveswithorwithout genome-wideassociationstudies.170,979,987Recentdataalsosupport
prolongationoftheQTinterval apotentialforprognostication.988,989
IIa C
(cid:129) Bidirectionaland/orpolymorphicPVCs/VT Psychotropic drugs, selected AADs, anaesthetic agents, cocaine,
(cid:129) Dysmorphicfeatures excessivealcoholintakeandfeverarepotentialtriggerstoexacer-
(cid:129) Periodicparalysis batethetype1patternandtriggerVF.231,297Theriskofrecurrent
(cid:129) KCNJ2pathogeniclossoffunction VFamongpatientspresentingwithCAis48%at10years.ICDim-
mutation.964,965,967,968,972 plantation is therefore indicated in symptomatic BrS patients who
Riskstratification,preventionofSCDandtreatmentofVA are survivors of CA or have documented spontaneous sustained
VA (Figure 33).980,990–994 Approximately one-third of BrS patients
ICDimplantationisrecommendedinpatients
present with syncope.995 The risk of arrhythmic events in BrS pa-
withAndersen–TawilsyndromeafterabortedCA I C
tients with unexplained syncope is 4 times higher than the risk in
ornot-toleratedsustainedVT.964,967 asymptomaticpatients.155,990–992,994,996Detailedpatienthistory,in-
Beta-blockersand/orflecainidewithorwithout
cludingabsenceofprodromeorspecifictriggers,isessentialfordis-
acetazolamideshouldbeconsideredinpatients
IIa C tinguishingarrhythmicfromnon-arrhythmicsyncope.Nonetheless,
withAndersen–Tawilsyndrometotreat
the aetiology of syncope is difficult to determine in up to 30% of
VA.964,970
BrS patients. In small studies, arrhythmia detected by ILR changed
AnILRshouldbeconsideredinpatientswith clinicalmanagementin20–36%oftheBrSpatientswithunexplained
Andersen–Tawilsyndromeandunexplained IIa C syncope.997–999
syncope.
Asymptomaticpatientsrepresentamajorityofnewlydiagnosed
ICDimplantationmaybeconsideredinpatients BrS patients with an incidence of arrhythmic events of 0.5% per
withAndersen–Tawilsyndromewhohavea
IIb C
year.1000,1001Theirriskstratificationremainschallenging.Aspon-
historyofunexplainedsyncopeorsufferfrom taneoustype1ECGpattern,aswellasotherECGmarkerssuchas
toleratedsustainedVT.967
earlyrepolarizationpatternandQRSfragmentation,havebeenas-
CA,cardiacarrest;ICD,implantablecardioverterdefibrillator;ILR,implantableloop sociatedwithhigherrisk.980,992,1002,1003Somehavebeenincorpo-
recorder;PVCs,prematureventricularcomplexes;SCD,suddencardiacdeath;SHD, rated into risk scores, although their utility in intermediate-risk
structuralheartdisease;VA,ventriculararrhythmia;VT,ventriculartachycardia. patientsremainslow.1004,1005Electrophysiologicalstudiesremain
aClassofrecommendation.
bLevelofevidence. controversial. A multicentre pooled analysis showed that
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4080 ESCGuidelines
A Brugada type 1 pattern ECG
I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
B Early repolarization pattern ECG
II
III
Figure32Typicalexamplesof(A)Brugadatype1electrocardiogram,and(B)earlyrepolarizationpatternelectrocardiogram.ECG,Electrocardiogram.
RecommendationTable43—Recommendationsfor
inductionofsustainedVAduringelectrophysiologicalstudieswas
managementofpatientswithBrugadasyndrome
associated with a higher future risk of VA.155 Inducibility, how-
ever,wasassociatedwithapotentiallyclinicallyactionableresult Recommendations Classa Levelb
onlyinasymptomaticpatientswithaspontaneoustype1Brugada
patternECG. Diagnosis
IncaseofrecurrentICDshocksforVF,quinidineorcatheterab- ItisrecommendedthatBrSisdiagnosedin
lationhavebeensuccessfulinreducingshockfrequency.922,1006,1007 patientswithnootherheartdiseaseanda I C
Isoproterenol infusion can suppress electrical storm.1008 In several spontaneoustype1BrugadaECGpattern.974–976
smallstudies,quinidinewaseffectiveinreducingorevenpreventing ItisrecommendedthatBrSisdiagnosedin
arrhythmia inducibility during programmed stimulation.922,1006,1007 patientswithnootherheartdiseasewhohave
However,adverseeffectsofquinidinecanoccurinupto37%ofpa- survivedaCAduetoVForPVTandexhibitatype I C
tients, and quinidine is inaccessible in many countries. Cilostazol 1BrugadaECGinducedbysodiumchannel
(phosphodiesterase-3 inhibitor) can be an alternative to quini- blockerchallengeorduringfever.135,136,975,981,982
dine.1008 Electrophysiological mapping data linked to histopatho-
GenetictestingforSCN5Ageneisrecommended
logical studies suggest that an abnormal fibrotic arrhythmogenic forprobandswithBrS.164,1016 I C
substrateintheepicardialRVOTisresponsiblefortheST-segment
BrSshouldbeconsideredinpatientswithno
elevationintherightprecordialleadsandVFoccurrenceinBrSpa-
otherheartdiseaseandinducedtype1Brugada
tients.1009Ablationoftheseabnormalareascanmarkedlysuppress
patternwhohaveatleastoneof:
recurrentVFandnormalizetheECGin.75%ofpatients.1009–1015
(cid:129) Arrhythmicsyncopeornocturnalagonal
In patients with recurrent episodes of VF triggered by a similar
respiration IIa C
PVC non-responsive to medical treatment, catheter ablation may (cid:129) AfamilyhistoryofBrS
targetthePVC,whichmostcommonlyoriginatesfromtheRVOT (cid:129) AfamilyhistoryofSD(,45yearsold)witha
or Purkinje system.1013 However, data regarding the long-term
negativeautopsyandcircumstancesuspicious
follow-upafterablationarelimited,withneithertrialdatanorevi-
forBrS.
denceforablationinasymptomaticpatients.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4081
BrSmaybeconsideredasadiagnosisin 7.2.5.Earlyrepolarizationsyndromes
patientswithnootherheartdiseasewho Early repolarization syndrome (ERS) is diagnosed in a patient
IIb C
exhibitaninducedtype1Brugada resuscitated from PVT or VF without any heart disease and
ECG.136,973,975,978,984,985 the early repolarization pattern (ERP); J-point elevation
≥1mm in ≥2 adjacent inferior and/or lateral ECG leads
Sodiumchannelblockertestisnot
recommendedinpatientswithapriortypeI III C (Figure
32).135,231,1017–1019
However, ERP is most often a benign
finding and the prevalence of ERP has been reported as 5.8% in
Brugadapattern.
adults and is more common in young males and ath-
Generalrecommendations
letes.135,231,1017–1021
Nonetheless, ERP is over-represented in
Thefollowingisrecommendedinallpatientswith relatives of SADS cases282,1022 and of CA survivors.182,916 The
BrS:
diagnostic yield and utility of genetic testing is
low.1023–1025
(a) Avoidance of drugs that may induce
High-risk ECG features have been proposed to increase likeli-
ST-segmentelevationinrightprecordial I C hood of ERS: prominent J-waves ≥2mm, dynamic changes in
leads( J-point elevation (.0.1mV) and J-waves associated with a hori-
(b) Avoidanceofcocaine,cannabis,andexcessive zontal or descending ST-segment (Figure 34).231,1026,1027 ERP
alcoholintake.
with a horizontal ST-segment was associated with arrhythmic
(c) Treatmentoffeverwithantipyreticdrugs. risk in an elderly and IVF population.1027 Nonetheless, ERS sur-
Riskstratification,preventionofSCDandtreatmentofVA
vivors and relatives of SADS cases also exhibit a higher preva-
ICDimplantationisrecommendedinpatients lence of the ascending/upsloping ST segment than
withBrSwho: controls.282,1018 At least 40% of ERS patients with VF have sub-
(a) AresurvivorsofanabortedCAand/or I C sequent episodes, with 27% suffering multiple epi-
(b) Have documented spontaneous sustained sodes.231,1028,1029 Isoproterenol infusion is effective in acute
VT.980,990–992 suppression of recurrent ICD discharges and electrical
ICDimplantationshouldbeconsideredinpatients
storm.1030–1032
AADs that block the transient outward potas-
withtype1Brugadapatternandanarrhythmic IIa C sium current can prevent VF.922,1030,1033 A retrospective multi-
syncope.990,992,996 centre study showed a reduction of recurrent VF after initiation
of quinidine.1030 Phosphodiesterase-3 inhibitors such as cilosta-
Implantationofalooprecordershouldbe
consideredinBrSpatientswithanunexplained IIa C zol and milrinone also reduced the recurrence of VF.1032
syncope.997,999 Ablation of a PVC trigger, usually from the Purkinje system,
has an acute success rate of 87–100% and may be effective in
Quinidineshouldbeconsideredinpatientswith
preventing recurrence in patients with drug-refractory
BrSwhoqualifyforanICDbuthavea
IIa C VF.1010,1017 Detailed electroanatomic mapping may reveal loca-
contraindication,decline,orhaverecurrentICD
shocks.922,1006,1007 lized structural alterations in 39% of ERS patients.1010 Ablation
of these areas successfully suppressed electrical storm and
Isoproterenolinfusionshouldbeconsideredin
IIa C may be a therapeutic option in experienced centres. Whether
BrSpatientssufferingelectricalstorm.1008
catheter ablation improves long-term outcomes is currently
CatheterablationoftriggeringPVCsand/or
unknown.
RVOTepicardialsubstrateshouldbeconsidered
IIa C Data for risk stratification of patients with suspected ERS with-
inBrSpatientswithrecurrentappropriateICD
out prior CA are unavailable. In individuals with ERP and unex-
shocksrefractorytodrugtherapy.1010–1015
plained syncope, this panel has recommended that follow-up
PESmaybeconsideredinasymptomaticpatients
IIb B withanILRshouldbeconsidered.Astheprognosisofasymptom-
withaspontaneoustypeIBrSECG.155
atic subjects with ERP is good, ICD therapy is usually not indi-
ICDimplantationmaybeconsideredinselected cated.1034–1036
If, however, there is a high-risk ERP and a strong
asymptomaticBrSpatientswithinducibleVF IIb C
family history of unexplained juvenile SD, then ICD implantation
duringPESusingupto2extrastimuli.155
or quinidine may be considered.
CatheterablationinasymptomaticBrSpatientsis
III C
notrecommended.
BrS,Brugadasyndrome;CA,cardiacarrest;ECG,electrocardiogram;ICD,implantable
cardioverterdefibrillator;PES,programmedelectricalstimulation;PVCs,premature
ventricular complexes; PVT, polymorphic ventricular tachycardia; RVOT, right
ventricular outflow tract; SCD, sudden cardiac death; SD, sudden death; VA,
ventriculararrhythmia;VF,ventricularfibrillation.
aClassofrecommendation.
bLevelofevidence.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4082 ESCGuidelines
Patient with ECG suspicious of Brugada Syndrome
SustainedVVVA or
No documentedVVVA
aborted cardiac arrest
Spontaneous type 1 BrS ECG No type I BrS ECG
Exclude alternative diagnosis consistent with ECGa
General recommendationsb Arrhythmic syncope/
(Class I) nocturnal agonical respiration
Y N
Sodium channelblockkker test
(ClassIII)
Family history
Y
off BrS orSADS
Y Syncope N Follow-up N
Sodium channel Sodium channel
blockkkertest blockkkertest Discharge
(Class I) (Class I)
Positive Results Results
Arrhyyythmic ICDimplantaation Negative Negative Positive
Y
syncope (Class IIa)
Further Discharge General
N evaluation recommen-
Recurrent according dationsb
Unexplained symptomaaaticVVVA to ESC (Class I)
syncope syncope
Guidelines
Quinidine Follow-up
ILR (Class IIa)
(Class IIa)
Recurrent
symptomaaaticVVVA
Caaatheterr ablaaation
(ClassIIa)
Figure33PartOne.AlgorithmforthemanagementofpatientswithBrugadapatternelectrocardiogram.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4083
SustainedVVVA or abortedcardiac arrest
Exclude alternative diagnoosis consistent with ECGa
Spontaneoustttype1
Y N
BrSECG
General recommendationsb Sodium channelblockkker test
(Class I) (Class I)
ICD implantation
(Class I)
Results
Sodium channel blockkker test
(Class III)
Positive Negative
Recurrentt symptomaaaticVVVA General recommendationsb Further evaluaationfffor
(Class I) alternaative cause of VVVA/CA
ICD implantation
(Class I)
Recurrentt symptomaaaticVVVA
Quinidine
(ClassIIa)
Recurrentt symptomaaticVVVA
Caatheter ablaaation
(Class IIa)
Figure33PartTwo.AlgorithmforthemanagementofpatientswithBrugadapatternelectrocardiogram.BrS,Brugadasyndrome;CA,cardiacarrest;
ECG,electrocardiogram;ICD,implantablecardioverterdefibrillator;ILR,implantablelooprecorder;N,No;SADS,suddenarrhythmicdeathsyndrome;
VA,ventriculararrhythmia;Y,Yes.aEcho,CMR,cardiacCT,CAGindicatedaccordingtopatientclinicalpresentationandriskfactors.bGeneralrecom-
mendations:avoidanceofdrugsthatmayinduceST-segmentationelevationinrightprecordialleads(
andexcessivealcoholintake,treatmentoffeverwithantipyreticdrugs.
RecommendationTable44—Recommendationsfor
GenetictestinginERSpatientsmaybe
IIb C
themanagementofpatientswithearlyrepolarization considered.1023,1025
pattern/syndrome
Clinicalevaluationisnotrecommendedroutinelyin
III C
asymptomaticsubjectswithERP.1038,1039
Recommendations Classa Levelb
Riskstratification,preventionofSCDandtreatmentofVA
Diagnosis ICDimplantationisrecommendedinpatientswitha
I B
ItisrecommendedthattheERPisdiagnosedasJ-point diagnosisofERSwhohavesurvivedaCA.1017
elevationof≥1mmintwoadjacentinferiorand/or I C IsoproterenolinfusionshouldbeconsideredforERS
IIa B
lateralECGleads.1017,1018 patientswithelectricalstorm.1017,1030–1032
ItisrecommendedthattheERSisdiagnosedinapatient QuinidineinadditiontoanICDshouldbeconsideredfor
IIa B
resuscitatedfromunexplainedVF/PVTinthepresenceof I C recurrentVFinERSpatients.922,1030,1033
ERP.1017,1018 ILRshouldbeconsideredinindividualswithERPandat
IIa C
InanSCDvictimwithanegativeautopsyandmedical leastoneriskfeaturedorarrhythmicsyncope.1020
chartreview,andanante-mortemECGdemonstrating IIa C PVCablationshouldbeconsideredinERSpatientswith
theERP,thediagnosisofERSshouldbe recurrentVFepisodestriggeredbyasimilarPVC IIa C
considered.1017,1018 non-responsivetomedicaltreatment.1010
First-degreerelativesofERSpatientsshouldbe ICDimplantationorquinidinemaybeconsideredin
consideredforclinicalevaluationforERPwithadditional IIa B individualswithERPandarrhythmicsyncopeand IIb C
high-riskfeatures.c,1022,1037 additionalriskfeatures.d,1030,1033
Continued Continued
Downloaded
from

by
guest
on
22
January
2026

4084 ESCGuidelines
ICDimplantationorquinidinemaybeconsideredin 7.2.6.Catecholaminergicpolymorphicventricular
asymptomaticindividualswhodemonstrateahigh-risk tachycardia
IIb C
ERPcinthepresenceofafamilyhistoryofunexplained CPVT is a heritable disorder characterized by catecholamine-
juvenileSD.1030,1033 inducedbidirectionalVTandPVTintheabsenceofSHDorischaemia.
ICDimplantationisnotrecommendedinasymptomatic
III C
Thediseasehasanestimatedprevalenceof1in10000(Figure35).135
patientswithanisolatedERP.1034,1035,1040
Therearetwomaingenetictypes:adominantdisorderduetomu-
CA,cardiacarrest;ECG,electrocardiogram;ERP,earlyrepolarizationpattern;ERS, tations in the gene encoding for the cardiac ryanodine receptor
early repolarization syndrome; ICD, implantable cardioverter defibrillator; ILR, (RYR2)andarecessivedisordercausedbymutationsinthecardiac
implantablelooprecorder;PVC,prematureventricularcomplexes;PVT,ventricular calsequestrin gene (CASQ2).135,178 Mutations in TRDN and
tachycardia; SCD, sudden cardiac death; SD, sudden death; VA, ventricular
arrhythmia;VF,ventricularfibrillation.
CALM1-3havebeenidentifiedinpatientswithatypicalformsofcate-
aClassofrecommendation. cholaminergic VAs.1042 At the present time, however, it is unclear
bLevelofevidence. whether they are distinct arrhythmic entities.1043 Patients with
cERP high-risk features: J waves .2mm, dynamic changes in J point and ST morphology.1020,1041 KCNJ2 mutations causing Andersen–Tawil syndrome type 1 may
dHigh-riskERP:familyhistoryofunexplainedSD,40years,familyhistoryofERS. sometimes exhibit bidirectional and PVT, but are distinguished by
theirsyndromicassociations.1044
Patient with early repolarization pattern
N Aborted cardiac arrest Y
Arrhythmic syncope N
Y
At least one risk factor: ICD implantation
(Class I)
High risk ERPa
Family history of juvenile unexplained SD
Family history of ERS
Recurrent
Electrical storm
Y N ICD shocks
ILR ILR
(Class IIa) (Class IIa)
Isoproterenol Quinidine
ICD implantation (Class IIa) (Class IIa)
(Class IIb)
Quinidine
(Class IIa)
Quinidine
(Class IIb)
At least one risk factor: Recurrence
High risk ERPa
Family history of juvenile unexplained SD
Family history of ERS Catheter ablation
of PVC triggers
N Y (Class IIa)
No further
High risk ERPaAND
investigation
Family history of juvenile unexplained SD
(Class III)
Y N
ILR ILR
(Class IIa) (Class IIa)
ICD implantation
(Class IIb)
Quinidine
(Class IIb)
Figure34Managementofpatientswithearlyrepolarizationpattern/syndrome.ERP,earlyrepolarizationpattern;ERS,earlyrepolarizationsyndrome;
ICD,implantablecardioverterdefibrillator;ILR,implantablelooprecorder;N,No;PVC,prematureventricularcomplex;SD,suddendeath;Y,Yes.aERP
highriskfeatures:Jwaves.2mm,dynamicchangesinSTmorphology.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4085
Patient with CPVT
Arrhythmic syncope or Asymptomatic,, no documented
Aborted cardiac arrest
bidirectional or polymorphicVT VVVA,, but pathogenic mutation
Generalrecommendationsa (Class I)
Beta-blockkkerb (Class I) Beta-blockkkerb (Class IIa)
ICD implantation (Class I)
Syncope or exertional PVCs orVT Syncope or exertional PVCs orVT
Flecainide (Class IIa) Flecainide (Class IIa)
Syncope or documentedVT Syncope or documentedVT
LCSD (Class IIa)
ICD implantation (Class IIa)
LCSD (Class IIa)
Figure35Managementofpatientswithcatecholaminergicpolymorphicventriculartachycardia.CPVT,catecholaminergicpolymorphicventricular
tachycardia;ICD,implantablecardioverterdefibrillator;LCSD,leftcardiacsympatheticdenervation;PVC,prematureventricularcomplex;VA,ventricular
arrhythmia;VT,ventriculartachycardia.aGeneralrecommendations:avoidanceofcompetitivesports,avoidanceofstrenuousexercise,avoidanceof
stressfulenvironments.bPreferredbeta-blockers:nadolol,propranolol.
The clinical manifestations of CPVT usually occur in the first patientswhoshowintolerancetobeta-blockertherapy,pharmaco-
decade of life prompted by physical activity or emotional logicaltherapywithflecainidealoneisanoption.1054
stress.1045MostCPVTpatientshavenormalECGandechocardio- Maximalprotectionwithbeta-blockers,flecainideandICDisindi-
gram. Nonetheless, some patients present mild ECG abnormal- cated in survivors of a CA. An ICD should also be considered in
ities, suchassinusbradycardia and prominent Uwaves.Exercise CPVT patients with breakthroughVA on beta-blockers and flecai-
stresstestisthemostimportantdiagnostictest,becauseitelicits nide.135TheICDshould,however,beprogrammedwithlongdelays
thedistinguishingbidirectionalorPVTthatestablishthediagnosis andhighratesbeforedefibrillation,becauseinitiatingbidirectionalVT
(Figure36).135Adiagnosiscanalsobemadeinthepresenceofa responds less effectively to defibrillation than subsequent PVT/VF,
mutation in genes associated with CPVT. Epinephrine or iso- andpainfulshockscantriggerfurtherandincessantarrhythmias.1055
proterenolchallengemaybeconsideredwhenexercisestresstest- LCSDhasbeenproposedasanadditionaltherapyinpatientsin
ingisnotfeasible.1046 whom pharmacological treatment is not effective or feasible.
Diagnosisinchildhood,thelackofbeta-blockertherapy,andcom- AlthoughLCSDreducestherecurrenceofmajorcardiaceventsin
plexarrhythmiasduringtheexercisestresstestonafulldoseofbeta- previouslysymptomaticpatients,one-thirdofpatientsstillsufferre-
blockers are independent predictors for arrhythmic events.1047 currencesofarrhythmia.1056Therefore,LCSDhasnotbeenconsid-
Exercise restriction and beta-blockers without intrinsic sympatho- ered to be a replacement for ICD therapy but a complementary
mimetic activity are the first-line therapy for CPVT patients.135 therapyinsymptomaticpatients.
Non-selective beta-blockers such as nadolol and propranolol are Arecentsystematicreviewof53studiesincludingCPVTpatients
preferred.1048,1049Thispanelhasconfirmedtheindicationtotreat withanICDconcludedthatsecondarypreventionpatientsmanaged
geneticallypositivefamilymemberswithbeta-blockers,eveninthe withOMT,LCSDandexerciserestrictioncouldreduceICDuse.1057
absence of documented exercise- or stress-induced VAs.1047,1050 Thisobservationwassupportedbyasubsequentmulticentricinvesti-
Data suggest that flecainide significantly reduces the VA burden in gationshowingthatallthethreeSCDobservedoccurredinpatients
CPVTpatientsandshouldbeconsideredinadditiontobeta-blockers withanICD.1058Atpresentitseemspremature,onthebaseofthisevi-
when control of arrhythmias is incomplete.1051–1053 In selected dence,todemoteICDimplantinsurvivorsofCAwithCPVT.1057
Downloaded
from

by
guest
on
22
January
2026

4086 ESCGuidelines
Bidirectional PVCs during exercise
II
III
Figure36Exercisetestofapatientwithcatecholaminergicpolymorphicventriculartachycardia.PVC,prematureventricularcomplex.
RecommendationTable45—Recommendationsfor
Therapywithbeta-blockersshouldbeconsidered
the management of patients with catecholaminergic forgeneticallypositiveCPVTpatientswithout IIa C
polymorphicventriculartachycardia
phenotype.1047,1050
Recommendations Classa Levelb LCSDshouldbeconsideredinpatientswith
diagnosisofCPVTwhenthecombinationof
Diagnosis beta-blockersandflecainideattherapeuticdosage IIa C
ItisrecommendedthatCPVTisdiagnosedinthe areeithernoteffective,nottolerated,or
presenceofastructurallynormalheart,normal contraindicated.1056
I C
ECG,andexercise-oremotion-induced ICDimplantationshouldbeconsideredinpatients
bidirectional,orPVT. withCPVTwhoexperiencearrhythmogenic
ItisrecommendedthatCPVTisdiagnosedin syncopeand/ordocumentedbidirectional/PVT IIa C
patientswhoarecarriersofamutationin I C whileonhighesttoleratedbeta-blockerdoseand
disease-causinggenes. onflecainide.1047,1050
Genetictestingandgeneticcounsellingare Flecainideshouldbeconsideredinpatientswith
indicatedinpatientswithclinicalsuspicionor I C CPVTwhoexperiencerecurrentsyncope,
clinicaldiagnosisofCPVT. polymorphic/bidirectionalVT,orpersistent IIa C
Epinephrineorisoproterenolchallengemaybe exertionalPVCs,whileonbeta-blockersatthe
consideredforthediagnosisofCPVTwhenan IIb C highesttolerateddose.1052,1053,1060
exercisetestisnotpossible. PESisnotrecommendedforstratificationofSCD
III C
risk.
Generalrecommendations
Avoidanceofcompetitivesports,strenuous CA, cardiac arrest; CPVT, catecholaminergic ventricular tachycardia; ECG,
exercise,andexposuretostressfulenvironments I C electrocardiogram; ICD, implantable cardioverter defibrillator; LCSD, left cardiac
sympathetic denervation; PVT, polymorphic ventricular tachycardia; VT, ventricular
isrecommendedinallpatientswithCPVT.
tachycardia.
Therapeuticinterventions
aClassofrecommendation.
bLevelofevidence.
Beta-blockers,ideallynon-selective(nadololor
propranolol)arerecommendedinallpatients I C
withaclinicaldiagnosisofCPVT.1045,1048,1059 7.2.7.ShortQTsyndrome
ICDimplantationcombinedwithbeta-blockers Short QT syndrome (SQTS) is a rare genetic disorder charac-
andflecainideisrecommendedinCPVTpatients I C terisedbyashortQTinterval,prematureAFandVFinthecon-
afterabortedCA.1045,1047,1060 text of a structurally normal heart.1061 It has been associated
Continued with gain of function mutations in KCNH2, KCNQ1 and loss of
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4087
Short QT syndrome
Figure37ShortQTsyndrome.
function inSLC4A.1062,1063 Thispanel proposed twoQTccut-off SQTSshouldbeconsideredinthepresenceofa
IIa C
threshold for diagnosis: A QTc ≤320 ms alone, or B a QTc≤320ms.1064–1067,1073,1074
QTc ≤360 ms combined with a family history of SQTS,
SQTSshouldbeconsideredinthepresenceofa
abortedCAintheabsenceofheartdiseaseorpathogenicmuta- QTc≥320msand≤360msandarrhythmic IIa C
tion1064–1067
(Figure 37). The disease has high lethality in all age
syncope.
groups, including the first months of life.1063,1068,1069 The prob-
SQTSmaybeconsideredinthepresenceofa
abilityofafirstCAbytheageof40yearsis.40%.1068Whilean
QTc≥320msand≤360msandafamilyhistory IIb C
ICD is used for secondary prevention,1069 primary prevention ofSDatage,40years.
remains contentious and is based upon prior symptoms and
Riskstratification,SCDpreventionandtreatmentofVA
QTc interval.1063,1068,1069 Quinidine is currently the best sup-
ported AAD, but should be monitored for excessive QT pro- ICDimplantationisrecommendedinpatients
longation, while isoprenaline may be considered in electrical withadiagnosisofSQTSwho:(a)aresurvivorsof I C
storm.1070,1071 Drugs that shorten QT interval should be anabortedCAand/or(b)havedocumented
avoided, e.g. nicorandil.1072 Loop recorder implantation should spontaneoussustainedVT.1063
be considered in children and young asymptomatic SQTS ILRshouldbeconsideredinyoungSQTSpatients. IIa C
patients.
ICDimplantationshouldbeconsideredinSQTS
IIa C
patientswitharrhythmicsyncope.
RecommendationTable46—Recommendationsfor
Quinidinemaybeconsideredin(a)SQTSpatients
themanagementofpatientswithshortQTsyndrome whoqualifyforanICDbutpresenta
contraindicationtotheICDorrefuseit,and(b) IIb C
Recommendations Classa Levelb
asymptomaticSQTSpatientsandafamilyhistory
Diagnosis
ofSCD.1069–1071
ItisrecommendedthatSQTSisdiagnosedinthe IsoproterenolmaybeconsideredinSQTS IIb C
presenceofaQTc≤360msandoneormoreof patientswithanelectricalstorm.1075
thefollowing:(a)apathogenicmutation,(b)a I C PESisnotrecommendedforSCDrisk III C
familyhistoryofSQTS,(c)survivalfromaVT/VF
stratificationinSQTSpatients.
episodeintheabsenceofheartdisease.1061,1068
CA,cardiacarrest;ICD,implantablecardioverterdefibrillator;ILR,implantableloop
Genetictestingisindicatedinpatientsdiagnosed recorder,SCD,suddencardiacdeath;SD,suddendeath;SQTS,shortQTsyndrome;
withSQTS.1063
I C VA,ventriculararrhythmia;VF,ventricularfibrillation;VT,ventriculartachycardia.
aClassofrecommendation.
Continued bLevelofevidence.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4088 ESCGuidelines
8. Special aspects in selected InLQTS(LQT2inparticular),riskofcardiaceventsincreasessub-
stantially in the post-partum period (up to one year after deliv-
populations
ery).1094 Therefore, it is important to continue beta-blocker
therapy throughout pregnancy and post-partum.955,1094,1095
8.1. Pregnant patients and peri-partum
Continuationofbeta-blockertreatmentisrecommendedinLQTS
cardiomyopathy andCPVT1096andshouldbeconsideredinARVC.1097–1099Noadd-
Pregnancyandthepost-partumperiodcontributeasignificantriskin itional risk by pregnancy is known in women with BrS1100,1101
women with arrhythmic heart disease and is covered in the 2018 ( ESCCardioMedchapter53.6).1102
ESCGuidelinesforthemanagementofcardiovasculardiseasesduring In patients with PPCM, use of bromocriptine as disease-specific
pregnancy.1076–1080New-onsetVTmaypresentduringpregnancyand
therapy in addition to standard heart failure therapy has shown
riskofrecurrentVTishigherinpatientswithpreviousVTandSHD.1081 promisingresultsintwoclinicaltrials.1103,1104
Peri-partumcardiomyopathy(PPCM)shouldberuledoutinthecase
ofnew-onsetVTduringthelast6weeksofpregnancyorintheearly
post-partumperiod.1082Ageneticcontributionmaybepresentinup
8.1.3.Catheterablation
to 20% of patients with PPCM (in particular titin-truncating var-
In planned pregnancies, symptomatic tachyarrhythmia should be
iants)1083 and future studies should reveal if genetic testing plays a
treated by catheter ablation before pregnancy. If catheter ablation
roleinPPCMpatientswithapositivefamilyhistory.
is indicated ina pregnant patient,one should avoidthe procedure
inthefirsttrimester,andelectroanatomicalmapping-guidedproce-
8.1.1.Electrocardioversionandimplantable duresshouldbepreferred.1105,1106
cardioverterdefibrillatortherapyinpregnancy
Cardioversionseemssafeinallphasesofpregnancyandcasereports
showneithercompromiseinfetalbloodflownorinitiationofpre-
RecommendationTable47—Recommendationsfor
term labour.1084 Foetal heart rate should be routinely controlled
thepreventionofsuddencardiacdeathandmanage-
after cardioversion.1085 If an ICD is indicated, ICD implantation mentofventriculararrhythmiaduringpregnancy
should be performed beyond 8 weeks of gestation with radiation
protection by experienced operator teams.1086 Echocardiographic Recommendations Classa Levelb
guidanceora3DmappingsystemmaybehelpfulinICDimplantation
to avoid radiation.1087,1088 In pregnant patients with existing ICD, AcutemanagementofVA
routineICDinterrogationisrecommendedpriortodelivery.Inpa- Duringpregnancy,electricalcardioversionis
I C
tientswithPPCM,thresholdsforearlyICDimplantationsarehigher recommendedforsustainedVT.1084
thaninotherconditionsbecauseofahighrateofspontaneousrecov- Foracuteconversionofhaemodynamically
ery after delivery.1089 WCD have been suggested to temporarily toleratedSMVTduringpregnancy,abeta-blocker,
IIa C
preventSCDduringthefirst3–6monthsafterdiagnosisofPPCM sotalol,flecainide,procainamide,oroverdrive
withLVEF≤35%,whileawaitingrecovery.1090,1091 ventricularpacingshouldbeconsidered.
Long-termmanagementofVA
8.1.2.Pharmacologicaltreatment IfICDimplantationisindicatedduringpregnancy,
Pharmacologicaltreatmentofarrhythmiasandheartfailureinpregnant implantationisrecommendedwithoptimal I C
womenshouldfollowtreatmentinnon-pregnantpatientswithavoid- radiationprotection.1087,1107
ance of drugs contraindicated in pregnancy, such as ACE inhibitors, Continuationofbeta-blockersisrecommended
ARBinhibitors/ARNIandrenininhibitors.1080,1082,1092,1093Thefirsttri- duringpregnancyandpost-partuminwomenwith I C
mesterisassociatedwiththegreatestteratogenicrisk.Startofpharma- LQTSorCPVT.955,1094–1096
cologicaltherapyisadvisedtobeginatthelatestpossiblepointinthe Continuationofbeta-blockersshouldbe
pregnancyandwiththelowesteffectivedose.Drugexposureinthese- consideredduringpregnancyinwomenwith IIa C
condandthirdtrimesteramayconferadverseeffectsonfoetalgrowth ARVC.1097–1099
anddevelopmentaswellasincreasingtheriskofpro-arrhythmia.
Oralmetoprolol,propranolol,orverapamil
Itisrecommendedtocheckdrugsandsafetydatabeforeinitiationof shouldbeconsideredforlong-termmanagement IIa C
anewdrugduringpregnancy,accordingtothe2018ESCGuidelinesfor
ofidiopathicsustainedVTduringpregnancy.
themanagementofcardiovasculardiseasesduringpregnancy.1080From
Catheterablationusingnon-fluoroscopicmapping
thislist,AADscanbesummarizedasfollowed:
systemsshouldbeconsidered,preferablyafterthe
(cid:129) Welltolerated:sotalol,oralverapamil firsttrimester,inwomenwithhighlysymptomatic IIa C
(cid:129) Useonlyifpotentialbenefitoutweighspotentialrisk:bi- recurrentSMVTrefractoryorwhoareintolerant
soprolol, carvedilol, digoxin, diltiazem (possible teratogenic ef- toAADs.1105
fects), disopyramide (uterine contractions), flecainide, lidocaine,
AAD,anti-arrhythmicdrug;ARVC,arrhythmogenicrightventricularcardiomyopathy;
metoprolol,nadolol,propranolol,verapamilIV,quinidine CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable
(cid:129) Inadequate data: Ivabradine, mexiletine, proprafenone, cardioverterdefibrillator;LQTS,longQTsyndrome;SMVT,sustainedmonomorphic
VT;VA,ventriculararrhythmia;VT,ventriculartachycardia.
vernakalant
aClassofrecommendation.
(cid:129) Contraindicated:amiodarone,atenolol,dronedarone. bLevelofevidence.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4089
8.2. Heart transplantation it is unfeasible as a routine test in mass screening. More cardio-
PatientslistedforHTXareexposedtoanSCDriskandhaveahigh vascular diseases are identified by serial (annual) evaluations of
incidenceofVA.Datafromlargeregistriessuggestasurvivalbenefit adolescent athletes.1129,1131 The prevalence of false-positive re-
from ICDs.1108–1111 The only randomized study including patients sults strongly depends on the criteria used to define an ECG
listed for HTX was prematurely stopped because of low enrol- as ‘abnormal’.1132,1133 Additional tests, such as echocardiog-
ment.1112TherearenodataregardingtheroleofWCDinpatients raphy, 24-hour Holter monitoring, stress testing, and CMR, are
listedforHTX.Themedianexpectedtimeonthewaitinglist,8–16 requested for athletes who had positive findings at the initial
months,needstobeconsidered.1108,1110However,thispanelshares evaluation. Athletes diagnosed with clinically relevant cardiovas-
theopinionthataWCDmaybeanalternativeforanICDinselected cular disease are managed according to available ESC
patientswaitingforHTX.371,1113
Guidelines.4,1134–1136
In post-HTX patients, SCD is responsible for around 10% of In middle-aged/senior athletes, the most common cause of
deaths.1114,1115 Transplant rejection and allograft vasculopathy are SCD is CAD.1125,1137 Before engaging in a vigorous physical
associatedwithSCD1114,1116,1117;therefore,ICDimplantationmay activity, asymptomatic middle-aged/senior athletes should be
beappropriateinselectedhigh-riskpatients.1118 evaluated using risk score systems such as the ESC
SCORE2.4,65
Excellentratesofsurvivalwithfavourableneurologicaloutcome
RecommendationTable48—Recommendationsfor after CA has been reported in sports centres equipped with
the prevention of sudden cardiac death before and
AED.1137,1138Thisjustifiestheeffortsforimplementingemergency
afterhearttransplantation programs for SCD prevention, with distribution of AED in sports
arenas and training of coaches and staff to perform CPR and
Recommendations Classa Levelb defibrillation.1139
Priortohearttransplant
Inpatientsawaitinghearttransplantation,ICD
implantationforprimarypreventionshouldbe IIa C
considered.1108,1111,1112 RecommendationTable49—Recommendationsfor
Inpatientsawaitinghearttransplantation,WCD risk stratification and prevention of sudden cardiac
IIb C
maybeconsidered.1109,1113,1119 deathinathletes
Posthearttransplant
Recommendations Classa Levelb
Inselectedtransplantedpatientswithcardiac
allograftvasculopathyortreatedrejection,ICD IIb C Inathleteswithpositivemedicalhistory,abnormal
implantationmaybeconsidered.1114,1116 physicalexamination,orECGalterations,further
investigationsincludingechocardiographyand/or I C
ICD,implantablecardioverterdefibrillator;WCD,wearablecardioverterdefibrillator.
CMRtoconfirm(orexclude)anunderlying
aClassofrecommendation.
bLevelofevidence. diseasearerecommended.1123,1133,1135
Itisrecommendedthatathletesdiagnosedwitha
cardiovasculardiseaseassociatedwithSCDare
I C
8.3. Sudden cardiac death in athletes managedaccordingtocurrentguidelinesfor
TheincidenceofSCDinathletesincreaseswithage.4,1120Inappar- sportseligibility.
entlyhealthyathletes(.35years),theestimatedincidenceofSCD
Itisrecommendedthatstaffatsportingfacilities
I C
rangesfrom2to6.3per100000participant-years.Incomparison, aretrainedinCPRandintheuseofAED.93,1137
in young competitive athletes (≤35 years) the incidence of fatal Pre-participationcardiovascularevaluationof
events is significantly lower, 0.4–3 per 100000 participant- competitiveathletesshouldbe IIa C
years.46,47,1120WomenathletesareatlowriskofSCD;onaverage, considered.46,1122,1123,1127
1in14SCDinathletesoccursinwomen.1121
Itshouldbeconsideredthatcardiovascular
Pre-participationcardiovascularevaluationoffersthepotential evaluationofyoung(,35years)competitive
IIa C
to identify athletes at-risk for cardiovascular disease before on-
athletesincludeshistory,physicalexamination,
set of
symptoms.1122–1126
The evaluation protocol needs to be and12-leadECG.1123,1126,1130,1140
adaptedtotheageoftheathletetoaccountforage-specificcar-
Thecardiovascularriskofmiddle-agedandelderly
diovascular disease.1125 Pre-participation evaluation, including
individualsshouldbeevaluatedbeforeengagingin
medical history, physical examination, and ECG, appears effect- IIa C
strenuoussportsthroughestablishedscoressuch
ive in identifying cardiovascular disease in young athletes (≤35
astheSCORE2riskchart.46,1141,1142
years of age) by identification of relevant symptoms (e.g. exer-
tionalsyncope)orECGabnormalitiesconsistentwithinheritable AED, automated external defibrillator; CMR, cardiac magnetic resonance; CPR,
cardiomyopathies or
channelopathies.1127–1130
Although echo-
cardiopulmonaryresuscitation;ECG,electrocardiogram;SCD,suddencardiacdeath.
aClassofrecommendation.
cardiography can increase the sensitivity of screening for SHD, bLevelofevidence.
2202CSE©
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4090 ESCGuidelines
8.4. Wolff–Parkinson–White syndrome RecommendationTable50—Recommendationsfor
In patients with Wolff–Parkinson–White (WPW) syndrome, the
implantablecardioverterdefibrillatorimplantationin
theelderly
most common arrhythmia is AV re-entry tachycardia (AVRT;
80%),followedbyAF(20–30%).SCDsecondarytopre-excitedAF
Recommendations Classa Levelb
resultinginVFisthemostfearedmanifestationofWPWsyndrome.
TheriskofCA/VFinuntreatedWPWpatientshasbeenestimatedat
Inelderlypatientsinwhomabenefitfromthe
0.9–2.4per 1000person-year.1143,1144ThemanagementofWPW defibrillatorisnotexpectedduetothepatient’s
patients has recently been reviewed in the 2019 ESC Guidelines ageandcomorbidities,omissionofICD IIb B
forthemanagementofpatientswithSVT302andupdatedwithapar- implantationforprimarypreventionmaybe
ticular focus on athletes in 2020.1145 In patients with ventricular considered.647,1150,1152
pre-excitationandsymptomaticAVRT,catheterablationisrecom- ICD,implantablecardioverterdefibrillator.
mended (class I). In asymptomatic patients with ventricular aClassofrecommendation.
pre-excitation, both invasive (class IIa) and non-invasive (class IIb)
bLevelofevidence.
assessmentareoptionsforriskstratificationforSCD.Whilecath-
eterablationisrecommendedforasymptomaticaccessorypathways 9. Key messages
withhigh-riskfeatures(classI),clinicalfollow-up(classIIa),orcath-
eter ablations (class IIb) are options based on informed patient 9.1. General aspects
choice.Thisdecisionshouldtakeintoaccountthelocationoftheac-
cessory pathway, the local ablation experience and the fact that (cid:129) Increasedavailabilityofpublicaccessdefibrillatorsandcommunity
symptomatic arrhythmias will frequently develop during follow- traininginbasiclifesupportarekeyelementstoimprovesurvivalof
up.1146Forthepaediatricpopulation,SVTduetoWPWcanusually
out-of-hospitalcardiacarrestvictims.
be managed pharmacologically, and accessory pathways often lose (cid:129) RiskcalculatorsforSCDandVAimplementedinclinicalpractice
antegrade conduction in the first years of life.1147 In children with needtomeetagreedhighstandardsforthedevelopment,external
asymptomatic accessory pathways,risk stratification isnot recom- validation,andreportingofpredictionmodels.
mendbeforetheageof8years.1148 (cid:129) Patientswithgeneticcardiomyopathiesandarrhythmiasyndromes
requiregenetictestingasaroutinepartoftheircare.
8.5. Prevention of sudden cardiac death (cid:129) Genetictestingandcounsellingrequireaccesstoanexpertmulti-
disciplinaryteam.
in the elderly
(cid:129) Asystematicworkupofcardiacarrestsurvivorsrequiresamulti-
Ageisastrongriskfactorfordeath.Inseveralstudies,advanced
modalapproach.
age was one of the factors associated with a reduced expected (cid:129) A comprehensive autopsy is recommended in all cases of sudden
benefitfromICDtreatment.Inpatientswithischaemiccardiomy-
deathunder50yearsandisdesirableinallsuddendeathvictims.
opathy enrolled in MADIT-II trial, a risk scheme composed of 5 (cid:129) ClinicalandgeneticevaluationofSADSdecedentsandtheirfam-
clinicalfactorsincludingage.70yearswaspredictiveoftheab-
ilies leads to a diagnosis of genetic heart disease in a substantial
senceoflong-termbenefitconferredbytheICD.1149Inarecent
proportionoffamilies.
analysisofICDpatientsenrolledinfourMADITstudies,age,75
(cid:129) Anelectricalstormrefractorytodrugtreatmentrequirestheavail-
yearswasapredictorofVT/VFwhereasage≥75yearswasapre-
abilityofadvancedcatheterablationtechniques,mechanicalcircu-
dictorofnon-arrhythmicmortality.365Consistently,intherecent
latorysupport,andautonomicmodulation.
randomized DANISH trial in patients with non-ischaemic heart (cid:129) WhenconsideringICDtherapybenefit,competingriskfactorsfor
failure, the association between the ICD and survival decreased non-arrhythmicdeathandthepatient’swishesandqualityoflife
linearly with increasing age, while an age cut-off at ≤70 years
needtobetakenintoaccount.
yielded the highest survival.647 Contemporary non-randomized
datacorroboratethesefindings.IntheEU-CERT-ICDprospect-
ive cohort study in patients with CAD or cardiomyopathies 9.2. Structural heart disease
with indication for primary prevention ICD implantation, no
ICDbenefitwasobservedinpatientsaged≥75years.357Incon- (cid:129) CatheterablationisrecommendedinCADpatientswithrecurrent
trast, there was a significant survival benefit in patients aged symptomaticSMVTdespitechronicamiodaronetherapy.
,75 years. Further retrospective data are in line with this (cid:129) Catheter ablation is the first-line treatment for PVC-induced
observation.1150 cardiomyopathy.
Biological age may vary in part according to comorbidities. (cid:129) In HNDCM/DCM patients, indication for primary prevention
Indeed,comorbiditiessignificantlyinfluencesurvivalofICDrecipi- ICD implantation should not be restricted to an LVEF ≤35%.
entsandahighcomorbidityindexisassociatedwithlesssurvival Additional risk factors (e.g. CMR and genetics) are important to
gain in primary or secondary prevention ICD patients.1149,1151 consider.
Therefore,asimpleagecut-offcannotguidethedecisiononICD (cid:129) PatientswithanLMNAmutationrequirespecificriskstratification
implantationadequatelyandtheICDindicationinelderlypatients forSCD.
should be based on a personalized assessment considering the (cid:129) ARVCpatientshaveahighrateofappropriateICDinterventions
overallconditionandcomorbidities. whichmaynotnecessarilybeclassifiedaslifesaving.
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4091
(cid:129) Avalidatedriskcalculator(HCMRisk-Kidsscore)isusefultoassess 10.3. Idiopathic premature ventricular
theriskforSCDinHCMpatientsyoungerthan16years. complexes/ventricular tachycardia
(cid:129) Myotonic dystrophy patients with palpitations suspected of ar-
rhythmia,syncopeorabortedsuddendeathneedtobeevaluated (cid:129) The beneficial role of catheter ablation or anti-arrhythmic drug
byinvasiveelectrophysiologicalstudy. treatmentinpatientswithasymptomatic,frequentPVCsandpre-
(cid:129) InpatientswithrepairedtetralogyofFallotandmonomorphicVT, servedcardiacfunctionneedstobedetermined.
catheterablationisthepreferredtreatment.
10.4. Coronary artery disease
9.3. Primary electrical disease (cid:129) ItisunknownwhichpatientswithchronicCADandseverelyim-
pairedLVEFareatlowriskforSCD.
(cid:129) Nadololorpropranololarethepreferredbeta-blockersinLQTS (cid:129) The role of LGE-CMR for risk stratification for SCD in chronic
andCPVTpatients. CADisunclear.
(cid:129) InasymptomaticLQTSpatientsthearrhythmicrisk(1-2-3Riskcal- (cid:129) RCTsareneededtodeterminetheroleofICDsaftersuccessful
culator)maybeusefultocalculate. VT ablation in chronic CAD with mildly reduced or preserved
(cid:129) A type 1 Brugada ECG pattern provoked by sodium channel LVEF.
blockertestintheabsenceofotherfindingsdoesnotdiagnose
theBrS. 10.5. Cardiomyopathies
(cid:129) SCDriskstratificationinasymptomaticBrSpatientswithaspon-
taneoustype1patternremainscontroversial. (cid:129) ItisunknownifPVC-inducedcardiomyopathyisadiagnosisonits
(cid:129) Routine catheter ablation is notrecommended in asymptomatic ownorifanunderlyingpredispositionisneeded.
BrSpatients. (cid:129) The predictive value of LGE-CMR findings (e.g. pattern and
(cid:129) The diagnosis of idiopathic VF requires exclusion of an amountofLGE)forindividualriskstratificationforSCDinpatients
underlying structural, channelopathic, or metabolic withcardiacsarcoidosis,HCM,andDCM/HNDCisunclear.
aetiology. (cid:129) StudiesareneededtodeterminetheroleofPESinpatientswith
(cid:129) ERPcanbeabenignfindingandisdistinctfromERS. cardiacsarcoidosisandDCM/HNDCwhohaveamildlyreduced
(cid:129) Left cardiac denervation plays an important role in the manage- orpreservedcardiacfunctionandLGEonCMR.
mentofCPVTandLQTSpatients. (cid:129) Prospective data on the association between intensity and dur-
ationofexerciseandmanifestationandseverityofthephenotype
inhealthyARVCmutationcarriersarelacking.
10. Gaps in evidence (cid:129) ThebeneficialroleofICDsaftersuccessfulablationinARVCpa-
tients who present with haemodynamically tolerated VT needs
10.1. General aspects tobestudied.
(cid:129) Dataonclinicaloutcome,predictorsforarrhythmicevents,andin-
(cid:129) Accurate screening tests to detect heart conditions associated dicationfortreatment,includingICDtherapy,inpatientswithbi-
with SCD in asymptomatic individuals in the general population ventricularandleft-dominantarrhythmogeniccardiomyopathyare
arerequired. required.
(cid:129) InpatientswithSHD,theoptimaltimeintervalbetweenrepeated
non-invasive and invasive prognostic tests, in case of a negative 10.6. Valvular heart disease
test,isunknown.
(cid:129) Improvedassessmentofgeneticvariantsofuncertainsignificance (cid:129) ThereisalackofknowledgetoidentifypatientswithMVPatrisk
andlikelypathogenicvariantsisneeded. forVAandSCD.
(cid:129) TheutilityofpolygenicriskscoresinpatientsatriskofSCDre-
quiresinvestigation.
10.7. Congenital heart disease
10.2. Structural heart disease—general (cid:129) ThereisalackofknowledgeregardingtheabsoluteriskforVAand
SCDinCHDthathaveundergonerepairwithcontemporarysur-
gicalapproaches.
(cid:129) Thelong-termsafetyandefficacyofS-ICDsisunknown.
(cid:129) TheroleofprimarypreventiveICDtherapyinpatientswithSHD
and mildly reduced or preserved ejection fraction has not been 10.8. Primary electrical disease
studiedsystematically.
(cid:129) TheoptimaltechniquestoundertakeVTsubstratemappingand (cid:129) Robustevidenceisrequiredtosupporttheprophylacticuseofthe
ablationinSHDremaintobedetermined. ICD on top of medical therapy with beta-blockers and gene-
(cid:129) The role of ICD implantation in end-stage heart failure patients specifictherapyinLQTSpatients.
supported by current-generation, continuous-flow LVADs is (cid:129) MoredataarerequiredtodeterminetheroleofLCSDandICDin
unclear. high-riskLQTSpatientswhodonottoleratemedicaltherapy.
Downloaded
from

by
guest
on
22
January
2026

4092 ESCGuidelines
(cid:129) Improveddiagnosticandriskstratificationtoolsforasymptomatic (cid:129) Long-termdataarerequiredontheefficacyoftheICDvs.noICD
Brugadapatientsandsuspectedearlyrepolarizationsyndromeare inCPVTsurvivorsofcardiacarrest.
needed. (cid:129) It is poorly understood why women are at low risk of
(cid:129) Theroleofendo-epicardialmappingtoidentifylocalizedstructural sport-relatedSCD.
alterationspotentiallyrelatedtoIVFandtargetedcatheterablation
needstobefurtherstudied.
‘ ’ ‘ ’
11. What to do and what not to do messages from the Guidelines
Recommendations Classa Levelb
Recommendationsforpublicbasiclifesupportandaccesstoautomatedexternaldefibrillator
Itisrecommendedthatpublicaccessdefibrillationbeavailableatsiteswherecardiacarrestismorelikelytooccur.c
I B
PromptCPRbybystandersisrecommendedatOHCA.
I B
ItisrecommendedtopromotecommunitytraininginbasiclifesupporttoincreasebystanderCPRrateandAEDuse.
I B
Recommendationsforgenetictesting
GenetictestingisrecommendedwhenaconditionisdiagnosedinalivingordeceasedindividualwithalikelygeneticbasisandariskofVA
I B
andSCD.
Whenaputativecausativevariantisfirstidentified,evaluationforpathogenicityisrecommendedusinganinternationallyaccepted
I C
framework.
WhenaClassIVorClassVvarianthasbeenidentifiedinalivingordeceasedindividualwithaconditionthatcarriesariskofVAandSCD,
I C
genetictestingoffirst-degreeandsymptomaticrelativesandobligatecarriersisrecommended.
Itisrecommendedthatgenetictestingandcounsellingonitspotentialconsequencesshouldbeundertakenbyanexpert
I C
multidisciplinaryteam.
ItisrecommendedthatClassIIIvariants(ofuncertainsignificance)andClassIVvariantsshouldbeevaluatedforsegregationinfamilies
I C
wherepossible,andthevariantre-evaluatedperiodically.
Itisnotrecommendedtoundertakegenetictestinginindexpatientswithinsufficientevidenceofageneticdisease.
III C
Recommendationsforevaluationofpatientspresentingwithnewlydocumentedventriculararrhythmia
InpatientswithnewlydocumentedVA(frequentPVCs,NSVT,SMVT),abaseline12-leadECG,recordingoftheVAon12-leadECG,
I C
wheneverpossible,andanechocardiogramarerecommendedasfirst-lineevaluation.
Recommendationsforevaluationofsuddencardiacarrestsurvivors
TheinvestigationofaSCAsurvivorwithoutobviousextra-cardiaccauseisrecommendedtobeoverseenbyamultidisciplinaryteam.
I B
InelectricallyunstablepatientsafterSCA,withsuspicionofongoingmyocardialischaemia,acoronaryangiogramisindicated.
I C
InSCAsurvivors,collectionofbloodsamplesatpresentationisrecommendedforpotentialtoxicologyandgenetictesting.
I B
RetrievalofrecordingsfromCIEDsandwearablemonitorsisrecommendedforallSCAsurvivors.
I B
InSCAsurvivors,repeated12-leadECGsduringstablerhythm(includinghighprecordialleadECG)aswellascontinuouscardiac
I B
monitoringarerecommended.
EchocardiographyisrecommendedforevaluationofcardiacstructureandfunctioninallSCAsurvivors.
I C
CoronaryimagingandCMRwithLGEarerecommendedforevaluationofcardiacstructureandfunctioninallSCAsurvivorswithouta
I B
clearunderlyingcause.
SodiumchannelblockertestandexercisetestingisrecommendedinSCAsurvivorswithoutaclearunderlyingcause.
I B
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4093
Recommendationsforevaluationofsuddendeathvictims
InvestigationofunexpectedSD,especiallyincaseofsuspicionofinheriteddisease,shouldbemadeapublichealthpriority.
I B
IncasesofSD,itisrecommendedtocollectadetaileddescriptionofcircumstancesofdeath,symptomspriortodeath,thefamily
I B
history,andtoreviewpriormedicalfiles.
Acomprehensiveautopsyisrecommended,ideally,inallcasesofunexpectedSD,andalwaysinthoseunder50yearsofage.
I B
IncasesofSCD,itisrecommendedtoretainsamplessuitableforDNAextractionandconsultacardiacpathologistwhenaninherited
I B
causeissuspectedorthecauseofdeathunexplained.
ToxicologyscreensarerecommendedinSDcaseswithuncertaincauseofdeath.
I B
ForSCDwherethecauseisknownorsuspectedtobeheritable,genetictestingtargetedtothecauseisrecommended.
I B
FollowingSADS,post-mortemgenetictestingtargetedtoprimaryelectricaldiseaseisrecommendedwhenthedecedentisyoung(,50
I B
yearsofage)and/orthecircumstancesand/orfamilyhistorysupportaprimaryelectricaldisease.
Whenanautopsydiagnosespossibleheritablecardiacdisease,itisrecommendedtoreferfirst-degreerelativesforcardiacassessmentin
I B
aspecializedclinic.
Innon-autopsiedcasesofSDwhereinheritedcardiacdiseaseissuspected,itisrecommendedtoreferfirst-degreerelativesforcardiac
I B
assessmentinaspecializedclinic.
Recommendationsforevaluationofrelativesofsuddenarrhythmicdeathsyndromedecedents
FollowingSADS,hypothesis-freepost-mortemgenetictestingusingexomeorgenomesequencingisnotrecommended.
III B
FamilialevaluationofSADSdecedentsisrecommended:
(cid:129) forfirst-degreerelatives
(cid:129) forrelativeswhomustcarryamutationbasedonanalysisofthefamilyhistory I B
(cid:129) forrelativeswithsuspicioussymptoms
(cid:129) whenthedecedent’sageis,50yearsorifthereareothercircumstantialdataorfamilyhistorytosuggestheritabledisease.
FamilialevaluationofSADSdecedentsisrecommendedtoincludegenetictestingwhenpost-mortemgenetictestinginaSADS
I B
decedentdetectsapathogenicmutation.
BaselinefamilialevaluationofSADSdecedentsisrecommendedtoincludetakingamedicalhistoryandperformingphysicalexamination,
I B
standard-andhigh-precordialleadECG,echocardiography,andexercisetesting.
InSADSfamilieswithoutadiagnosisafterclinicalevaluation,follow-upisrecommendedforchildrenofdecedentsuntiltheyreach
I C
adulthood.
InSADSfamilieswithoutadiagnosisafterclinicalevaluation,follow-upisnotrecommendedforasymptomaticadultswhocanbe
III C
dischargedwithadvicetoreturniftheydevelopsymptomsorifthefamilyhistorychanges.
Recommendationsfortreatmentofreversibleconditions
Withdrawalofoffendingagentsisrecommendedwheneverdrug-inducedVAaresuspected. I B
Investigationforreversiblecauses(e.g.electrolyteimbalances,ischaemia,hypoxaemia,fever)disrecommendedinpatientswithVA.
I C
Recommendationsfortheacutetreatmentofsustainedventriculartachycardiaandelectricalstorm
DCcardioversionisrecommendedasthefirst-linetreatmentforpatientswithhaemodynamicallynot-toleratedSMVT.
I B
DCcardioversionisrecommendedasthefirst-linetreatmentforpatientspresentingwithtoleratedSMVTprovidedthatthe
I C
anaesthetic/sedationriskislow.
InpatientspresentingwithahaemodynamicallytoleratedidiopathicVT,treatmentwithintravenousbeta-blocker(RVOTVT)or
I C
verapamil(fascicularVT)isrecommended.
IntravenousverapamilisnotrecommendedinbroadQRScomplextachycardiaofunknownmechanism.
III B
Mildtomoderatesedationisrecommendedinpatientswithelectricalstormtoalleviatepsychologicaldistressandreducesympathetic
I C
tone.
Antiarrhythmictherapywithbeta-blockers(non-selectivepreferred)incombinationwithintravenousamiodaroneisrecommendedin
I B
patientswithSHDandelectricalstormunlesscontraindicated.
Continued
Downloaded
from

by
guest
on
22
January
2026

4094 ESCGuidelines
IntravenousmagnesiumwithsupplementationofpotassiumisrecommendedinpatientswithTdP.
I C
IsoproterenolortransvenouspacingtoincreaseheartrateisrecommendedinpatientswithacquiredLQTsyndromeandrecurrent
I C
TdPdespitecorrectionofprecipitatingconditionsandmagnesium.
CatheterablationisrecommendedinpatientspresentingwithincessantVTorelectricalstormduetoSMVTrefractorytoAADs.
I B
Recommendationsfortreatmentwithheartfailuremedication
OptimalmedicaltreatmentincludingACE-I/ARB/ARNIs,MRAs,beta-blockers,andSGLT2inhibitorsisindicatedinallheartfailure
I A
patientswithreducedEF.
Recommendationsforimplantablecardioverterdefibrillationimplantation(generalaspects)
Implantationofacardioverterdefibrillatorisonlyrecommendedinpatientswhohaveanexpectationofgoodqualitysurvival.1year.
I C
ItisnotrecommendedtoimplantanICDinpatientswithincessantVAsuntiltheVAiscontrolled.
III C
Recommendationsforsecondarypreventionofsuddencardiacdeath
ICDimplantationisrecommendedinpatientswithdocumentedVForhaemodynamicallynot-toleratedVTintheabsenceofreversible
I A
causes.
Recommendationsforaddingcardiacresynchronizationtherapytoimplantablecardioverterdefibrillator
WhenanICDisindicated,itisrecommendedtoevaluatewhetherthepatientcouldbenefitfromCRT-defibrillator.
I C
Recommendationsforoptimizationofdeviceprogramming
OptimizationofICDprogrammingisindicatedtoavoidinappropriateandunnecessarytherapiesandtoreducemortality.
I A
Insingle-ordual-chamberICDpatientswithoutbradycardiapacingindications,itisrecommendedtominimizeventricularpacing.
I A
Programmingofprolongeddetectionsettingsisindicated(durationcriteriaofatleast6–12sor30intervals).
I A
Itisrecommendedtoprogramtheslowesttachycardiatherapyzonelimit≥188b.p.m.inprimarypreventionICDpatients.
I A
InpatientswithSHD,programmingofatleastoneATPtherapyisrecommendedinalltachyarrhythmiaszones.
I A
ItisrecommendedtoprogramalgorithmsforSVTvs.VTdiscriminationfortachycardiaswithratesupto230b.p.m.
I B
Itisrecommendedtoactivateleadfailurealerts.
I B
Remotemonitoringisrecommendedtoreducetheincidenceofinappropriateshocks.
I B
ProgrammingofburstATPasafirstattemptisrecommendedoverrampATP.
I B
ForS-ICDs,adualdetectionzoneconfigurationisrecommendedwithactivationofdiscriminationalgorithminthelowerconditional
I B
shockzone
Recommendationsforconcomitanttreatmenttoavoidinappropriateimplantablecardioverterdefibrillatortherapy
CatheterablationisrecommendedforICDpatientswithrecurrentSVTresultingininappropriateICDtherapies.
I C
PharmacologicaltreatmentorcatheterablationisrecommendedinpatientswithAF-relatedinappropriateICDtherapiesdespite
I C
optimalICDprogramming.
Recommendationforpsychosocialmanagementafterimplantablecardioverterdefibrillatorimplantation
AssessmentofpsychologicalstatusandtreatmentofdistressisrecommendedinICDpatients.
I C
Communicationbetweenpatientandphysician/healthcareprofessionalisrecommendedtoaddressICD-relatedconcernsandto
I C
discussquality-of-lifeissuesbeforeICDimplantationandduringdiseaseprogression.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4095
Recommendationsforpreventionofimplantablecardioverterdefibrillatorcomplications
Single-chamberICDisrecommendedoverdual-chamberICDinprimarypreventionpatientswithoutcurrentorexpectedindication
I A
foratrialorAVsequentialpacingduetoalowerriskofdevice-relatedcomplications.
Recommendationsforend-of-lifeissuesinimplantablecardioverterdefibrillatorcarriers
InformeddiscussionwithpatientandfamilyaboutICDdeactivationoptionsandshareddecision-makingisindicatedpriorto
I C
implantationandincaseofsignificanthealthstatusdeterioration.
Recommendationsfortreatmentofventriculararrhythmiainacutecoronarysyndromeandvasospasm
Intravenousbeta-blockertreatmentisindicatedforpatientswithrecurrentPVT/VFduringSTEMIunlesscontraindicated.
I B
ProphylactictreatmentwithAADs(otherthanbeta-blockers)isnotrecommendedinACS.
III B
Recommendationsforriskstratificationandtreatmentofventriculararrhythmiaearlyaftermyocardialinfarction
Early(beforedischarge)assessmentofLVEFisrecommendedinallpatientswithacuteMI.
I B
Inpatientswithpre-dischargeLVEF≤40%,re-evaluationofLVEF6–12weeksafterMIisrecommendedtoassessthepotentialneedfor
I C
primarypreventionICDimplantation.
Recommendationsforriskstratification,suddencardiacdeathprevention,andtreatmentofventriculararrhythmiainchronic
coronaryarterydisease
InpatientswithsyncopeandpreviousSTEMI,PESisindicatedwhensyncoperemainsunexplainedafternon-invasiveevaluation.
I C
ICDtherapyisrecommendedinpatientswithCAD,symptomaticheartfailure(NYHAclassII–III),andLVEF≤35%despite≥3months
I A
ofOMT.
InpatientswithCAD,prophylactictreatmentwithAADsotherthanbeta-blockersisnotrecommended.
III A
ICDimplantationisrecommendedinpatientswithoutongoingischaemiawithdocumentedVForhaemodynamicallynot-toleratedVT
I A
occurringlaterthan48hafterMI.
InpatientswithCADandrecurrent,symptomaticSMVTorICDshocksforSMVTdespitechronicamiodaronetherapy,catheter
I B
ablationisrecommendedinpreferencetoescalatingAADtherapy.
Recommendationsforsuddencardiacdeathpreventioninpatientswithcoronaryanomalies
Cardiacstressimagingduringphysicalexerciseisrecommendedinadditiontocardiopulmonaryexercisetestinpatientswithanomalous
I C
aorticoriginofacoronaryarterywithaninterarterialcoursetoconfirm/excludemyocardialischaemia.
Cardiacstressimagingduringphysicalexerciseisrecommendedinadditiontocardiopulmonaryexercisetestaftersurgeryinpatients
I C
withanomalousaorticoriginofacoronaryarterywithahistoryofabortedCA.
SurgeryisrecommendedinpatientswithanomalousaorticoriginofacoronaryarterywithCA,syncopesuspectedtobeduetoVAsor
I C
anginawhenothercauseshavebeenexcluded.
Recommendationsforthemanagementofpatientswithidiopathicprematureventricularcomplexes/ventriculartachycardia
RegularassessmentofventricularfunctionofpatientswithPVCburden.10%andnormalventricularfunctionisindicated.
I C
Catheterablationasfirst-linetreatmentisrecommendedforsymptomaticidiopathicVT/PVCsfromtheRVOTortheleftfascicles.e
I B
Beta-blockersornon-dihydropyridineCCBareindicatedinsymptomaticpatientswithidiopathicVT/PVCsfromanoriginotherthan
I C
theRVOTortheleftfascicles.
Catheterablationisnotrecommendedinchildren,5yearsofageor,10kgweightexceptwhenpreviousmedicaltherapyfailsor
III C
whenVTisnothaemodynamicallytolerated.
Amiodaroneasafirst-linetreatmentisnotrecommendedinpatientswithidiopathicVTs/PVCs.
III C
Verapamilisnotrecommendedinchildren,1yearofagewithPVC/VT,particularlyiftheyhavesignsofheartfailureorconcurrentuse
III C
ofotherAADs.
Recommendationsforthemanagementofpatientswithprematureventricularcomplex-inducedoraggravatedcardiomyopathy
InpatientswithacardiomyopathysuspectedtobecausedbyfrequentandpredominatelymonomorphicPVCs,catheterablationis
I C
recommended.
Continued
Downloaded
from

by
guest
on
22
January
2026

4096 ESCGuidelines
Recommendationsforriskstratification,suddencardiacdeathprevention,andtreatmentofventriculararrhythmiaindilated
cardiomyopathy/hypokineticnon-dilatedcardiomyopathy
Genetictesting(includingatleastLMNA,PLN,RBM20,andFLNCgenes)isrecommendedinpatientswithDCM/HNDCMandAV
I B
conductiondelayat,50years,orwhohaveafamilyhistoryofDCM/HNDCMorSCDinafirst-degreerelative(atage,50years).
Participationinhigh-intensityexerciseincludingcompetitivesportsisnotrecommendedforindividualswithDCM/HNDCManda
III C
LMNAmutation.
ICDimplantationisrecommendedinpatientswithDCM/HNDCM,whosurviveSCAduetoVT/VForexperiencehaemodynamically
I B
not-toleratedSMVT.
Inafirst-degreerelativeofaDCM/HNDCMpatient,anECG,andanechocardiogramarerecommendedif:
(cid:129) theindexpatientwasdiagnosed,50yearsofageorhasclinicalfeaturessuggestiveofaninheritedcause,or I C
(cid:129) thereisfamilyhistoryofDCM/HNDCM,orprematureunexpectedSD.
Recommendationsfordiagnostic,riskstratification,suddencardiacdeathpreventionandtreatmentofventriculararrhythmiain
arrhythmogenicrightventricularcardiomyopathy
InpatientswithsuspectedARVC,CMRisrecommended.
I B
InpatientswithasuspectedordefinitediagnosisofARVC,geneticcounsellingandtestingarerecommended.
I B
Avoidanceofhigh-intensityexerciseisrecommendedinpatientswithadefinitediagnosisofARVC.
I B
ICDimplantationisrecommendedinARVCpatientswithhaemodynamicallynot-toleratedVTorVF.
I C
InpatientswithARVCandnon-sustainedorsustainedVAs,beta-blockertherapyisrecommended.
I C
Inafirst-degreerelativeofapatientwithARVC,ECG,andechocardiogramarerecommended.
I C
Recommendationsforriskstratification,suddencardiacdeathprevention,andtreatmentofventriculararrhythmiainhypertrophic
cardiomyopathy
CMRwithLGEisrecommendedinHCMpatientsfordiagnosticwork-up.
I B
GeneticcounsellingandtestingarerecommendedinHCMpatients.
I B
Itisrecommendedthatthe5-yearriskofSCDisassessedatfirstevaluationandat1–3-yearintervalsorwhenthereisachangeinclinical
I C
status.
ICDimplantationisrecommendedinHCMpatientswithhaemodynamicallynot-toleratedVTorVF.
I B
Inafirst-degreerelativeofapatientwithHCM,ECG,andechocardiogramarerecommended.
I C
Recommendationsforriskstratification,suddencardiacdeathprevention,andtreatmentofventriculararrhythmiain
neuromusculardiseases
Annualfollow-upwithatleasta12-leadECGisrecommendedinpatientswithmusculardystrophies,evenintheconcealedphaseofthe
I C
disease.
ItisrecommendedthatpatientswithneuromusculardisorderswhohaveVAsorventriculardysfunctionaretreatedinthesamewayfor
I C
arrhythmiaaspatientswithoutneuromusculardisorders.
Invasiveelectrophysiologicalevaluationisrecommendedinpatientswithmyotonicdystrophyandpalpitationsorsyncopesuggestiveof
I C
VA,VT,orsurvivingaCA.
ICDimplantationisrecommendedinpatientswithmyotonicdystrophyandSMVTorabortedCAnotcausedbyBBR-VT.
I C
Inmyotonicdystrophypatients,serialelectrophysiologicalevaluationofAVconductionandarrhythmiainductionisnotrecommended
III C
withoutarrhythmiasuspicionorprogressionofECGconductiondisorders.
InsymptomaticpatientswithBBR-VT,catheterablationisrecommended.
I C
InpatientswithmyotonicdystrophyundergoingablationforBBR-VT,pacemaker/ICDimplantationisrecommended.
I C
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4097
Recommendationsforsuddencardiacdeathprevention,andtreatmentofventriculararrhythmiainmyocarditis
Inconfirmedorclinicallysuspectedacutemyocarditis,itisrecommendedthatpatientswhopresentwithlife-threateningVAare
I C
referredtoaspecializedcentre.
Inpatientswithhaemodynamicallynot-toleratedSMVToccurringinthechronicphaseofmyocarditis,anICDimplantationis
I C
recommended.
Recommendationsforriskstratification,suddencardiacdeathprevention,andtreatmentofventriculararrhythmiaincardiac
sarcoidosis
ICDimplantationisrecommendedinpatientswithcardiacsarcoidosiswhohaveanLVEF≤35%.
I B
ICDimplantationisrecommendedinpatientswithcardiacsarcoidosiswho(a)havedocumentedsustainedVT,or(2)abortedCA.
I B
Recommendationsforsuddencardiacdeathprevention,andtreatmentofventriculararrhythmiainvalvularheartdisease
PESwithstandbycatheterablationisrecommendedinpatientswithaorticvalvediseaseandSMVTtoidentifyandablateBBR-VT,
I C
especiallyifitoccursfollowingavalveintervention.
InpatientswithvalvularheartdiseaseandpersistentLVdysfunctionaftersurgicalcorrection(ifpossible)itisrecommendedthatICD
I C
implantationforprimarypreventionfollowsDCM/HNDCMrecommendations.
Recommendationsforsuddencardiacdeathprevention,andtreatmentofventriculararrhythmiaincongenitalheartdisease
InadultswithCHDwithbiventricularphysiologyandaleftsystemicventriclepresentingwithsymptomaticheartfailure(NYHAII/III)
I C
andEF≤35%despite≥3monthsofOMT,ICDimplantationisindicated.
InpatientswithCHDpresentingwithsustainedVAs,evaluationforresidualornewanatomicalabnormalitiesisrecommended.
I B
InpatientswithCHDwithnot-toleratedVT/abortedCAduetoVF,ICDimplantationisindicatedafterexclusionofreversiblecauses.
I C
InpatientswithrepairedTOFwhopresentwithSMVTorrecurrent,symptomaticappropriateICDtherapyforSMVT,catheterablation
I C
performedinspecializedcentresisrecommended.
Recommendationsformanagementofpatientswithidiopathicventricularfibrillation
ItisrecommendedthatidiopathicVFisdiagnosedinaSCAsurvivor,preferablywithdocumentationofVF,afterexclusionofan
I B
underlyingstructural,channelopathic,metabolic,ortoxicologicalaetiology.
ICDimplantationisrecommendedinidiopathicVF.
I B
RecommendationsformanagementofpatientswithlongQTsyndrome
ItisrecommendedthatLQTSisdiagnosedwitheitherQTc≥480msinrepeated12-leadECGswithorwithoutsymptomsorLQTS
I C
diagnosticscore.3.
InpatientswithclinicallydiagnosedlongQTsyndrome,genetictesting,andgeneticcounsellingarerecommended.
I C
ItisrecommendedthatLQTSisdiagnosedinthepresenceofapathogenicmutation,irrespectiveoftheQTduration. I C
RoutinediagnostictestingwithepinephrinechallengeisnotrecommendedinLQTS.
III C
ThefollowingisrecommendedinLQTS:
(cid:129) AvoidQT-prolongingdrugs.f
I C
(cid:129) Avoidandcorrectelectrolyteabnormalities.
(cid:129) Avoidgenotype-specifictriggersforarrhythmias.
Beta-blockers,ideallynon-selectivebeta-blockers(nadololorpropranolol),arerecommendedinLQTSpatientswithdocumentedQT
I B
intervalprolongation,toreduceriskofarrhythmicevents.
MexiletineisindicatedinLQT3patientswithaprolongedQTinterval.
I C
ICDimplantationinadditiontobeta-blockersisrecommendedinLQTSpatientswithCA.
I B
ICDimplantationisrecommendedinpatientswithLQTSwhoaresymptomaticgwhilereceivingbeta-blockersandgenotype-specific
I C
therapies.
Continued
Downloaded
from

by
guest
on
22
January
2026

4098 ESCGuidelines
LCSDisindicatedinpatientswithsymptomaticgLQTSwhen:(a)ICDtherapyiscontraindicatedordeclined;(b)patientison
I C
beta-blockersandgenotype-specifictherapieswithanICDandexperiencesmultipleshocksorsyncopeduetoVA.
InvasiveelectrophysiologicstudyisnotrecommendedinLQTS.
III C
RecommendationsformanagementofpatientswithAndersen–Tawilsyndrome
GenetictestingisrecommendedinpatientswithsuspectedAndersen–Tawilsyndrome.
I C
ICDimplantationisrecommendedinpatientswithAndersen–TawilsyndromeafterabortedCAnottoleratedsustainedVT.
I C
RecommendationsformanagementofpatientswithBrugadasyndrome
ItisrecommendedthatBrSisdiagnosedinpatientswithnootherheartdiseaseandaspontaneoustype1BrugadaECGpattern.
I C
ItisrecommendedthatBrSisdiagnosedinpatientswithnootherheartdiseasewhohavesurvivedaCAduetoVForPVTandexhibita
I C
type1BrugadaECGinducedbysodiumchannelblockerchallengeorduringfever.
GenetictestingforSCN5AgeneisrecommendedforprobandswithBrS. I C
SodiumchannelblockertestisnotrecommendedinpatientswithapriortypeIBrugadapattern.
III C
ThefollowingisrecommendedinallpatientswithBrS:
(a) AvoidanceofdrugsthatmayinduceST-segmentelevationinrightprecordialleads(
I C
(b) Avoidanceofcocaine,cannabis,andexcessivealcoholintake.
(c) Treatmentoffeverwithantipyreticdrugs.
ICDimplantationisrecommendedinpatientswithBrSwho:
(a) AresurvivorsofanabortedCA,and/or I C
(b) HavedocumentedspontaneoussustainedVT.
CatheterablationinasymptomaticBrSpatientsisnotrecommended.
III C
Recommendationsformanagementofpatientswithearlyrepolarizatonpattern/syndrome
ItisrecommendedthattheERPisdiagnosedasJ-pointelevationof≥1mmintwoadjacentinferiorand/orlateralECGleads.
I C
ItisrecommendedthattheERSisdiagnosedinapatientresuscitatedfromunexplainedVF/PVTinthepresenceofERP.
I C
ClinicalevaluationisnotrecommendedroutinelyinasymptomaticsubjectswithERP.
III C
ICDimplantationisrecommendedinpatientswithadiagnosisofERSwhohavesurvivedaCA.
I B
ICDimplantationisnotrecommendedinasymptomaticpatientswithanisolatedERP. III C
Recommendationsformanagementofpatientswithcatecholaminergicpolymorphicventriculartachycardia
ItisrecommendedthatCPVTisdiagnosedinthepresenceofastructurallynormalheart,normalECG,andexercise-or
I C
emotion-inducedbidirectionalorPVT.
ItisrecommendedthatCPVTisdiagnosedinpatientswhoarecarriersofamutationindisease-causinggenes.
I C
GenetictestingandgeneticcounsellingareindicatedinpatientswithclinicalsuspicionorclinicaldiagnosisofCPVT.
I C
Avoidanceofcompetitivesports,strenuousexercise,andexposuretostressfulenvironmentsisrecommendedinallpatientswith
I C
CPVT.
Beta-blockers,ideallynon-selective(nadololorpropranolol),arerecommendedinallpatientswithaclinicaldiagnosisofCPVT.
I C
ICDimplantationcombinedwithbeta-blockersandflecainideisrecommendedinCPVTpatientsafterabortedCA.
I C
PESisnotrecommendedforstratificationofSCDrisk.
III C
Continued
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4099
RecommendationsformanagementofpatientswithshortQTsyndrome
ItisrecommendedthatSQTSisdiagnosedinthepresenceofaQTc≤360msandoneormoreofthefollowing:(a)apathogenic
I C
mutation,(b)afamilyhistoryofSQTS,(c)survivalfromaVT/VFepisodeintheabsenceofheartdisease.
GenetictestingisindicatedinpatientsdiagnosedwithSQTS. I C
ICDimplantationisrecommendedinpatientswithadiagnosisofSQTSwho:(a)aresurvivorsofanabortedCA,and/or(b)have
I C
documentedspontaneoussustainedVT.
PESisnotrecommendedforSCDriskstratificationinSQTSpatients.
III C
Recommendationsforthepreventionofsuddencardiacdeathandmanagementofventriculararrhythmiaduringpregnancy
Duringpregnancy,electricalcardioversionisrecommendedforsustainedVT.
I C
IfICDimplantationisindicatedduringpregnancy,implantationisrecommendedwithoptimalradiationprotection.
I C
Continuationofbeta-blockersisrecommendedduringpregnancyandpost-partuminpatientswithLQTSorCPVT.
I C
Recommendationsforriskstratificationandpreventionofsuddencardiacdeathinathletes
Inathleteswithpositivemedicalhistory,abnormalphysicalexamination,orECGalterations,furtherinvestigationsincluding
I C
echocardiographyand/orCMRtoconfirm(orexclude)anunderlyingdiseasearerecommended.
ItisrecommendedthatathletesdiagnosedwithacardiovasculardiseaseassociatedwithSCDaremanagedaccordingtocurrent
I C
guidelinesforsportseligibility.
ItisrecommendedthatstaffatsportingfacilitiesaretrainedinCPRandintheuseofAED.
I C
AAD,anti-arrhythmicdrug;ACE-I,angiotensin-converting-enzymeinhibitor;AED,automatedexternaldefibrillator;ARB,angiotensinreceptorblockers;ARNIs,angiotensinreceptor
neprilysin inhibitor; ARVC, arrhythmogenic right ventricular cardiomyopathy; ATP, anti-tachycardia pacing; AV, atrioventricular; BBR-VT, bundle branch re-entry;
BrS,Brugadasyndrome;CA,cardiacarrest;CAD,coronaryarterydisease;CCB,calciumchannelblocker;CHD,congenitalheartdisease;CIED,cardiacimplantableelectronic
devices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization
therapy;DC,directcurrent;DCM,dilatedcardiomyopathy;ECG,electrocardiogram;EF,ejectionfraction;ERP,earlyrepolarizationpattern;ERS,earlyrepolarizationsyndrome;
HCM,hypertrophiccardiomyopathy;HNDCM,hypokineticnon-dilatedcardiomyopathy;ICD,implantablecardioverterdefibrillator;CAD,coronaryarterydisease;ILR,implantable
looprecorder;LCSD,leftcardiacsympatheticdenervation;LGE,lategadoliniumenhancement;LQTS,longQTsyndrome;LV,leftventricular;LVEF,leftventricularejectionfraction;
MRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,
optimalmedicaltherapy;PES,programmedelectricalstimulation;PVC,prematureventricularcomplex;PVT,polymorphicventriculartachycardia;RVOT,rightventricularoutflow
tract;SADS, suddenarrhythmicdeathsyndrome;SCA, sudden cardiacarrest;SCD, suddencardiacdeath; SD,suddendeath; SGLT2, sodium–glucoseco-transporter2; SHD,
structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular
tachycardia;VA,ventriculararrhythmia;VF,ventricularfibrillation;VT,ventriculartachycardia.
aClassofrecommendation.
bLevelofevidence.
cShoppingmalls,stadiums,publictransportstations,casinos.
dListnotexhaustive.
eLOECforVT/PVCsfromleftfascicles.
f
gArrhythmicsyncopeorhaemodynamicallynon-toleratedVA
12. Quality indicators Association. These QIs, alongside their specifications and develop-
mentprocess,willbepublishedseparately.
Qualityindicators(QIs)aretoolsthatmaybeusedtoevaluatecarequal-
ity,includingstructuralaspects,process,andoutcomesofcare.1153They
13. Supplementary data
serveasamechanismforenhancingadherencetoguidelinerecommen-
dations, through associated quality improvement initiatives and the
SupplementarydataisavailableatEuropeanHeartJournalonline.
benchmarkingofcareproviders.1154,1155Assuch,theroleofQIsinim-
provingcareandoutcomesisincreasinglyrecognizedbyhealthcareau-
thorities,professionalorganizations,payers,andthepublic.1153 14. Data availability statement
TheESCunderstandstheneedformeasuringandreportingqual-
Nonewdataweregeneratedoranalysedinsupportofthisresearch.
ityandoutcomesofcardiovascularcare,andhasestablishedmeth-
ods for the development of the ESC QIs for the quantification of
care and outcomes for cardiovascular disease.1153 In parallel with 15. Author information
the writing of this Clinical Practice Guideline document, a process
has been initiated to develop QIs for patients with, or at risk of, Author/taskforceMemberAffiliations:
VAorSCDusingtheESCmethodologyandthroughthecollabor- Marta de Riva, Cardiology, Leiden University MedicalCentre,
ation with domain experts and the European Heart Rhythm Leiden, Netherlands; Bo Gregers Winkel, Cardiology,
2202CSE©
Downloaded
from

by
guest
on
22
January
2026

4100 ESCGuidelines
Rigshospitalet, Copenhagen, Denmark, European Reference and DZHKPartnersite Berlin, Charité,Berlin, Germany; Christian
Networks for rare, low prevalence and complex diseases of the Sticherling, Department of Cardiology, University Hospital Basel,
heart, ERN-GUARD HEART; Elijah R. Behr, Cardiovascular UniversityofBasel,Basel,Switzerland;StylianosTzeis,Cardiology
Clinical Academic Group, Cardiology Section, St George’s, Department,MiteraHospital,HygeiaGroup,Athens,Greece;Axel
University of London, London, United Kingdom, Department of Verstrael (Belgium), ESC Patient Forum,Sophia Antipolis, France;
Cardiology, St George’s University Hospitals NHS Foundation andMaurizioVolterrani,DepartmentofCardiology,IRCCSSan
Trust, London, United Kingdom, and Cardiology, Mayo Clinic Raffaele Roma, Rome, Italy, and Professor of Exercise Science and
Healthcare, London, United Kingdom; Nico A. Blom, Paediatric Medicine,SanRaffaeleTelematicUniversityofRome,Rome.
Cardiology, Leiden University Medical Centre, Leiden,
Netherlands, and Paediatric Cardiology, Amsterdam University 16. Appendix
Medical Center, Amsterdam, Netherlands; Philippe Charron,
APHP,CentredeRéférencedesMaladiesCardiaquesHéréditaires ESCScientificDocumentGroup
ouRares,HôpitalPitié-Salpêtrière,Paris,France,UMR_S1166,and Includes Document Reviewers and ESC National Cardiac
ICAN Institute for Cardiometabolism, and Nutrition, Sorbonne Societies.
Université, Paris, France, and European Reference Networks for DocumentReviewers:MajaCikes(CPGReviewCoordinator)
rare, low prevalence and complex diseases of the heart, (Croatia), Paulus Kirchhof (CPG Review Coordinator) (Germany),
ERN-Guard HEART, Paris, France; Domenico Corrado, Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo
DepartmentofCardiac,ThoracicandVascularSciencesandPublic (Spain),FernandoArribas(Spain),RiccardoAsteggiano(Italy),Cristina
Health, University of Padova, Padova, Italy; Nikolaos Dagres, Basso (Italy), Axel Bauer (Austria), Emanuele Bertaglia (Italy), Tor
Department of Electrophysiology, Heart Center Leipzig at Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),
University of Leipzig, Leipzig, Germany; Christian de Chillou, Michael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard
Department of Cardiology, CHRU-Nancy, Nancy, France, and Cosyns (Belgium), Volkmar Falk (Germany), Laurent Fauchier
IADI,INSERMU1254,UniversitédeLorraine,Nancy,France;Lars (France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway),
Eckardt, Department of Cardiology II—Electrophysiology, Robert Hatala (Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab
University Hospital Münster, Münster, Germany; Tim Friede, (Germany), Aleksandra Konradi (Russian Federation), Konstantinos
Department of Medical Statistics, University Medical Center C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Goettingen, Goettingen, Germany, and Partner Site Goettingen, Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech
DZHK(GermanCenterforCardiovascularResearch),Goettingen, Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),
Germany;KristinaH.Haugaa,DepartmentofCardiology,Oslo Andreas Metzner (Germany), Richard Mindham (United Kingdom),
University Hospital, Rikshospitalet, Oslo, Norway, and Faculty of Jens Cosedis Nielsen (Denmark), Tone M. Norekvål (Norway),
Medicine, University of Oslo, Oslo, Norway; Mélèze Hocini, MonicaPatten(Germany),EvaPrescott(Denmark),AminaRakisheva
Cardiology Department, Liryc Institute, Pessac, France, Hopital (Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque
Cardiologique duHautLévêque,Pessac,France,andUniversitéde (Spain), Andrea Sarkozy (Belgium), Daniel Scherr (Austria), Marta
Bordeaux, Bordeaux, France; Pier D. Lambiase, Institute of Sitges(Spain),RhianM.Touyz(Canada/UnitedKingdom),NicolasVan
Cardiovascular Science, University College, London, United Mieghem(Netherlands),VedranVelagic(Croatia),SamiViskin(Israel),
Kingdom, BartsHeartCentre,StBartholomewsHospital, London, andPaulG.A.Volders(Netherlands).
United Kingdom, and Heart, Vascular and Thoracic Institute, ESCNationalCardiacSocietiesactivelyinvolvedinthere-
Cleveland Clinic, London, United Kingdom; Eloi Marijon, viewprocessofthe2022ESCGuidelinesforthemanagementofpa-
Cardiology Department, European Georges Pompidou Hospital, tients with ventricular arrhythmias and the prevention of sudden
Paris, France; Jose L. Merino, Arrhythmia and Electrophysiology cardiacdeath.
Robotic Unit, La Paz University Hospital, Universidad Autonoma, Algeria:AlgerianSocietyofCardiology,BrahimKichou;Armenia:
IdiPaz,Madrid,Spain,CardiologyDepartment,HospitalRuberJuan Armenian Cardiologists Association, Mihran Martirosyan; Austria:
Bravo, Madrid, Spain, and Cardiac Electrophysiology, Hospital Austrian Society of Cardiology, Daniel Scherr; Azerbaijan:
Viamed Santa Elena, Madrid, Spain; Petr Peichl, Cardiology Azerbaijan Society of Cardiology, Farid Aliyev; Belgium: Belgian
Department, IKEM, Prague, Czech Republic; Silvia G. Priori, Society of Cardiology, Rik Willems; Bosnia and Herzegovina:
Molecular Medicine Department, University of Pavia, Pavia, Italy, AssociationofCardiologistsofBosniaandHerzegovina,NabilNaser;
Molecular Cardiology Department, Istituti Clinici Scientifici Bulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov;
Maugeri SpA SB, Pavia, Italy, and Molecular Cardiology Croatia: Croatian Cardiac Society, Davor Milicic; Cyprus: Cyprus
Department, Centro Nacional de Investigaciones Cardiovasculares Society of Cardiology, Theodoros Christophides; Czech Republic:
Carlos III (CNIC), Madrid, Spain, European Reference Networks Czech Society of Cardiology, Josef Kautzner; Denmark: Danish
for rare, low prevalence and complex diseases of the heart, ERN- Society of Cardiology, Jim Hansen; Egypt: Egyptian Society of
GUARD HEART; Tobias Reichlin, Department of Cardiology, Cardiology, Lamyaa Allam; Estonia: Estonian Society of Cardiology,
Inselspital—University Hospital Bern, University of Bern, Bern, Priit Kampus; Finland: Finnish Cardiac Society, Juhani Junttila;
Switzerland; Jeanette Schulz-Menger, Cardiology, ECRC, France: French Society of Cardiology, Christophe Leclercq;
Charité—Universitätsmedizin Berlin, corporate member of Freie Georgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;
Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany: German Cardiac Society, Daniel Steven; Greece:
Germany, Cardiology, Helios Clinics Berlin-Buch, Berlin, Germany, Hellenic Society of Cardiology, Konstantinos Gatzoulis; Hungary:
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4101
Hungarian Society of Cardiology, László Gellér; Iceland: Icelandic 2.GliksonM,NielsenJC,KronborgMB,MichowitzY,AuricchioA,BarbashIM,etal.
SocietyofCardiology,DavidO.Arnar;Ireland:IrishCardiacSociety, 2021ESCGuidelinesoncardiacpacingandcardiacresynchronizationtherapy.Eur
HeartJ2021;42:3427–3520.
JosephGalvin,EuropeanReferenceNetworksforrare,lowprevalence
3.IbanezB,JamesS,AgewallS,AntunesMJ,Bucciarelli-DucciC,BuenoH,etal.2017
andcomplexdiseasesoftheheart,ERN-GUARDHEART;Israel:Israel ESCGuidelinesforthemanagementofacutemyocardialinfarctioninpatientspre-
HeartSociety,MotiHaim;Italy:ItalianFederationofCardiology,Carlo sentingwithST-segmentelevation:thetaskforceforthemanagementofacute
myocardial infarction in patients presenting with ST-segment elevation of the
Pappone; Kosovo (Republic of): Kosovo Society of Cardiology, EuropeanSocietyofCardiology(ESC).EurHeartJ2018;39:119–177.
Shpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina 4.PellicciaA,SharmaS,GatiS,BäckM,BörjessonM,CaselliS,etal.2020ESC
Kerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs; Guidelinesonsportscardiologyandexerciseinpatientswithcardiovasculardis-
ease.EurHeartJ2021;42:17–96.
Lebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:
5.WahbiK,BabutyD,ProbstV,WissocqueL,LabombardaF,PorcherR,etal.
Lithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg: Incidenceandpredictorsofsuddendeath,majorconductiondefectsandsustained
LuxembourgSocietyofCardiology,CarloDimmer;Malta:Maltese ventriculartachyarrhythmiasin1388patientswithmyotonicdystrophytype1.Eur
HeartJ2017;38:751–758.
Cardiac Society, Mark Adrian Sammut; Moldova (Republic of):
6.BucciE,TestaM,LicchelliL,FrattariA,ElHalabiehNA,GabrieleE,etal.A34-year
Moldavian Society of Cardiology, Lilia David; Montenegro: longitudinalstudyonlong-termcardiacoutcomesinDM1patientswithnormal
Montenegro Society of Cardiology, Aneta Boskovic; Morocco: ECGatbaselineatanItalianclinicalcentre.JNeurol2018;265:885–895.
Moroccan Society of Cardiology, Abdelhamid Moustaghfir; 7.Chong-NguyenC,WahbiK,AlgalarrondoV,BécaneHM,Radvanyi-HoffmanH,
ArnaudP,etal.Associationbetweenmutationsizeandcardiacinvolvementin
Netherlands: Netherlands Society of Cardiology, Alexander myotonicdystrophytype1:ananalysisoftheDM1-heartregistry.CircCardiovasc
H. Maass; North Macedonia: North Macedonian Society of Genet2017;10:e001526.
8.SabovicM,MedicaI,LogarN,MandićE,ZidarJ,PeterlinB.RelationofCTGexpan-
Cardiology, Lidija Poposka; Norway: Norwegian Society of
sionandclinicalvariablestoelectrocardiogramconductionabnormalitiesandsud-
Cardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society, den death in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:
PrzemysławMitkowski;Portugal:PortugueseSocietyofCardiology, 822–826.
9.Clarke NR, Kelion AD, Nixon J, Hilton-Jones D, Forfar JC. Does
LeonorParreira;Romania:RomanianSocietyofCardiology,Dragos
cytosine-thymine-guanine(CTG)expansionsizepredictcardiaceventsandelec-
Cozma;RussianFederation:RussianSocietyofCardiology,Elena trocardiographicprogressioninmyotonicdystrophy?Heart2001;86:411–416.
Golukhova; San Marino: San Marino Society of Cardiology, 10.Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al.
Roberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic; CorrelationbetweencardiacinvolvementandCTGtrinucleotiderepeatlength
inmyotonicdystrophy.JAmCollCardiol1995;25:239–245.
Slovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:
11.Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al.
Slovenian Society of Cardiology, Andrej Pernat; Spain: Spanish Relationshipsamongelectrophysiologicalfindingsandclinicalstatus,heartfunction,
Society of Cardiology, Nicasio Perez Castellano; Sweden: Swedish and extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:
1041–1046.
Society of Cardiology, Pyotr G. Platonov; Switzerland: Swiss
12.SansoneVA,BrigonziE,SchoserB,VillaniS,GaetaM,DeAmbroggiG,etal.The
Society of Cardiology, Firat Duru; Syrian Arab Republic: Syrian frequency and severity of cardiac involvement in myotonic dystrophy type 2
Cardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:
(DM2):long-termoutcomes.IntJCardiol2013;168:1147–1153.
13.BretonR,MathieuJ.Usefulnessofclinicalandelectrocardiographicdataforpre-
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Sana
dictingadversecardiaceventsinpatientswithmyotonicdystrophy.CanJCardiol
Ouali; Turkey: Turkish Society of Cardiology, Sabri Demircan; 2009;25:e23–e27.
Ukraine: Ukrainian Association of Cardiology, Oleg Sychov; and 14.Hermans MCE, Faber CG, Bekkers SCAM, de Die-Smulders CEM, Gerrits MM,
MerkiesISJ,etal.Structuralandfunctionalcardiacchangesinmyotonicdystrophy
United Kingdom of Great Britain and Northern Ireland:
type1:acardiovascularmagneticresonancestudy.JCardiovascMagnReson2012;14:48.
BritishCardiovascularSociety,AlistairSlade. 15.SchmachtL,TraberJ,GriebenU,UtzW,DieringerMA,KellmanP,etal.Cardiac
ESC Clinical Practice Guidelines (CPG) Committee: involvementinmyotonicdystrophytype2patientswithpreservedejectionfrac-
tion: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging
Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
2016;9:e004615.
(Egypt), Victor Aboyans (France), Sotiris Antoniou (United 16.Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.
Kingdom),ElenaArbelo(Spain),RiccardoAsteggiano(Italy),Andreas Electrocardiographic abnormalities and sudden death in myotonic dystrophy
type1.NEnglJMed2008;358:2688–2697.
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
17.BhaktaD,GrohMR,ShenC,PascuzziRM,GrohWJ.Increasedmortalitywithleft
Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet ventricularsystolicdysfunctionandheartfailureinadultswithmyotonicdystrophy
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris type1.AmHeartJ2010;160:1137–1141.
18.PetriH,AhtarovskiKA,VejlstrupN,VissingJ,WittingN,KøberL,etal.Myocardial
P.Gale(UnitedKingdom),SigrunHalvorsen(Norway),BernardIung
fibrosisinpatientswithmyotonicdystrophytype1:acardiovascularmagneticres-
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian onancestudy.JCardiovascMagnReson2014;16:59.
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha 19.MyerburgRJ,JunttilaMJ.Suddencardiacdeathcausedbycoronaryheartdisease.
(UnitedKingdom),UlfLandmesser(Germany),BasilS.Lewis(Israel),
Circulation2012;125:1043–1052.
20.SteckerEC,ReinierK,MarijonE,NarayananK,TeodorescuC,Uy-EvanadoA,etal.
Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard
PublichealthburdenofsuddencardiacdeathintheUnitedStates.CircArrhythm
Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark), Electrophysiol2014;7:212–217.
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark),
21.ChenLY,SotoodehniaN,BůžkováP,LopezFL,YeeLM,HeckbertSR,etal.Atrial
fibrillationandtheriskofsuddencardiacdeath:theatherosclerosisriskincommu-
Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian nitiesstudyandcardiovascularhealthstudy.JAMAInternMed2013;173:29–35.
M.Touyz(Canada/UnitedKingdom). 22.MarijonE,Uy-EvanadoA,DumasF,KaramN,ReinierK,TeodorescuC,etal.
Warningsymptomsareassociatedwithsurvivalfromsuddencardiacarrest.Ann
InternMed2016;164:23–29.
23.GlingeC,JabbariR,RisgaardB,LyngeTH,EngstrømT,AlbertCM,etal.Symptoms
17. References
beforesuddenarrhythmicdeathsyndrome:anationwidestudyamongtheyoungin
Denmark.JCardiovascElectrophysiol2015;26:761–767.
1.BrignoleM,MoyaA,deLangeFJ,DeharoJ-C,ElliottPM,FanciulliA,etal.2018ESC 24.ÅgesenFN,LyngeTH,BlancheP,BannerJ,PrescottE,JabbariR,etal.Temporal
Guidelinesforthediagnosisandmanagementofsyncope.EurHeartJ2018;39: trends and sex differences in sudden cardiac death in the Copenhagen City
1883–1948. HeartStudy.Heart2021;107:1303–1309.
Downloaded
from

by
guest
on
22
January
2026

4102 ESCGuidelines
25. WinkelBG,HolstAG,TheiladeJ,KristensenIB,ThomsenJL,OttesenGL,etal. 50.Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE.
Nationwidestudyofsuddencardiacdeathinpersonsaged1–35years.EurHeart Triggeringofsuddendeathfromcardiaccausesbyvigorousexertion.NEnglJ
J2011;32:983–990. Med2000;343:1355–1361.
26. PilmerCM,KirshJA,HildebrandtD,KrahnAD,GowRM.Suddencardiacdeathin 51.SiscovickDS,WeissNS,FletcherRH,LaskyT.Theincidenceofprimarycardiacar-
childrenandadolescentsbetween1and19yearsofage.HeartRhythm2014;11: restduringvigorousexercise.NEnglJMed1984;311:874–877.
239–245. 52.MarijonE,TaffletM,CelermajerDS,DumasF,Perier M-C,MustaficH,etal.
27. RisgaardB,WinkelBG,JabbariR,BehrER,Ingemann-HansenO,ThomsenJL,etal. Sports-related sudden death in the general population. Circulation 2011;124:
Burdenofsuddencardiacdeathinpersonsaged1to49years:nationwidestudyin 672–681.
Denmark.CircArrhythmElectrophysiol2014;7:205–211.
53.Heidbuchel H, Willems R, JordaensL, Olshansky B,CarreF, LozanoIF, et al.
28. FishmanGI,ChughSS,DiMarcoJP,AlbertCM,AndersonME,BonowRO,etal. IntensiverecreationalathletesintheprospectivemultinationalICDsportssafety
Suddencardiacdeathpredictionandpreventionreportfromanationalheart, registry:resultsfromtheEuropeancohort.EurJPrevCardiol2019;26:764–775.
lung,andbloodinstituteandheartrhythmsocietyworkshop.Circulation2010; 54.MarijonE,BougouinW,PérierM-C,CelermajerDS,JouvenX.Incidenceofsports-
122:2335–2348. relatedsuddendeathinFrancebyspecificsportsandsex.JAMA2013;310:642–643.
29. WongCX,BrownA,LauDH,ChughSS,AlbertCM,KalmanJM,etal.Epidemiology 55.MarijonE,Uy-EvanadoA,ReinierK,TeodorescuC,NarayananK,JouvenX,etal.
ofsuddencardiacdeath:globalandregionalperspectives.HeartLungCirc2019;28:
Suddencardiacarrestduringsportsactivityinmiddleage.Circulation2015;131:
6–14.
1384–1391.
30. BougouinW,LamhautL,MarijonE,JostD,DumasF,DeyeN,etal.Characteristics 56.BagnallRD,WeintraubRG,InglesJ,DuflouJ,YeatesL,LamL,etal.Aprospective
andprognosisofsuddencardiacdeathinGreaterParis:population-basedapproach
studyofsuddencardiacdeathamongchildrenandyoungadults.NEnglJMed2016;
fromtheParisSuddenDeathExpertiseCenter(Paris-SDEC).IntensiveCareMed 374:2441–2452.
2014;40:846–854.
57.WistenA,ForsbergH,KrantzP,MessnerT.Suddencardiacdeathin15-35-year
31. DeoR,AlbertCM.Epidemiologyandgeneticsofsuddencardiacdeath.Circulation
2012;125:620–637.
oldsinSwedenduring1992-99.JInternMed2002;252:529–536.
58.ChughSS,JuiJ,GunsonK,SteckerEC,JohnBT,ThompsonB,etal.Currentburden
32. GerberY,JacobsenSJ,FryeRL,WestonSA,KillianJM,RogerVL.Seculartrendsin
ofsuddencardiacdeath:multiplesourcesurveillanceversusretrospectivedeath
deathsfromcardiovasculardiseases:a25-yearcommunitystudy.Circulation2006;
113:2285–2292. certificate-based review in a large US. community. J Am Coll Cardiol 2004;44:
1268–1275.
33. KrahnAD,ConnollySJ,RobertsRS,GentM,ATMAInvestigators.Diminishingpro-
59.Winkel BG, Risgaard B, Sadjadieh G, Bundgaard H, Haunsø S, Tfelt-Hansen J.
portionalriskofsuddendeathwithadvancingage:implicationsforpreventionof
suddendeath.AmHeartJ2004;147:837–840. Suddencardiacdeathinchildren(1–18years):symptomsandcausesofdeathin
34. BeckerLB,HanBH,MeyerPM,WrightFA,RhodesKV,SmithDW,etal.Racialdif-
anationwidesetting.EurHeartJ2014;35:868–875.
ferences in the incidence of cardiac arrest and subsequent survival. The CPR 60.ByrneR,ConstantO,SmythY,CallagyG,NashP,DalyK,etal.Multiplesource
ChicagoProject.NEnglJMed1993;329:600–606. surveillanceincidenceandaetiologyofout-of-hospitalsuddencardiacdeathina
35. ZhaoD,PostWS,Blasco-ColmenaresE,ChengA,ZhangY,DeoR,etal.Racial
ruralpopulationintheWestofIreland.EurHeartJ2008;29:1418–1423.
differencesinsuddencardiacdeath.Circulation2019;139:1688–1697. 61.EckartRE,ShryEA,BurkeAP,McNearJA,AppelDA,Castillo-RojasLM,etal.
36. deVreede-SwagemakersJJ,GorgelsAP,Dubois-ArbouwWI,vanReeJW,Daemen Suddendeathinyoungadultsanautopsy-basedseriesofapopulationundergoing
MJ,HoubenLG,etal.Out-of-hospitalcardiacarrestinthe1990’s:apopulation- activesurveillance.JAmCollCardiol2011;58:1254–1261.
basedstudyintheMaastrichtareaonincidence,characteristicsandsurvival.JAm 62.WaldmannV,KaramN,BougouinW,SharifzadehganA,DumasF,NarayananK,
CollCardiol1997;30:1500–1505. etal.Burdenofcoronaryarterydiseaseasacauseofsuddencardiacarrestin
37. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al. theyoung.JAmCollCardiol2019;73:2118–2120.
Nationwide burden of sudden cardiac death: a study of 54,028 deaths in 63.WaldmannV,KaramN,RischardJ,BougouinW,SharifzadehganA,DumasF,etal.
Denmark.HeartRhythm2021;18:1657–1665. Lowratesofimmediatecoronaryangiographyamongyoungadultsresuscitated
38. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated fromsuddencardiacarrest.Resuscitation2020;147:34–42.
out-of-hospitalcardiacarrestinEurope.Resuscitation2005;67:75–80. 64.Lloyd-JonesDM,WilsonPWF,LarsonMG,BeiserA,LeipEP,D’AgostinoRB,etal.
39. EmpanaJ-P,BlomMT,BöttigerBW,DagresN,DekkerJM,GislasonG,etal. Framinghamriskscoreandpredictionoflifetimeriskforcoronaryheartdisease.
Determinants of occurrence and survival after sudden cardiac arrest—a AmJCardiol2004;94:20–24.
Europeanperspective:TheESCAPE-NETproject.Resuscitation2018;124:7–13. 65.VisserenFLJ,MachF,SmuldersYM,CarballoD,KoskinasKC,BäckM,etal.2021
40. FoxCS,EvansJC,LarsonMG,KannelWB,LevyD.Temporaltrendsincoronary ESCGuidelinesoncardiovasculardiseasepreventioninclinicalpractice.EurHeartJ
heart disease mortality and sudden cardiac death from 1950 to 1999: the 2021;42:3227–3337.
FraminghamHeartStudy.Circulation2004;110:522–527.
66.JouvenX,DesnosM,GuerotC,DucimetièreP.Predictingsuddendeathinthe
41. NiemeijerMN,vandenBergME,LeeningMJG,HofmanA,FrancoOH,Deckers population:theParisProspectiveStudyI.Circulation1999;99:1978–1983.
JW,etal.Decliningincidenceofsuddencardiacdeathfrom1990–2010inageneral
67.DekkerLRC,BezzinaCR,HenriquesJPS,TanckMW,KochKT,AlingsMW,etal.
middle-agedandelderlypopulation:theRotterdamStudy.HeartRhythm2015;12: Familialsuddendeathisanimportantriskfactorforprimaryventricularfibrillation:
123–129.
acase-controlstudyinacutemyocardialinfarctionpatients.Circulation2006;114:
42. LyngeTH,NielsenJL,BlancheP,GislasonG,Torp-PedersenC,WinkelBG,etal. 1140–1145.
Declineinincidenceofsuddencardiacdeathintheyoung:a10-yearnationwide
68.KaikkonenKS,KortelainenM-L,LinnaE,HuikuriHV.Familyhistoryandtheriskof
studyof8756deathsinDenmark.Europace2019;21:909–917.
suddencardiacdeathasamanifestationofanacutecoronaryevent.Circulation
43. ZhengZJ,CroftJB,GilesWH,MensahGA.SuddencardiacdeathintheUnited 2006;114:1462–1467.
States,1989to1998.Circulation2001;104:2158–2163.
69.JabbariR,EngstrømT,GlingeC,RisgaardB,JabbariJ,WinkelBG,etal.Incidence 44. tD ou cd oa rs oK n, aL ryap hp ea as rtG d, iS sete aw sear intS S, wR eo ds ee nng (1re 9n 91A t. oTr 2e 0n 0d 6s ).in Cio rcu ut l- ao tf io-h no 2s 0p 1it 1a ;l 1d 2e 3at :4h 6s –d 5u 2e
.
andriskfactorsofventricularfibrillationbeforeprimaryangioplastyinpatients
withfirstST-elevationmyocardialinfarction:anationwidestudyinDenmark.J
45. HarmonKG,AsifIM,MaleszewskiJJ,OwensDS,PrutkinJM,SalernoJC,etal.
AmHeartAssoc2015;4:e001399.
Incidence,cause,andcomparativefrequencyofsuddencardiacdeathinnational
70.FriedlanderY,SiscovickDS,WeinmannS,AustinMA,PsatyBM,LemaitreRN,etal.
collegiateathleticassociationathletes:adecadeinreview.Circulation2015;132:
10–19. Family history as a risk factor for primary cardiac arrest. Circulation 1998;97:
46. RisgaardB,WinkelBG,JabbariR,GlingeC,Ingemann-HansenO,ThomsenJL,etal.
155–160.
71.Deo R, Norby FL, Katz R, Sotoodehnia N, Adabag S, DeFilippi CR, et al.
Sports-relatedsuddencardiacdeathinacompetitiveandanoncompetitiveathlete
populationaged12to49years:datafromanunselectednationwidestudyin Developmentandvalidationofasuddencardiacdeathpredictionmodelforthe
Denmark.HeartRhythm2014;11:1673–1681. generalpopulation.Circulation2016;134:806–816.
47. HolstAG,WinkelBG,TheiladeJ,KristensenIB,ThomsenJL,OttesenGL,etal. 72.AroAL,ReinierK,RusinaruC,Uy-EvanadoA,DarouianN,PhanD,etal.Electrical
Incidenceandetiologyofsports-relatedsuddencardiacdeathinDenmark—impli- riskscorebeyondtheleftventricularejectionfraction:predictionofsuddencardiac
cationsforpreparticipationscreening.HeartRhythm2010;7:1365–1371. deathintheOregonSuddenUnexpectedDeathStudyandtheAtherosclerosis
48. MaronBJ,DoererJJ,HaasTS,TierneyDM,MuellerFO.Suddendeathsinyoung RiskinCommunitiesStudy.EurHeartJ2017;38:3017–3025.
competitiveathletes:analysisof1866deathsintheUnitedStates,1980–2006. 73.WaksJW,SitlaniCM,SolimanEZ,KabirM,GhafooriE,BiggsML,etal.Globalelec-
Circulation2009;119:1085–1092. tricheterogeneityriskscoreforpredictionofsuddencardiacdeathinthegeneral
49. CorradoD,BassoC,ThieneG.Suddencardiacdeathinathletes:whatistheroleof population:theAtherosclerosisRiskinCommunities(ARIC)andCardiovascular
screening?CurrOpinCardiol2012;27:41–48. Health(CHS)studies.Circulation2016;133:2222–2234.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4103
74.YoshinagaM,UshinohamaH,SatoS,TauchiN,HorigomeH,TakahashiH,etal. Support training in France: further needs for coordinated implementation.
Electrocardiographicscreeningof1-month-oldinfantsforidentifyingprolonged Resuscitation2017;118:49–54.
QTintervals.CircArrhythmElectrophysiol2013;6:932–938. 98.MpotosN,DeWeverB,CleymansN,RaemaekersJ,LoeysT,HerregodsL,etal.
75.YoshinagaM,KuchoY,SarantuyaJ,NinomiyaY,HorigomeH,UshinohamaH,etal. Repetitivesessionsofformativeself-testingtorefreshCPRskills:arandomised
Geneticcharacteristicsofchildrenandadolescentswithlong-QTsyndromediag- non-inferioritytrial.Resuscitation2014;85:1282–1286.
nosed by school-based electrocardiographic screening programs. Circ Arrhythm 99.GundryJW,ComessKA,DeRookFA,JorgensonD,BardyGH.Comparisonofna-
Electrophysiol2014;7:107–112. ivesixth-gradechildrenwithtrainedprofessionalsintheuseofanautomatedex-
76.JørgensenT,JacobsenRK,ToftU,AadahlM,GlümerC,PisingerC.Effectofscreen- ternaldefibrillator.Circulation1999;100:1703–1707.
ingandlifestylecounsellingonincidenceofischaemicheartdiseaseingeneralpopu- 100. BlewerAL,PuttME,BeckerLB,RiegelBJ,LiJ,LearyM,etal.Video-onlycardiopul-
lation:Inter99randomisedtrial.BMJ2014;348:g3617. monaryresuscitationeducationforhigh-riskfamiliesbeforehospitaldischarge:a
77.BoasR,SapplerN,vonStülpnagelL,KlemmM,DixenU,ThuneJJ,etal.Periodic multicenterpragmatictrial.CircCardiovascQualOutcomes2016;9:740–748.
repolarizationdynamicsidentifiesICD-respondersinnon-ischemiccardiomyop- 101. RinghM,RosenqvistM,HollenbergJ,JonssonM,FredmanD,NordbergP,etal.
athy:aDANISHsubstudy.Circulation2022;145:754–764. Mobile-phonedispatchoflaypersonsforCPRinout-of-hospitalcardiacarrest.N
78.SpiritoP,BelloneP,HarrisKM,BernaboP,BruzziP,MaronBJ.Magnitudeofleft EnglJMed2015;372:2316–2325.
ventricularhypertrophyandriskofsuddendeathinhypertrophiccardiomyopathy. 102. Stroop R, Kerner T, Strickmann B,Hensel M. Mobile phone-based alertingof
NEnglJMed2000;342:1778–1785. CPR-trained volunteers simultaneously with the ambulance can reduce the
79.BarsheshetA,GoldenbergI,O-UchiJ,MossAJ,JonsC,ShimizuW,etal.Mutations resuscitation-freeintervalandimproveoutcomeafterout-of-hospitalcardiacar-
incytoplasmicloopsoftheKCNQ1channelandtheriskoflife-threateningevents: rest:aGerman,population-basedcohortstudy.Resuscitation2020;147:57–64.
implicationsformutation-specificresponsetoβ-blockertherapyintype1long-QT 103. LeeSY,ShinSD,LeeYJ,SongKJ,HongKJ,RoYS,etal.Textmessagealertsystem
syndrome.Circulation2012;125:1988–1996. andresuscitationoutcomesafterout-of-hospitalcardiacarrest:abefore-and-after
80.WahbiK,BenYaouR,GandjbakhchE,AnselmeF,GossiosT,LakdawalaNK,etal. population-basedstudy.Resuscitation2019;138:198–207.
Developmentandvalidationofanewriskpredictionscoreforlife-threateningven- 104. FordyceCB,HansenCM,KragholmK,DupreME,JollisJG,RoettigML,etal.
triculartachyarrhythmiasinlaminopathies.Circulation2019;140:293–302. Associationofpublichealthinitiativeswithoutcomesforout-of-hospitalcardiacar-
81.Cadrin-TourignyJ,BosmanLP,NozzaA,WangW,TadrosR,BhonsaleA,etal.A restathomeandinpubliclocations.JAMACardiol2017;2:1226–1235.
newpredictionmodelforventriculararrhythmiasinarrhythmogenicrightventricu- 105. AndeliusL,MaltaHansenC,LippertFK,KarlssonL,Torp-PedersenC,KjærErsbøll
larcardiomyopathy.EurHeartJ2019;40:1850–1858. A,etal.Smartphoneactivationofcitizenresponderstofacilitatedefibrillationin
82.PrioriSG,SchwartzPJ,NapolitanoC,BloiseR,RonchettiE,GrilloM,etal.Risk out-of-hospitalcardiacarrest.JAmCollCardiol2020;76:43–53.
stratificationinthelong-QTsyndrome.NEnglJMed2003;348:1866–1874. 106. RantheMF,WinkelBG,AndersenEW,RisgaardB,WohlfahrtJ,BundgaardH,etal.
83.MironA,Lafreniere-RoulaM,SteveFanC-P,ArmstrongKR,DragulescuA,Papaz Riskofcardiovasculardiseaseinfamilymembersofyoungsuddencardiacdeathvic-
T,etal.Avalidatedmodelforsuddencardiacdeathriskpredictioninpediatric tims.EurHeartJ2013;34:503–511.
hypertrophiccardiomyopathy.Circulation2020;142:217–229. 107. PattonKK,SotoodehniaN,DeFilippiC,SiscovickDS,GottdienerJS,KronmalRA.
84.Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, et al. N-terminalpro-B-typenatriureticpeptideisassociatedwithsuddencardiacdeath
Developmentofanovelriskpredictionmodelforsuddencardiacdeathinchild- risk:theCardiovascularHealthStudy.HeartRhythm2011;8:228–233.
hood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol 2019;4: 108. EverettBM,MoorthyMV,TikkanenJT,CookNR,AlbertCM.Markersofmyocar-
918–927. dialstress,myocardialinjury,andsubclinicalinflammationandtheriskofsudden
85.O’MahonyC,JichiF,PavlouM,MonserratL,AnastasakisA,RapezziC,etal.Anovel death.Circulation2020;142:1148–1158.
clinicalriskpredictionmodelforsuddencardiacdeathinhypertrophiccardiomy- 109. BergerR,HuelsmanM,StreckerK,BojicA,MoserP,StanekB,etal.B-typenatri-
opathy(HCMrisk-SCD).EurHeartJ2014;35:2010–2020. uretic peptide predicts sudden death in patients with chronic heart failure.
86.SteyerbergEW,VergouweY.Towardsbetterclinicalpredictionmodels:seven Circulation2002;105:2392–2397.
steps for development and an ABCD for validation. Eur Heart J 2014;35: 110. ScottPA,BarryJ,RobertsPR,MorganJM.Brainnatriureticpeptideforthepredic-
1925–1931. tionofsuddencardiacdeathandventriculararrhythmias:ameta-analysis.EurJ
87.CollinsGS,ReitsmaJB,AltmanDG,MoonsKGM,TRIPODGroup.Transparentre- HeartFail2009;11:958–966.
portingofamultivariablepredictionmodelforindividualprognosisordiagnosis 111. AhmadT,FiuzatM,NeelyB,NeelyML,PencinaMJ,KrausWE,etal.Biomarkersof
(TRIPOD):theTRIPODstatement.Circulation2015;131:211–219. myocardialstressandfibrosisaspredictorsofmodeofdeathinpatientswith
88.Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. chronicheartfailure.JACCHeartFail2014;2:260–268.
Discriminationandcalibrationofclinicalpredictionmodels:users’guidestothe 112. GoldbergerJJ,CainME,HohnloserSH,KadishAH,KnightBP,LauerMS,etal.
medicalliterature.JAMA2017;318:1377–1384. AmericanHeartAssociation/AmericanCollegeofCardiologyFoundation/Heart
89.YanS,GanY,JiangN,WangR,ChenY,LuoZ,etal.Theglobalsurvivalrateamong RhythmSocietyscientificstatementonnoninvasiveriskstratificationtechniques
adultout-of-hospitalcardiacarrestpatientswhoreceivedcardiopulmonaryresus- for identifying patients at risk for sudden cardiac death: a scientific statement
citation:asystematicreviewandmeta-analysis.CritCare2020;24:61. from the American Heart Association Council on Clinical Cardiology
90.HallstromAP,OrnatoJP,WeisfeldtM,TraversA,ChristensonJ,McBurnieMA, Committee on Electrocardiography and Arrhythmias and Council on
etal.Public-accessdefibrillationandsurvivalafterout-of-hospitalcardiacarrest. EpidemiologyandPrevention.Circulation2008;118:1497–1518.
NEnglJMed2004;351:637–646. 113. VarmaN,CygankiewiczI,TurakhiaMP,HeidbuchelH,HuY-F,ChenLY,etal.2021
91.NakashimaT,NoguchiT,TaharaY,NishimuraK,YasudaS,OnozukaD,etal. ISHNE/HRS/EHRA/APHRSexpertcollaborativestatementonmHealthinarrhyth-
Public-access defibrillation and neurological outcomes in patients with miamanagement:digitalmedicaltoolsforheartrhythmprofessionals:fromthe
out-of-hospitalcardiacarrestinJapan:apopulation-basedcohortstudy.Lancet internationalsocietyforholterandnoninvasiveelectrocardiology/heartrhythmso-
2019;394:2255–2262. ciety/Europeanheartrhythmassociation/Asia-Pacificheartrhythmsociety.Circ
92.PollackRA,BrownSP,ReaT,AufderheideT,BarbicD,BuickJE,etal.Impactof ArrhythmElectrophysiol2021;14:e009204.
bystanderautomatedexternaldefibrillatoruseonsurvivalandfunctionaloutcomes 114. SolbiatiM,CasazzaG,DipaolaF,BarbicF,CaldatoM,MontanoN,etal.Thediag-
inshockableobservedpubliccardiacarrests.Circulation2018;137:2104–2113. nosticyieldofimplantablelooprecordersinunexplainedsyncope:asystematicre-
93.Kragholm K, Wissenberg M, Mortensen RN, Hansen SM, Malta Hansen C, viewandmeta-analysis.IntJCardiol2017;231:170–176.
ThorsteinssonK,etal.Bystandereffortsand1-yearoutcomesinout-of-hospital 115. GatzoulisKA,ArsenosP,TrachanasK,DilaverisP,AntoniouC,TsiachrisD,etal.
cardiacarrest.NEnglJMed2017;376:1737–1747. Signal-averagedelectrocardiography:past,present,andfuture.JArrhythmia2018;
94.KitamuraT,KiyoharaK,SakaiT,MatsuyamaT,HatakeyamaT,ShimamotoT,etal. 34:222–229.
Public-accessdefibrillationandout-of-hospitalcardiacarrestinJapan.NEnglJMed 116. MarcusFI,McKennaWJ,SherrillD,BassoC,BauceB,BluemkeDA,etal.Diagnosis
2016;375:1649–1659. ofarrhythmogenicrightventricularcardiomyopathy/dysplasia:proposedmodifica-
95.Hasselqvist-AxI,RivaG,HerlitzJ,RosenqvistM,HollenbergJ,NordbergP,etal. tionofthetaskforcecriteria.EurHeartJ2010;31:806–814.
Early cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N Engl J 117. GiudicessiJR,AckermanMJ.Exercisetestingoversightsunderliemissedanddelayed
Med2015;372:2307–2315. diagnosisofcatecholaminergicpolymorphicventriculartachycardiainyoungsud-
96.MarijonE,BougouinW,CelermajerDS,PerierM-C,BenameurN,LamhautL,etal. dencardiacarrestsurvivors.HeartRhythm2019;16:1232–1239.
Majorregionaldisparitiesinoutcomesaftersuddencardiacarrestduringsports. 118. RostonTM,KallasD,DaviesB,FranciosiS,DeSouzaAM,LaksmanZW,etal.Burst
EurHeartJ2013;34:3632–3640. exercisetestingcanunmaskarrhythmiasinpatientswithincompletelypenetrant
97.KaramN,NarayananK,BougouinW,BenameurN,BegantonF,JostD,etal.Major catecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol
regionaldifferencesinAutomatedExternalDefibrillatorplacementandBasicLife 2021;7:437–441.
Downloaded
from

by
guest
on
22
January
2026

4104 ESCGuidelines
119. SyRW,vanderWerfC,ChatthaIS,ChockalingamP,AdlerA,HealeyJS,etal. 142. SuedaS,KohnoH,OchiT,UraokaT.Overviewoftheacetylcholinespasmprovo-
Derivationandvalidationofasimpleexercise-basedalgorithmforpredictionof cationtest.ClinCardiol2015;38:430–438.
genetictestinginrelativesofLQTSprobands.Circulation2011;124:2187–2194. 143. TakagiY,YasudaS,TakahashiJ,TsunodaR,OgataY,SekiA,etal.Clinicalimplica-
120. Binder T. Transthoracic echocardiography and the standard examination of tionsofprovocationtestsforcoronaryarteryspasm:safety,arrhythmiccomplica-
specific cardiac structures. ESC CardioMed. 3rd ed. Oxford University Press; tions,andprognosticimpact:multicentreregistrystudyoftheJapaneseCoronary
2022.p425–431. SpasmAssociation.EurHeartJ2013;34:258–267.
121. HaugaaKH,BassoC,BadanoLP,Bucciarelli-DucciC,CardimN,GaemperliO,etal. 144. GarrattCJ,AntoniouA,GriffithMJ,WardDE,CammAJ.Useofintravenousad-
Comprehensivemulti-modalityimagingapproachinarrhythmogeniccardiomyop- enosineinsinusrhythmasadiagnostictestforlatentpreexcitation.AmJCardiol
athy—an expert consensus document of the European Association of 1990;65:868–873.
CardiovascularImaging.EurHeartJCardiovascImaging2017;18:237–253. 145. BourkeJP,RichardsDA,RossDL,WallaceEM,McGuireMA,UtherJB.Routine
122. HaugaaKH,GrenneBL,EekCH,ErsbollM,ValeurN,SvendsenJH,etal.Strain programmedelectricalstimulationinsurvivorsofacutemyocardialinfarctionfor
echocardiographyimprovesriskpredictionofventriculararrhythmiasaftermyo- predictionofspontaneousventriculartachyarrhythmiasduringfollow-up:results,
cardialinfarction.JACCCardiovascImaging2013;6:841–850. optimalstimulationprotocolandcost-effectivescreening.JAmCollCardiol1991;
123. HaugaaKH,HasselbergNE,EdvardsenT.Mechanicaldispersionbystrainechocar- 18:780–788.
diography:apredictorofventriculararrhythmiasinsubjectswithlaminA/Cmuta- 146. GatzoulisKA,TsiachrisD,ArsenosP,ArchontakisS,DilaverisP,VouliotisA,etal.
tions.JACCCardiovascImaging2015;8:104–106. Prognosticvalueofprogrammedventricularstimulationforsuddendeathinse-
124. ErsbollM,ValeurN,AndersenMJ,MogensenUM,VintherM,SvendsenJH,etal. lectedhighriskpatientswithstructuralheartdiseaseandpreservedsystolicfunc-
Earlyechocardiographicdeformationanalysisforthepredictionofsuddencardiac tion.IntJCardiol2014;176:1449–1451.
deathandlife-threateningarrhythmiasaftermyocardialinfarction.JACCCardiovasc 147. GatzoulisKA,VouliotisA-I,TsiachrisD,SalourouM,ArchontakisS,DilaverisP,
Imaging2013;6:851–860. etal.Primarypreventionofsuddencardiacdeathinanonischemicdilatedcardio-
125. Biering-SørensenT,KnappeD,PouleurA-C,ClaggettB,WangPJ,MossAJ,etal. myopathypopulation:reappraisaloftheroleofprogrammedventricularstimula-
Regionallongitudinaldeformationimprovespredictionofventriculartachyarrhyth- tion.CircArrhythmElectrophysiol2013;6:504–512.
miasinpatientswithheartfailurewithreducedejectionfraction:aMADIT-CRT 148. BrilakisES,ShenWK,HammillSC,HodgeDO,ReaRF,LexvoldNY,etal.Roleof
substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac programmedventricularstimulationandimplantablecardioverterdefibrillatorsin
ResynchronizationTherapy).CircCardiovascImaging2017;10:e005096. patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin
126. Garg R, Friedrich MG. Cardiomyopathies. ESC CardioMed. 3rd ed. Oxford Electrophysiol2001;24:1623–1630.
UniversityPress;2022,p510–515. 149. Brembilla-PerrotB,Suty-SeltonC,BeurrierD,HouriezP,NippertM,delaChaise
127. BorgquistR,HaugaaKH,GilljamT,BundgaardH,HansenJ,EschenO,etal.The AT,etal.Differencesinmechanismsandoutcomesofsyncopeinpatientswithcor-
diagnosticperformanceofimagingmethodsinARVCusingthe2010taskforcecri- onarydiseaseoridiopathicleftventriculardysfunctionasassessedbyelectrophy-
teria.EurHeartJCardiovascImaging2014;15:1219–1225. siologictesting.JAmCollCardiol2004;44:594–601.
128. ElliottPM,AnastasakisA,BorgerMA,BorggrefeM,CecchiF,CharronP,etal.2014 150. SchmittC,BarthelP,NdrepepaG,SchreieckJ,PlewanA,SchömigA,etal.Valueof
ESCGuidelinesondiagnosisandmanagementofhypertrophiccardiomyopathy: programmed ventricular stimulation for prophylactic internal cardioverter-
the task force for the Diagnosis and Management of Hypertrophic defibrillator implantation in postinfarction patients preselected by noninvasive
CardiomyopathyoftheEuropeanSocietyofCardiology(ESC).EurHeartJ2014; riskstratifiers.JAmCollCardiol2001;37:1901–1907.
35:2733–2779. 151. GatzoulisKA,TsiachrisD,ArsenosP,AntoniouC-K,DilaverisP,SiderisS,etal.
129. DiMarcoA,AngueraI,SchmittM,KlemI,NeilanTG,WhiteJA,etal.Lategado- Arrhythmicriskstratificationinpost-myocardialinfarctionpatientswithpreserved
liniumenhancementandtheriskforventriculararrhythmiasorsuddendeathindi- ejectionfraction:thePRESERVEEFstudy.EurHeartJ2019;40:2940–2949.
latedcardiomyopathy:systematicreviewandmeta-analysis.JACCHeartFail2017;5: 152. DenisA,SacherF,DervalN,LimHS,CochetH,ShahAJ,etal.Diagnosticvalueof
28–38. isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ
130. DejgaardLA,SkjølsvikET,LieØH,RibeM,StokkeMK,HegbomF,etal.Themitral ArrhythmElectrophysiol2014;7:590–597.
annulusdisjunctionarrhythmicsyndrome.JAmCollCardiol2018;72:1600–1609. 153. MerinoJL,CarmonaJR,Fernández-LozanoI,PeinadoR,BasterraN,SobrinoJA.
131. BassoC,IlicetoS,ThieneG,PerazzoloMarraM.Mitralvalveprolapse,ventricular Mechanismsofsustainedventriculartachycardiainmyotonicdystrophy:implica-
arrhythmias,andsuddendeath.Circulation2019;140:952–964. tionsforcatheterablation.Circulation1998;98:541–546.
132. AchenbachS.Technologyofcardiaccomputedtomography.ESCCardioMed.3rd 154. PezawasT,StixG,KastnerJ,WolztM,MayerC,MoertlD,etal.Unexplainedsyn-
ed.OxfordUniversityPress;2022,p537–541. copeinpatientswithstructuralheartdiseaseandnodocumentedventricularar-
133. MeijboomWB,vanMieghemCAG,MolletNR,PuglieseF,WeustinkAC,vanPelt rhythmias: value of electrophysiologically guided implantable cardioverter
N,etal.64-Slicecomputedtomographycoronaryangiographyinpatientswithhigh, defibrillatortherapy.Europace2003;5:305–312.
intermediate,orlowpretestprobabilityofsignificantcoronaryarterydisease.JAm 155. SroubekJ,ProbstV,MazzantiA,DeliseP,HeviaJC,OhkuboK,etal.Programmed
CollCardiol2007;50:1469–1475. ventricularstimulationforriskstratificationintheBrugadasyndrome:apooledana-
134. DouglasPS,HoffmannU,PatelMR,MarkDB,Al-KhalidiHR,CavanaughB,etal. lysis.Circulation2016;133:622–630.
Outcomesofanatomicalversusfunctionaltestingforcoronaryarterydisease.N 156. NayyarS,DownarE,BhaskaranAP,MasséS,NanthakumarK.Signaturesignal
EnglJMed2015;372:1291–1300. strategy:electrogram-basedventriculartachycardiamapping.HeartRhythm2020;
135. PrioriSG,WildeAA,HorieM,ChoY,BehrER,BerulC,etal.Executivesummary: 17:2000–2009.
HRS/EHRA/APHRSexpertconsensusstatementonthediagnosisandmanagement 157. LazarusA,VarinJ,BabutyD,AnselmeF,CosteJ,DubocD.Long-termfollow-upof
of patients with inherited primary arrhythmia syndromes. Europace 2013;15: arrhythmiasinpatientswithmyotonicdystrophytreatedbypacing:amulticenter
1389–1406. diagnosticpacemakerstudy.JAmCollCardiol2002;40:1645–1652.
136. GovindanM,BatchvarovVN,RajuH,ShanmugamN,BizrahM,BastiaenenR,etal. 158. TandriH,AsimakiA,AbrahamT,DalalD,TopsL,JainR,etal.ProlongedRVendo-
Utilityofhighandstandardrightprecordialleadsduringajmalinetestingforthe cardialactivationduration:anovelmarkerofarrhythmogenicrightventriculardys-
diagnosisofBrugadasyndrome.Heart2010;96:1904–1908. plasia/cardiomyopathy.HeartRhythm2009;6:769–775.
137. ChuretM,LuttooK,HociniM,HaïssaguerreM,SacherF,DuchateauJ.Diagnostic 159. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Saffitz JE, et al.
reproducibilityofepinephrinedrugchallengeinterpretationinsuspectedlongQT Electrophysiologicalabnormalitiesprecedeovertstructuralchangesinarrhythmo-
syndrome.JCardiovascElectrophysiol2019;30:896–901. genicrightventricularcardiomyopathyduetomutationsindesmoplakin-Acom-
138. RolfS.TheajmalinechallengeinBrugadasyndrome:diagnosticimpact,safety,and binedmurineandhumanstudy.EurHeartJ2012;33:1942–1953.
recommendedprotocol.EurHeartJ2003;24:1104–1112. 160. OriniM,GrahamAJ,SrinivasanNT,CamposFO,HansonBM,ChowA,etal.
139. TadrosR,NannenbergEA,LieveKV,Škorić-MilosavljevićD,LahrouchiN,Lekanne Evaluationofthereentryvulnerabilityindextopredictventriculartachycardiacir-
DeprezRH,etal.Yieldandpitfallsofajmalinetestingintheevaluationofunex- cuitsusinghigh-densitycontactmapping.HeartRhythm2020;17:576–583.
plained cardiac arrest and sudden unexplained death: single-center experience 161. Jackson N, Gizurarson S, Viswanathan K, King B, Massé S, Kusha M, et al.
with482families.JACCClinElectrophysiol2017;3:1400–1408. Decrementevokedpotentialmapping:basisofamechanisticstrategyforventricu-
140. MeregalliPG,RuijterJM,HofmanN,BezzinaCR,WildeAAM,TanHL.Diagnostic lartachycardiaablation.CircArrhythmElectrophysiol2015;8:1433–1442.
value of flecainide testing in unmasking SCN5A-related Brugada syndrome. 162. AvellaA,d’AmatiG,PappalardoA,ReF,SilenziPF,LaurenziF,etal.Diagnosticva-
JCardiovascElectrophysiol2006;17:857–864. lueofendomyocardialbiopsyguidedbyelectroanatomicvoltagemappinginar-
141. KrahnAD,HealeyJS,ChauhanVS,BirnieDH,ChampagneJ,SanataniS,etal. rhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc
Epinephrineinfusionintheevaluationofunexplainedcardiacarrestandfamilialsud- Electrophysiol2008;19:1127–1134.
den death: fromthe cardiac arrest survivors with preservedEjection Fraction 163. WildeAAM,BehrER.Genetictestingforinheritedcardiacdisease.NatRevCardiol
Registry.CircArrhythmElectrophysiol2012;5:933–940. 2013;10:571–583.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4105
164.HosseiniSM,KimR,UdupaS,CostainG,JoblingR,ListonE,etal.Reappraisalof 187. BelhassenB,ViskinS.Idiopathicventriculartachycardiaandfibrillation.JCardiovasc
reportedgenesforsuddenarrhythmicdeath:evidence-basedevaluationofgene Electrophysiol1993;4:356–368.
validityforBrugadasyndrome.Circulation2018;138:1195–1205. 188. ZarebaW,PlatonovP.ECGpatternsrelatedtoarrhythmiasandsuddendeath:
165.InglesJ,GoldsteinJ,ThaxtonC,CaleshuC,CortyEW,CrowleySB,etal.Evaluating channelopathies, early repolarization, and pre-excitation. ESC CardioMed. 3rd
theclinicalvalidityofhypertrophiccardiomyopathygenes.CircGenomPrecisMed ed.OxfordUniversityPress;2022,p382–389.
2019;12:e002460. 189. VoigtJ-U.Leftventricularfunction,heartfailure,andresynchronizationtherapy.
166.AdlerA,NovelliV,AminAS,AbiusiE,CareM,NannenbergEA,etal.Aninter- ESCCardioMed.3rded.OxfordUniversityPress;2022,p450–454.
national,multicentered,evidence-basedreappraisalofgenesreportedtocause 190. Edvardsen T. Cardiomyopathies, myocarditis, and the transplanted heart. ESC
congenitallongQTsyndrome.Circulation2020;141:418–428. CardioMed.3rded.OxfordUniversityPress;2022,p456–460.
167.RisgaardB,JabbariR,RefsgaardL,HolstAG,HaunsøS,SadjadiehA,etal.High 191. CygankiewiczI.AmbulatoryECGmonitoring.ESCCardioMed.3rded.Oxford
prevalenceofgeneticvariantspreviouslyassociatedwithBrugadasyndromein UniversityPress;2022,p393–400.
newexomedata.ClinGenet2013;84:489–495. 192. GrayB,KirbyA,KabungaP,FreedmanSB,YeatesL,KanthanA,etal.Twelve-lead
168.JamesCA,JongbloedJDH,HershbergerRE,MoralesA,JudgeDP,SyrrisP,etal.An ambulatoryelectrocardiographicmonitoringinBrugadasyndrome:potentialdiag-
internationalevidencebasedreappraisalofgenesassociatedwitharrhythmogenic
nosticandprognosticimplications.HeartRhythm2017;14:866–874.
right ventricular cardiomyopathy (ARVC) using the ClinGen framework. Circ 193. KarogiannisN,SeniorR.Stressechocardiography.ESCCardioMed.3rded.Oxford
GenomPrecisMed2021;14:e003273.
UniversityPress;2022,p431–434.
169.LahrouchiN,TadrosR,CrottiL,MizusawaY,PostemaPG,BeekmanL,etal. 194. NuciforaG,MuserD,MasciPG,BarisonA,RebellatoL,PiccoliG,etal.Prevalence
Transethnicgenome-wideassociationstudyprovidesinsightsinthegeneticarchi- andprognosticvalueofconcealedstructuralabnormalitiesinpatientswithappar-
tectureandheritabilityoflongQTsyndrome.Circulation2020;142:324–338. entlyidiopathicventriculararrhythmiasofleftversusrightventricularorigin:amag-
170.WijeyeratneYD,TanckMW,MizusawaY,BatchvarovV,BarcJ,CrottiL,etal.
neticresonanceimagingstudy.CircArrhythmElectrophysiol2014;7:456–462.
SCN5AmutationtypeandageneticriskscoreassociatevariablywithBrugadasyn- 195. MuserD,NuciforaG,MuserD,NuciforaG,PieroniM,CastroSA,etal.Prognostic
dromephenotypeinSCN5Afamilies.CircGenomPrecisMed2020;13:e002911. valueofnonischemicringlikeleftventricularscarinpatientswithapparentlyidio-
171.HarperAR,GoelA,GraceC,ThomsonKL,PetersenSE,XuX,etal.Commongen-
pathicnonsustainedventriculararrhythmias.Circulation2021;143:1359–1373.
eticvariantsandmodifiableriskfactorsunderpinhypertrophiccardiomyopathy 196. JosephsonME,CallansDJ.Usingthetwelve-leadelectrocardiogramtolocalizethe
susceptibilityandexpressivity.NatGenet2021;53:135–142.
siteoforiginofventriculartachycardia.HeartRhythm2005;2:443–446.
197. CorradoD,BassoC,LeoniL,TokajukB,BauceB,FrigoG,etal.Three-dimensional
172.TadrosR,FrancisC,XuX,VermeerAMC,HarperAR,HuurmanR,etal.Shared
electroanatomicvoltagemappingincreasesaccuracyofdiagnosingarrhythmogenic
geneticpathwayscontributetoriskofhypertrophicanddilatedcardiomyopathies
withoppositedirectionsofeffect.NatGenet2021;53:128–134.
rightventricularcardiomyopathy/dysplasia.Circulation2005;111:3042–3050.
198. CasellaM,DelloRussoA,BergontiM,CattoV,ConteE,SommarivaE,etal.
173.TadrosR,TanHL,ESCAPE-NETInvestigators,ElMathariS,KorsJA,PostemaPG,
Diagnosticyieldofelectroanatomicvoltagemappinginguidingendomyocardialbi-
et al. Predicting cardiac electrical response to sodium-channel blockade and
Brugadasyndromeusingpolygenicriskscores.EurHeartJ2019;40:3097–3107.
opsies.Circulation2020;142:1249–1260.
199. HaanschotenDM,AdiyamanA,‘tHartNA,JagerPL,ElvanA.Valueof3Dmapping-
174.WareJS,RobertsAM,CookSA.Nextgenerationsequencingforclinicaldiagnostics
guidedendomyocardialbiopsyincardiacsarcoidosis:caseseriesandnarrativere-
andpersonalisedmedicine:implicationsforthenextgenerationcardiologist.Heart
2012;98:276–281. viewonthevalueofelectro-anatomicmapping-guidedendomyocardialbiopsies.
EurJClinInvest2021;51:e13497.
175.AsharFN,MitchellRN,AlbertCM,Newton-ChehC,BrodyJA,Müller-NurasyidM,
200. TungR,BauerB,SchelbertH,LynchJP,AuerbachM,GuptaP,etal.Incidenceof
etal.Acomprehensiveevaluationofthegeneticarchitectureofsuddencardiacar-
abnormalpositronemissiontomographyinpatientswithunexplainedcardiomyop-
rest.EurHeartJ2018;39:3961–3969.
athyandventriculararrhythmias:thepotentialroleofoccultinflammationinar-
176.RichardsS,AzizN,BaleS,BickD,DasS,Gastier-FosterJ,etal.Standardsandguide- rhythmogenesis.HeartRhythm2015;12:2488–2498.
linesfortheinterpretationofsequencevariants:ajointconsensusrecommenda-
201. PalmisanoA,VignaleD,PerettoG,BusnardoE,CalcagnoC,CampochiaroC,etal.
tion of the American College of Medical Genetics and Genomics and the
HybridFDG-PET/MRorFDG-PET/CTtodetectdiseaseactivityinpatientswith
AssociationforMolecularPathology.GenetMed2015;17:405–424.
persisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:
177.InglesJ,LindJM,PhongsavanP,SemsarianC.Psychosocialimpactofspecializedcar- 288–292.
diacgeneticclinicsforhypertrophiccardiomyopathy.GenetMed2008;10:117–120.
202. VenletJ,PiersSRD,JongbloedJDH,AndroulakisAFA,NaruseY,denUijlDW,etal.
178.AckermanMJ,PrioriSG,WillemsS,BerulC,BrugadaR,CalkinsH,etal.HRS/EHRA Isolatedsubepicardialrightventricularoutflowtractscarinathleteswithventricu-
expertconsensusstatementonthestateofgenetictestingforthechannelopathies lartachycardia.JAmCollCardiol2017;69:497–507.
andcardiomyopathies:thisdocumentwasdevelopedasapartnershipbetweenthe
203. GeriG,DumasF,BougouinW,VarenneO,DaviaudF,PèneF,etal.Immediateper-
Heart Rhythm Society (HRS) and the European Heart Rhythm Association
cutaneouscoronaryinterventionisassociatedwithimprovedshort-andlong-term
(EHRA).Europace2011;13:1077–1109.
survivalafterout-of-hospitalcardiacarrest.CircCardiovascInterv2015;8:e002303.
179.Conte G, Wilde A, Behr ER, Scherr D, Lenarczyk R, Gandjbachkh E, et al.
204. VyasA,ChanPS,CramP,NallamothuBK,McNallyB,GirotraS.Earlycoronary
Importanceofdedicatedunitsforthemanagementofpatientswithinheritedar- angiographyandsurvivalafterout-of-hospitalcardiacarrest.CircCardiovascInterv
rhythmiasyndromes.CircGenomPrecisMed2021;14:e003313. 2015;8:e002321.
180.MinierM,ProbstV,BerthomeP,TixierR,BriandJ,GeoffroyO,etal.Ageatdiag- 205. KalarusZ,SvendsenJH,CapodannoD,DanG-A,DeMariaE,GorenekB,etal.
nosisofBrugadasyndrome:influenceonclinicalcharacteristicsandriskofarrhyth-
Cardiacarrhythmiasintheemergencysettingsofacutecoronarysyndromeandre-
mia.HeartRhythm2020;17:743–749.
vascularization:anEuropeanHeartRhythmAssociation(EHRA)consensusdocu-
181.WongLCH,Roses-NoguerF,TillJA,BehrER.Cardiacevaluationofpediatricre- ment, endorsed by the European Association of Percutaneous Cardiovascular
latives in sudden arrhythmic death syndrome: a 2-center experience. Circ Interventions (EAPCI), and European Acute Cardiovascular Care Association
ArrhythmElectrophysiol2014;7:800–806. (ACCA).Europace2019;21:1603–1604.
182.MellorGJ,BlomLJ,GroeneveldSA,WinkelBG,EnsamB,BargehrJ,etal.Familial 206. NocM,FajadetJ,LassenJF,KalaP,MacCarthyP,OlivecronaGK,etal.Invasivecor-
evaluationinidiopathicventricularfibrillation:diagnosticyieldandsignificanceofJ
onarytreatmentstrategiesforout-of-hospitalcardiacarrest:aconsensusstate-
WaveSyndromes.CircArrhythmElectrophysiol2021;14:e009089. ment from the European association for percutaneous cardiovascular
183.LahrouchiN,RajuH,LodderEM,PapatheodorouE,WareJS,PapadakisM,etal. interventions(EAPCI)/stentforlife(SFL)groups.EuroIntervention2014;10:31–37.
Utilityofpost-mortemgenetictestingincasesofsuddenarrhythmicdeathsyn- 207. VermaBR,SharmaV,ShekharS,KaurM,KhubberS,BansalA,etal.Coronaryangi-
drome.JAmCollCardiol2017;69:2134–2145.
ographyinpatientswithout-of-hospitalcardiacarrestwithoutST-segmenteleva-
184.FaberTS,GradingerR,TreuschS,MorkelC,BrachmannJ,BodeC,etal.Incidence tion: a systematic review and meta-analysis. JACC Cardiovasc Interv 2020;13:
ofventriculartachyarrhythmiasduringpermanentpacemakertherapyinlow-risk 2193–2205.
patientsresultsfromtheGermanmulticentreEVENTSstudy.EurHeartJ2007; 208. BarbarawiM,ZayedY,KheiriB,BarbarawiO,Al-AbdouhA,DhillonH,etal.
28:2238–2242. Optimaltimingofcoronaryinterventioninpatientsresuscitatedfromcardiacar-
185.MiddlekauffHR,StevensonWG,StevensonLW,SaxonLA.Syncopeinadvanced restwithoutST-segmentelevationmyocardialinfarction(NSTEMI):asystematic
heartfailure:highriskofsuddendeathregardlessoforiginofsyncope.JAmColl reviewandmeta-analysis.Resuscitation2019;144:137–144.
Cardiol1993;21:110–116. 209. Meng-Chang Y, Meng-Jun W, Xiao-Yan X, Peng KL, Peng YG, RuRong W.
186.NodaT,ShimizuW,TaguchiA,AibaT,SatomiK,SuyamaK,etal.Malignantentity CoronaryangiographyornotaftercardiacarrestwithoutSTsegmentelevation:
ofidiopathicventricularfibrillationandpolymorphicventriculartachycardiain- asystematicreviewandmeta-analysis.Medicine(Baltimore)2020;99:e22197.
itiatedbyprematureextrasystolesoriginatingfromtherightventricularoutflow 210. KhanMS,ShahSMM,MubashirA,KhanAR,FatimaK,SchenoneAL,etal.Earlycor-
tract.JAmCollCardiol2005;46:1288–1294. onary angiography in patients resuscitated from out of hospital cardiac arrest
Downloaded
from

by
guest
on
22
January
2026

4106 ESCGuidelines
withoutST-segmentelevation:asystematicreviewandmeta-analysis.Resuscitation 232. AdlerA,vanderWerfC,PostemaPG,RossoR,BhuiyanZA,KalmanJM,etal.The
2017;121:127–134. phenomenonof‘QTstunning’:theabnormalQTprolongationprovokedbystand-
211. WelsfordM,BossardM,ShorttC,PritchardJ,NatarajanMK,Belley-CôtéEP.Does ingpersistsevenastheheartratereturnstonormalinpatientswithlongQTsyn-
earlycoronaryangiographyimprovesurvivalafterout-of-hospitalcardiacarrest?A drome.HeartRhythm2012;9:901–908.
systematicreviewwithmeta-analysis.CanJCardiol2018;34:180–194. 233. DionneA,FournierA,DahdahN,AbramsD,KhairyP,AbadirS.DynamicQT
212. ChellyJ,MongardonN,DumasF,VarenneO,SpauldingC,VignauxO,etal.Benefit intervalchangesfromsupinetostandinginhealthychildren.CanJCardiol2018;
ofanearlyandsystematicimagingprocedureaftercardiacarrest:insightsfromthe 34:66–72.
PROCAT(ParisianRegionOutofHospitalCardiacArrest)registry.Resuscitation 234. FooFS,StilesMK,HeavenD.Unmaskinglatentpreexcitationofaright-sidedacces-
2012;83:1444–1450. sorypathwaywithintravenousadenosineafterunexplainedsuddencardiacarrest.J
213. StilesMK,WildeAAM,AbramsDJ,AckermanMJ,AlbertCM,BehrER,etal.2020 Arrhythm2020;36:939–941.
APHRS/HRSexpertconsensusstatementontheinvestigationofdecedentswith 235. MarjamaaA,HiippalaA,ArrheniusB,LahtinenAM,KontulaK,ToivonenL,etal.
suddenunexplaineddeathandpatientswithsuddencardiacarrest,andoftheir Intravenousepinephrineinfusiontestindiagnosisofcatecholaminergicpolymorph-
families.HeartRhythm2021;18:e1–e50. icventriculartachycardia.JCardiovascElectrophysiol2012;23:194–199.
214. TsengZH,OlginJE,VittinghoffE,UrsellPC,KimAS,SporerK,etal.Prospective 236. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen W-K, Porter CJ.
countywide surveillanceandautopsycharacterizationof suddencardiacdeath: Epinephrine-induced QT interval prolongation: a gene-specific paradoxical re-
POSTSCDstudy.Circulation2018;137:2689–2700. sponseincongenitallongQTsyndrome.MayoClinProc2002;77:413–421.
215. Fellmann F,van El CG,Charron P, MichaudK,Howard HC, BoersSN, etal. 237. ShimizuW,NodaT,TakakiH,NagayaN,SatomiK,KuritaT,etal.Diagnosticvalue
Europeanrecommendationsintegratinggenetictestingintomultidisciplinaryman- ofepinephrinetestforgenotypingLQT1,LQT2,andLQT3formsofcongenital
agementofsuddencardiacdeath.EurJHumGenet2019;27:1763–1773. longQTsyndrome.HeartRhythm2004;1:276–283.
216. Yamamoto T, Takayama M, Sato N, Yodogawa K,Iwasaki Y-K, Kato K, et al. 238. MagnanoAR,TalathotiN,HallurR,BloomfieldDM,GaranH.Sympathomimetic
Inappropriateanalysesofautomatedexternaldefibrillatorsusedduringin-hospital infusionandcardiacrepolarization:thenormativeeffectsofepinephrineandiso-
ventricularfibrillation.CircJ2008;72:679–681. proterenolinhealthysubjects.JCardiovascElectrophysiol2006;17:983–989.
217. SweeneyMO,RuetzLL,BelkP,MullenTJ,JohnsonJW,SheldonT.Bradycardia 239. VyasH,HejlikJ,AckermanMJ.EpinephrineQTstresstestingintheevaluationof
pacing-inducedshort-long-shortsequencesattheonsetofventriculartachyar- congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT re-
rhythmias: apossiblemechanismof proarrhythmia? J AmColl Cardiol2007;50:
sponse.Circulation2006;113:1385–1392.
614–622. 240. WaldmannV,BougouinW,KaramN,NarayananK,SharifzadehganA,SpauldingC,
etal.Coronaryvasospasm-relatedsuddencardiacarrestinthecommunity.JAm
218. TsengZH,HaywardRM,ClarkNM,MulvannyCG,ColburnBJ,UrsellPC,etal.
CollCardiol2018;72:814–815.
Suddendeathinpatientswithcardiacimplantableelectronicdevices.JAMAIntern
Med2015;175:1342–1350. 241. EtienneP,HuchetF,GaboritN,BarcJ,TholletA,KyndtF,etal.Mentalstresstest:a
rapid,simple,andefficienttesttounmasklongQTsyndrome.Europace2018;20:
219. LacourP,BuschmannC,StormC,NeeJ,ParwaniAS,HuemerM,etal.Cardiacim-
2014–2020.
plantableelectronicdeviceinterrogationatforensicautopsy:anunderestimatedre-
source?Circulation2018;137:2730–2740. 242. KopWJ,KrantzDS,NearingBD,GottdienerJS,QuigleyJF,O’CallahanM,etal.
220. CurcioA,MazzantiA,BloiseR,MonteforteN,IndolfiC,PrioriSG,etal.Clinical EffectsofacutementalstressandexerciseonT-wavealternansinpatientswithim-
plantablecardioverterdefibrillatorsandcontrols.Circulation2004;109:1864–1869.
presentationandoutcomeofBrugadasyndromediagnosedwiththenew2013cri-
teria.JCardiovascElectrophysiol2016;27:937–943. 243. Schwartz PJ, Lia C. QTc behavior during exercise and genetic testing for the
long-QTsyndrome.Circulation2011;124:2181–2184.
221. HaïssaguerreM,ShahDC,JaïsP,ShodaM,KautznerJ,ArentzT,etal.Roleof
Purkinje conducting system in triggering of idiopathic ventricular fibrillation. 244. WangYS,ScheinmanMM,ChienWW,CohenTJ,LeshMD,GriffinJC.Patients
Lancet2002;359:677–678. w mi et ch hs au np isr mave an nt dric lou nla gr -tt ea rc mhyc foa lr lodi wa -p ur pe .se Jn At ming Cw ollit Ch aa rb do ior lt 1e 9d 9s 1u ;d 1d 8e :1n 7d 1e 1a –th 1: 7i 1n 9ci .dence,
222. KrahnAD,HealeyJS,ChauhanV,BirnieDH,SimpsonCS,ChampagneJ,etal.
245. RobertsJD,GollobMH,YoungC,ConnorsSP,GrayC,WiltonSB,etal.Bundle
Systematicassessmentofpatientswithunexplainedcardiacarrest:cardiacarrest
branch re-entrant ventricular tachycardia: novel genetic mechanisms in a life-
survivors with preservedejection fractionregistry (CASPER).Circulation 2009; threateningarrhythmia.JACCClinElectrophysiol2017;3:276–288.
120:278–285.
246. SantangeliP,Hamilton-CraigC,DelloRussoA,PieroniM,CasellaM,PelargonioG,
223. vanderWerfC,HofmanN,TanHL,vanDesselPF,AldersM,vanderWalAC,etal.
etal.Imagingofscarinpatientswithventriculararrhythmiasofrightventricularori-
Diagnosticyieldinsuddenunexplaineddeathandabortedcardiacarrestinthe
gin: cardiac magnetic resonance versus electroanatomic mapping. J Cardiovasc
young: the experience of a tertiary referral center in The Netherlands. Heart Electrophysiol2011;22:1359–1366.
Rhythm2010;7:1383–1389.
247. HaïssaguerreM, DuchateauJ, Dubois R, Hocini M,ChenitiG, Sacher F,et al.
224. EckartRE,ScovilleSL,CampbellCL,ShryEA,StajduharKC,PotterRN,etal. Idiopathicventricularfibrillation:roleofPurkinjesystemandmicrostructuralmyo-
Suddendeathinyoungadults:a25-yearreviewofautopsiesinmilitaryrecruits. cardialabnormalities.JACCClinElectrophysiol2020;6:591–608.
AnnInternMed2004;141:829–834.
248. HaïssaguerreM,HociniM,ChenitiG,DuchateauJ,SacherF,PuyoS,etal.Localized
225. KunadianV,ChieffoA,CamiciPG,BerryC,EscanedJ,MaasAHEM,etal.AnEAPCI
structuralalterationsunderlyingasubsetofunexplainedsuddencardiacdeath.Circ
expertconsensusdocumentonischaemiawithnon-obstructivecoronaryarteries ArrhythmElectrophysiol2018;11:e006120.
in collaboration with European Society of Cardiology Working Group on 249. MellorG,LaksmanZWM,TadrosR,RobertsJD,GerullB,SimpsonCS,etal.
Coronary Pathophysiology & Microcirculation Endorsed by Coronary Genetic testing in the evaluation of unexplained cardiac arrest: from the
VasomotorDisordersInternationalStudyGroup.EurHeartJ2020;41:3504–3520.
CASPER(CardiacArrestSurvivorsWithPreservedEjectionFractionRegistry).
226. RodriguesP,JoshiA,WilliamsH,WestwoodM,PetersenSE,ZemrakF,etal. CircCardiovascGenet2017;10:e001686.
Diagnosisandprognosisinsuddencardiacarrestsurvivorswithoutcoronaryartery 250. BurnsC,BagnallRD,LamL,SemsarianC,InglesJ.Multiplegenevariantsinhyper-
disease:utilityofaclinicalapproachusingcardiacmagneticresonanceimaging.Circ trophiccardiomyopathyintheeraofnext-generationsequencing.CircCardiovasc
CardiovascImaging2017;10:e006709. Genet2017;10:e001666.
227. WhiteJA,FineNM,GulaL,YeeR,SkanesA,KleinG,etal.Utilityofcardiovascular 251. KaramN,JabreP,NarayananK,SharifzadehganA,PerierM-C,TennenbaumJ,etal.
magneticresonanceinidentifyingsubstrateformalignantventriculararrhythmias. Psychologicalsupportandmedicalscreeningoffirst-degreerelativesofsuddencar-
CircCardiovascImaging2012;5:12–20. diacarrestvictims.JACCClinElectrophysiol2020;6:586–587.
228. BassoC,PerazzoloMarraM,RizzoS,DeLazzariM,GiorgiB,CiprianiA,etal. 252. BehrE,WoodDA,WrightM,SyrrisP,SheppardMN,CaseyA,etal.Cardiological
Arrhythmicmitralvalveprolapseandsuddencardiacdeath.Circulation2015;132: assessmentoffirst-degreerelativesinsuddenarrhythmicdeathsyndrome.Lancet
556–566. 2003;362:1457–1459.
229. ObeyesekereMN,KleinGJ,ModiS,Leong-SitP,GulaLJ,YeeR,etal.Howtoper- 253. TanHL,HofmanN,vanLangenIM,vanderWalAC,WildeAAM.Suddenunex-
formandinterpretprovocativetestingforthediagnosisofBrugadasyndrome, plaineddeath:heritabilityanddiagnosticyieldofcardiologicalandgeneticexamin-
long-QTsyndrome,andcatecholaminergicpolymorphicventriculartachycardia. ationinsurvivingrelatives.Circulation2005;112:207–213.
CircArrhythmElectrophysiol2011;4:958–964. 254. LemkesJS,JanssensGN,vanderHoevenNW,JewbaliLSD,DuboisEA,Meuwissen
230. CheungCC,MellorG,DeyellMW,EnsamB,BatchvarovV,PapadakisM,etal. M,etal.CoronaryangiographyaftercardiacarrestwithoutST-segmentelevation.
Comparisonofajmalineandprocainamideprovocationtestsinthediagnosisof NEnglJMed2019;380:1397–1407.
Brugadasyndrome.JACCClinElectrophysiol2019;5:504–512. 255. KernKB,RadselP,JentzerJC,SederDB,LeeKS,LotunK,etal.Randomizedpilot
231. AntzelevitchC,YanG-X,AckermanMJ,BorggrefeM,CorradoD,GuoJ,etal. clinicaltrialofearlycoronaryangiographyversusnoearlycoronaryangiography
J-Wavesyndromesexpertconsensusconferencereport:emergingconceptsand aftercardiacarrestwithoutST-segmentelevation:thePEARLstudy.Circulation
gapsinknowledge.Europace2017;19:665–694. 2020;142:2002–2012.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4107
256.DeschS,FreundA,AkinI,BehnesM,PreuschMR,ZelnikerTA,etal.Angiography 280. MellorG,RajuH,deNoronhaSV,PapadakisM,SharmaS,BehrER,etal.Clinical
afterout-of-hospitalcardiacarrestwithoutST-segmentelevation.NEnglJMed characteristicsandcircumstancesofdeathinthesuddenarrhythmicdeathsyn-
2021;385:2544–2553. drome.CircArrhythmElectrophysiol2014;7:1078–1083.
257.Arnaout M, Mongardon N, Deye N, Legriel S, Dumas F, Sauneuf B, et al. 281. PapadakisM,PapatheodorouE,MellorG,RajuH,BastiaenenR,WijeyeratneY,
Out-of-hospitalcardiacarrestfrombraincause:epidemiology,clinicalfeatures, etal.ThediagnosticyieldofBrugadasyndromeaftersuddendeathwithnormalaut-
andoutcomeinamulticentercohort.CritCareMed2015;43:453–460. opsy.JAmCollCardiol2018;71:1204–1214.
258.HornerJM,HornerMM,AckermanMJ.Thediagnosticutilityofrecoveryphase 282. MellorG,NelsonCP,RobbC,RajuH,WijeyeratneY,HengstenbergC,etal.The
QTcduringtreadmillexercisestresstestingintheevaluationoflongQTsyndrome. prevalenceandsignificanceoftheearlyrepolarizationpatterninsuddenarrhythmic
HeartRhythm2011;8:1698–1704. deathsyndromefamilies.CircArrhythmElectrophysiol2016;9:e003960.
259.PerrinMJ,AngaranP,LaksmanZ,ZhangH,PorepaLF,RutbergJ,etal.Exercisetest- 283. NunnLM,LopesLR,SyrrisP,MurphyC,PlagnolV,FirmanE,etal.Diagnosticyield
inginasymptomaticgenecarriersexposesalatentelectricalsubstrateofarrhyth- ofmolecularautopsyinpatientswithsuddenarrhythmicdeathsyndromeusingtar-
mogenicrightventricularcardiomyopathy.JAmCollCardiol2013;62:1772–1779. getedexomesequencing.Europace2016;18:888–896.
260.WaldmannV,BougouinW,KaramN,DumasF,SharifzadehganA,GandjbakhchE, 284. vanderWerfC,StiekemaL,TanHL,HofmanN,AldersM,vanderWalAC,etal.
etal.Characteristicsandclinicalassessmentofunexplainedsuddencardiacarrestin Lowrateofcardiaceventsinfirst-degreerelativesofdiagnosis-negativeyoungsud-
thereal-worldsetting:focusonidiopathicventricularfibrillation.EurHeartJ2018;
denunexplaineddeathsyndromevictimsduringfollow-up.HeartRhythm2014;11:
39:1981–1987. 1728–1732.
261.NakaoK,OhgushiM,YoshimuraM,MorookaK,OkumuraK,OgawaH,etal. 285. MadhavanM,FriedmanPA,LennonRJ,PrasadA,WhiteRD,SriramCS,etal.
Hyperventilationasaspecifictestfordiagnosisofcoronaryarteryspasm.AmJ Implantablecardioverter-defibrillatortherapyinpatientswithventricularfibrilla-
Cardiol1997;80:545–549.
tionoutofhospitalcardiacarrestsecondarytoacutecoronarysyndrome.JAm
262.BehrER,CaseyA,SheppardM,WrightM,BowkerTJ,DaviesMJ,etal.Suddenar- HeartAssoc2015;4:e001255.
rhythmicdeathsyndrome:anationalsurveyofsuddenunexplainedcardiacdeath. 286. WyseDG,FriedmanPL,BrodskyMA,BeckmanKJ,CarlsonMD,CurtisAB,etal. Heart2007;93:601–605.
Life-threateningventriculararrhythmiasduetotransientorcorrectablecauses:
263.BassoC,AguileraB,BannerJ,CohleS,d’AmatiG,deGouveiaRH,etal.Guidelines
highriskfordeathinfollow-up.JAmCollCardiol2001;38:1718–1724.
for autopsy investigation of sudden cardiac death: 2017 update from the 287. GoyalA,SpertusJA,GoschK,VenkitachalamL,JonesPG,VandenBergheG,etal.
Association for European Cardiovascular Pathology. Virchows Arch 2017;471:
Serumpotassiumlevelsandmortalityinacutemyocardialinfarction.JAMA2012;
691–705.
307:157–164.
264.deNoronhaSV,BehrER,PapadakisM,Ohta-OgoK,BanyaW,WellsJ,etal.The
288. HoppeLK,MuhlackDC,KoenigW,CarrPR,BrennerH,SchöttkerB.Association
importanceofspecialistcardiachistopathologicalexaminationintheinvestigation
ofabnormalserumpotassiumlevelswitharrhythmiasandcardiovascularmortality:
ofyoungsuddencardiacdeaths.Europace2014;16:899–907.
asystematicreviewandmeta-analysisofobservationalstudies.CardiovascDrugs
265.GulinoSP,BurnsK,GuntherWM,MacLeodH.Improvingforensicpathologicin- Ther2018;32:197–212.
vestigationofsuddendeathintheyoung.AcadForensicPathol2018;8:347–391.
289. RavnJacobsenM,JabbariR,GlingeC,KjærStampeN,ButtJH,BlancheP,etal.
266.HansenBL,JacobsenEM,KjerrumgaardA,Tfelt-HansenJ,WinkelBG,Bundgaard Potassium disturbances and risk of ventricular fibrillation among patients with
H,etal.Diagnosticyieldinvictimsofsuddencardiacdeathandtheirrelatives.
ST-segment-elevationmyocardialinfarction.JAmHeartAssoc2020;9:e014160.
Europace2020;22:964–971.
290. AhmedW,FlynnMA,AlpertMA.Cardiovascularcomplicationsofweightreduc-
267.BjuneT,RisgaardB,KruckowL,GlingeC,Ingemann-HansenO,LethPM,etal. tiondiets.AmJMedSci2001;321:280–284.
Post-mortemtoxicologyinyoungsuddencardiacdeathvictims:anationwideco- 291. StephensonV.Inpharmacynursing—adynamicnewfield.NursRSA1988;3:51–53.
hortstudy.Europace2018;20:614–621.
292. DumasF,CariouA,Manzo-SilbermanS,GrimaldiD,VivienB,RosencherJ,etal.
268.Allan KS, Morrison LJ, Pinter A, Tu JV, Dorian P, Rescu Epistry Investigators.
‘Presumedcardiac’arrestinchildrenandyoungadults:amisnomer?Resuscitation Immediatepercutaneouscoronaryinterventionisassociatedwithbettersurvival
2017;117:73–79. afterout-of-hospitalcardiacarrest:insightsfromthePROCAT(ParisianRegion
OutofhospitalCardiacArresT)registry.CircCardiovascInterv2010;3:200–207.
269.LahrouchiN,RajuH,LodderEM,PapatheodorouS,MilesC,WareJS,etal.The
yieldofpostmortemgenetictestinginsuddendeathcaseswithstructuralfindings 293. GibbsC,ThalamusJ,HeldalK,HollaØL,HaugaaKH,HysingJ.Predictorsofmor-
atautopsy.EurJHumGenet2020;28:17–22. talityinhigh-riskpatientswithQTprolongationinacommunityhospital.Europace
2018;20:f99–f107.
270.TesterDJ,Medeiros-DomingoA,WillML,HaglundCM,AckermanMJ.Cardiac
294. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al.
channel molecular autopsy: insights from 173 consecutive cases of autopsy-
AssociationofQT-prolongingmedicationswithriskofautopsy-definedcausesof
negative sudden unexplained death referred for postmortem genetic testing.
MayoClinProc2012;87:524–539.
suddendeath.JAMAInternMed2020;180:698–706.
295. TzivoniD,BanaiS,SchugerC,BenhorinJ,KerenA,GottliebS,etal.Treatmentof
271.PapadakisM,RajuH,BehrER,DeNoronhaSV,SpathN,KouloubinisA,etal.
Sudden cardiac death with autopsy findings of uncertain significance: potential
torsadedepointeswithmagnesiumsulfate.Circulation1988;77:392–397.
forerroneousinterpretation.CircArrhythmElectrophysiol2013;6:588–596. 296. LadejobiA,PasupulaDK,AdhikariS,JavedA,DurraniAF,PatilS,etal.Implantable
defibrillatortherapyincardiacarrestsurvivorswithareversiblecause.CircArrhythm
272.JacobsenEM,HansenBL,KjerrumgaardA,Tfelt-HansenJ,HassagerC,KjaergaardJ,
etal.Diagnosticyieldandlong-termoutcomeofnonischemicsuddencardiacarrest Electrophysiol2018;11:e005940.
297. PostemaPG,WolpertC,AminAS,ProbstV,BorggrefeM,RodenDM,etal.Drugs
survivorsandtheirrelatives:resultsfromatertiaryreferralcenter.HeartRhythm
2020;17:1679–1686. andBrugadasyndromepatients:reviewoftheliterature,recommendations,andan
273.KjerrumgaardA,JacobsenEM,HansenBL,Tfelt-HansenJ,WinkelBG,Christensen
up-to-datewebsite(www.brugadadrugs.org).HeartRhythm2009;6:1335–1341.
AH,etal.Diagnosticfindingsandfollow-upoutcomesinrelativestoyoungnon- 298. SchuppT,BehnesM,vonZworowskyM,KimS-H,WeidnerK,RusnakJ,etal.
autopsiedsuddendeathvictims.IntJCardiol2020;318:61–66. Hypokalemiabutnothyperkalemiaisassociatedwithrecurrencesofventricularta-
274.ShanksGW,TesterDJ,AckermanJP,SimpsonMA,BehrER,WhiteSM,etal. chyarrhythmiasinICDrecipients.ClinLab2020;66.
Importance of variant interpretation in whole-exome molecular autopsy: 299. GuptaA,PasupulaDK,BhonsaleA,KancharlaK,WangNC,AdelsteinE,etal.
population-basedcaseseries.Circulation2018;137:2705–2715. Implantablecardioverter-defibrillatortherapyindevicerecipientswhosurviveda
275.NarulaN,TesterDJ,PaulmichlA,MaleszewskiJJ,AckermanMJ.Post-mortem cardiacarrestassociatedwithareversiblecause.JCardiovascElectrophysiol2018;
Wholeexomesequencingwithgene-specificanalysisforautopsy-negativesudden 29:1413–1417.
unexplaineddeathintheyoung:acaseseries.PediatrCardiol2015;36:768–778. 300. MarillKA,WolframS,DesouzaIS,NishijimaDK,KayD,SetnikGS,etal.Adenosine
276.MilesCJ,BehrER.Theroleofgenetictestinginunexplainedsuddendeath.Transl for wide-complex tachycardia: efficacy and safety. Crit Care Med 2009;37:
Res2016;168:59–73. 2512–2518.
277.BehrER,DalageorgouC,ChristiansenM,SyrrisP,HughesS,TomeEstebanMT, 301. LermanBB,BelardinelliL,WestGA,BerneRM,DiMarcoJP.Adenosine-sensitive
etal.Suddenarrhythmicdeathsyndrome:familialevaluationidentifiesinheritable ventriculartachycardia:evidencesuggestingcyclicAMP-mediatedtriggeredactivity.
heartdiseaseinthemajorityoffamilies.EurHeartJ2008;29:1670–1680. Circulation1986;74:270–280.
278.KumarS,PetersS,ThompsonT,MorganN,MaccicocaI,TrainerA,etal.Familial 302. BrugadaJ,KatritsisDG,ArbeloE,ArribasF,BaxJJ,Blomström-LundqvistC,etal.
cardiologicalandtargetedgeneticevaluation:lowyieldinsuddenunexplaineddeath 2019 ESC Guidelines for the management of patients with supraventricular
andhighyieldinunexplainedcardiacarrestsyndromes.HeartRhythm2013;10: tachycardiaThetaskforceforthemanagementofpatientswithsupraventricular
1653–1660. tachycardiaoftheEuropeanSocietyofCardiology(ESC).EurHeartJ2020;41:
279.McGorrianC,ConstantO,HarperN,O’DonnellC,CoddM,KeelanE,etal. 655–720.
Family-basedcardiacscreeninginrelativesofvictimsofsuddenarrhythmicdeath 303. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al.
syndrome.Europace2013;15:1050–1058. Randomizedcomparisonofintravenousprocainamidevs.intravenousamiodarone
Downloaded
from

by
guest
on
22
January
2026

4108 ESCGuidelines
fortheacutetreatmentoftoleratedwideQRStachycardia:thePROCAMIOstudy. 327. DoDH,BradfieldJ,AjijolaOA,VaseghiM,LeJ,RahmanS,etal.Thoracicepidural
EurHeartJ2017;38:1329–1335. anesthesiacanbeeffectivefortheshort-termmanagementofventriculartachycar-
304. GillJS,MehtaD,WardDE,CammAJ.Efficacyofflecainide,sotalol,andverapamilin diastorm.JAmHeartAssoc2017;6:e007080.
thetreatmentofrightventriculartachycardiainpatientswithoutovertcardiacab- 328. VaseghiM,BarwadP,MalavassiCorralesFJ,TandriH,MathuriaN,ShahR,etal.
normality.BrHeartJ1992;68:392–397. Cardiacsympatheticdenervationforrefractoryventriculararrhythmias.JAmColl
305. ManzM,MletzkoR,JungW,LüderitzB.Electrophysiologicalandhaemodynamic Cardiol2017;69:3070–3080.
effectsoflidocaineandajmalineinthemanagementofsustainedventriculartachy- 329. GatzoulisKA,AndrikopoulosGK,ApostolopoulosT,SotiropoulosE,Zervopoulos
cardia.EurHeartJ1992;13:1123–1128. G,AntoniouJ,etal.Electricalstormisanindependentpredictorofadverselong-
306. BuxtonAE,MarchlinskiFE,DohertyJU,CassidyDM,VassalloJA,FloresBT,etal.
termoutcomeintheeraofimplantabledefibrillatortherapy.Europace2005;7:
Repetitive,monomorphicventriculartachycardia:clinicalandelectrophysiologic
184–192.
characteristicsinpatientswithandpatientswithoutorganicheartdisease.AmJ 330. CarbucicchioC,SantamariaM,TrevisiN,MaccabelliG,GiraldiF,FassiniG,etal.
Cardiol1984;54:997–1002. Catheterablationforthetreatmentofelectricalstorminpatientswithimplantable
307. GriffithMJ,GarrattCJ,RowlandE,WardDE,CammAJ.Effectsofintravenousad- cardioverter-defibrillators:short-andlong-termoutcomesinaprospectivesingle-
enosine on verapamil-sensitive ‘idiopathic’ ventricular tachycardia. Am J Cardiol
centerstudy.Circulation2008;117:462–469.
1994;73:759–764. 331. VergaraP,TungR,VaseghiM,BrombinC,FrankelDS,DiBiaseL,etal.Successful
ventriculartachycardiaablationinpatientswithelectricalstormreducesrecur-
308. BuxtonAE,MarchlinskiFE,DohertyJU,FloresB,JosephsonME.Hazardsofintra-
rencesandimprovessurvival.HeartRhythm2018;15:48–55.
venous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:
1107–1110. 332. lK ao tim onat os fu reY f, raH co toci rn yi vM en, tN rio cuga lam ri fiA br, ilM laa tiu or ny sP to,P rmeic ah ftl eP r, mIw ya os ca ak ri dY ia, le int fa al r. cC tia ot nh :e ate mr ua ltb i--
309. RankinAC,RaeAP,CobbeSM.Misuseofintravenousverapamilinpatientswith
centerstudy.Circulation2019;139:2315–2325.
ventriculartachycardia.Lancet1987;2:472–474.
333. KnechtS,SacherF,WrightM,HociniM,NogamiA,ArentzT,etal.Long-term
310. PedersenCT,KayGN,KalmanJ,BorggrefeM,Della-BellaP,DickfeldT,etal. follow-upofidiopathicventricularfibrillationablation:amulticenterstudy.JAm
EHRA/HRS/APHRSexpertconsensusonventriculararrhythmias.Europace2014; CollCardiol2009;54:522–528.
16:1257–1283.
334. PeichlP,CihákR,KozeluhováM,WichterleD,VancuraV,KautznerJ.Catheterab-
311. CroninEM,BogunFM,MauryP,PeichlP,ChenM,NamboodiriN,etal.2019HRS/
lationofarrhythmicstormtriggeredbymonomorphicectopicbeatsinpatients
EHRA/APHRS/LAHRSexpertconsensusstatementoncatheterablationofven- withcoronaryarterydisease.JIntervCardElectrophysiol2010;27:51–59.
triculararrhythmias.Europace2019;21:1143–1144.
335. LePennec-PrigentS,FlecherE,AuffretV,LeurentG,DaubertJ-C,LeclercqC,etal.
312. KowlgiGN,ChaY-M.Managementofventricularelectricalstorm:acontemporary Effectivenessofextracorporeallifesupportforpatientswithcardiogenicshockdue
appraisal.Europace2020;22:1768–1780. tointractablearrhythmicstorm.CritCareMed2017;45:e281–e289.
313. GuerraF,ShkozaM,ScappiniL,FloriM,CapucciA.Roleofelectricalstormasa 336. MarianiS,NappLC,LoCocoV,DelnoijTSR,LuermansJGLM,TerBekkeRMA,
mortality and morbidity risk factor and its clinical predictors: a meta-analysis. etal.Mechanicalcirculatorysupportforlife-threateningarrhythmia:asystematic
Europace2014;16:347–353. review.IntJCardiol2020;308:42–49.
314. NodaT,KuritaT,NittaT,ChibaY,FurushimaH,MatsumotoN,etal.Significant 337. MuserD,LiangJJ,CastroSA,HayashiT,EnriquezA,TroutmanGS,etal.Outcomes
impactofelectricalstormonmortalityinpatientswithstructuralheartdisease withprophylacticuseofpercutaneousleftventricularassistdevicesinhigh-riskpa-
andanimplantablecardiacdefibrillator.IntJCardiol2018;255:85–91. tients undergoing catheter ablation of scar-related ventricular tachycardia: a
315. SoarJ,MaconochieI,WyckoffMH,OlasveengenTM,SingletaryEM,GreifR,etal. propensity-scorematchedanalysis.HeartRhythm2018;15:1500–1506.
2019Internationalconsensusoncardiopulmonaryresuscitationandemergency 338. Mathuria N, Wu G, Rojas-Delgado F, Shuraih M, Razavi M, Civitello A, et al.
cardiovascular care science with treatment recommendations: summary from Outcomesofpre-emptiveandrescueuseofpercutaneousleftventricularassistde-
thebasiclifesupport;advancedlifesupport;pediatriclifesupport;neonatallifesup- viceinpatientswithstructuralheartdiseaseundergoingcatheterablationofven-
port;education,implementation,andteams;andfirstaidtaskforces.Circulation triculartachycardia.JIntervCardElectrophysiol2017;48:27–34.
2019;140:e826–e880. 339. PatelKK,SpertusJA,KharitonY,TangY,CurtisLH,ChanPS,etal.Associationbe-
316. EiflingM,RazaviM,MassumiA.Theevaluationandmanagementofelectricalstorm. tweenpromptdefibrillationandepinephrinetreatmentwithlong-termsurvival
TexHeartInstJ2011;38:111–121. afterin-hospitalcardiacarrest.Circulation2018;137:2041–2051.
317. ChatzidouS,KontogiannisC,TsilimigrasDI,GeorgiopoulosG,KosmopoulosM, 340. VaseghiM,GimaJ,KanaanC,AjijolaOA,MarmureanuA,MahajanA,etal.Cardiac
PapadopoulouE,etal.Propranololversusmetoprololfortreatmentofelectrical sympatheticdenervation inpatientswithrefractory ventriculararrhythmiasor
storm in patients with implantable cardioverter-defibrillator. J Am Coll Cardiol electricalstorm:Intermediateandlong-termfollow-up.HeartRhythm2014;11:
2018;71:1897–1906. 360–366.
318. ConnollySJ,DorianP,RobertsRS,GentM,BailinS,FainES,etal.Comparisonof 341. PonikowskiP,VoorsAA,AnkerSD,BuenoH,ClelandJGF,CoatsAJS,etal.2016
beta-blockers,amiodaroneplusbeta-blockers,orsotalolforpreventionofshocks ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure:
fromimplantablecardioverterdefibrillators:theOPTICStudy:arandomizedtrial. thetaskforceforthediagnosisandtreatmentofacuteandchronicheartfailureof
JAMA2006;295:165–171. theEuropeanSocietyofCardiology(ESC)Developedwiththespecialcontribution
319. ShigaT,IkedaT,ShimizuW,KinugawaK,SakamotoA,NagaiR,etal.Efficacyand oftheHeartFailureAssociation(HFA)oftheESC.EurHeartJ2016;37:2129–2200.
342. McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,BöhmM,etal.2021 safetyoflandiololinpatientswithventriculartachyarrhythmiaswithorwithoutre-
nalimpairment–subanalysisoftheJ-LandIIstudy.CircRep2020;2:440–445. ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure.
EurHeartJ2021;42:3599–3726.
320. KanamoriK,AoyagiT,MikamoT,TsutsuiK,KunishimaT,InabaH,etal.Successful
343. AlJaroudiWA,RefaatMM,HabibRH,Al-ShaarL,SinghM,GutmannR,etal.Effect
treatmentofrefractoryelectricalstormwithlandiololaftermorethan100electric-
ofangiotensin-convertingenzymeinhibitorsandreceptorblockersonappropriate
aldefibrillations.IntHeartJ2015;56:555–557.
implantablecardiacdefibrillatorshockinpatientswithseveresystolicheartfailure
321. GorgelsAP,vandenDoolA,HofsA,MulleneersR,SmeetsJL,VosMA,etal. (fromtheGRADEMulticenterStudy).AmJCardiol2015;115:924–931.
Comparisonofprocainamideandlidocaineinterminatingsustainedmonomorphic
344. PittB,RemmeW,ZannadF,NeatonJ,MartinezF,RonikerB,etal.Eplerenone,a
ventriculartachycardia.AmJCardiol1996;78:43–46.
selectivealdosteroneblocker,inpatientswithleftventriculardysfunctionafter
322. Martí-CarvajalAJ,Simancas-RacinesD,AnandV,BangdiwalaS.Prophylacticlido- myocardialinfarction.NEnglJMed2003;348:1309–1321.
caineformyocardialinfarction.CochraneDatabaseSystRev2015;2015:CD008553. 345. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.
323. Viskin S, Chorin E, Viskin D, Hochstadt A, Halkin A, Tovia-Brodie O, et al.
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med
Quinidine-responsivepolymorphicventriculartachycardiainpatientswithcoron- 2014;371:993–1004.
aryheartdisease.Circulation2019;139:2304–2314.
346. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.
324. Viskin S, Hochstadt A, Chorin E, Viskin D, Havakuk O, Khoury S, et al. Cardiovascularandrenaloutcomeswithempagliflozininheartfailure.NEnglJ
Quinidine-responsiveout-of-hospitalpolymorphicventriculartachycardiainpa- Med2020;383:1413–1424.
tientswithcoronaryheartdisease.Europace2020;22:265–273. 347. DesaiAS,McMurrayJJV,PackerM,SwedbergK,RouleauJL,ChenF,etal.Effectof
325. MartinsRP,UrienJ-M,BarbarotN,RieulG,SellalJ-M,BorellaL,etal.Effectiveness theangiotensin-receptor-neprilysininhibitorLCZ696comparedwithenalaprilon
ofdeepsedationforpatientswithintractableelectricalstormrefractorytoantiar- modeofdeathinheartfailurepatients.EurHeartJ2015;36:1990–1997.
rhythmicdrugs.Circulation2020;142:1599–1601. 348. HindricksG,PotparaT,DagresN,ArbeloE,BaxJJ,Blomström-LundqvistC,etal.
326. FudimM,Boortz-MarxR,GaneshA,WaldronNH,QadriYJ,PatelCB,etal.Stellate 2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillationdevel-
ganglionblockadeforthetreatmentofrefractoryventriculararrhythmias:asys- opedincollaborationwiththeEuropeanAssociationforCardio-ThoracicSurgery
tematicreviewandmeta-analysis.JCardiovascElectrophysiol2017;28:1460–1467. (EACTS):Thetaskforceforthediagnosisandmanagementofatrialfibrillationof
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4109
theEuropeanSocietyofCardiology(ESC)Developedwiththespecialcontribution 370. MasriA,AltibiAM,ErqouS,ZmailiMA,SalehA,Al-AdhamR,etal.Wearable
oftheEuropeanHeartRhythmAssociation(EHRA)oftheESC.EurHeartJ2021; cardioverter-defibrillatortherapyforthepreventionofsuddencardiacdeath:asys-
42:373–498. tematicreviewandmeta-analysis.JACCClinElectrophysiol2019;5:152–161.
349.ConnollySJ,GentM,RobertsRS,DorianP,RoyD,SheldonRS,etal.Canadianim- 371. GarciaR,CombesN,DefayeP,NarayananK,Guedon-MoreauL,BovedaS,etal.
plantabledefibrillatorstudy(CIDS):arandomizedtrialoftheimplantablecardio- Wearablecardioverter-defibrillatorinpatientswithatransientriskofsuddencar-
verterdefibrillatoragainstamiodarone.Circulation2000;101:1297–1302. diacdeath:theWEARIT-Francecohortstudy.Europace2021;23:73–81.
350.AntiarrhythmicsversusImplantableDefibrillators(AVID)Investigators.Acompari- 372. OlginJE,PletcherMJ,VittinghoffE,WraniczJ,MalikR,MorinDP,etal.Wearable
sonofantiarrhythmic-drugtherapywithimplantabledefibrillatorsinpatientsresus- cardioverter-defibrillator after myocardial infarction. N Engl J Med 2018;379:
citatedfromnear-fatalventriculararrhythmias.NEnglJMed1997;337:1576–1583. 1205–1215.
351.KuckKH,CappatoR,SiebelsJ,RüppelR.Randomizedcomparisonofantiarrhyth- 373. ScottPA,SilberbauerJ,McDonaghTA,MurgatroydFD.Impactofprolongedim-
micdrugtherapywithimplantabledefibrillatorsinpatientsresuscitatedfromcar- plantable cardioverter-defibrillator arrhythmia detection times on outcomes: a
diac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:
meta-analysis.HeartRhythm2014;11:828–835.
748–754. 374. TanVH,WiltonSB,KuriachanV,SumnerGL,ExnerDV.Impactofprogramming
352.ConnollySJ,HallstromAP,CappatoR,SchronEB,KuckKH,ZipesDP,etal. strategies aimed at reducing nonessential implantable cardioverter defibrillator
Meta-analysisoftheimplantablecardioverterdefibrillatorsecondaryprevention therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm
trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable
Electrophysiol2014;7:164–170.
Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable 375. SaeedM,HannaI,RobotisD,StyperekR,PolosajianL,KhanA,etal.Programming
DefibrillatorStudy.EurHeartJ2000;21:2071–2078. implantablecardioverter-defibrillatorsinpatientswithprimarypreventionindica-
353.MossAJ,HallWJ,CannomDS,DaubertJP,HigginsSL,KleinH,etal.Improvedsur-
tiontoprolongtimetofirstshock:resultsfromthePROVIDEstudy.JCardiovasc
vivalwithanimplanteddefibrillatorinpatientswithcoronarydiseaseathighriskfor Electrophysiol2014;25:52–59.
ventriculararrhythmia.NEnglJMed1996;335:1933–1940. 376. WilkoffBL,FauchierL,StilesMK,MorilloCA,Al-KhatibSM,AlmendralJ,etal.2015
354.MossAJ,ZarebaW,HallWJ,KleinH,WilberDJ,CannomDS,etal.Prophylactic HRS/EHRA/APHRS/SOLAECEexpertconsensusstatementonoptimalimplanta-
implantationofadefibrillatorinpatientswithmyocardialinfarctionandreduced ble cardioverter-defibrillator programming and testing. Europace 2016;18:
ejectionfraction.NEnglJMed2002;346:877–883.
159–183.
355.BuxtonAE,LeeKL,FisherJD,JosephsonME,PrystowskyEN,HafleyG.Arando- 377. StilesMK,FauchierL,MorilloCA,WilkoffBL,ESCScientificDocumentGroup.
2019HRS/EHRA/APHRS/LAHRSfocusedupdateto2015expertconsensusstate-
mizedstudyofthepreventionofsuddendeathinpatientswithcoronaryarterydis-
mentonoptimalimplantablecardioverter-defibrillatorprogrammingandtesting.
ease.MulticenterUnsustainedTachycardiaTrialInvestigators.NEnglJMed1999;
341:1882–1890.
Europace2019;21:1442–1443.
378. BarsheshetA,MossAJ,McNittS,JonsC,GliksonM,KleinHU,etal.Long-termim-
356.BardyGH,LeeKL,MarkDB,PooleJE,PackerDL,BoineauR,etal.Amiodaroneor
animplantablecardioverter-defibrillatorforcongestiveheartfailure.NEnglJMed plicationsofcumulativerightventricularpacingamongpatientswithanimplantable
2005;352:225–237.
cardioverter-defibrillator.HeartRhythm2011;8:212–218.
379. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al.
357.ZabelM,WillemsR,LubinskiA,BauerA,BrugadaJ,ConenD,etal.Clinicaleffect-
ivenessofprimarypreventionimplantablecardioverter-defibrillators:resultsofthe Dual-chamberpacingorventricularbackuppacinginpatientswithanimplantable
defibrillator:theDualChamberandVVIImplantableDefibrillator(DAVID)Trial.
EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;41:
3437–3447.
JAMA2002;288:3115–3123.
380. OlshanskyB,DayJD,MooreS,GeringL,RosenbaumM,McGuireM,etal.Isdual-
358.Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, et al.
chamberprogramminginferiortosingle-chamberprogramminginanimplantable
Association between use of primary-prevention implantable cardioverter- cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of
defibrillatorsandmortalityinpatientswithheartfailure:aprospectivepropensity
UnnecessaryRVPacingWithAVSHinICDs)study.Circulation2007;115:9–16.
score-matchedanalysisfromtheSwedishHeartFailureRegistry.Circulation2019; 381. HindricksG,KühlM,DagresN.Theimplantablecardioverterdefibrillator,conclu-
140:1530–1539.
sionsonsuddencardiacdeath,andfutureperspective.ESCCardioMed.3rded.
359.KøberL,ThuneJJ,NielsenJC,HaarboJ,VidebækL,KorupE,etal.Defibrillatorim-
OxfordUniversityPress;2022,p2370–2376.
plantationinpatientswithnonischemicsystolicheartfailure.NEnglJMed2016;
382. GaspariniM,ProclemerA,KlersyC,KloppeA,FerrerJBM,HersiA,etal.Effectof
375:1221–1230.
long-detectionintervalvsstandard-detectionintervalforimplantablecardioverter-
360.Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, et al. defibrillatorsonantitachycardiapacingandshockdelivery:theADVANCEIIIran-
Prophylacticuseofimplantablecardioverter-defibrillatorsinthepreventionofsud-
domizedclinicaltrial.JAMA2013;309:1903–1911.
dencardiacdeathindialysispatients.Circulation2019;139:2628–2638.
383. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al.
361.SticherlingC,ArendackaB,SvendsenJH,WijersS,FriedeT,StockingerJ,etal.Sex
ReductionininappropriatetherapyandmortalitythroughICDprogramming.N
differences in outcomes of primary prevention implantable cardioverter- EnglJMed2012;367:2275–2283.
defibrillator therapy: combined registry data from eleven European countries. 384. WilkoffBL,OusdigianKT,SternsLD,WangZJ,WilsonRD,MorganJM,etal.A
Europace2018;20:963–970.
comparison of empiric to physician-tailored programming of implantable
362.JunttilaMJ,PelliA,KenttäTV,FriedeT,WillemsR,BergauL,etal.Appropriate cardioverter-defibrillators:resultsfromtheprospectiverandomizedmulticenter
shocksandmortalityinpatientswithversuswithoutdiabeteswithprophylacticim- EMPIRICtrial.JAmCollCardiol2006;48:330–339.
plantablecardioverterdefibrillators.DiabetesCare2020;43:196–200.
385. WilkoffBL,WilliamsonBD,SternRS,MooreSL,LuF,LeeSW,etal.Strategicpro-
363.KollerMT,SchaerB,WolbersM,SticherlingC,BucherHC,OsswaldS.Deathwith- gramming of detection and therapy parameters in implantable cardioverter-
outpriorappropriateimplantablecardioverter-defibrillatortherapy:acompeting defibrillators reduces shocks in primary prevention patients: results from the
riskstudy.Circulation2008;117:1918–1926.
PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol
364.ClelandJGF,HallidayBP,PrasadSK.Selectingpatientswithnonischemicdilatedcar- 2008;52:541–550.
diomyopathyforICDs:myocardialfunction,fibrosis,andwhat’sattached?JAmColl
386. GilliamFR,HayesDL,BoehmerJP,DayJ,HeidenreichPA,SethM,etal.Realworld
Cardiol2017;70:1228–1231.
evaluationofdual-zoneICDandCRT-Dprogrammingcomparedtosingle-zone
365.YounisA,GoldbergerJJ,KutyifaV,ZarebaW,PolonskyB,KleinH,etal.Predicted programming:theALTITUDEREDUCESstudy.JCardiovascElectrophysiol2011;
benefitofanimplantablecardioverter-defibrillator:theMADIT-ICDbenefitscore. 22:1023–1029.
EurHeartJ2021;42:1676–1684. 387. Hernandez-OjedaJ,ArbeloE,BorrasR,BerneP,TolosanaJM,Gomez-JuanateyA,
366.Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J, etal.PatientswithBrugadasyndromeandimplantedcardioverter-defibrillators:
El-ChamiMF,etal.Subcutaneousortransvenousdefibrillatortherapy.NEnglJ long-termfollow-up.JAmCollCardiol2017;70:1991–2002.
Med2020;383:526–536. 388. GoldMR,WeissR,TheunsDAMJ,SmithW,LeonA,KnightBP,etal.Useofadis-
367.ClelandJGF,DaubertJ-C,ErdmannE,FreemantleN,GrasD,KappenbergerL,etal. criminationalgorithmtoreduceinappropriateshockswithasubcutaneousimplan-
Theeffectofcardiacresynchronizationonmorbidityandmortalityinheartfailure. tablecardioverter-defibrillator.HeartRhythm2014;11:1352–1358.
NEnglJMed2005;352:1539–1549. 389. Mesquita J, Cavaco D, Ferreira A, Lopes N, Santos PG, Carvalho MS, et al.
368.Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Effectivenessofsubcutaneousimplantablecardioverter-defibrillatorsanddetermi-
Cardiac-resynchronizationtherapywithorwithoutanimplantabledefibrillatorin nantsofinappropriateshockdelivery.IntJCardiol2017;232:176–180.
advancedchronicheartfailure.NEnglJMed2004;350:2140–2150. 390. GoldMR,LambiasePD,El-ChamiMF,KnopsRE,AasboJD,BongiorniMG,etal.
369.Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. PrimaryresultsfromtheunderstandingoutcomeswiththeS-ICDinprimarypre-
Cardiac-resynchronizationtherapyforthepreventionofheart-failureevents.N ventionpatientswithlowejectionfraction(UNTOUCHED)trial.Circulation2021;
EnglJMed2009;361:1329–1338. 143:7–17.
Downloaded
from

by
guest
on
22
January
2026

4110 ESCGuidelines
391. WathenMS,DeGrootPJ,SweeneyMO,StarkAJ,OtternessMF,AdkissonWO, 411. BergSK,ThygesenLC,SvendsenJH,ChristensenAV,ZwislerA-D.Anxietypre-
etal.Prospectiverandomizedmulticentertrialofempiricalantitachycardiapacing dicts mortality in ICD patients: results from the cross-sectional national
versusshocksforspontaneousrapidventriculartachycardiainpatientswithim- CopenHeartICDsurveywithregisterfollow-up.PacingClinElectrophysiol2014;
plantablecardioverter-defibrillators:PacingFastVentricularTachycardiaReduces 37:1641–1650.
ShockTherapies(PainFREERxII)trialresults.Circulation2004;110:2591–2596. 412. ThylénI,MoserDK,StrömbergA,DekkerRA,ChungML.Concernsaboutimplan-
392. GuliziaMM,PirainoL,ScherilloM,PuntrelloC,VascoC,ScianaroMC,etal.Aran- table cardioverter-defibrillator shocks mediate the relationship between actual
domizedstudytocomparerampversusburstantitachycardiapacingtherapiesto shocksandpsychologicaldistress.Europace2016;18:828–835.
treatfastventriculartachyarrhythmiasinpatientswithimplantablecardioverterde- 413. PedersenSS,vanDomburgRT,TheunsDAMJ,JordaensL,ErdmanRAM.Concerns
fibrillators:thePITAGORAICDtrial.CircArrhythmElectrophysiol2009;2:146–153. abouttheimplantablecardioverterdefibrillator:adeterminantofanxietyandde-
393. SaxonLA,HayesDL,GilliamFR,HeidenreichPA,DayJ,SethM,etal.Long-term pressivesymptomsindependentofexperiencedshocks.AmHeartJ2005;149:
outcomeafterICDandCRTimplantationandinfluenceofremotedevicefollow- 664–669.
up:theALTITUDEsurvivalstudy.Circulation2010;122:2359–2367. 414. FrizelleDJ,LewinB,KayeG,Moniz-CookED.Developmentofameasureofthe
394. VarmaN,PicciniJP,SnellJ,FischerA,DalalN,MittalS.Therelationshipbetween concernsheldbypeoplewithimplantedcardioverterdefibrillators:theICDC.Br
levelofadherencetoautomaticwirelessremotemonitoringandsurvivalinpace- JHealthPsychol2006;11:293–301.
makeranddefibrillatorpatients.JAmCollCardiol2015;65:2601–2610.
415. ZigmondAS,SnaithRP.Thehospitalanxietyanddepressionscale.ActaPsychiatr
395. Guédon-MoreauL,KouakamC,KlugD,MarquiéC,BrigadeauF,BouléS,etal. Scand1983;67:361–370.
Decreaseddeliveryofinappropriateshocksachievedbyremotemonitoringof 416. FrydensbergVS,JohansenJB,MöllerS,RiahiS,WehbergS,HaarboJ,etal.Anxiety
ICD:asubstudyoftheECOSTtrial.JCardiovascElectrophysiol2014;25:763–770.
anddepressionsymptomsinDanishpatientswithanimplantablecardioverter-
396. VarmaN,MichalskiJ,EpsteinAE,SchweikertR.Automaticremotemonitoringof defibrillator:prevalenceandassociationwithindicationandsexupto2yearsof
implantable cardioverter-defibrillator lead and generator performance: the follow-up (data from the national DEFIB-WOMEN study). Europace 2020;22:
Lumos-TSafelyRedUceSRouTineOfficeDeviceFollow-Up(TRUST)trial.Circ 1830–1840.
ArrhythmElectrophysiol2010;3:428–436.
417. HoogwegtMT,KupperN,TheunsDAMJ,ZijlstraWP,JordaensL,PedersenSS.
397. PlouxS,SwerdlowCD,StrikM,WelteN,KlotzN,RitterP,etal.Towardseradi- Undertreatment of anxiety and depression in patients with an implantable
cationofinappropriatetherapiesforICDleadfailurebycombiningcomprehensive cardioverter-defibrillator: impact on health status. Health Psychol 2012;31:
remote monitoring and lead noise alerts. J Cardiovasc Electrophysiol 2018;29: 745–753.
1125–1134.
418. LaneDA,AguinagaL,Blomström-LundqvistC,BorianiG,DanG-A,HillsMT,etal.
398. EllenbogenKA,GundersonBD,StrombergKD,SwerdlowCD.Performanceof
Cardiactachyarrhythmiasandpatientvaluesandpreferencesfortheirmanage-
LeadIntegrityAlerttoassistintheclinicaldiagnosisofimplantablecardioverterde-
ment:theEuropeanHeartRhythmAssociation(EHRA)consensusdocumenten-
fibrillatorleadfailures:analysisofdifferentimplantablecardioverterdefibrillator
dorsedbytheHeartRhythmSociety(HRS),AsiaPacificHeartRhythmSociety
leads.CircArrhythmElectrophysiol2013;6:1169–1177.
(APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y
399. Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Sachanandani H, Electrofisiología(SOLEACE).Europace2015;17:1747–1769.
EllenbogenKA.Downloadablesoftwarealgorithmreducesinappropriateshocks
419. DunbarSB,DoughertyCM,SearsSF,CarrollDL,GoldsteinNE,MarkDB,etal.
causedbyimplantablecardioverter-defibrillatorleadfractures:aprospectivestudy.
Educationalandpsychologicalinterventionstoimproveoutcomesforrecipients
Circulation2010;122:1449–1455.
ofimplantablecardioverterdefibrillatorsandtheirfamilies:ascientificstatement
400. RuwaldMH,Abu-ZeitoneA,JonsC,RuwaldA-C,McNittS,KutyifaV,etal.Impact
fromtheAmericanHeartAssociation.Circulation2012;126:2146–2172.
of carvedilol and metoprolol on inappropriate implantable cardioverter-
420. SearsSF,SowellLDV,KuhlEA,KovacsAH,SerberER,HandbergE,etal.TheICD
defibrillatortherapy:theMADIT-CRTtrial(MulticenterAutomaticDefibrillator
shockandstressmanagementprogram:arandomizedtrialofpsychosocialtreat-
ImplantationWithCardiacResynchronizationTherapy).JAmCollCardiol2013;
62:1343–1350. menttooptimizequalityoflifeinICDpatients.PacingClinElectrophysiol2007;
30:858–864.
401. MiyazakiS,TaniguchiH,KusaS,KomatsuY,IchiharaN,TakagiT,etal.Catheter
421. BergSK,RasmussenTB,HerningM,SvendsenJH,ChristensenAV,ThygesenLC.
ablationofatrialtachyarrhythmiascausinginappropriateimplantablecardioverter-
defibrillatorshocks.Europace2015;17:289–294.
Cognitivebehaviouraltherapysignificantlyreducesanxietyinpatientswithim-
planted cardioverter defibrillator compared with usual care: findings from the
402. MainigiSK,AlmutiK,FigueredoVM,GuttenplanNA,AouthmanyA,SmuklerJ,etal.
Screen-ICDrandomisedcontrolledtrial.EurJPrevCardiol2020;27:258–268.
Usefulnessofradiofrequencyablationofsupraventriculartachycardiatodecrease
inappropriate shocks from implantable cardioverter-defibrillators. Am J Cardiol 422. SchulzSM,RitterO,ZnivaR,NordbeckP,WackerC,JackM,etal.Efficacyofa
2012;109:231–237. web-basedinterventionforimprovingpsychosocialwell-beinginpatientswithim-
plantablecardioverter-defibrillators:therandomizedcontrolledICD-FORUMtrial.
403. KosiukJ,NediosS,DarmaA,RolfS,RichterS,AryaA,etal.Impactofsingleatrial
fibrillationcatheterablationonimplantablecardioverterdefibrillatortherapiesin EurHeartJ2020;41:1203–1211.
423. vandenBroekKC,TekleFB,HabibovićM,AlingsM,vanderVoortPH,DenolletJ. patientswithischaemicandnon-ischaemiccardiomyopathies.Europace2014;16:
1322–1326. Emotionaldistress,positiveaffect,andmortalityinpatientswithanimplantablecar-
404. KirchhofP,CammAJ,GoetteA,BrandesA,EckardtL,ElvanA,etal.Earlyrhythm-
dioverterdefibrillator.IntJCardiol2013;165:327–332.
control therapy in patients with atrial fibrillation. N Engl J Med 2020;383: 424. HauptmanPJ,ChibnallJT,GuildC,ArmbrechtES.Patientperceptions,physician
1305–1316. communication,andtheimplantablecardioverter-defibrillator.JAMAInternMed
405. GaspariniM,KloppeA,LunatiM,AnselmeF,LandolinaM,Martinez-FerrerJB,etal.
2013;173:571–577.
Atrioventricularjunctionablationinpatientswithatrialfibrillationtreatedwithcar- 425. CikesM,JakusN,ClaggettB,BrugtsJJ,TimmermansP,PouleurA-C,etal.Cardiac
diacresynchronizationtherapy:positiveimpactonventriculararrhythmias,implan-
implantableelectronicdeviceswithadefibrillatorcomponentandall-causemortal-
table cardioverter-defibrillator therapies and hospitalizations: atrioventricular ityinleftventricularassistdevicecarriers:resultsfromthePCHF-VADregistry.Eur
junctionablationinCRTpatientswithAF.EurJHeartFail2018;20:1472–1481. JHeartFail2019;21:1129–1141.
406. GaspariniM,GalimbertiP.Ratecontrol:ablationanddevicetherapy(ablateand 426. GalandV,FlécherE,AuffretV,BouléS,VincentelliA,DambrinC,etal.Predictors
pace).ESCCardioMed.3rded.OxfordUniversityPress;2022,p2159–2162. andclinicalimpactoflateventriculararrhythmiasinpatientswithcontinuous-flow
407. KitamuraT,FukamizuS,KawamuraI,HojoR,AoyamaY,KomiyamaK,etal. leftventricularassistdevices.JACCClinElectrophysiol2018;4:1166–1175.
Long-termefficacyofcatheterablationforparoxysmalatrialfibrillationinpatients 427. NakaharaS,ChienC,GelowJ,DaloukK,HenriksonCA,MuddJ,etal.Ventricular
withBrugadasyndromeandanimplantablecardioverter-defibrillatortopreventin- arrhythmiasafterleftventricularassistdevice.CircArrhythmElectrophysiol2013;6:
appropriateshocktherapy.HeartRhythm2016;13:1455–1459. 648–654.
408. Magyar-RussellG,ThombsBD,CaiJX,BavejaT,KuhlEA,SinghPP,etal.Thepreva- 428. ClerkinKJ,TopkaraVK,DemmerRT,DizonJM,YuzefpolskayaM,FriedJA,etal.
lenceofanxietyanddepressioninadultswithimplantablecardioverterdefibrilla- Implantablecardioverter-defibrillatorsinpatientswithacontinuous-flowleftven-
tors:asystematicreview.JPsychosomRes2011;71:223–231. tricularassistdevice:ananalysisoftheINTERMACSregistry.JACCHeartFail2017;
409. TzeisS,KolbC,BaumertJ,ReentsT,ZrennerB,DeisenhoferI,etal.Effectofde- 5:916–926.
pressiononmortalityinimplantablecardioverterdefibrillatorrecipients—findings 429. OzMC,RoseEA,SlaterJ,KuiperJJ,CataneseKA,LevinHR.Malignantventricular
fromtheprospectiveLICADstudy.PacingClinElectrophysiol2011;34:991–997. arrhythmiasarewelltoleratedinpatientsreceivinglong-termleftventricularassist
410. AndersenCM,TheunsDAMJ,JohansenJB,PedersenSS.Anxiety,depression,ven- devices.JAmCollCardiol1994;24:1688–1691.
triculararrhythmiasandmortalityinpatientswithanimplantablecardioverterde- 430. PotapovEV,AntonidesC,Crespo-LeiroMG,CombesA,FärberG,HannanMM,
fibrillator:7years’follow-upoftheMIDAScohort.GenHospPsychiatry2020;66: etal.2019EACTSExpertConsensusonlong-termmechanicalcirculatorysupport.
154–160. EurJCardiothoracSurg56:230–270.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4111
431.MakkiN,MesubiO,SteyersC,OlshanskyB,AbrahamWT.Meta-analysisofthe 451. EpsteinLM,LoveCJ,WilkoffBL,ChungMK,HacklerJW,BongiorniMG,etal.
relationofventriculararrhythmiastoall-causemortalityafterimplantationofa Superiorvenacavadefibrillatorcoilsmaketransvenousleadextractionmorechal-
leftventricularassistdevice.AmJCardiol2015;116:1385–1390. lengingandriskier.JAmCollCardiol2013;61:987–989.
432.YorukA,SheraziS,MasseyHT,KutyifaV,McNittS,HallinanW,etal.Predictors 452. LarsenJM,HjortshøjSP,NielsenJC,JohansenJB,PetersenHH,HaarboJ,etal.
andclinicalrelevanceofventriculartachyarrhythmiasinambulatorypatientswith Single-coilanddual-coildefibrillatorleadsandassociationwithclinicaloutcomes
acontinuousflowleftventricularassistdevice.HeartRhythm2016;13:1052–1056. inacompleteDanishnationwideICDcohort.HeartRhythm2016;13:706–712.
433.BediM,KormosR,WinowichS,McNamaraDM,MathierMA,MuraliS.Ventricular 453. KumarKR,MandleywalaSN,MadiasC,WeinstockJ,RowinEJ,MaronBJ,etal.
arrhythmiasduringleftventricularassistdevicesupport.AmJCardiol2007;99:
Singlecoilimplantablecardioverterdefibrillatorleadsinpatientswithhypertrophic
1151–1153. cardiomyopathy.AmJCardiol2020;125:1896–1900.
434.BrenyoA,RaoM,KoneruS,HallinanW,ShahS,MasseyHT,etal.Riskofmortality 454. FriedmanPA,RasmussenMJ,GriceS,TrustyJ,GliksonM,StantonMS.Defibrillation
forventriculararrhythmiainambulatoryLVADpatients.JCardiovascElectrophysiol thresholdsareincreasedbyright-sidedimplantationoftotallytransvenousimplan-
2012;23:515–520. tablecardioverterdefibrillators.PacingClinElectrophysiol1999;22:1186–1192.
435.VakilK,KazmirczakF,SathnurN,AdabagS,CantillonDJ,KiehlEL,etal.Implantable 455. StoevelaarR,Brinkman-StoppelenburgA,BhagwandienRE,vanBruchem-Visser
cardioverter-defibrillatoruseinpatientswithleftventricularassistdevices:asys- RL,TheunsDA,vanderHeideA,etal.Theincidenceandimpactofimplantable
tematicreviewandmeta-analysis.JACCHeartFail2016;4:772–779.
cardioverterdefibrillatorshocksinthelastphaseoflife:anintegratedreview.
EurJCardiovascNurs2018;17:477–485.
436.RefaatMM,TanakaT,KormosRL,McNamaraD,TeutebergJ,WinowichS,etal.
Survivalbenefitofimplantablecardioverter-defibrillatorsinleftventricularassist 456. KapaS,MuellerPS,HayesDL,AsirvathamSJ.Perspectivesonwithdrawingpace-
device-supportedheartfailurepatients.JCardFail2012;18:140–145.
makerandimplantablecardioverter-defibrillatortherapiesatendoflife:results
ofasurveyofmedicalandlegalprofessionalsandpatients.MayoClinProc2010;
437.Cantillon DJ,Tarakji KG, Kumbhani DJ, SmediraNG, Starling RC, WilkoffBL.
85:981–990.
Improvedsurvivalamongventricularassistdevicerecipientswithaconcomitantim-
457. PadelettiL,ArnarDO,BoncinelliL,BrachmanJ,CammJA,DaubertJC,etal.EHRA
plantablecardioverter-defibrillator.HeartRhythm2010;7:466–471.
ExpertConsensusStatementonthemanagementofcardiovascularimplantable
438.Joyce E, Starling RC. HFrEF other treatment: ventricular assist devices. ESC
electronicdevicesinpatientsnearingendoflifeorrequestingwithdrawalofther-
CardioMed.3rded.OxfordUniversityPress;2022,p1884–1889. apy.Europace2010;12:1480–1489.
439.YounesA,Al-KindiSG,AlajajiW,MackallJA,OliveiraGH.Presenceofimplantable
458. StoevelaarR,Brinkman-StoppelenburgA,vanDrielAG,TheunsDA,Bhagwandien
cardioverter-defibrillatorsandwait-listmortalityofpatientssupportedwithleft
RE,vanBruchem-VisserRL,etal.Trendsintimeinthemanagementoftheimplan-
ventricular assist devices as bridgeto heart transplantation. Int J Cardiol 2017; tablecardioverterdefibrillatorinthelastphaseoflife:aretrospectivestudyofmed-
231:211–215.
icalrecords.EurJCardiovascNurs2019;18:449–457.
440.AgrawalS,GargL,NandaS,SharmaA,BhatiaN,MandaY,etal.Theroleofimplan-
459. KirkpatrickJN,GottliebM,SehgalP,PatelR,VerdinoRJ.Deactivationofimplanta-
tablecardioverter-defibrillatorsinpatientswithcontinuousflowleftventricularas- blecardioverterdefibrillatorsinterminalillnessandendoflifecare.AmJCardiol
sistdevices–ameta-analysis.IntJCardiol2016;222:379–384. 2012;109:91–94.
441.Blomström-LundqvistC,TraykovV,ErbaPA,BurriH,NielsenJC,BongiorniMG, 460. StevensonWG,KhanH,SagerP,SaxonLA,MiddlekauffHR,NattersonPD,etal.
etal.EuropeanHeartRhythmAssociation(EHRA)internationalconsensusdocu- Identificationofreentrycircuitsitesduringcathetermappingandradiofrequency
mentonhowtoprevent,diagnose,andtreatcardiacimplantableelectronicdevice ablation of ventricular tachycardia late after myocardial infarction. Circulation
infections-endorsedbytheHeartRhythmSociety(HRS),theAsiaPacificHeart 1993;88:1647–1670.
RhythmSociety(APHRS),theLatinAmericanHeartRhythmSociety(LAHRS), 461. deBakkerJM,vanCapelleFJ,JanseMJ,TasseronS,VermeulenJT,deJongeN,etal.
International Society for Cardiovascular Infectious Diseases (ISCVID) and the Slow conduction in the infarcted human heart. “Zigzag” course of activation.
EuropeanSocietyofClinicalMicrobiologyandInfectiousDiseases(ESCMID)incol- Circulation1993;88:915–926.
laborationwiththeEuropeanAssociationforCardio-ThoracicSurgery(EACTS). 462. deChillouC,LacroixD,KlugD,Magnin-PoullI,MarquiéC,MessierM,etal.Isthmus
Europace2020;22:515–549. characteristics of reentrant ventricular tachycardia after myocardial infarction.
442.BurriH,StarckC,AuricchioA,BiffiM,BurriM,D’AvilaA,etal.EHRAexpertcon- Circulation2002;105:726–731.
sensusstatementandpracticalguideonoptimalimplantationtechniqueforcon- 463. HsiaHH,CallansDJ,MarchlinskiFE.Characterizationofendocardialelectrophysio-
ventional pacemakers and implantable cardioverter-defibrillators: endorsed by logicalsubstrateinpatientswithnonischemiccardiomyopathyandmonomorphic
the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society ventriculartachycardia.Circulation2003;108:704–710.
(APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace 464. SoejimaK,StevensonWG,SappJL,SelwynAP,CouperG,EpsteinLM.Endocardial
2021;23:983–1008. andepicardialradiofrequencyablationofventriculartachycardiaassociatedwithdi-
443.TarakjiKG,MittalS,KennergrenC,CoreyR,PooleJE,SchlossE,etal.Antibacterial
latedcardiomyopathy.JAmCollCardiol2004;43:1834–1842.
envelopetopreventcardiacimplantabledeviceinfection.NEnglJMed2019;380: 465. MiljoenH,StateS,DechillouC,MagninpoullI,DottoP,AndronacheM,etal.
1895–1905. Electroanatomic mapping characteristics of ventricular tachycardia in patients
444.AttiV,TuragamMK,GargJ,KoerberS,AngirekulaA,GopinathannairR,etal. witharrhythmogenicrightventricularcardiomyopathy/dysplasia.Europace2005;
7:516–524.
Subclavianandaxillaryveinaccessversuscephalicveincutdownforcardiacimplan-
466. PrioriSG,Blomström-LundqvistC,MazzantiA,BlomN,BorggrefeM,CammJ,etal.
tableelectronicdeviceimplantation:ameta-analysis.JACCClinElectrophysiol2020;6:
661–671. 2015ESCGuidelinesforthemanagementofpatientswithventriculararrhythmias
andthepreventionofsuddencardiacdeath:ThetaskforcefortheManagementof
445.BenzAP,VamosM,ErathJW,HohnloserSH.Cephalicvs.subclavianleadimplant-
PatientswithVentricularArrhythmiasandthePreventionofSuddenCardiacDeath
ation in cardiac implantable electronic devices: a systematic review and
of the European Society of Cardiology (ESC). Endorsed by: Association for
meta-analysis.Europace2019;21:121–129.
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:
446.ChanN-Y,KwongN-P,CheongA-P.Venousaccessandlong-termpacemakerlead 2793–2867.
failure:comparingcontrast-guidedaxillaryveinpuncturewithsubclavianpuncture
467. Al-KhatibSM,StevensonWG,AckermanMJ,BryantWJ,CallansDJ,CurtisAB,etal.
andcephaliccutdown.Europace2017;19:1193–1197.
2017AHA/ACC/HRSGuidelineformanagementofpatientswithventricularar-
447.DefayeP,BovedaS,KlugD,BegantonF,PiotO,NarayananK,etal.Dual-vs.single-
rhythmiasandthepreventionofsuddencardiacdeath:executivesummary.JAm
chamberdefibrillatorsforprimarypreventionofsuddencardiacdeath:long-term
CollCardiol2018;72:1677–1749.
follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire
468. TowbinJA,McKennaWJ,AbramsDJ,AckermanMJ,CalkinsH,DarrieuxFCC,etal.
registry.Europace2017;19:1478–1484. 2019HRSexpertconsensusstatementonevaluation,riskstratification,andman-
448.Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. agementofarrhythmogeniccardiomyopathy:executivesummary.HeartRhythm
Dual-chamberimplantablecardioverter-defibrillatorselectionisassociatedwithin- 2019;16:e373–e407.
creasedcomplicationratesandmortalityamongpatientsenrolledintheNCDRim- 469. MossAJ,GreenbergH,CaseRB,ZarebaW,HallWJ,BrownMW,etal.Long-term
plantablecardioverter-defibrillatorregistry.JAmCollCardiol2011;58:1007–1013.
clinicalcourseofpatientsafterterminationofventriculartachyarrhythmiabyanim-
449.FriedmanPA,BradleyD,KoestlerC,SlusserJ,HodgeD,BaileyK,etal.Aprospect- planteddefibrillator.Circulation2004;110:3760–3765.
ive randomized trial of single- or dual-chamber implantable cardioverter- 470. PooleJE,JohnsonGW,HellkampAS,AndersonJ,CallansDJ,RaittMH,etal.
defibrillatorstominimizeinappropriateshockriskinprimarysuddencardiacdeath Prognostic importance of defibrillator shocks in patients with heart failure. N
prevention.Europace2014;16:1460–1468. EnglJMed2008;359:1009–1017.
450.Chen B-W, Liu Q, Wang X, Dang A-M. Are dual-chamber implantable 471. SappJL,WellsGA,ParkashR,StevensonWG,BlierL,SarrazinJ-F,etal.Ventricular
cardioverter-defibrillatorsreallybetterthansingle-chamberones?Asystematicre- tachycardiaablationversusescalationofantiarrhythmicdrugs.NEnglJMed2016;
viewandmeta-analysis.JIntervCardElectrophysiol2014;39:273–280. 375:111–121.
Downloaded
from

by
guest
on
22
January
2026

4112 ESCGuidelines
472. PicciniJP,BergerJS,O’ConnorCM.Amiodaroneforthepreventionofsuddencar- 495. BhaskaranA,TungR,StevensonWG,KumarS.CatheterablationofVTinnon-
diacdeath:ameta-analysisofrandomizedcontrolledtrials.EurHeartJ2009;30: ischaemiccardiomyopathies:endocardial,epicardial andintramuralapproaches.
1245–1253. HeartLungCirc2019;28:84–101.
473. PalaniswamyC,KolteD,HarikrishnanP,KheraS,AronowWS,MujibM,etal. 496. TungR,RaimanM,LiaoH,ZhanX,ChungFP,NagelR,etal.Simultaneousendo-
Catheterablationofpostinfarctionventriculartachycardia:ten-yeartrendsinutil- cardialandepicardialdelineationof3Dreentrantventriculartachycardia.JAmColl
ization,in-hospitalcomplications,andin-hospitalmortalityintheUnitedStates. Cardiol2020;75:884–897.
HeartRhythm2014;11:2056–2063. 497. Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C, et al.
474. CaceresJ,JazayeriM,McKinnieJ,AvitallB,DenkerST,TchouP,etal.Sustainedbun- Outcomesincatheterablationofventriculartachycardiaindilatednonischemic
dle branchreentryasamechanismof clinicaltachycardia.Circulation1989;79: cardiomyopathy compared with ischemic cardiomyopathy: results from the
256–270. ProspectiveHeartCentreofLeipzigVT(HELP-VT)Study.Circulation2014;129:
475. BlanckZ,DhalaA,DeshpandeS,SraJ,JazayeriM,AkhtarM.Bundlebranchre- 728–736.
entrantventriculartachycardia:cumulativeexperiencein48patients.JCardiovasc 498. Proietti R, Essebag V, Beardsall J, Hache P, Pantano A, Wulffhart Z, et al.
Electrophysiol1993;4:253–262. Substrate-guided ablation of haemodynamically tolerated and untolerated ven-
476. ChenH,ShiL,YangB,JuW,ZhangF,YangG,etal.Electrophysiologicalcharacter- triculartachycardiainpatientswithstructuralheartdisease:effectofcardiomyop-
isticsofbundlebranchreentryventriculartachycardiainpatientswithoutstructural athytypeandacutesuccessonlong-termoutcome.Europace2015;17:461–467.
heartdisease.CircArrhythmElectrophysiol2018;11:e006049. 499. EbertM,RichterS,DinovB,ZeppenfeldK,HindricksG.Evaluationandmanage-
477. PathakRK,FahedJ,SantangeliP,HymanMC,LiangJJ,KubalaM,etal.Long-term mentofventriculartachycardiainpatientswithdilatedcardiomyopathy.Heart
outcomeofcatheterablationfortreatmentofbundlebranchre-entranttachycar- Rhythm2019;16:624–631.
dia.JACCClinElectrophysiol2018;4:331–338. 500. ProiettiR,LichelliL,LelloucheN,DhanjalT.Thechallengeofoptimisingablation
478. StevensonWG,WilberDJ,NataleA,JackmanWM,MarchlinskiFE,TalbertT,etal. lesions in catheter ablation of ventricular tachycardia. J Arrhythmia 2021;37:
Irrigatedradiofrequencycatheterablationguidedbyelectroanatomicmappingfor 140–147.
recurrentventriculartachycardiaaftermyocardialinfarction:themulticenterther- 501. TokudaM,SobieszczykP,EisenhauerAC,KojodjojoP,InadaK,KoplanBA,etal.
mocoolventriculartachycardiaablationtrial.Circulation2008;118:2773–2782. Transcoronaryethanolablationforrecurrentventriculartachycardiaafterfailed
479. Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, et al. catheterablation:anupdate.CircArrhythmElectrophysiol2011;4:889–896.
Managementofventriculartachycardiainthesettingofadedicatedunitforthe 502. Kreidieh B, Rodríguez-Mañero M, Schurmann P, Ibarra-Cortez SH, Dave AS,
treatmentofcomplexventriculararrhythmias:long-termoutcomeafterablation. ValderrábanoM.Retrogradecoronaryvenousethanolinfusionforablationofre-
Circulation2013;127:1359–1368. fractoryventriculartachycardia.CircArrhythmElectrophysiol2016;9:e004352.
480. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al. 503. NguyenDT,TzouWS,SandhuA,GianniC,AnterE,TungR,etal.Prospectivemul-
Radio-frequency ablation as primary management of well-tolerated sustained ticenterexperiencewithcooledradiofrequencyablationusinghighimpedanceir-
monomorphic ventricular tachycardia in patients with structural heart disease riganttotargetdeepmyocardialsubstraterefractorytostandardablation.JACCClin
andleftventricularejectionfractionover30%.EurHeartJ2014;35:1479–1485. Electrophysiol2018;4:1176–1185.
481. TungR,VaseghiM,FrankelDS,VergaraP,DiBiaseL,NagashimaK,etal.Freedom 504. StevensonWG,TedrowUB,ReddyV,AbdelWahabA,DukkipatiS,JohnRM,etal.
fromrecurrentventriculartachycardiaaftercatheterablationisassociatedwithim- Infusionneedleradiofrequencyablationfortreatmentofrefractoryventricularar-
proved survival in patients with structural heart disease: an International VT rhythmias.JAmCollCardiol2019;73:1413–1425.
AblationCenterCollaborativeGroupstudy.HeartRhythm2015;12:1997–2007. 505. IgarashiM,NogamiA,FukamizuS,SekiguchiY,NittaJ,SakamotoN,etal.Acuteand
482. SantangeliP,ZadoES,SuppleGE,HaqqaniHM,GarciaFC,TschabrunnCM,etal. long-termresultsofbipolarradiofrequencycatheterablationofrefractoryven-
Long-termoutcomewithcatheterablationofventriculartachycardiainpatients triculararrhythmiasofdeepintramuralorigin.HeartRhythm2020;17:1500–1507.
with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm 506. DellaBellaP,PerettoG,PaglinoG,BiscegliaC,RadinovicA,SalaS,etal.Bipolar
Electrophysiol2015;8:1413–1421. radiofrequencyablationforventriculartachycardiasoriginatingfromtheinterven-
483. MarchlinskiFE,HaffajeeCI,BeshaiJF,DickfeldT-ML,GonzalezMD,HsiaHH,etal. tricularseptum:safetyandefficacyinapilotcohortstudy.HeartRhythm2020;17:
Long-termsuccessofirrigatedradiofrequencycatheterablationofsustainedven- 2111–2118.
triculartachycardia.JAmCollCardiol2016;67:674–683. 507. CuculichPS,SchillMR,KashaniR,MuticS,LangA,CooperD,etal.Noninvasive
484. ReddyVY,ReynoldsMR,NeuzilP,RichardsonAW,TaborskyM,JongnarangsinK, cardiacradiationforablationofventriculartachycardia.NEnglJMed2017;377:
etal.Prophylacticcatheterablationforthepreventionofdefibrillatortherapy.N 2325–2336.
EnglJMed2007;357:2657–2665. 508. RobinsonCG,SamsonPP,MooreKMS,HugoGD,KnutsonN,MuticS,etal.Phase
485. KuckK-H,SchaumannA,EckardtL,WillemsS,VenturaR,DelacrétazE,etal. I/IItrialofelectrophysiology-guidednoninvasivecardiacradioablationforventricu-
Catheterablationofstableventriculartachycardiabeforedefibrillatorimplantation lartachycardia.Circulation2019;139:313–321.
inpatientswithcoronaryheartdisease(VTACH):amulticentrerandomisedcon- 509. AnterE,HutchinsonMD,DeoR,HaqqaniHM,CallansDJ,GerstenfeldEP,etal.
trolledtrial.Lancet2010;375:31–40. Surgicalablationofrefractoryventriculartachycardiainpatientswithnonischemic
486. AnterE,KleberAG,RottmannM,LeshemE,BarkaganM,TschabrunnCM,etal. cardiomyopathy.CircArrhythmElectrophysiol2011;4:494–500.
Infarct-relatedventriculartachycardia.JACCClinElectrophysiol2018;4:1033–1048. 510. Fernández-ArmentaJ,BerruezoA,AndreuD,CamaraO,SilvaE,SerraL,etal.
487. MarchlinskiFE,CallansDJ,GottliebCD,ZadoE.Linearablationlesionsforcontrol Three-dimensionalarchitectureofscarandconductingchannelsbasedonhigh
ofunmappableventriculartachycardiainpatientswithischemicandnonischemic resolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm
cardiomyopathy.Circulation2000;101:1288–1296. Electrophysiol2013;6:528–537.
488. deChillouC,GrobenL,Magnin-PoullI,AndronacheM,AbbasMM,ZhangN,etal. 511. MahidaS,SacherF,DuboisR,SermesantM,BogunF,HaïssaguerreM,etal.Cardiac
Localizingthecriticalisthmusofpostinfarctventriculartachycardia:thevalueof imaginginpatientswithventriculartachycardia.Circulation2017;136:2491–2507.
pace-mappingduringsinusrhythm.HeartRhythm2014;11:175–181. 512. AndreuD,PenelaD,AcostaJ,Fernández-ArmentaJ,PereaRJ,Soto-IglesiasD,etal.
489. JaïsP,MauryP,KhairyP,SacherF,NaultI,KomatsuY,etal.Eliminationoflocalab- Cardiacmagneticresonance–aidedscardechanneling:influenceonacuteandlong-
normalventricularactivities:anewendpointforsubstratemodificationinpatients termoutcomes.HeartRhythm2017;14:1121–1128.
withscar-relatedventriculartachycardia.Circulation2012;125:2184–2196. 513. KuoL,LiangJJ,NazarianS,MarchlinskiFE.Multimodalityimagingtoguideventricu-
490. BerruezoA,Fernandez-ArmentaJ.Lines,circles,channels,andclouds:lookingfor lartachycardiaablationinpatientswithnon-ischaemiccardiomyopathy.Arrhythm
thebestdesignforsubstrate-guidedablationofventriculartachycardia.Europace ElectrophysiolRev2020;8:255–264.
2014;16:943–945. 514. Roca-LuqueI,VanBreukelenA,AlarconF,GarreP,TolosanaJM,BorrasR,etal.
491. DiBiaseL,BurkhardtJD,LakkireddyD,CarbucicchioC,MohantyS,MohantyP, Ventricularscarchannelentrancesidentifiedbynewwidebandcardiacmagnetic
etal.AblationofstableVTsversussubstrateablationinischemiccardiomyopathy. resonancesequencetoguideventriculartachycardiaablationinpatientswithcar-
JAmCollCardiol2015;66:2872–2882. diacdefibrillators.Europace2020;22:598–606.
492. BerruezoA,Fernández-ArmentaJ,AndreuD,PenelaD,HerczkuC,EvertzR,etal. 515. BetenskyBP,MarchlinskiFE.Outcomesofcatheterablationofventriculartachy-
Scardechanneling:newmethodforscar-relatedleftventriculartachycardiasub- cardiainthesettingofstructuralheartdisease.CurrCardiolRep2016;18:68.
strateablation.CircArrhythmElectrophysiol2015;8:326–336. 516. DukkipatiSR,KoruthJS,ChoudryS,MillerMA,WhangW,ReddyVY.Catheterab-
493. HaïssaguerreM,ShodaM,JaïsP,NogamiA,ShahDC,KautznerJ,etal.Mappingand lationofventriculartachycardiainstructuralheartdisease.JAmCollCardiol2017;
ablationofidiopathicventricularfibrillation.Circulation2002;106:962–967. 70:2924–2941.
494. ShiraiY,LiangJJ,SantangeliP,ArklesJS,SchallerRD,SuppleGE,etal.Comparison 517. ZeppenfeldK.Ventriculartachycardiaablationinnonischemiccardiomyopathy.
oftheventriculartachycardiacircuitbetweenpatientswithischemicandnonis- JACCClinElectrophysiol2018;4:1123–1140.
chemiccardiomyopathies:detailedcharacterizationbyentrainment.CircArrhythm 518. GuandaliniGS,LiangJJ,MarchlinskiFE.Ventriculartachycardiaablation.JACCClin
Electrophysiol2019;12:e007249. Electrophysiol2019;5:1363–1383.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4113
519.PeichlP,WichterleD,PavluL,CihakR,AldhoonB,KautznerJ.Complicationsof 544. DemirelF,RasoulS,ElvanA,OttervangerJP,DambrinkJ-HE,GosselinkATM,etal.
catheter ablation of ventricular tachycardia: a single-center experience. Circ Impactofout-of-hospitalcardiacarrestduetoventricularfibrillationinpatients
ArrhythmElectrophysiol2014;7:684–690. withST-elevationmyocardialinfarctionadmittedforprimarypercutaneouscoron-
520.KatzDF,TurakhiaMP,SauerWH,TzouWS,HeathRR,ZipseMM,etal.Safetyof aryintervention:ImpactofventricularfibrillationinSTEMIpatients.EurHeartJ
ventriculartachycardiaablationinclinicalpractice:findingsfrom9699hospitaldis- AcuteCardiovascCare2015;4:16–23.
chargerecords.CircArrhythmElectrophysiol2015;8:362–370. 545. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al.
521.CheungJW,YeoI,IpJE,ThomasG,LiuCF,MarkowitzSM,etal.Outcomes,costs, Incidenceofandoutcomesassociatedwithventriculartachycardiaorfibrillation
and30-dayreadmissionsaftercatheterablationofmyocardialinfarct–associated inpatientsundergoingprimarypercutaneouscoronaryintervention.JAMA2009;
ventriculartachycardiaintherealworld:nationwidereadmissionsdatabase2010 301:1779–1789.
to2015.CircArrhythmElectrophysiol2018;11:e006754. 546. DemidovaMM,CarlsonJ,ErlingeD,PlatonovPG.Predictorsofventricularfibrilla-
522.HendriksAA,AkcaF,DabiriAbkenariL,KhanM,BhagwandienR,YapS-C,etal. tionatreperfusioninpatientswithacuteST-elevationmyocardialinfarctiontreated
Safetyandclinicaloutcomeofcatheterablationofventriculararrhythmiasusing byprimarypercutaneouscoronaryintervention.AmJCardiol2015;115:417–422.
contactforcesensing:consecutivecaseseries.JCardiovascElectrophysiol2015;26: 547. ChengY-J,LiZ-Y,YaoF-J,XuX-J,JiC-C,ChenX-M,etal.Earlyrepolarizationis
1224–1229. associatedwithasignificantlyincreasedriskofventriculararrhythmiasandsudden
523.NogamiA.Purkinje-relatedarrhythmiaspartI:monomorphicventriculartachycar- cardiacdeathinpatientswithstructuralheartdiseases.HeartRhythm2017;14:
dias.PacingClinElectrophysiol2011;34:624–650. 1157–1164.
524.LermanBB.Mechanism,diagnosis,andtreatmentofoutflowtracttachycardia.Nat 548. DumasF,BougouinW,GeriG,LamhautL,RosencherJ,PèneF,etal.Emergency
RevCardiol2015;12:597–608. percutaneous coronary intervention in post-cardiac arrest patients without
525.KobayashiY.Idiopathicventricularprematurecontractionandventriculartachy- ST-segment elevation pattern: insights from the PROCAT II registry. JACC
cardia: distribution of the origin, diagnostic algorithm, and catheter ablation. J CardiovascInterv2016;9:1011–1018.
NipponMedSch2018;85:87–94. 549. ChatterjeeS,ChaudhuriD,VedanthanR,FusterV,IbanezB,BangaloreS,etal.Early
526.TadaH,ItoS,NaitoS,KurosakiK,KubotaS,SugiyasuA,etal.Idiopathicventricular intravenous beta-blockers in patients with acute coronary syndrome–a
arrhythmiaarisingfromthemitralannulus:adistinctsubgroupofidiopathicven- meta-analysisofrandomizedtrials.IntJCardiol2013;168:915–921.
triculararrhythmias.JAmCollCardiol2005;45:877–886. 550. RoolvinkV,IbáñezB,OttervangerJP,PizarroG,vanRoyenN,MateosA,etal.Early
527.WasmerK,KöbeJ,DecheringDG,BittnerA,PottC,MönnigG,etal.Ventricular intravenousbeta-blockersinpatientswithST-segmentelevationmyocardialinfarc-
arrhythmiasfromthemitralannulus:patientcharacteristics,electrophysiological tionbeforeprimarypercutaneouscoronaryintervention.JAmCollCardiol2016;67:
findings,ablation,andprognosis.HeartRhythm2013;10:783–788. 2705–2715.
528.TadaH,TadokoroK,ItoS,NaitoS,HashimotoT,KasenoK,etal.Idiopathicven- 551. Piccini JP, Hranitzky PM, Kilaru R, Rouleau J-L, White HD, Aylward PE, et al.
triculararrhythmiasoriginatingfromthetricuspidannulus:prevalence,electrocar- Relationofmortalitytofailuretoprescribebetablockersacutelyinpatientswith
diographiccharacteristics,andresultsofradiofrequencycatheterablation.Heart sustainedventriculartachycardiaandventricularfibrillationfollowingacutemyo-
Rhythm2007;4:7–16. cardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial
529.YamadaT,DoppalapudiH,McElderryHT,OkadaT,MurakamiY,IndenY,etal. [VALIANT]Registry).AmJCardiol2008;102:1427–1432.
Electrocardiographicandelectrophysiologicalcharacteristicsinidiopathicventricu- 552. NademaneeK,TaylorR,BaileyWE,RiedersDE,KosarEM.Treatingelectrical
lararrhythmiasoriginatingfromthepapillarymusclesintheleftventricle:relevance storm:sympatheticblockadeversusadvancedcardiaclifesupport-guidedtherapy.
forcatheterablation.CircArrhythmElectrophysiol2010;3:324–331. Circulation2000;102:742–747.
530.MaciasC,NakamuraK,TungR,BoyleNG,KalyanamS,BradfieldJS.Importanceof 553. BundgaardJS,JacobsenPK,GrandJ,LindholmMG,HassagerC,PehrsonS,etal.
delayedenhancedcardiacMRIinidiopathicRVOT-VT:differentiatingmimicsin- Deepsedationastemporarybridgetodefinitivetreatmentofventriculararrhyth-
cludingearlystageARVCandcardiacsarcoidosis.JAtrFibrillation2014;7:1097. miastorm.EurHeartJAcuteCardiovascCare2020;9:657–664.
531.HeegerC-H,HayashiK,KuckK-H,OuyangF.Catheterablationofidiopathicven- 554. PicciniJP,SchultePJ,PieperKS,MehtaRH,WhiteHD,VandeWerfF,etal.
triculararrhythmiasarisingfromthecardiacoutflowtracts—recentinsightsand Antiarrhythmicdrugtherapyforsustainedventriculararrhythmiascomplicating
techniquesforthesuccessfultreatmentofcommonandchallengingcases.CircJ acutemyocardialinfarction.CritCareMed2011;39:78–83.
2016;80:1073–1086. 555. DorianP,CassD,SchwartzB,CooperR,GelaznikasR,BarrA.Amiodaroneas
532.PathakRK,AriyarathnaN,GarciaFC,SandersP,MarchlinskiFE.Catheterablation comparedwithlidocaineforshock-resistantventricularfibrillation.NEnglJMed
ofidiopathicventriculararrhythmias.HeartLungCirc2019;28:102–109. 2002;346:884–890.
533.YamadaT,McElderryHT,DoppalapudiH,MurakamiY,YoshidaY,YoshidaN,etal. 556. EchtDS,LiebsonPR,MitchellLB,PetersRW,Obias-MannoD,BarkerAH,etal.
Idiopathicventriculararrhythmiasoriginatingfromtheaorticrootprevalence,elec- Mortality and morbidity in patients receiving encainide, flecainide, or placebo.
trocardiographic andelectrophysiologic characteristics, andresults of radiofre- TheCardiacArrhythmiaSuppressionTrial.NEnglJMed1991;324:781–788.
quencycatheterablation.JAmCollCardiol2008;52:139–147. 557. BaudryG,SonnevilleR,WaintraubX,LebretonG,DeguillardC,MertensE,etal.
534.VanHerendaelH,GarciaF,LinD,RileyM,BalaR,CooperJ,etal.Idiopathicright Extracorporealmembraneoxygenationtosupportlife-threateningdrug-refractory
ventriculararrhythmiasnotarisingfromtheoutflowtract:prevalence,electrocar- electricalstorm.CritCareMed2020;48:e856–e863.
diographiccharacteristics,andoutcomeofcatheterablation.HeartRhythm2011;8: 558. Demidova MM, Smith JG, Höijer C-J, Holmqvist F, Erlinge D, Platonov PG.
511–518. PrognosticimpactofearlyventricularfibrillationinpatientswithST-elevationmyo-
535.Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al. cardialinfarctiontreatedwithprimaryPCI.EurHeartJAcuteCardiovascCare2012;
Multicenteroutcomesforcatheterablationofidiopathicprematureventricular 1:302–311.
complexes.JACCClinElectrophysiol2015;1:116–123. 559. PodoleckiT,LenarczykR,KowalczykJ,Jedrzejczyk-PatejE,ChodorP,MazurekM,
536.LiuY,FangZ,YangB,KojodjojoP,ChenH,JuW,etal.Catheterablationoffasci- et al. Prognostic significance of complex ventricular arrhythmias complicating
cularventriculartachycardia:long-termclinicaloutcomesandmechanismsofre- ST-segmentelevationmyocardialinfarction.AmJCardiol2018;121:805–809.
currence.CircArrhythmElectrophysiol2015;8:1443–1451. 560. BougouinW,MarijonE,PuymiratE,DefayeP,CelermajerDS,LeHeuzeyJ-Y,etal.
537.HayashiT,LiangJJ,ShiraiY,KuoL,MuserD,KubalaM,etal.Trendsinsuccessful Incidenceofsuddencardiacdeathafterventricularfibrillationcomplicatingacute
ablationsitesandoutcomesofablationforidiopathicoutflowtractventricularar- myocardialinfarction:a5-yearcause-of-deathanalysisoftheFAST-MI2005regis-
rhythmias.JACCClinElectrophysiol2020;6:221–230. try.EurHeartJ2014;35:116–122.
538.FarréJ,WellensHJ.PhilippeCoumel:afoundingfatherofmodernarrhythmology. 561. LiangJJ,HodgeDO,MehtaRA,RussoAM,PrasadA,ChaY-M.Outcomesinpa-
Europace2004;6:464–465. tientswithsustainedventriculartachyarrhythmiasoccurringwithin48hofacute
539.NeiraV,EnriquezA,SimpsonC,BaranchukA.UpdateonlongQTsyndrome.J myocardialinfarction:whenisICDappropriate?Europace2014;16:1759–1766.
CardiovascElectrophysiol2019;30:3068–3078. 562. AhnJ-M,LeeKH,YooS-Y,ChoY-R,SuhJ,ShinE-S,etal.Prognosisofvariantangina
540.WinboA,PatersonDJ.Thebrain-heartconnectioninsympatheticallytriggeredin- manifestingasabortedsuddencardiacdeath.JAmCollCardiol2016;68:137–145.
heritedarrhythmiasyndromes.HeartLungCirc2020;29:529–537. 563. SuedaS,KohnoH.Optimalmedicationsandappropriateimplantablecardioverter-
541.SchwartzPJ,PrioriSG,CerroneM,SpazzoliniC,OderoA,NapolitanoC,etal.Left defibrillatorshocksinabortedsuddencardiacdeathduetocoronaryspasm.Intern
cardiacsympatheticdenervationinthemanagementofhigh-riskpatientsaffected Med2018;57:1361–1369.
bythelong-QTsyndrome.Circulation2004;109:1826–1833. 564. Rodríguez-MañeroM,OlorizT,lePolaindeWarouxJ-B,BurriH,KreidiehB,de
542.SurmanTL,StuklisRG,ChanJC.ThoracoscopicsympathectomyforlongQTsyn- AsmundisC,etal.Long-termprognosisofpatientswithlife-threateningventricular
drome.Literaturereviewandcasestudy.HeartLungCirc2019;28:486–494. arrhythmiasinducedbycoronaryarteryspasm.Europace2018;20:851–858.
543.Orvin K, Eisen A, Goldenberg I, Gottlieb S, Kornowski R, Matetzky S, et al. 565. SolomonSD,ZelenkofskeS,McMurrayJJV,FinnPV,VelazquezE,ErtlG,etal.
Outcomeofcontemporaryacutecoronarysyndromecomplicatedbyventricular Suddendeathinpatientswithmyocardialinfarctionandleftventriculardysfunction,
tachyarrhythmias.Europace2016;18:219–226. heartfailure,orboth.NEnglJMed2005;352:2581–2588.
Downloaded
from

by
guest
on
22
January
2026

4114 ESCGuidelines
566. BuskM,MaengM,KristensenSD,ThuesenL,KrusellLR,MortensenLS,etal. 587. JegatheeswaranA,DevlinPJ,McCrindleBW,WilliamsWG,JacobsML,Blackstone
Timing, causes, and predictors of death after three years’ follow-up in the EH,etal.Featuresassociatedwithmyocardialischemiainanomalousaorticorigin
DanishMulticenterRandomizedStudyofFibrinolysisversusPrimaryAngioplasty ofacoronaryartery:acongenitalheartsurgeons’societystudy.JThoracCardiovasc
inAcuteMyocardialInfarction(DANAMI-2)trial.AmJCardiol2009;104:210–215. Surg2019;158:822–834.
567. StJohnSuttonM,PfefferMA,PlappertT,RouleauJL,MoyéLA,DagenaisGR,etal. 588. JegatheeswaranA,DevlinPJ,WilliamsWG,BrothersJA,JacobsML,DeCampli
Quantitativetwo-dimensionalechocardiographicmeasurementsaremajorpredic- WM,etal.Outcomesafteranomalousaorticoriginofacoronaryarteryrepair:
torsofadversecardiovasculareventsafteracutemyocardialinfarction.Thepro- a congenital heart surgeons’ society study. J Thorac Cardiovasc Surg 2020;160:
tectiveeffectsofcaptopril.Circulation1994;89:68–75. 757–771.
568. SøholmH,LønborgJ,AndersenMJ,VejlstrupN,EngstrømT,MøllerJE,etal. 589. HoffmayerKS,BhavePD,MarcusGM,JamesCA,TichnellC,ChopraN,etal.An
RepeatedechocardiographyafterfirsteverST-segmentelevationmyocardialin- electrocardiographic scoring system for distinguishing right ventricular outflow
farctiontreatedwithprimarypercutaneouscoronaryintervention–isitnecessary?
tractarrhythmiasinpatientswitharrhythmogenicrightventricularcardiomyopathy
EurHeartJAcuteCardiovascCare2015;4:528–536. fromidiopathicventriculartachycardia.HeartRhythm2013;10:477–482.
569. SteinbeckG,AndresenD,SeidlK,BrachmannJ,HoffmannE,WojciechowskiD, 590. YokokawaM,SiontisKC,KimHM,StojanovskaJ,LatchamsettyR,CrawfordT,etal.
et al. Defibrillator implantation earlyafter myocardial infarction. NEngl J Med Valueofcardiacmagneticresonanceimagingandprogrammedventricularstimula-
2009;361:1427–1436.
tioninpatientswithfrequentprematureventricularcomplexesundergoingradio-
570. Hohnloser SH, Kuck KH,Dorian P, RobertsRS, Hampton JR,Hatala R,etal. frequencyablation.HeartRhythm2017;14:1695–1701.
Prophylacticuseofanimplantablecardioverter-defibrillatorafteracutemyocardial
591. MuserD,SantangeliP,CastroSA,CasadoArroyoR,MaedaS,BenhayonDA,etal.
infarction.NEnglJMed2004;351:2481–2488. Riskstratificationofpatientswithapparentlyidiopathicprematureventricularcon-
571. ExnerDV,KavanaghKM,SlawnychMP,MitchellLB,RamadanD,AggarwalSG,etal. tractions:amulticenterinternationalCMRregistry.JACCClinElectrophysiol2020;6:
NoninvasiveriskassessmentearlyafteramyocardialinfarctiontheREFINEstudy.J 722–735.
AmCollCardiol2007;50:2275–2284.
592. KjekshusJ,BathenJ,OrningOM,StorsteinL.Adouble-blind,crossovercomparison
572. ZamanS,NarayanA,ThiagalingamA,SivagangabalanG,ThomasS,RossDL,etal. offlecainideacetateanddisopyramidephosphateinthetreatmentofventricular
Long-termarrhythmia-freesurvivalinpatientswithsevereleftventriculardysfunc- prematurecomplexes.AmJCardiol1984;53:72B–78B.
tionandnoinducibleventriculartachycardiaaftermyocardialinfarction.Circulation
593. HamonD,SwidMA,RajendranPS,LiuA,BoyleNG,ShivkumarK,etal.Premature
2014;129:848–854.
ventricularcontractiondiurnalprofilespredictdistinctclinicalcharacteristicsand
573. DaubertMA,WhiteJA,Al-KhalidiHR,VelazquezEJ,RaoSV,CrowleyAL,etal. beta-blockerresponses.JCardiovascElectrophysiol2019;30:836–843.
CardiacremodelingafterlargeST-elevationmyocardialinfarctioninthecurrent 594. PrimeauR,AghaA,GiorgiC,ShenasaM,NadeauR.Longtermefficacyandtoxicity
therapeuticera.AmHeartJ2020;223:87–97.
ofamiodaroneinthetreatmentofrefractorycardiacarrhythmias.CanJCardiol
574. ChewDS,HeikkiH,SchmidtG,KavanaghKM,DommaschM,BlochThomsenPE, 1989;5:98–104.
etal.Changeinleftventricularejectionfractionfollowingfirstmyocardialinfarction
595. LingZ,LiuZ,SuL,ZipunnikovV,WuJ,DuH,etal.Radiofrequencyablationversus
andoutcome.JACCClinElectrophysiol2018;4:672–682.
antiarrhythmicmedicationfortreatmentofventricularprematurebeatsfromthe
575. BänschD,OyangF,AntzM,ArentzT,WeberR,Val-MejiasJE,etal.Successfulcath- right ventricular outflow tract: prospective randomized study. Circ Arrhythm
eterablationofelectricalstormaftermyocardialinfarction.Circulation2003;108: Electrophysiol2014;7:237–243.
3011–3016.
596. BaksieneD,SileikieneR,SileikisV,KazakeviciusT,ZabielaV,ZebieneM,etal.
576. AltmannDR,MutschelknaussM,EhlN,KollerM,SchaerB,JörgL,etal.Prevalence
Idiopathicventriculartachycardiainchildren:curativetherapywithradiofrequency
ofseverelyimpairedleftventricularejectionfractionafterreperfusedST-elevation
ablation.Medicina(Kaunas)2007;43:803–807.
myocardialinfarction.SwissMedWkly2013;143:w13869.
597. BlaufoxAD,FelixGL,SaulJP,PediatricCatheterAblationRegistry.Radiofrequency
577. ShenL,JhundPS,PetrieMC,ClaggettBL,BarleraS,ClelandJGF,etal.Decliningrisk
ofsuddendeathinheartfailure.NEnglJMed2017;377:41–51.
catheterablationininfants,/=18monthsold:whenisitdoneandhowdothey
fare?:Short-termdatafromthepediatricablationregistry.Circulation2001;104:
578. CairnsJA,ConnollySJ,RobertsR,GentM.Randomisedtrialofoutcomeaftermyo-
2803–2808.
cardialinfarctioninpatientswithfrequentorrepetitiveventricularprematurede-
598. LapageMJ,BradleyDJ,DickM.Verapamilininfants:anexaggeratedfear?Pediatr
polarisations:CAMIAT.CanadianAmiodaroneMyocardialInfarctionArrhythmia
TrialInvestigators.Lancet1997;349:675–682.
Cardiol2013;34:1532–1534.
599. LeeAKY,AndradeJ,HawkinsNM,AlexanderG,BennettMT,ChakrabartiS,etal.
579. JulianDG,CammAJ,FranginG,JanseMJ,MunozA,SchwartzPJ,etal.Randomised
Outcomesofuntreatedfrequentprematureventricularcomplexeswithnormal
trialofeffectofamiodaroneonmortalityinpatientswithleft-ventriculardysfunc-
leftventricularfunction.Heart2019;105:1408–1413.
tion after recent myocardial infarction: EMIAT. European Myocardial Infarct
AmiodaroneTrialInvestigators.Lancet1997;349:667–674. 600. BamanTS,LangeDC,IlgKJ,GuptaSK,LiuT-Y,AlguireC,etal.Relationshipbe-
580. ClemensM,PeichlP,WichterleD,PavlůL,ČihákR,AldhoonB,etal.Catheterab- tweenburdenofprematureventricularcomplexesandleftventricularfunction.
lationofventriculartachycardiaasthefirst-linetherapyinpatientswithcoronary HeartRhythm2010;7:865–869.
601. vanHulsvanTaxisCFB,PiersSRD,deRivaSilvaM,DekkersOM,PijnappelsDA,
arterydiseaseandpreservedleftventricularsystolicfunction:long-termresults:
SchalijMJ,etal.Fatigueaspresentingsymptomandahighburdenofprematureven-
VT ablation in patients with preserved LV function. J Cardiovasc Electrophysiol
2015;26:1105–1110. tricularcontractionsareindependentlyassociatedwithincreasedventricularwall
581. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al. stress in patients with normal left ventricular function. Circ Arrhythm
Prevention of implantable-defibrillator shocks by treatment with sotalol. D, Electrophysiol2015;8:1452–1459.
L-SotalolImplantableCardioverter-DefibrillatorStudyGroup.NEnglJMed1999; 602. SharmaN,CortezD,ImundoJR.Highburdenofprematureventricularcontrac-
340:1855–1862. tionsinstructurallynormalhearts: toworryor notinpediatricpatients?Ann
582. WillemsS,TilzRR,StevenD,KääbS,WegscheiderK,GellérL,etal.Preventiveor NoninvasiveElectrocardiol2019;24:e12663.
deferredablationofventriculartachycardiainpatientswithischemiccardiomyop- 603. NiwanoS,WakisakaY,NiwanoH,FukayaH,KurokawaS,KiryuM,etal.Prognostic
athyandimplantabledefibrillator(BERLINVT):amulticenterrandomizedtrial. significanceoffrequentprematureventricularcontractionsoriginatingfromthe
Circulation2020;141:1057–1067. ventricularoutflowtractinpatientswithnormalleftventricularfunction.Heart
583. KuckK-H,TilzRR,DenekeT,HoffmannBA,VenturaR,HansenPS,etal.Impactof 2009;95:1230–1237.
substratemodificationbycatheterablationonimplantablecardioverter–defibrilla- 604. KrittayaphongR,SriratanasathavornC,DumavibhatC,PumpruegS,Boonyapisit
torinterventionsinpatientswithunstableventriculararrhythmiasandcoronaryar- W,PooranawattanakulS,etal.Electrocardiographicpredictorsoflong-termout-
terydisease:resultsfromthemulticenterrandomizedcontrolledSMS(substrate comesafterradiofrequencyablationinpatientswithright-ventricularoutflowtract
modificationstudy).CircArrhythmElectrophysiol2017;10:e004422. tachycardia.Europace2006;8:601–606.
584. OlshanskyB,HahnEA,HartzVL,PraterSP,MasonJW.Clinicalsignificanceofsyn- 605. Komatsu Y, Nogami A, Kurosaki K, Morishima I, Masuda K, Ozawa T, et al.
cope in the electrophysiologic study versus electrocardiographic monitoring Fascicularventriculartachycardiaoriginatingfrompapillarymuscles:Purkinjenet-
(ESVEM)trial.TheESVEMInvestigators.AmHeartJ1999;137:878–886. workinvolvementinthereentrantcircuit.CircArrhythmElectrophysiol2017;10:
585. MolossiS,AgrawalH,MeryCM,KrishnamurthyR,MasandP,SexsonTejtelSK, e004549.
etal.Outcomesinanomalousaorticoriginofacoronaryarteryfollowingapro- 606. KirkCR,GibbsJL,ThomasR,Radley-SmithR,QureshiSA.Cardiovascularcollapse
spectivestandardizedapproach.CircCardiovascInterv2020;13:e008445. afterverapamilinsupraventriculartachycardia.ArchDisChild1987;62:1265–1266.
586. KrasuskiRA,MagyarD,HartS,KalahastiV,LorberR,HobbsR,etal.Long-term 607. DuffeeDF,ShenWK,SmithHC.Suppressionoffrequentprematureventricular
outcomeandimpactofsurgeryonadultswithcoronaryarteriesoriginatingfrom contractionsandimprovementofleftventricularfunctioninpatientswithpre-
theoppositecoronarycusp.Circulation2011;123:154–162. sumedidiopathicdilatedcardiomyopathy.MayoClinProc1998;73:430–433.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4115
608.ChughSS,ShenWK,LuriaDM,SmithHC.Firstevidenceofprematureventricular with an increased risk of dilated cardiomyopathy caused by a Nav1.5
complex-inducedcardiomyopathy:apotentiallyreversiblecauseofheartfailure.J gain-of-functionmutation(G213D).IntJCardiol2018;257:160–167.
CardiovascElectrophysiol2000;11:328–329. 629. MannSA,CastroML,OhanianM,GuoG,ZodgekarP,SheuA,etal.R222Q
609.Penela D, Van Huls Van Taxis C, Van Huls Vans Taxis C, Aguinaga L, SCN5Amutationisassociatedwithreversibleventricularectopyanddilatedcar-
Fernández-ArmentaJ,MontL,etal.Neurohormonal,structural,andfunctionalre- diomyopathy.JAmCollCardiol2012;60:1566–1573.
coverypatternafterprematureventricularcomplexablationisindependentof 630. BeckermannTM,McLeodK,MurdayV,PotetF,GeorgeAL.NovelSCN5Amuta-
structuralheartdiseasestatusinpatientswithdepressedleftventricularejection tioninamiodarone-responsivemultifocalventricularectopy-associatedcardiomy-
fraction:aprospectivemulticenterstudy.JAmCollCardiol2013;62:1195–1202. opathy.HeartRhythm2014;11:1446–1453.
610.PenelaD,AcostaJ,AguinagaL,TercedorL,OrdoñezA,Fernández-ArmentaJ,etal. 631. DoisneN,WaldmannV,RedheuilA,WaintraubX,FressartV,AderF,etal.Anovel
AblationoffrequentPVCinpatientsmeetingcriteriaforprimarypreventionICD gain-of-function mutation in SCN5A responsible for multifocal ectopic
implant:safetyofwithholdingtheimplant.HeartRhythm2015;12:2434–2442. Purkinje-relatedprematurecontractions.HumMutat2020;41:850–859.
611.VoskoboinikA,HadjisA,AlhedeC,ImSI,ParkH,MossJ,etal.Predictorsofadverse 632. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al.
outcomeinpatientswithfrequentprematureventricularcomplexes:theABC-VT
Classificationofthecardiomyopathies:apositionstatementfromtheEuropean
riskscore.HeartRhythm2020;17:1066–1074. SocietyOfCardiologyWorkingGrouponMyocardialandPericardialDiseases.
612.LeeA,DenmanR,HaqqaniHM.Ventricularectopyinthecontextofleftventricular
EurHeartJ2008;29:270–276.
systolicdysfunction:riskfactorsandoutcomesfollowingcatheterablation.Heart 633. CoddMB,SugrueDD,GershBJ,MeltonLJ.Epidemiologyofidiopathicdilatedand
LungCirc2019;28:379–388. hypertrophic cardiomyopathy. A population-based study in Olmsted County,
613.SadronBlaye-FeliceM,HamonD,SacherF,PascaleP,RollinA,DuparcA,etal.
Minnesota,1975–1984.Circulation1989;80:564–572.
Prematureventricularcontraction-inducedcardiomyopathy:relatedclinicaland 634. WeintraubRG,SemsarianC,MacdonaldP.Dilatedcardiomyopathy.Lancet2017;
electrophysiologicparameters.HeartRhythm2016;13:103–110. 390:400–414.
614.PenelaD,Fernández-ArmentaJ,AguinagaL,TercedorL,OrdoñezA,BisbalF,etal. 635. BeggsSAS,JhundPS,JacksonCE,McMurrayJJV,GardnerRS.Non-ischaemiccar- Clinicalrecognitionofpureprematureventricularcomplex-inducedcardiomyop- diomyopathy, sudden death and implantable defibrillators: a review and
athyatpresentation.HeartRhythm2017;14:1864–1870. meta-analysis.Heart2018;104:144–150.
615.AquaroGD,PingitoreA,StrataE,DiBellaG,MolinaroS,LombardiM.Cardiac 636. TowbinJA,LoweAM,ColanSD,SleeperLA,OravEJ,ClunieS,etal.Incidence,
magneticresonancepredictsoutcomeinpatientswithprematureventricularcom- causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:
1867–1876.
plexes of left bundle branch block morphology. J Am Coll Cardiol 2010;56:
1235–1243. 637. PahlE,SleeperLA,CanterCE,HsuDT,LuM,WebberSA,etal.Incidenceofand
riskfactorsforsuddencardiacdeathinchildrenwithdilatedcardiomyopathy:are-
616.OebelS,DinovB,AryaA,HilbertS,SommerP,BollmannA,etal.ECGmorphology
ofprematureventricularcontractionspredictsthepresenceofmyocardialfibrotic port from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol 2012;59:
607–615.
substrateoncardiacmagneticresonanceimaginginpatientsundergoingablation.J
CardiovascElectrophysiol2017;28:1316–1323. 638. BharuchaT,LeeKJ,DaubeneyPEF,NugentAW,TurnerC,ShollerGF,etal.
Sudden deathin childhood cardiomyopathy:resultsfrom along-termnational
617.MountantonakisSE,FrankelDS,GerstenfeldEP,DixitS,LinD,HutchinsonMD,
etal.Reversalofoutflowtractventricularprematuredepolarization–inducedcar-
population-basedstudy.JAmCollCardiol2015;65:2302–2310.
639. PintoYM,ElliottPM,ArbustiniE,AdlerY,AnastasakisA,BöhmM,etal.Proposal
diomyopathywithablation:effectofresidualarrhythmiaburdenandpreexisting
cardiomyopathyonoutcome.HeartRhythm2011;8:1608–1614.
forareviseddefinitionofdilatedcardiomyopathy,hypokineticnon-dilatedcardio-
618.ZangM,ZhangT,MaoJ,ZhouS,HeB.Beneficialeffectsofcatheterablationoffre- myopathy,anditsimplicationsforclinicalpractice:apositionstatementoftheESC
working group on myocardial and pericardial diseases. Eur Heart J 2016;37:
quentprematureventricularcomplexesonleftventricularfunction.Heart2014;
100:787–793.
1850–1858.
640. AsselbergsFW,SammaniA,ElliottP,GimenoJR,TavazziL,TenderaM,etal.
619.WijnmaalenAP,DelgadoV,SchalijMJ,vanHulsvanTaxisCFB,HolmanER,BaxJJ,
Differences between familial and sporadic dilated cardiomyopathy: ESC EORP
etal.Beneficialeffectsofcatheterablationonleftventricularandrightventricular
Cardiomyopathy&Myocarditisregistry.ESCHeartFail2021;8:95–105.
functioninpatientswithfrequentprematureventricularcontractionsandpre-
641. AderF,DeGrooteP,RéantP,Rooryck-ThamboC,Dupin-DeguineD,RambaudC,
servedejectionfraction.Heart2010;96:1275–1280.
etal.FLNCpathogenicvariantsinpatientswithcardiomyopathies:prevalenceand
620.Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al. genotype-phenotypecorrelations.ClinGenet2019;96:317–329.
Radiofrequencyablationoffrequent,idiopathicprematureventricularcomplexes:
642. KayvanpourE, Sedaghat-HamedaniF,Amr A, LaiA, HaasJ, HolzerDB,et al.
comparison with a control group without intervention. Heart Rhythm 2007;4:
Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on
863–867.
morethan8000individuals.ClinResCardiol2017;106:127–139.
621.SarrazinJ-F,LabountyT,KuhneM,CrawfordT,ArmstrongWF,DesjardinsB,etal.
643. Ortiz-GengaMF,CuencaS,DalFerroM,ZorioE,Salgado-ArandaR,ClimentV,
Impactofradiofrequencyablationoffrequentpost-infarctionprematureventricu-
etal.TruncatingFLNCmutationsareassociatedwithhigh-riskdilatedandarrhyth-
lar complexes on left ventricular ejection fraction. Heart Rhythm 2009;6: mogeniccardiomyopathies.JAmCollCardiol2016;68:2440–2451.
1543–1549. 644. vandenHoogenhofMMG,BeqqaliA,AminAS,vanderMadeI,AufieroS,Khan
622.ElKadriM,YokokawaM,LabountyT,MuellerG,CrawfordT,GoodE,etal.Effect MAF,etal.RBM20mutationsinduceanarrhythmogenicdilatedcardiomyopathy
ofablationoffrequentprematureventricularcomplexesonleftventricularfunc- relatedtodisturbedcalciumhandling.Circulation2018;138:1330–1342.
tion in patients with nonischemic cardiomyopathy. Heart Rhythm 2015;12: 645. GigliM,MerloM,GrawSL,BarbatiG,RowlandTJ,SlavovDB,etal.Geneticriskof
706–713.
arrhythmicphenotypesinpatientswithdilatedcardiomyopathy.JAmCollCardiol
623.Lakkireddy D, Di Biase L, Ryschon K, Biria M, Swarup V, Reddy YM, et al. 2019;74:1480–1490.
Radiofrequencyablationofprematureventricularectopyimprovestheefficacy
646. HeliöT,ElliottP,KoskenvuoJW,GimenoJR,TavazziL,TenderaM,etal.ESCEORP
ofcardiacresynchronizationtherapyinnonresponders.JAmCollCardiol2012; cardiomyopathyregistry:real-lifepracticeofgeneticcounsellingandtestinginadult
60:1531–1539. cardiomyopathypatients.ESCHeartFail2020;7:3013–3021.
624.SinghSN,FletcherRD,FisherSG,SinghBN,LewisHD,DeedwaniaPC,etal. 647. ElmingMB,NielsenJC,HaarboJ,VidebækL,KorupE,SignorovitchJ,etal.Ageand
Amiodaroneinpatientswithcongestiveheartfailureandasymptomaticventricular outcomesofprimarypreventionimplantablecardioverter-defibrillatorsinpatients
arrhythmia.Survivaltrialofantiarrhythmictherapyincongestiveheartfailure.N withnonischemicsystolicheartfailure.Circulation2017;136:1772–1780.
EnglJMed1995;333:77–82. 648. KristensenSL,LevyWC,ShadmanR,NielsenJC,HaarboJ,VidebækL,etal.Risk
625.ZhongL,LeeY-H,HuangX-M,AsirvathamSJ,ShenW-K,FriedmanPA,etal. models for prediction of implantable cardioverter-defibrillator benefit. JACC
Relativeefficacyofcatheterablationvsantiarrhythmicdrugsintreatingpremature HeartFail2019;7:717–724.
ventricularcontractions:asingle-centerretrospectivestudy.HeartRhythm2014; 649. Wolff G, Lin Y, Karathanos A, Brockmeyer M, Wolters S, Nowak B, et al.
11:187–193. Implantablecardioverter/defibrillatorsforprimarypreventionindilatedcardiomy-
626.HymanMC,MustinD,SuppleG,SchallerRD,SantangeliP,ArklesJ,etal.ClassIC opathypost-DANISH:anupdatedmeta-analysisandsystematicreviewofrando-
antiarrhythmicdrugsforsuspectedprematureventricularcontraction-inducedcar- mizedcontrolledtrials.ClinResCardiol2017;106:501–513.
diomyopathy.HeartRhythm2018;15:159–163. 650. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al.
627.LaurentG,SaalS,AmarouchMY,BéziauDM,MarsmanRFJ,FaivreL,etal.Multifocal Prophylacticdefibrillatorimplantationinpatientswithnonischemicdilatedcardio-
ectopicPurkinje-relatedprematurecontractions:anewSCN5A-relatedcardiac myopathy.NEnglJMed2004;350:2151–2158.
channelopathy.JAmCollCardiol2012;60:144–156. 651. KlemI,KleinM,KhanM,YangEY,NabiF,IvanovA,etal.RelationshipofLVEFand
628.Calloe K,BroendbergAK, ChristensenAH,Pedersen LN,Olesen MS,de Los myocardialscartolong-termmortalityriskandmodeofdeathinpatientswithnon-
AngelesTejadaM,etal.Multifocalatrialandventricularprematurecontractions ischemiccardiomyopathy.Circulation2021;143:1343–1358.
Downloaded
from

by
guest
on
22
January
2026

4116 ESCGuidelines
652. vanRijsingenIAW,ArbustiniE,ElliottPM,MogensenJ,Hermans-vanAstJF,vander 675. ChivulescuM,LieØH,PopescuBA,SkulstadH,EdvardsenT,JurcutRO,etal.High
KooiAJ,etal.Riskfactorsformalignantventriculararrhythmiasinlamina/cmuta- penetranceandsimilardiseaseprogressioninprobandsandinfamilymemberswith
tioncarriersaEuropeancohortstudy.JAmCollCardiol2012;59:493–500. arrhythmogeniccardiomyopathy.EurHeartJ2020;41:1401–1410.
653. ThuillotM,MaupainC,GandjbakhchE,WaintraubX,Hidden-LucetF,IsnardR, 676. RastegarN,TeRieleASJM,JamesCA,BhonsaleA,MurrayB,TichnellC,etal.
etal.Externalvalidationofriskfactorsformalignantventriculararrhythmiasinla- Fibrofattychanges:incidenceatcardiacMRimaginginpatientswitharrhythmogenic
minA/Cmutationcarriers.EurJHeartFail2019;21:253–254. rightventriculardysplasia/cardiomyopathy.Radiology2016;280:405–412.
654. PasottiM,KlersyC,PilottoA,MarzilianoN,RapezziC,SerioA,etal.Long-term 677. AquaroGD,BarisonA,TodiereG,GrigoratosC,AitAliL,DiBellaG,etal.
outcomeandriskstratificationindilatedcardiolaminopathies.JAmCollCardiol Usefulness of combined functional assessment by cardiac magnetic resonance
2008;52:1250–1260. andtissuecharacterizationversustaskforcecriteriafordiagnosisofarrhythmo-
655. SkjølsvikET,HasselbergNE,DejgaardLA,LieØH,AndersenK,HolmT,etal. genicrightventricularcardiomyopathy.AmJCardiol2016;118:1730–1736.
Exerciseisassociatedwithimpairedleftventricularsystolicfunctioninpatients 678. te Riele ASJM, Bhonsale A, James CA, Rastegar N, Murray B, Burt JR, et al.
withlaminA/Cgenotype.JAmHeartAssoc2020;9:e012937. Incrementalvalueofcardiacmagneticresonanceimaginginarrhythmicriskstrati-
656. VerstraelenTE,vanLintFHM,BosmanLP,deBrouwerR,ProostVM,AbelnBGS, ficationofarrhythmogenicrightventriculardysplasia/cardiomyopathy-associated
etal.Predictionofventriculararrhythmiainphospholambanp.Arg14delmutation
desmosomalmutationcarriers.JAmCollCardiol2013;62:1761–1769.
carriers-reachingthefrontiersofindividualriskprediction.EurHeartJ2021;42: 679. CorradoD,vanTintelenPJ,McKennaWJ,HauerRNW,AnastastakisA,AsimakiA,
2842–2850. etal.Arrhythmogenicrightventricularcardiomyopathy:evaluationofthecurrent
657. KnightBP,GoyalR,PelosiF,FlemmingM,HorwoodL,MoradyF,etal.Outcomeof
diagnosticcriteriaanddifferentialdiagnosis.EurHeartJ2020;41:1414–1429.
patientswithnonischemicdilatedcardiomyopathyandunexplainedsyncopetrea- 680. Sen-ChowdhryS,SyrrisP,WardD,AsimakiA,SevdalisE,McKennaWJ.Clinical
tedwithanimplantabledefibrillator.JAmCollCardiol1999;33:1964–1970. andgeneticcharacterizationoffamilieswitharrhythmogenicrightventriculardys-
658. DesaiAS,FangJC,MaiselWH,BaughmanKL.Implantabledefibrillatorsforthepre- plasia/cardiomyopathyprovidesnovelinsightsintopatternsofdiseaseexpression.
ventionofmortalityinpatientswithnonischemiccardiomyopathy:ameta-analysis
Circulation2007;115:1710–1720.
ofrandomizedcontrolledtrials.JAMA2004;292:2874–2879. 681. Cipriani A, Bauce B, De Lazzari M, Rigato I, Bariani R, Meneghin S, et al.
659. MerloM,GentileP,ArticoJ,CannatàA,PaldinoA,DeAngelisG,etal.Arrhythmic Arrhythmogenic right ventricular cardiomyopathy: characterization of left ven-
riskstratificationinpatientswithdilatedcardiomyopathyandintermediateleftven- tricularphenotypeanddifferentialdiagnosiswithdilatedcardiomyopathy.JAm
triculardysfunction.JCardiovascMed(Hagerstown)2019;20:343–350. HeartAssoc2020;9:e014628.
660. ZecchinM,DiLenardaA,GregoriD,MerloM,PivettaA,VitrellaG,etal.Arenon- 682. CorradoD,PerazzoloMarraM,ZorziA,BeffagnaG,CiprianiA,LazzariMD,etal.
Diagnosisofarrhythmogeniccardiomyopathy:thePaduacriteria.IntJCardiol2020;
sustainedventriculartachycardiaspredictiveofmajorarrhythmiasinpatientswith
319:106–114.
dilatedcardiomyopathyonoptimalmedicaltreatment?PacingClinElectro2008;31:
290–299. 683. SaberniakJ,HasselbergNE,BorgquistR,PlatonovPG,SarvariSI,SmithH,etal.
661. LinkMS,CosteasXF,GriffithJL,ColburnCD,EstesNA,WangPJ.Highincidenceof Vigorousphysicalactivityimpairsmyocardialfunctioninpatientswitharrhythmo-
appropriateimplantablecardioverter-defibrillatortherapyinpatientswithsyncope genicrightventricularcardiomyopathyandinmutationpositivefamilymembers.
EurJHeartFail2014;16:1337–1344.
ofunknownetiologyandinducibleventriculararrhythmias.JAmCollCardiol1997;
29:370–375. 684. LieØH,DejgaardLA,SaberniakJ,RootweltC,StokkeMK,EdvardsenT,etal.
Harmfuleffectsofexerciseintensityandexercisedurationinpatientswitharrhyth-
662. DiMarcoA,BrownPF,BradleyJ,NuciforaG,ClaverE,deFrutosF,etal.Improved
riskstratificationforventriculararrhythmiasandsuddendeathinpatientswithnon-
mogeniccardiomyopathy.JACCClinElectrophysiol2018;4:744–753.
ischemicdilatedcardiomyopathy.JAmCollCardiol2021;77:2890–2905. 685. JamesCA,BhonsaleA,TichnellC,MurrayB,RussellSD,TandriH,etal.Exercise
increasesage-relatedpenetranceandarrhythmicriskinarrhythmogenicrightven-
663. KumarS,RomeroJ,MehtaNK,FujiiA,KapurS,BaldingerSH,etal.Long-termout-
triculardysplasia/cardiomyopathy-associateddesmosomalmutationcarriers.JAm
comesaftercatheterablationofventriculartachycardiainpatientswithandwith- CollCardiol2013;62:1290–1297.
outstructuralheartdisease.HeartRhythm2016;13:1957–1963.
686. RuwaldA-C,MarcusF,EstesNAM,LinkM,McNittS,PolonskyB,etal.Association
664. MuserD,SantangeliP,CastroSA,PathakRK,LiangJJ,HayashiT,etal.Long-term
ofcompetitiveandrecreationalsportparticipationwithcardiaceventsinpatients
outcomeaftercatheterablationofventriculartachycardiainpatientswithnonis-
witharrhythmogenicrightventricularcardiomyopathy:resultsfromtheNorth
chemicdilatedcardiomyopathy.CircArrhythmElectrophysiol2016;9:e004328.
Americanmultidisciplinarystudyofarrhythmogenicrightventricularcardiomyop-
665. KumarS,AndroulakisAFA,SellalJ-M,MauryP,GandjbakhchE,WaintraubX,etal. athy.EurHeartJ2015;36:1735–1743.
Multicenterexperiencewithcatheterablationforventriculartachycardiainlamin
687. SawantAC,teRieleASJM,TichnellC,MurrayB,BhonsaleA,TandriH,etal.Safety
A/Ccardiomyopathy.CircArrhythmElectrophysiol2016;9:e004357.
ofAmericanHeartAssociation-recommendedminimumexercisefordesmosomal
666. OlorizT,SilberbauerJ,MaccabelliG,MizunoH,BarattoF,KirubakaranS,etal. mutationcarriers.HeartRhythm2016;13:199–207.
Catheterablationofventriculararrhythmiainnonischemiccardiomyopathy:ante-
688. ThieneG,NavaA,CorradoD,RossiL,PennelliN.Rightventricularcardiomyop-
roseptalversusinferolateralscarsub-types.CircArrhythmElectrophysiol2014;7: athyandsuddendeathinyoungpeople.NEnglJMed1988;318:129–133.
414–423.
689. FinocchiaroG,PapadakisM,RobertusJ-L,DhutiaH,SteriotisAK,TomeM,etal.
667. FranconeM.Roleofcardiacmagneticresonanceintheevaluationofdilatedcardio-
Etiology of sudden death in sports: insights from a United Kingdom Regional
myopathy:diagnosticcontributionandprognosticsignificance.ISRNRadiol2014; Registry.JAmCollCardiol2016;67:2108–2115.
2014:365404. 690. MarcusGM,GliddenDV,PolonskyB,ZarebaW,SmithLM,CannomDS,etal.
668. GoldbergerJJ,SubačiusH,PatelT,CunnaneR,KadishAH.Suddencardiacdeath Efficacyofantiarrhythmicdrugsinarrhythmogenicrightventricularcardiomyop-
riskstratificationinpatientswithnonischemicdilatedcardiomyopathy.JAmColl
athy:areportfromtheNorthAmericanARVCRegistry.JAmCollCardiol2009;
Cardiol2014;63:1879–1889. 54:609–615.
669. EbertM,WijnmaalenAP,deRivaM,TrinesSA,AndroulakisAFA,GlashanCA,etal. 691. HulotJ-S,JouvenX,EmpanaJ-P,FrankR,FontaineG.Naturalhistoryandriskstrati-
Prevalenceandprognosticimpactofpathogenicvariantsinpatientswithdilated ficationofarrhythmogenicrightventriculardysplasia/cardiomyopathy.Circulation
cardiomyopathy referred for ventricular tachycardia ablation. JACC Clin 2004;110:1879–1884.
Electrophysiol2020;6:1103–1114.
692. WangW,Cadrin-TourignyJ,BhonsaleA,TichnellC,MurrayB,MonfrediO,etal.
670. CorradoD,LinkMS,CalkinsH.Arrhythmogenicrightventricularcardiomyopathy. Arrhythmicoutcomeofarrhythmogenicrightventricularcardiomyopathypatients
NEnglJMed2017;376:1489–1490. withoutimplantabledefibrillators.JCardiovascElectrophysiol2018;29:1396–1402.
671. QuartaG,MuirA,PantazisA,SyrrisP,GehmlichK,Garcia-PaviaP,etal.Familial 693. Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, et al.
evaluationinarrhythmogenicrightventricularcardiomyopathy:impactofgenetics Prognosticpredictorsinarrhythmogenicrightventricularcardiomyopathy:results
andrevisedtaskforcecriteria.Circulation2011;123:2701–2709. froma10-yearregistry.EurHeartJ2011;32:1105–1113.
672. BhonsaleA,GroenewegJA,JamesCA,DooijesD,TichnellC,JongbloedJDH,etal. 694. BrunF,GroenewegJA,GearK,SinagraG,vanderHeijdenJ,MestroniL,etal.Risk
Impactofgenotypeonclinicalcourseinarrhythmogenicrightventriculardysplasia/ stratificationinarrhythmicrightventricularcardiomyopathywithoutimplantable
cardiomyopathy-associatedmutationcarriers.EurHeartJ2015;36:847–855. cardioverter-defibrillators.JACCClinElectrophysiol2016;2:558–564.
673. RigatoI,BauceB,RampazzoA,ZorziA,PilichouK,MazzottiE,etal.Compoundand 695. BhonsaleA,JamesCA,TichnellC,MurrayB,GagarinD,PhilipsB,etal.Incidence
digenicheterozygositypredictslifetimearrhythmicoutcomeandsuddencardiac andpredictorsofimplantablecardioverter-defibrillatortherapyinpatientswithar-
deathindesmosomalgene-relatedarrhythmogenicrightventricularcardiomyop- rhythmogenicrightventriculardysplasia/cardiomyopathyundergoingimplantable
athy.CircCardiovascGenet2013;6:533–542. cardioverter-defibrillatorimplantationforprimaryprevention.JAmCollCardiol
674. teRieleASJM,JamesCA,GroenewegJA,SawantAC,KammersK,MurrayB,etal. 2011;58:1485–1496.
Approachtofamilyscreeninginarrhythmogenicrightventriculardysplasia/cardio- 696. CorradoD,CalkinsH,LinkMS,LeoniL,FavaleS,BevilacquaM,etal.Prophylactic
myopathy.EurHeartJ2016;37:755–763. implantable defibrillator in patients with arrhythmogenic right ventricular
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4117
cardiomyopathy/dysplasiaandnopriorventricularfibrillationorsustainedven- 716. ChanRH,MaronBJ,OlivottoI,PencinaMJ,AssenzaGE,HaasT,etal.Prognostic
triculartachycardia.Circulation2010;122:1144–1152. valueofquantitativecontrast-enhancedcardiovascularmagneticresonanceforthe
697.PlatonovPG,HaugaaKH,BundgaardH,SvenssonA,GilljamT,HansenJ,etal. evaluationofsuddendeathriskinpatientswithhypertrophiccardiomyopathy.
Primary prevention of sudden cardiac death with implantable cardioverter- Circulation2014;130:484–495.
defibrillatortherapyinpatientswitharrhythmogenicrightventricularcardiomyop- 717. HeD,YeM,ZhangL,JiangB.Prognosticsignificanceoflategadoliniumenhance-
athy.AmJCardiol2019;123:1156–1162. mentoncardiacmagneticresonanceinpatientswithhypertrophiccardiomyop-
698.LinkMS,LaidlawD,PolonskyB,ZarebaW,McNittS,GearK,etal.Ventricularar- athy.HeartLung2018;47:122–126.
rhythmiasintheNorthAmericanmultidisciplinarystudyofARVC:predictors, 718. Weissler-SnirA,DorianP,RakowskiH,CareM,SpearsD.Primarypreventionim-
characteristics,andtreatment.JAmCollCardiol2014;64:119–125. plantablecardioverter-defibrillatorsinhypertrophiccardiomyopathy—arethere
699.SchinkelAFL.Implantablecardioverterdefibrillatorsinarrhythmogenicrightven- predictorsofappropriatetherapy?HeartRhythm2021;18:63–70.
tricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate 719. KhannaS,WenI,BhatA,ChenHHL,GanGCH,PathanF,etal.Theroleofmulti-
and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol modalityimaginginthediagnosisofcardiacamyloidosis:afocusedupdate.Front
2013;6:562–568.
CardiovascMed2020;7:590557.
700.CorradoD,LeoniL,LinkMS,DellaBellaP,GaitaF,CurnisA,etal.Implantable 720. PradellaS,GrazziniG,DeAmicisC,LetterielloM,AcquafrescaM,MieleV.Cardiac
cardioverter-defibrillator therapy for prevention of sudden death in patients magnetic resonance in hypertrophic and dilated cardiomyopathies. Radiol Med
witharrhythmogenicrightventricularcardiomyopathy/dysplasia.Circulation2003; 2020;125:1056–1071.
108:3084–3091. 721. RosminiS,BiaginiE,O’MahonyC,BulluckH,RuoziN,LopesLR,etal.Relationship
701.Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al. betweenaetiologyandleftventricularsystolicdysfunctioninhypertrophiccardio-
Arrhythmogenicrightventricularcardiomyopathy:clinicalcourseandpredictors myopathy.Heart2017;103:300–306.
ofarrhythmicrisk.JAmCollCardiol2016;68:2540–2550.
722. HoCY,DaySM,AshleyEA,MichelsM,PereiraAC,JacobyD,etal.Genotypeand
702.Cadrin-TourignyJ,BosmanLP,WangW,TadrosR,BhonsaleA,BourfissM,etal.
lifetime burden of disease in hypertrophic cardiomyopathy: insights from the
Suddencardiacdeathpredictioninarrhythmogenicrightventricularcardiomyop-
Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018;138:
athy:amultinationalcollaboration.CircArrhythmElectrophysiol2021;14:e008509. 1387–1398.
703.BosmanLP,SammaniA,JamesCA,Cadrin-TourignyJ,CalkinsH,vanTintelenJP,
723. KimHY,ParkJE,LeeS-C,JeonE-S,OnYK,KimSM,etal.Genotype-relatedclinical
etal.Predictingarrhythmicriskinarrhythmogenicrightventricularcardiomyop- characteristics and myocardial fibrosis and their association with prognosis in
athy:asystematicreviewandmeta-analysis.HeartRhythm2018;15:1097–1107.
hypertrophiccardiomyopathy.JClinMed2020;9:1671.
704.Saguner AM, Vecchiati A, Baldinger SH, Rüeger S, Medeiros-Domingo A,
724. MaronBJ,MaronMS,SemsarianC.Doubleorcompoundsarcomeremutationsin
Mueller-BurriAS,etal.Differentprognosticvalueoffunctionalrightventricular
hypertrophiccardiomyopathy:apotentiallinktosuddendeathintheabsenceof
parameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ conventionalriskfactors.HeartRhythm2012;9:57–63.
CardiovascImaging2014;7:230–239.
725. WangJ,WangY,ZouY,SunK,WangZ,DingH,etal.Malignanteffectsofmultiple
705.SagunerAM,Medeiros-DomingoA,SchwyzerMA,OnC-J,HaegeliLM,WolberT,
rarevariantsinsarcomeregenesontheprognosisofpatientswithhypertrophic
etal.Usefulnessofinducibleventriculartachycardiatopredictlong-termadverse cardiomyopathy.EurJHeartFail2014;16:950–957.
outcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol
726. SemsarianC,InglesJ,MaronMS,MaronBJ.Newperspectivesontheprevalenceof
2013;111:250–257.
hypertrophiccardiomyopathy.JAmCollCardiol2015;65:1249–1254.
706.Orgeron GM, Te Riele A, TichnellC, Wang W, Murray B,Bhonsale A, et al.
727. MaronBJ,RowinEJ,CaseySA,LinkMS,LesserJR,ChanRHM,etal.Hypertrophic
Performanceofthe2015internationaltaskforceconsensusstatementriskstrati-
cardiomyopathyinadulthoodassociatedwithlowcardiovascularmortalitywith
ficationalgorithmforimplantablecardioverter-defibrillatorplacementinarrhyth-
contemporarymanagementstrategies.JAmCollCardiol2015;65:1915–1928.
mogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol 728. O’MahonyC,JichiF,OmmenSR,ChristiaansI,ArbustiniE,Garcia-PaviaP,etal.
2018;11:e005593.
International External Validation Study of the 2014 European Society of
707.OrgeronGM,JamesCA,TeRieleA,TichnellC,MurrayB,BhonsaleA,etal.
Implantablecardioverter-defibrillatortherapyinarrhythmogenicrightventricular Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic
Cardiomyopathy(EVIDENCE-HCM).Circulation2018;137:1015–1023.
dysplasia/cardiomyopathy:predictorsofappropriatetherapy,outcomes,andcom-
729. VriesendorpPA,SchinkelAFL,LiebregtsM,TheunsDAMJ,vanCleemputJ,ten
plications.JAmHeartAssoc2017;6:e006242.
708.WichterT,BorggrefeM,HaverkampW,ChenX,BreithardtG.Efficacyofantiar- CateFJ,etal.Validationofthe2014EuropeanSocietyofCardiologyguidelines
riskpredictionmodelfortheprimarypreventionofsuddencardiacdeathinhyper-
rhythmicdrugsinpatientswitharrhythmogenicrightventriculardisease.Resultsin
trophiccardiomyopathy.CircArrhythmElectrophysiol2015;8:829–835.
patientswithinducibleandnoninducibleventriculartachycardia.Circulation1992;
86:29–37. 730. LorenziniM,AnastasiouZ,O’MahonyC,GuttmanOP,GimenoJR,MonserratL,
etal.Mortalityamongreferralpatientswithhypertrophiccardiomyopathyvsthe 709.MahidaS,VenletJ,SagunerAM,KumarS,BaldingerSH,AbdelWahabA,etal.
Ablationcomparedwithdrugtherapyforrecurrentventriculartachycardiainar-
generalEuropeanpopulation.JAMACardiol2020;5:73–80.
731. MaronBJ,RowinEJ,CaseySA,HaasTS,ChanRHM,UdelsonJE,etal.Riskstrati-
rhythmogenicrightventricularcardiomyopathy:resultsfromamulticenterstudy.
HeartRhythm2019;16:536–543. ficationandoutcomeofpatientswithhypertrophiccardiomyopathy.=60years
710.ErmakovS,GerstenfeldEP,SvetlichnayaY,ScheinmanMM.Useofflecainidein ofage.Circulation2013;127:585–593.
combinationantiarrhythmictherapyinpatientswitharrhythmogenicrightven- 732. Gimeno JR, Tomé-Esteban M, Lofiego C, Hurtado J, Pantazis A, MistB, et al.
tricularcardiomyopathy.HeartRhythm2017;14:564–569. Exercise-inducedventriculararrhythmiasandriskofsuddencardiacdeathinpa-
711.CanpolatU,KabakçiG,AytemirK,DuralM,ŞahinerL,YorgunH,etal.Fragmented tientswithhypertrophiccardiomyopathy.EurHeartJ2009;30:2599–2605.
QRScomplexpredictsthearrhythmiceventsinpatientswitharrhythmogenicright 733. PellicciaA,LemmeE,MaestriniV,DiPaoloFM,PisicchioC,DiGioiaG,etal.Does
ventricular cardiomyopathy/dysplasia: frQRS and outcomes in ARVC/D. J sportparticipationworsentheclinicalcourseofhypertrophiccardiomyopathy?
CardiovascElectrophysiol2013;24:1260–1266. Clinicaloutcomeofhypertrophiccardiomyopathyinathletes.Circulation2018;
712.MartinA,CrawfordJ,SkinnerJR,SmithW.Higharrhythmicburdenbutlowmor-
137:531–533.
talityduringlong-termfollow-upinarrhythmogenicrightventricularcardiomyop- 734. DejgaardLA,HalandTF,LieOH,RibeM,BjuneT,LerenIS,etal.Vigorousexercise
athy.HeartLungCirc2016;25:275–281. inpatientswithhypertrophiccardiomyopathy.IntJCardiol2018;250:157–163.
713.SantangeliP,DelloRussoA,PieroniM,CasellaM,DiBiaseL,BurkhardtJD,etal. 735. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ.
Fragmentedanddelayedelectrogramswithinfibrofattyscarpredictarrhythmic Non-sustainedventriculartachycardiainhypertrophiccardiomyopathy:aninde-
eventsinarrhythmogenicrightventricularcardiomyopathy:Resultsfromapro- pendentmarkerofsuddendeathriskinyoungpatients.JAmCollCardiol2003;
spectiveriskstratificationstudy.HeartRhythm2012;9:1200–1206. 42:873–879.
714.BerruezoA,Fernández-ArmentaJ,MontL,ZeljkoH,AndreuD,HerczkuC,etal. 736. RowinEJ,MaronBJ,CarrickRT,PatelPP,KoetheB,WellsS,etal.Outcomesin
Combinedendocardialandepicardialcatheterablationinarrhythmogenicright patientswithhypertrophiccardiomyopathyandleftventricularsystolicdysfunc-
ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm tion.JAmCollCardiol2020;75:3033–3043.
Electrophysiol2012;5:111–121. 737. RowinEJ,MaronBJ,HaasTS,GarberichRF,WangW,LinkMS,etal.Hypertrophic
715.OmmenSR,MitalS,BurkeMA,DaySM,DeswalA,ElliottP,etal.2020AHA/ACC cardiomyopathywithleftventricularapicalaneurysm:implicationsforriskstratifi-
guidelineforthediagnosisandtreatmentofpatientswithhypertrophiccardiomy- cationandmanagement.JAmCollCardiol2017;69:761–773.
opathy: executive summary: a report of the American College of Cardiology/ 738. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ.
American Heart Association Joint Committee on Clinical Practice Guidelines. Prospectiveprognosticassessmentofbloodpressureresponseduringexercise
Circulation2020;142:e533–e557. inpatientswithhypertrophiccardiomyopathy.Circulation1997;96:2987–2991.
Downloaded
from

by
guest
on
22
January
2026

4118 ESCGuidelines
739. ElliottPM,PolonieckiJ,DickieS,SharmaS,MonserratL,VarnavaA,etal.Sudden 762. SperryBW,IkramA,HachamovitchR,ValentJ,VranianMN,PhelanD,etal.Efficacy
deathinhypertrophiccardiomyopathy:identificationofhighriskpatients.JAmColl ofchemotherapyforlight-chainamyloidosisinpatientspresentingwithsymptom-
Cardiol2000;36:2212–2218. aticheartfailure.JAmCollCardiol2016;67:2941–2948.
740. BehrER,ElliottP,McKennaWJ.RoleofinvasiveEPtestingintheevaluationand 763. KristenAV,DenglerTJ,HegenbartU,SchonlandSO,GoldschmidtH,SackF-U,
management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 2002;6: etal.Prophylacticimplantationofcardioverter-defibrillatorinpatientswithsevere
482–486. cardiacamyloidosisandhighriskforsuddencardiacdeath.HeartRhythm2008;5:
741. GatzoulisKA,GeorgopoulosS,AntoniouC-K,AnastasakisA,DilaverisP,Arsenos 235–240.
P,etal.Programmedventricularstimulationpredictsarrhythmiceventsandsurvival 764. MerinoJL,PeinadoR.Arrhythmiasassociatedwithneuromusculardisorders.Card
inhypertrophiccardiomyopathy.IntJCardiol2018;254:175–181. ElectrophysiolRev2002;6:132–135.
742. NorrishG,QuC,FieldE,CerviE,KhraicheD,KlaassenS,etal.Externalvalidation 765. PunnooseAR,KaltmanJR,PastorW,McCarterR,HeJ,SpurneyCF.Cardiacdis-
oftheHCMRisk-Kidsmodelforpredictingsuddencardiacdeathinchildhood easeburden andriskof mortalityinhospitalized musculardystrophypatients.
hypertrophiccardiomyopathy.EurJPrevCardiol2022;29:678–686. PediatrCardiol2016;37:1290–1296.
743. Petryka-MazurkiewiczJ,ZiolkowskaL,Kowalczyk-DomagalaM,MazurkiewiczL, 766. Wahbi K, Meune C, Porcher R, Bécane HM, Lazarus A, Laforêt P, et al.
BorucA,SpiewakM,etal.LGEforriskstratificationinprimarypreventioninchil- Electrophysiologicalstudywithprophylacticpacingandsurvivalinadultswithmyo-
drenwithHCM.JACCCardiovascImaging2020;13:2684–2686. tonicdystrophyandconductionsystemdisease.JAMA2012;307:1292–1301.
744. ElliottPM,SharmaS,VarnavaA,PolonieckiJ,RowlandE,McKennaWJ.Survival 767. LallemandB,ClementyN,Bernard-BrunetA,PierreB,CorciaP,FauchierL,etal.
aftercardiacarrestorsustainedventriculartachycardiainpatientswithhyper- Theevolutionofinfrahissianconductiontimeinmyotonicdystrophypatients:clin-
trophiccardiomyopathy.JAmCollCardiol1999;33:1596–1601. icalimplications.Heart2012;98:291–296.
745. CecchiF,MaronBJ,EpsteinSE.Long-termoutcomeofpatientswithhypertrophic 768. NogamiA.Bundlebranchreentrytachycardia.ESCCardioMed.3rded.Oxford
cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol UniversityPress;2022,pp.2270–2275.
1989;13:1283–1288. 769. SannaT,DelloRussoA,TonioloD,VytopilM,PelargonioG,DeMartinoG,etal.
746. MaronBJ,SpiritoP,ShenW-K,HaasTS,FormisanoF,LinkMS,etal.Implantable CardiacfeaturesofEmery-DreifussmusculardystrophycausedbylaminA/Cgene
cardioverter-defibrillatorsandpreventionofsuddencardiacdeathinhypertrophic mutations.EurHeartJ2003;24:2227–2236.
cardiomyopathy.JAMA2007;298:405–412. 770. MenonSC,EtheridgeSP,LiesemerKN,WilliamsRV,BardsleyT,HeywoodMC,
747. MelaciniP,MaronBJ,BobboF,BassoC,TokajukB,ZucchettoM,etal.Evidence etal.PredictivevalueofmyocardialdelayedenhancementinDuchennemuscular
thatpharmacologicalstrategieslackefficacyforthepreventionofsuddendeath dystrophy.PediatrCardiol2014;35:1279–1285.
inhypertrophiccardiomyopathy.Heart2007;93:708–710. 771. FlorianA,LudwigA,EngelenM,WaltenbergerJ,RöschS,SechtemU,etal.Leftven-
748. McKennaWJ,OakleyCM,KriklerDM,GoodwinJF.Improvedsurvivalwithamio- tricularsystolicfunctionandthepatternoflate-gadolinium-enhancementinde-
daroneinpatientswithhypertrophiccardiomyopathyandventriculartachycardia. pendentlyandadditivelypredictadverse cardiaceventsinmuscular dystrophy
BrHeartJ1985;53:412–416. patients.JCardiovascMagnReson2014;16:81.
749. LinkMS,BockstallK,WeinstockJ,Alsheikh-AliAA,SemsarianC,EstesNAM,etal. 772. PrystowskyEN,PritchettEL,RosesAD,GallagherJ.Thenaturalhistoryofconduc-
Ventriculartachyarrhythmiasinpatientswithhypertrophiccardiomyopathyand tionsystemdiseaseinmyotonicmusculardystrophyasdeterminedbyserialelec-
defibrillators: triggers, treatment, and implications. J Cardiovasc Electrophysiol trophysiologicstudies.Circulation1979;60:1360–1364.
2017;28:531–537. 773. TrachtenbergBH,HareJM.Inflammatorycardiomyopathicsyndromes.CircRes
750. DallaglioPD,diMarcoA,MorenoWeidmannZ,PerezL,AlzuetaJ,García-Alberola 2017;121:803–818.
A,etal.Antitachycardiapacingforshockpreventioninpatientswithhypertrophic 774. HulsmansM,ClaussS,XiaoL,AguirreAD,KingKR,HanleyA,etal.Macrophages
cardiomyopathyandventriculartachycardia.HeartRhythm2020;17:1084–1091. facilitateelectricalconductionintheheart.Cell2017;169:510–522.
751. AdduciC,SempriniL,PalanoF,MusumeciMB,VolpeM,AutoreC,etal.Safetyand 775. YoukerKA,Assad-KottnerC,Cordero-ReyesAM,TrevinoAR,Flores-Arredondo
efficacyofanti-tachycardiapacinginpatientswithhypertrophiccardiomyopathy JH,BarriosR,etal.Highproportionofpatientswithend-stageheartfailureregard-
implantedwithanICD.PacingClinElectrophysiol2019;42:610–616. lessofaetiologydemonstratesanti-cardiacantibodydepositioninfailingmyocar-
752. VaseghiM,HuTY,TungR,VergaraP,FrankelDS,DiBiaseL,etal.Outcomesof dium: humoral activation, a potential contributor of disease progression. Eur
catheterablationofventriculartachycardiabasedonetiologyinnonischemicheart HeartJ2014;35:1061–1068.
disease:aninternationalventriculartachycardiaablationcentercollaborativestudy. 776. AdamoL,Rocha-ResendeC,PrabhuSD,MannDL.Reappraisingtheroleofinflam-
JACCClinElectrophysiol2018;4:1141–1150. mationinheartfailure.NatRevCardiol2020;17:269–285.
753. Igarashi M, Nogami A, Kurosaki K, Hanaki Y, Komatsu Y, Fukamizu S, et al. 777. SagarS,LiuPP,CooperLT.Myocarditis.Lancet2012;379:738–747.
Radiofrequencycatheterablationofventriculartachycardiainpatientswithhyper- 778. AmmiratiE,CiprianiM,MoroC,RaineriC,PiniD,SormaniP,etal.Clinicalpres-
trophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol 2018;4: entationandoutcomeinacontemporarycohortofpatientswithacutemyocardi-
339–350. tis:multicenterLombardyregistry.Circulation2018;138:1088–1099.
754. DukkipatiSR,d’AvilaA,SoejimaK,BalaR,InadaK,SinghS,etal.Long-termout- 779. FabreA.Suddenadultdeathsyndromeandothernon-ischaemiccausesofsudden
comesofcombinedepicardialandendocardialablationofmonomorphicventricu- cardiacdeath.Heart2005;92:316–320.
lartachycardiarelatedtohypertrophiccardiomyopathy.CircArrhythmElectrophysiol 780. LyngeTH,NielsenTS,GregersWinkelB,Tfelt-HansenJ,BannerJ.Suddencardiac
2011;4:185–194. deathcausedbymyocarditisinpersonsaged1–49years:anationwidestudyof14
755. RossSB,SingerES,DriscollE,NowakN,YeatesL,PuranikR,etal.Geneticarchi- 294deathsinDenmark.ForensicSciRes2019;4:247–256.
tectureofleftventricularnoncompactioninadults.HumGenomeVar2020;7:33. 781. MaronBJ,UdelsonJE,BonowRO,NishimuraRA,AckermanMJ,EstesNAM,etal.
756. Weir-McCallJR,YeapPM,PapagiorcopuloC,FitzgeraldK,GandySJ,LambertM, Eligibilityanddisqualificationrecommendationsforcompetitiveathleteswithcar-
etal.Leftventricularnoncompaction:anatomicalphenotypeordistinctcardiomy- diovascularabnormalities:taskforce3:hypertrophiccardiomyopathy,arrhythmo-
opathy?JAmCollCardiol2016;68:2157–2165. genic right ventricular cardiomyopathy and other cardiomyopathies, and
757. Aung N, Doimo S, Ricci F, Sanghvi MM, Pedrosa C, Woodbridge SP, et al. myocarditis.JAmCollCardiol2015;66:2362–2371.
Prognosticsignificanceofleftventricularnoncompaction:systematicreviewand 782. KindermannI,BarthC,MahfoudF,UkenaC,LenskiM,YilmazA,etal.Updateon
meta-analysisofobservationalstudies.CircCardiovascImaging2020;13:e009712. myocarditis.JAmCollCardiol2012;59:779–792.
758. GrigoratosC,BarisonA,IvanovA,AndreiniD,AmzulescuM-S,MazurkiewiczL, 783. CaforioALP,PankuweitS,ArbustiniE,BassoC,Gimeno-BlanesJ,FelixSB,etal.
etal.Meta-analysisoftheprognosticroleoflategadoliniumenhancementandglo- Currentstateofknowledgeonaetiology,diagnosis,management,andtherapyof
balsystolicimpairmentinleftventricularnoncompaction.JACCCardiovascImaging myocarditis: a position statement of the European Society of Cardiology
2019;12:2141–2151. Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:
759. RichardP,AderF,RouxM,DonalE,EicherJ-C,AoutilN,etal.Targetedpanelse- 2636–2648.
quencinginadultpatientswithleftventricularnon-compactionrevealsalargegen- 784. SinghV,MendirichagaR,SavaniGT,RodriguezA,BlumerV,ElmariahS,etal.
eticheterogeneity.ClinGenet2019;95:356–367. Comparisonofutilizationtrends,indications,andcomplicationsofendomyocardial
760. SeferovićPM,PolovinaM,BauersachsJ,AradM,GalTB,LundLH,etal.Heartfail- biopsyinnativeversusdonorhearts(fromtheNationwideInpatientSample2002
ureincardiomyopathies:apositionpaperfromtheHeartFailureAssociationofthe to2014).AmJCardiol2018;121:356–363.
EuropeanSocietyofCardiology.EurJHeartFail2019;21:553–576. 785. AoyamaN,IzumiT,HiramoriK,IsobeM,KawanaM,HiroeM,etal.Nationalsurvey
761. BaigS,EdwardNC,KotechaD,LiuB,NordinS,KozorR,etal.Ventriculararrhyth- offulminantmyocarditisinJapan:therapeuticguidelinesandlong-termprognosisof
miaandsuddencardiacdeathinFabrydisease:asystematicreviewofriskfactorsin usingpercutaneouscardiopulmonarysupportforfulminantmyocarditis(specialre-
clinicalpractice.Europace2018;20:f153–f161. portfromascientificcommittee).CircJ2002;66:133–144.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4119
786.ShahZ,MohammedM,VuddandaV,AnsariMW,MasoomiR,GuptaK.National 810. BirnieDH,KandolinR,NeryPB,KupariM.Cardiacmanifestationsofsarcoidosis:
trends,gender,management,andoutcomesofpatientshospitalizedformyocardi- diagnosisandmanagement.EurHeartJ2016;38:2663–2670.
tis.AmJCardiol2019;124:131–136. 811. TrivieriMG,SpagnoloP,BirnieD,LiuP,DrakeW,KovacicJC,etal.Challengesin
787.AndersonBR,SilverES,RichmondME,LibermanL.Usefulnessofarrhythmiasas cardiacandpulmonarysarcoidosis:JACCstate-of-the-artreview.JAmCollCardiol
predictorsofdeathandresourceutilizationinchildrenwithmyocarditis.AmJ 2020;76:1878–1901.
Cardiol2014;114:1400–1405. 812. KandolinR,LehtonenJ,AiraksinenJ,VihinenT,MiettinenH,YlitaloK,etal.Cardiac
788.KandolinR,LehtonenJ,SalmenkiviK,Räisänen-SokolowskiA,LommiJ,KupariM. sarcoidosis:epidemiology,characteristics,andoutcomeover25yearsinanation-
Diagnosis,treatment,andoutcomeofgiant-cellmyocarditisintheeraofcombined widestudy.Circulation2015;131:624–632.
immunosuppression.CircHeartFail2013;6:15–22. 813. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al.
789.CooperLT,BerryGJ,ShabetaiR.Idiopathicgiant-cellmyocarditis—naturalhistory Electroanatomicalvoltagemappingtodistinguishright-sidedcardiacsarcoidosis
andtreatment.NEnglJMed1997;336:1860–1866. from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol
790.McMurrayJJV,AdamopoulosS,AnkerSD,AuricchioA,BöhmM,DicksteinK,etal. 2020;6:696–707.
ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure 814. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al.
2012:thetaskforcefortheDiagnosisandTreatmentofAcuteandChronicHeart Relationshipbetweenarrhythmogenesisanddiseaseactivityincardiacsarcoidosis.
Failure2012oftheEuropeanSocietyofCardiology.Developedincollaboration
HeartRhythm2007;4:1292–1299.
with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33: 815. TakayaY,KusanoKF,NakamuraK,ItoH.Outcomesinpatientswithhigh-degree
1787–1847. atrioventricularblockastheinitialmanifestationofcardiacsarcoidosis.AmJCardiol
791.BlauwetLA,CooperLT.Myocarditis.ProgCardiovascDis2010;52:274–288. 2015;115:505–509.
792.JCSJointWorkingGroup.Guidelinesfordiagnosisandtreatmentofmyocarditis 816. NordenswanH-K,LehtonenJ,EkströmK,KandolinR,SimonenP,MäyränpääM,
(JCS2009):digestversion.CircJ2011;75:734–743. etal.Outcomeofcardiacsarcoidosispresentingwithhigh-gradeatrioventricular
793.Ali-AhmedF,DalgaardF,Al-KhatibSM.Suddencardiacdeathinpatientswithmyo- block.CircArrhythmElectrophysiol2018;11.
carditis: Evaluation, risk stratification, and management. Am Heart J 2020;220: 817. GreulichS,DeluigiCC,GloeklerS,WahlA,ZürnC,KramerU,etal.CMRimaging
29–40. predictsdeathandotheradverseeventsinsuspectedcardiacsarcoidosis.JACC
794.RosierL,ZouaghiA,BarréV,MartinsR,ProbstV,MarijonE,etal.Highriskofsus-
CardiovascImaging2013;6:501–511.
tainedventriculararrhythmiarecurrenceafteracutemyocarditis.JClinMed2020;9: 818. NadelJ,LancefieldT,VoskoboinikA,TaylorAJ.Lategadoliniumenhancementiden-
tifiedwithcardiacmagneticresonanceimaginginsarcoidosispatientsisassociated
E848.
with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J
795.Maron BJ,TowbinJA, ThieneG,Antzelevitch C,CorradoD,Arnett D,et al.
Contemporary definitions and classification of the cardiomyopathies: an
CardiovascImaging2015;16:631–641.
American HeartAssociation ScientificStatementfromtheCouncil onClinical 819. MurtaghG,LaffinLJ,BeshaiJF,MaffessantiF,BonhamCA,PatelAV,etal.Prognosis
ofmyocardialdamageinsarcoidosispatientswithpreservedleftventricularejec-
Cardiology,HeartFailureandTransplantationCommittee;QualityofCareand
tion fraction: risk stratification using cardiovascular magnetic resonance. Circ
Outcomes Research and Functional Genomics and Translational Biology
CardiovascImaging2016;9:e003738.
InterdisciplinaryWorkingGroups;andCouncilonEpidemiologyandPrevention.
Circulation2006;113:1807–1816. 820. EkströmK,LehtonenJ,HänninenH,KandolinR,KivistöS,KupariM.Magneticres-
796.D’AmbrosioA,PattiG,ManzoliA,SinagraG,DiLenardaA,SilvestriF,etal.Thefate onanceimagingasapredictorofsurvivalfreeoflife-threateningarrhythmiasand
transplantationincardiacsarcoidosis.JAmHeartAssoc2016;5:e003040.
ofacutemyocarditisbetweenspontaneousimprovementandevolutiontodilated
821. ColemanGC,ShawPW,BalfourPC,GonzalezJA,KramerCM,PatelAR,etal.
cardiomyopathy:areview.Heart2001;85:499–504.
PrognosticvalueofmyocardialscarringonCMRinpatientswithcardiacsarcoid-
797.KasperEK,AgemaWRP,HutchinsGM,DeckersJW,HareJM,BaughmanKL.The osis.JACCCardiovascImaging2017;10:411–420.
causesofdilatedcardiomyopathy:aclinicopathologicreviewof673consecutivepa-
822. AizerA,SternEH,GomesJA,TeirsteinAS,EckartRE,MehtaD.Usefulnessofpro-
tients.JAmCollCardiol1994;23:586–590.
grammedventricularstimulationinpredictingfuturearrhythmiceventsinpatients
798.GrünS,SchummJ,GreulichS,WagnerA,SchneiderS,BruderO,etal.Long-term withcardiacsarcoidosis.AmJCardiol2005;96:276–282.
follow-upofbiopsy-provenviralmyocarditis.JAmCollCardiol2012;59:1604–1615.
823. MehtaD,MoriN,GoldbargSH,LubitzS,WisniveskyJP,TeirsteinA.Primarypre-
799.BennettMK,GilotraNA,HarringtonC,RaoS,DunnJM,FreitagTB,etal.Evaluation
ventionofsuddencardiacdeathinsilentcardiacsarcoidosis:roleofprogrammed
oftheroleofendomyocardialbiopsyin851patientswithunexplainedheartfailure ventricularstimulation.CircArrhythmElectrophysiol2011;4:43–48.
from2000–2009.CircHeartFail2013;6:676–684.
824. OkadaDR,SmithJ,DerakhshanA,GowaniZ,ZimmermanSL,MisraS,etal.
800.SchummJ,GreulichS,WagnerA,GrünS,OngP,BentzK,etal.Cardiovascular Electrophysiologystudyforriskstratificationinpatientswithcardiacsarcoidosis
magneticresonanceriskstratificationinpatientswithclinicallysuspectedmyocar-
andabnormalcardiacimaging.IntJCardiolHeartVasc2019;23:100342.
ditis.JCardiovascMagnReson2014;16:14.
825. Zipse MM, Tzou WS, Schuller JL, Aleong RG, Varosy PD, Tompkins C, et al.
801.RussoAD,CasellaM,PieroniM,PelargonioG,BartolettiS,SantangeliP,etal. Electrophysiologictestingfordiagnosticevaluationandriskstratificationinpatients
Drug-refractoryventriculartachycardiasaftermyocarditis:endocardialandepicar-
withsuspectedcardiacsarcoidosiswithpreservedleftandrightventricularsystolic
dialradiofrequencycatheterablation.CircArrhythmElectrophysiol2012;5:492–498. function.JCardiovascElectrophysiol2019;30:1939–1948.
802.MaccabelliG,TsiachrisD,SilberbauerJ,EspositoA,BiscegliaC,BarattoF,etal. 826. BlanksteinR,OsborneM,NayaM,WallerA,KimCK,MurthyVL,etal.Cardiac
Imaging and epicardial substrate ablation of ventricular tachycardia in patients positronemissiontomographyenhancesprognosticassessmentsofpatientswith
lateaftermyocarditis.Europace2014;16:1363–1372. suspectedcardiacsarcoidosis.JAmCollCardiol2014;63:329–336.
803.BerteB,SacherF,CochetH,MahidaS,YamashitaS,LimH,etal.Postmyocarditis 827. CrawfordT, Mueller G, Sarsam S,Prasitdumrong H, ChaiyenN, Gu X,et al.
ventriculartachycardiainpatientswithepicardial-onlyscar:aspecificentityrequir-
Magneticresonanceimagingforidentifyingpatientswithcardiacsarcoidosisand
ingaspecificapproach:epicardial-onlyVTablation.JCardiovascElectrophysiol2015;
preservedormildlyreducedleftventricularfunctionatriskofventriculararrhyth-
26:42–50. mias.CircArrhythmElectrophysiol2014;7:1109–1115.
804.MaleszewskiJJ,OrellanaVM,HodgeDO,KuhlU,SchultheissH-P,CooperLT. 828. SchullerJL,ZipseM,CrawfordT,BogunF,BeshaiJ,PatelAR,etal.Implantablecar-
Long-termriskofrecurrence,morbidityandmortalityingiantcellmyocarditis. dioverter defibrillator therapy in patients with cardiacsarcoidosis. J Cardiovasc
AmJCardiol2015;115:1733–1738. Electrophysiol2012;23:925–929.
805.El-AssaadI,Al-KindiSG,OliveiraGH,BoyleGJ,AzizPF.Implantablecardioverter- 829. BetenskyBP,TschabrunnCM,ZadoES,GoldbergLR,MarchlinskiFE,GarciaFC,
defibrillatorandwait-listoutcomesinpediatricpatientsawaitinghearttransplant- etal.Long-termfollow-upofpatientswithcardiacsarcoidosisandimplantable
ation.HeartRhythm2015;12:2443–2448. cardioverter-defibrillators.HeartRhythm2012;9:884–891.
806.EkströmK,LehtonenJ,KandolinR,Räisänen-SokolowskiA,SalmenkiviK,KupariM. 830. KronJ,SauerW,SchullerJ,BogunF,CrawfordT,SarsamS,etal.Efficacyandsafety
Long-termoutcomeanditspredictorsingiantcellmyocarditis:giantcellmyocar- ofimplantablecardiacdefibrillatorsfortreatmentofventriculararrhythmiasinpa-
ditis.EurJHeartFail2016;18:1452–1458. tientswithcardiacsarcoidosis.EPEuropace2013;15:347–354.
807.RybickiBA,IannuzziMC,FrederickMM,ThompsonBW,RossmanMD,Bresnitz 831. MohsenA,JimenezA,HoodRE,DickfeldT,SaliarisA,ShorofskyS,etal.Cardiac
EA,etal.Familialaggregationofsarcoidosis.Acase-controletiologicstudyofsar- sarcoidosis:electrophysiologicaloutcomesonlong-termfollow-upandtherole
coidosis(ACCESS).AmJRespirCritCareMed2001;164:2085–2091. oftheimplantablecardioverter-defibrillator.JCardiovascElectrophysiol2014;25:
808.MuchtarE,BlauwetLA,GertzMA.Restrictivecardiomyopathy:genetics,pathogen- 171–176.
esis,clinicalmanifestations,diagnosis,andtherapy.CircRes2017;121:819–837. 832. AzoulayL-D,WaintraubX,HarocheJ,AmouraZ,CohenAubartF.Factorsasso-
809.BirnieDH,SauerWH,BogunF,CooperJM,CulverDA,DuvernoyCS,etal.HRS ciatedwithimplantablecardioverterdefibrillatorsappropriatetherapyincardiac
expertconsensusstatementonthediagnosisandmanagementofarrhythmiasas- sarcoidosis:ameta-analysis:implantablecardioverterdefibrillatorsincardiacsar-
sociatedwithcardiacsarcoidosis.HeartRhythm2014;11:1304–1323. coidosis.SarcoidosisVascDiffuseLungDis2020;37:17–23.
Downloaded
from

by
guest
on
22
January
2026

4120 ESCGuidelines
833. SmedemaJ-P,vanGeunsR-J,EctorJ,HeidbuchelH,AinslieG,CrijnsHJGM.Right 857. SteinC,MigliavacaCB,ColpaniV,daRosaPR,SganzerlaD,GiordaniNE,etal.
ventricularinvolvementandtheextentofleftventricularenhancementwithmag- Amiodaroneforarrhythmiainpatientswithchagasdisease:asystematicreview
neticresonancepredictadverseoutcomeinpulmonarysarcoidosis.ESCHeartFail andindividualpatientdatameta-analysis.PLoSNeglTropDis2018;12:e0006742.
2018;5:157–171. 858. SosaE,ScanavaccaM,D’AvilaA,PiccioniJ,SanchezO,VelardeJL,etal.Endocardial
834. VelangiPS,ChenK-HA,KazmirczakF,OkashaO,vonWaldL,RoukozH,etal. andepicardialablationguidedbynonsurgicaltransthoracicepicardialmappingto
Rightventricularabnormalitiesoncardiovascularmagneticresonanceimagingin treatrecurrentventriculartachycardia.JCardiovascElectrophysiol1998;9:229–239.
patientswithsarcoidosis.JACCCardiovascImaging2020;13:1395–1405. 859. Soto-BecerraR,BazanV,BautistaW,MalavassiF,AltamarJ,RamirezJD,etal.
835. IseT,HasegawaT,MoritaY,YamadaN,FunadaA,TakahamaH,etal.Extensivelate Ventriculartachycardiainthesettingofchagasiccardiomyopathy:useofvoltage
gadoliniumenhancementoncardiovascularmagneticresonancepredictsadverse mapping to characterize endoepicardial nonischemic scar distribution. Circ
outcomesandlackofimprovementinLVfunctionaftersteroidtherapyincardiac ArrhythmElectrophysiol2017;10:e004950.
sarcoidosis.Heart2014;100:1165–1172. 860. PisaniCF,RomeroJ,LaraS,HardyC,ChokrM,SacilottoL,etal.Efficacyandsafety
836. YodogawaK,SeinoY,OharaT,TakayamaH,KatohT,MizunoK.Effectofcortico- ofcombinedendocardial/epicardialcatheterablationforventriculartachycardiain
steroidtherapyonventriculararrhythmiasinpatientswithcardiacsarcoidosis:ef- chagasdisease:arandomizedcontrolledstudy.HeartRhythm2020;17:1510–1518.
fectofcorticosteroidtherapy.AnnNoninvasiveElectrocardiol2011;16:140–147. 861. ChiznerMA,PearleDL,deLeonAC.Thenaturalhistoryofaorticstenosisinadults.
837. Naruse Y, Sekiguchi Y, Nogami A, Okada H, Yamauchi Y, Machino T, et al. AmHeartJ1980;99:419–424.
Systematictreatmentapproachtoventriculartachycardiaincardiacsarcoidosis. 862. DelahayeJP,GareJP,ViguierE,DelahayeF,DeGevigneyG,MilonH.Naturalhis-
CircArrhythmElectrophysiol2014;7:407–413. toryofseveremitralregurgitation.EurHeartJ1991;12:5–9.
838. SegawaM,FukudaK,NakanoM,KondoM,SatakeH,HiranoM,etal.Timecourse 863. GrovesP.Valvedisease:surgeryofvalvedisease:lateresultsandlatecomplications.
andfactorscorrelatingwithventriculartachyarrhythmiasafterintroductionofster- Heart2001;86:715–721.
oidtherapyincardiacsarcoidosis.CircArrhythmElectrophysiol2016;9:e003353. 864. BlackstoneEH,KirklinJW.Deathandothertime-relatedeventsaftervalvereplace-
839. Kumar S, Barbhaiya C, Nagashima K, Choi E-K, Epstein LM, John RM, et al. ment.Circulation1985;72:753–767.
Ventriculartachycardiaincardiacsarcoidosis:characterizationofventricularsub- 865. UrenaM,WebbJG,EltchaninoffH,Muñoz-GarcíaAJ,BouletiC,TamburinoC,etal.
strate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015;8: Latecardiacdeathinpatientsundergoingtranscatheteraorticvalvereplacement:
87–93. incidence and predictors of advanced heart failure and sudden cardiac death.
840. Muser D, Santangeli P, Liang JJ, Castro SA, Magnani S, Hayashi T, et al. JAmCollCardiol2015;65:437–448.
Characterization of the electroanatomic substrate in cardiac sarcoidosis. JACC 866. YangF,ShahB,IwaiS,MarkowitzSM,LermanBB,SteinKM.ICDimplantationand
ClinElectrophysiol2018;4:291–303. arrhythmia-freesurvivalinpatientswithdepressedLVfunctionfollowingsurgery
841. JeficD,JoelB,GoodE,MoradyF,RosmanH,KnightB,etal.Roleofradiofrequency forvalvularheartdisease.PacingClinElectrophysiol2008;31:1419–1424.
catheterablationofventriculartachycardiaincardiacsarcoidosis:reportfroma 867. VallesAG,KhawajaFJ,GershBJ,Enriquez-SaranoM,FriedmanPA,ParkSJ,etal.
multicenterregistry.HeartRhythm2009;6:189–195. Implantablecardioverterdefibrillatorsinpatientswithvalvularcardiomyopathy.
842. PapageorgiouN,ProvidênciaR,BronisK,DecheringDG,SrinivasanN,EckardtL, JCardiovascElectrophysiol2012;23:1326–1332.
etal.Catheterablationforventriculartachycardiainpatientswithcardiacsarcoid- 868. Rodríguez-Mañero M, Barrio-López MT, Assi EA, Expósito-García V,
osis:asystematicreview.EPEuropace2018;20:682–691. Bertomeu-GonzálezV,Sánchez-GómezJM,etal.Primarypreventionofsudden
843. SiontisKC,SantangeliP,MuserD,MarchlinskiFE,ZeppenfeldK,HoogendoornJC, deathinpatientswithvalvularcardiomyopathy.RevEspCardiol(EnglEd)2016;
etal.Outcomesassociatedwithcatheterablationofventriculartachycardiainpa- 69:272–278.
tientswithcardiacsarcoidosis.JAMACardiol2022;7:175. 869. Fischer-RasokatU,RenkerM,LiebetrauC,WeferlingM,RolfA,HainA,etal.
844. HoogendoornJC,VenletJ,OutYNJ,ManS,KumarS,SramkoM,etal.Theprecor- Long-termsurvivalinpatientswithorwithoutimplantablecardioverterdefibrilla-
dialR’wave:anoveldiscriminatorbetweencardiacsarcoidosisandarrhythmogenic toraftertranscatheteraorticvalveimplantation.JClinMed2021;10:2929.
rightventricularcardiomyopathyinpatientspresentingwithventriculartachycar- 870. NiesRJ,FrerkerC,AdamM,KuhnE,MauriV,NettersheimFS,etal.Isthereabene-
dia.HeartRhythm2021;18:1539–1547. fitofICDtreatmentinpatientswithpersistentseverelyreducedsystolicleftven-
845. BernC.Chagas’disease.NEnglJMed2015;373:456–466. tricularfunctionafterTAVI?ClinResCardiol2022;111:492–501.
846. BocchiEA,BestettiRB,ScanavaccaMI,CunhaNetoE,IssaVS.Chronicchagasheart 871. EckartRE,HruczkowskiTW,TedrowUB,KoplanBA,EpsteinLM,StevensonWG.
diseasemanagement.JAmCollCardiol2017;70:1510–1524. Sustained ventricular tachycardia associated with corrective valve surgery.
847. NunesMCP,DonesW,MorilloCA,EncinaJJ,RibeiroAL.Chagasdisease.JAmColl Circulation2007;116:2005–2011.
Cardiol2013;62:767–776. 872. Liang JJ, Castro SA, Muser D, Briceno DF, Shirai Y, Enriquez A, et al.
848. NunesMCP,BeatonA,AcquatellaH,BernC,BolgerAF,EcheverríaLE,etal. Electrophysiologicsubstrate,safety,proceduralapproaches,andoutcomesofcath-
Chagascardiomyopathy:anupdateofcurrentclinicalknowledgeandmanagement: eterablationforventriculartachycardiainpatientsafteraorticvalvereplacement.
ascientificstatementfromtheAmericanheartassociation.Circulation2018;138: JACCClinElectrophysiol2019;5:28–38.
e169–e209. 873. DellingFN,VasanRS.Epidemiologyandpathophysiologyofmitralvalveprolapse:
849. RassiA,RassiA,LittleWC,XavierSS,RassiSG,RassiAG,etal.Developmentand newinsightsintodiseaseprogression,genetics,andmolecularbasis.Circulation
validationofariskscoreforpredictingdeathinChagas’heartdisease.NEnglJMed 2014;129:2158–2170.
2006;355:799–808. 874. NalliahCJ,MahajanR,ElliottAD,HaqqaniH,LauDH,VohraJK,etal.Mitralvalve
850. SenraT,IanniBM,CostaACP,MadyC,Martinelli-FilhoM,Kalil-FilhoR,etal. prolapseandsuddencardiacdeath:asystematicreviewandmeta-analysis.Heart
Long-termprognosticvalueofmyocardialfibrosisinpatientswithchagascardio- 2019;105:144–151.
myopathy.JAmCollCardiol2018;72:2577–2587. 875. Nishimura RA, McGoon MD, Shub C, Miller FA, Ilstrup DM, Tajik AJ.
851. Rassi FM, Minohara L, Rassi A, Correia LCL, Marin-Neto JA, Rassi A, et al. Echocardiographicallydocumentedmitral-valveprolapse.Long-termfollow-upof
Systematic review and meta-analysis of clinical outcome after implantable 237patients.NEnglJMed1985;313:1305–1309.
cardioverter-defibrillatortherapyinpatientswithchagasheartdisease.JACCClin 876. PerazzoloMarraM,BassoC,DeLazzariM,RizzoS,CiprianiA,GiorgiB,etal.
Electrophysiol2019;5:1213–1223. Morphofunctionalabnormalitiesofmitralannulusandarrhythmicmitralvalvepro-
852. Cardinalli-NetoA,BestettiRB,CordeiroJA,RodriguesVC.Predictorsofall-cause lapse.CircCardiovascImaging2016;9:e005030.
mortalityforpatientswithchronicChagas’heartdiseasereceivingimplantablecar- 877. SriramCS,SyedFF,FergusonME,JohnsonJN,Enriquez-SaranoM,CettaF,etal.
dioverterdefibrillatortherapy.JCardiovascElectrophysiol2007;18:1236–1240. Malignantbileafletmitralvalveprolapsesyndromeinpatientswithotherwiseidio-
853. MuratoreCA,BatistaSaLA,ChialePA,EloyR,TentoriMC,EscuderoJ,etal. pathicout-of-hospitalcardiacarrest.JAmCollCardiol2013;62:222–230.
Implantablecardioverterdefibrillatorsandchagas’disease:resultsoftheICDregis- 878. KitkungvanD,NabiF,KimRJ,BonowRO,KhanMA,XuJ,etal.Myocardialfibrosis
tryLatinAmerica.Europace2008;11:164–168. inpatientswithprimarymitralregurgitationwithandwithoutprolapse.JAmColl
854. MartinelliM,deSiqueiraSF,SternickEB,RassiA,CostaR,RamiresJAF,etal. Cardiol2018;72:823–834.
Long-termfollow-upofimplantablecardioverter-defibrillatorforsecondarypre- 879. NordhuesBD,SiontisKC,ScottCG,NkomoVT,AckermanMJ,AsirvathamSJ,
ventioninchagas’heartdisease.AmJCardiol2012;110:1040–1045. etal.Bileafletmitralvalveprolapseandriskofventriculardysrhythmiasanddeath.
855. GaliWL,SarabandaAV,BaggioJM,FerreiraLG,GomesGG,Marin-NetoJA,etal. JCardiovascElectrophysiol2016;27:463–468.
Implantablecardioverter-defibrillatorsfortreatmentofsustainedventricularar- 880. EssayaghB,SabbagA,AntoineC,BenfariG,YangL-T,MaaloufJ,etal.Presentation
rhythmiasinpatientswithchagas’heartdisease:comparisonwithacontrolgroup and outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:
treatedwithamiodaronealone.Europace2014;16:674–680. 637–649.
856. CarmoAAL,deSousaMR,AgudeloJF,BoersmaE,RochaMOC,RibeiroALP,etal. 881. NarasimhanC,JazayeriMR,SraJ,DhalaA,DeshpandeS,BiehlM,etal.Ventricular
Implantablecardioverter-defibrillatorinchagasheartdisease:asystematicreview tachycardiainvalvularheartdisease:facilitationofsustainedbundle-branchreentry
andmeta-analysisofobservationalstudies.IntJCardiol2018;267:88–93. byvalvesurgery.Circulation1997;96:4307–4313.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4121
882.MoonsP,BovijnL,BudtsW,BelmansA,GewilligM.Temporaltrendsinsurvivalto 904. KhairyP,HarrisL,LandzbergMJ,ViswanathanS,BarlowA,GatzoulisMA,etal.
adulthoodamongpatientsbornwithcongenitalheartdiseasefrom1970to1992in Implantablecardioverter-defibrillatorsintetralogyofFallot.Circulation2008;117:
Belgium.Circulation2010;122:2264–2272. 363–370.
883.MarelliAJ,Ionescu-IttuR,MackieAS,GuoL,DendukuriN,KaouacheM.Lifetime 905. KoyakZ,deGrootJR,VanGelderIC,BoumaBJ,vanDesselPFHM,BudtsW,etal.
prevalenceofcongenitalheartdiseaseinthegeneralpopulationfrom2000to2010. Implantablecardioverterdefibrillatortherapyinadultswithcongenitalheartdis-
Circulation2014;130:749–756. ease:whoisatriskofshocks?CircArrhythmElectrophysiol2012;5:101–110.
884.KoyakZ,HarrisL,deGrootJR,SilversidesCK,OechslinEN,BoumaBJ,etal. 906. CochetH,IriartX,Allain-NicolaïA,CamaioniC,SridiS,NivetH,etal.Focalscar
Sudden cardiac death in adult congenital heart disease. Circulation 2012;126: anddiffusemyocardialfibrosisareindependentimagingmarkersinrepairedtetral-
1944–1954. ogyofFallot.EurHeartJCardiovascImaging2019;20:990–1003.
885.GallegoP,GonzalezAE,Sanchez-RecaldeA,PeinadoR,PoloL,Gomez-RubinC, 907. Babu-NarayanSV,KilnerPJ,LiW,MoonJC,GoktekinO,DavlourosPA,etal.
etal.Incidenceandpredictorsofsuddencardiacarrestinadultswithcongenital Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults
heartdefectsrepairedbeforeadultlife.AmJCardiol2012;110:109–117. withrepairedtetralogyoffallotanditsrelationshiptoadversemarkersofclinical
886.GhaiA,SilversidesC,HarrisL,WebbGD,SiuSC,TherrienJ.Leftventriculardys- outcome.Circulation2006;113:405–413.
functionisariskfactorforsuddencardiacdeathinadultslateafterrepairoftetral- 908. GatzoulisMA,BalajiS,WebberSA,SiuSC,HokansonJS,PoileC,etal.Riskfactors
ogyofFallot.JAmCollCardiol2002;40:1675–1680. forarrhythmiaandsuddencardiacdeathlateafterrepairoftetralogyofFallot:a
887.KhairyP,LandzbergMJ,GatzoulisMA,LucronH,LambertJ,MarçonF,etal.Value
multicentrestudy.Lancet2000;356:975–981.
ofprogrammedventricularstimulationaftertetralogyoffallotrepair:amulticenter 909. BokmaJP,WinterMM,VehmeijerJT,VliegenHW,vanDijkAP,vanMelleJP,etal.
study.Circulation2004;109:1994–2000. QRSfragmentationissuperiortoQRSdurationinpredictingmortalityinadults
888.KapelGFL,SacherF,DekkersOM,WatanabeM,BlomNA,ThamboJ-B,etal.
withtetralogyofFallot.Heart2017;103:666–671.
Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping 910. Egbe AC, Kothapalli S, Borlaug BA, Ammash NM, Najam M, Bajwa N, et al.
arethesubstrateforventriculartachycardiainrepairedtetralogyofFallot.Eur Mechanism and risk factors for death in adults with tetralogy of Fallot. Am J HeartJ2017;38:268–276. Cardiol2019;124:803–807.
889.AtallahJ,GonzalezCorciaMC,WalshEP.Participatingmembersofthepediatric 911. Survivorsofout-of-hospitalcardiacarrestwithapparentlynormalheart.Needfor
and congenital electrophysiology society. Ventricular arrhythmia and life-
definitionandstandardizedclinicalevaluation.Consensusstatementofthejoint
steeringcommitteesoftheunexplainedcardiacarrestregistryofEuropeandof
threateningeventsinpatientswithrepairedtetralogyofFallot.AmJCardiol2020;
132:126–132. the idiopathic ventricular fibrillation registry of the United States. Circulation
890.KammeraadJAE,vanDeurzenCHM,SreeramN,Bink-BoelkensMTE,Ottenkamp
1997;95:265–272.
912. LeenhardtA,GlaserE,BurgueraM,NürnbergM,Maison-BlancheP,CoumelP.
J,HelbingWA,etal.PredictorsofsuddencardiacdeathafterMustardorSenning
repairfortranspositionofthegreatarteries.JAmCollCardiol2004;44:1095–1102. Short-coupledvariantoftorsadedepointes.Anewelectrocardiographicentity
inthespectrumofidiopathicventriculartachyarrhythmias.Circulation1994;89:
891.SchwerzmannM,SalehianO,HarrisL,SiuSC,WilliamsWG,WebbGD,etal.
206–215.
VentriculararrhythmiasandsuddendeathinadultsafteraMustardoperation
fortranspositionofthegreatarteries.EurHeartJ2009;30:1873–1879. 913. EisenbergSJ,ScheinmanMM,DulletNK,FinkbeinerWE,GriffinJC,EldarM,etal.
Suddencardiacdeathandpolymorphousventriculartachycardiainpatientswith
892.MiyazakiA,SakaguchiH,OhuchiH,MatsuokaM,KomoriA,YamamotoT,etal.
Efficacyofhemodynamic-basedmanagementoftachyarrhythmiaafterrepairoftet- normalQTintervalsandnormalsystoliccardiacfunction.AmJCardiol1995;75:
ralogyofFallot.CircJ2012;76:2855–2862.
687–692.
914. AsatryanB,SchallerA,SeilerJ,ServatiusH,NotiF,BaldingerSH,etal.Usefulnessof
893.HarrisonDA,HarrisL,SiuSC,MacLoghlinCJ,ConnellyMS,WebbGD,etal.
genetictestinginsuddencardiacarrestsurvivorswithorwithoutpreviousclinical
Sustainedventriculartachycardiainadultpatientslateafterrepairoftetralogyof
Fallot.JAmCollCardiol1997;30:1368–1373.
evidenceofheartdisease.AmJCardiol2019;123:2031–2038.
915. VisserM,DooijesD,vanderSmagtJJ,vanderHeijdenJF,DoevendansPA,LohP,
894.SabateRotesA,ConnollyHM,WarnesCA,AmmashNM,PhillipsSD,DearaniJA,
etal.VentriculararrhythmiariskstratificationinpatientswithtetralogyofFallotat e wt ita hl.N idie ox pt a-g then ice vr eat nio trn ics ue laq rue fin bc rii ln lag to iof na .l Har eg ae rtge Rn he ytp ha mne 2l 0in 17p ;a 1t 4ie :n 1t 0s 3in 5i –t 1ia 0ll 4y 0d .iagnosed
the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 2015;8:
916. Honarbakhsh S, Srinivasan N, Kirkby C, Firman E, Tobin L, Finlay M, et al.
110–116.
Medium-termoutcomesofidiopathicventricularfibrillationsurvivorsandfamily
895.KhairyP,HarrisL,LandzbergMJ,FernandesSM,BarlowA,MercierL-A,etal. screening:amulticentreexperience.Europace2017;19:1874–1880.
Sudden death and defibrillators in transposition of the great arteries with
917. MeissnerMD,LehmannMH,SteinmanRT,MostellerRD,AkhtarM,CalkinsH,etal.
intra-atrialbaffles:amulticenterstudy.CircArrhythmElectrophysiol2008;1:250–257.
Ventricularfibrillationinpatientswithoutsignificantstructuralheartdisease:amul-
896.Roca-LuqueI,RivasGándaraN,DosSubiràL,FranciscoPascualJ,Pérez-RodonJ, ticenterexperiencewithimplantablecardioverter-defibrillatortherapy.JAmColl
PijuanDomenechA,etal.Intra-atrialre-entranttachycardiainpatientswithcon- Cardiol1993;21:1406–1412.
genitalheartdisease:factorsassociatedwithdiseaseseverity.Europace2018;20:
918. ConteG,CaputoML,RegoliF,MarconS,KlersyC,AdjibodouB,etal.Trueidio-
1343–1351. pathicventricularfibrillationinout-of-hospitalcardiacarrestsurvivorsintheSwiss
897.ZeppenfeldK,SchalijMJ,BartelingsMM,TedrowUB,KoplanBA,SoejimaK,etal.
CantonTicino:prevalence,clinicalfeatures,andlong-termfollow-up.Europace
Catheterablationofventriculartachycardiaafterrepairofcongenitalheartdisease: 2017;19:259–266.
electroanatomicidentificationofthecriticalrightventricularisthmus.Circulation
919. StampeNK,JespersenCB,GlingeC,BundgaardH,Tfelt-HansenJ,WinkelBG.
2007;116:2241–2252.
Clinicalcharacteristicsandriskfactorsofarrhythmiaduringfollow-upofpatients
898.KriebelT,SaulJP,SchneiderH,SiglerM,PaulT.Noncontactmappingandradiofre- with idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 2020;31:
quencycatheterablationoffastandhemodynamicallyunstableventriculartachy- 2677–2686.
cardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 2007;50: 920. ConteG,BelhassenB,LambiaseP,CiconteG,deAsmundisC,ArbeloE,etal.
2162–2168. Out-of-hospitalcardiacarrestduetoidiopathicventricularfibrillationinpatients
899.vanZylM,KapaS,PadmanabhanD,ChenFC,MulpuruSK,PackerDL,etal. withnormalelectrocardiograms:resultsfromamulticentrelong-termregistry.
Mechanismandoutcomesofcatheterablationforventriculartachycardiainadults Europace2019;21:1670–1677.
withrepairedcongenitalheartdisease.HeartRhythm2016;13:1449–1454.
921. BlomLJ,VisserM,ChristiaansI,ScholtenMF,BootsmaM,vandenBergMP,etal.
900.LaredoM,FrankR,WaintraubX,GandjbakhchE,IserinL,HascoëtS,etal.Ten-year Incidenceandpredictorsofimplantablecardioverter-defibrillatortherapyandits
outcomesofmonomorphicventriculartachycardiacatheterablationinrepaired complications in idiopathic ventricular fibrillation patients. Europace 2019;21:
tetralogyofFallot.ArchCardiovascDis2017;110:292–302. 1519–1526.
901.KapelGFL,ReichlinT,WijnmaalenAP,PiersSRD,HolmanER,TedrowUB,etal. 922. MalhiN,CheungCC,DeifB,RobertsJD,GulaLJ,GreenMS,etal.Challengeand
Re-entryusinganatomicallydeterminedisthmuses:acurableventriculartachycar- impact of quinidine access in sudden deathsyndromes: a national experience.
dia in repaired congenital heart disease. Circ Arrhythm Electrophysiol 2015;8: JACCClinElectrophysiol2019;5:376–382.
102–109. 923. BelhassenB,GlickA,ViskinS.Excellentlong-termreproducibilityoftheelectro-
902.BokmaJP,deWildeKC,VliegenHW,vanDijkAP,vanMelleJP,MeijboomFJ,etal. physiologicefficacyofquinidineinpatientswithidiopathicventricularfibrillation
Valueofcardiovascularmagneticresonanceimaginginnoninvasiveriskstratifica- andBrugadasyndrome.PacingClinElectrophysiol2009;32:294–301.
tionintetralogyofFallot.JAMACardiol2017;2:678–683. 924. BelhassenB,ShapiraI,ShoshaniD,ParedesA,MillerH,LaniadoS.Idiopathicven-
903.KoyakZ,deGrootJR,BoumaBJ,VanGelderIC,BudtsW,ZwindermanAH,etal. tricularfibrillation:inducibilityandbeneficialeffectsofclassIantiarrhythmicagents.
Symptomaticbutnotasymptomaticnon-sustainedventriculartachycardiaisasso- Circulation1987;75:809–816.
ciatedwithappropriateimplantablecardiovertertherapyintetralogyofFallot.IntJ 925. Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990;120:
Cardiol2013;167:1532–1535. 661–671.
Downloaded
from

by
guest
on
22
January
2026

4122 ESCGuidelines
926. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of 951. PrioriSG,NapolitanoC,SchwartzPJ,BloiseR,CrottiL,RonchettiE.Theelusive
electrophysiologic-guidedtherapywithClassIAantiarrhythmicdrugsonthelong- link between LQT3 and Brugada syndrome: the role of flecainide challenge.
termoutcomeofpatientswithidiopathicventricularfibrillationwithorwithoutthe Circulation2000;102:945–947.
Brugadasyndrome.JCardiovascElectrophysiol1999;10:1301–1312. 952. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al.
927. Sadek MM, Benhayon D, Sureddi R, Chik W, Santangeli P, Supple GE, et al. Effectivenessandlimitationsofbeta-blockertherapyincongenitallong-QTsyn-
Idiopathicventriculararrhythmiasoriginatingfromthemoderatorband:electro- drome.Circulation2000;101:616–623.
cardiographiccharacteristicsandtreatmentbycatheterablation.HeartRhythm 953. JonsC,MossAJ,GoldenbergI,LiuJ,McNittS,ZarebaW,etal.Riskoffatalarrhyth-
2015;12:67–75. miceventsinlongQTsyndromepatientsaftersyncope.JAmCollCardiol2010;55:
928. VanHerendaelH,ZadoES,HaqqaniH,TschabrunnCM,CallansDJ,FrankelDS, 783–788.
etal.Catheterablationofventricularfibrillation:importanceofleftventricularout- 954. LiuJF,JonsC,MossAJ,McNittS,PetersonDR,QiM,etal.Riskfactorsforrecurrent
flowtractandpapillarymuscletriggers.HeartRhythm2014;11:566–573. syncopeandsubsequentfatalornear-fataleventsinchildrenandadolescentswith
929. Santoro F, Di Biase L, Hranitzky P, Sanchez JE, Santangeli P, Perini AP, et al.
longQTsyndrome.JAmCollCardiol2011;57:941–950.
VentricularfibrillationtriggeredbyPVCsfrompapillarymuscles:clinicalfeatures 955. SethR,MossAJ,McNittS,ZarebaW,AndrewsML,QiM,etal.LongQTsyndrome
andablation.JCardiovascElectrophysiol2014;25:1158–1164. andpregnancy.JAmCollCardiol2007;49:1092–1098.
930. NakamuraT,SchaefferB,TanigawaS,MuthalalyRG,JohnRM,MichaudGF,etal. 956. GoldenbergI,HorrS,MossAJ,LopesCM,BarsheshetA,McNittS,etal.Riskfor
Catheter ablation of polymorphic ventricular tachycardia/fibrillation in patients life-threateningcardiaceventsinpatientswithgenotype-confirmedlong-QTsyn-
withandwithoutstructuralheartdisease.HeartRhythm2019;16:1021–1027. dromeandnormal-rangecorrectedQTintervals.JAmCollCardiol2011;57:51–59.
931. MossAJ,SchwartzPJ,CramptonRS,TzivoniD,LocatiEH,MacCluerJ,etal.The 957. JangSY,ChoY,KimNK,KimC-Y,SohnJ,RohJ-H,etal.Video-assistedthoraco-
long QT syndrome. Prospective longitudinal study of 328 families. Circulation scopicleftcardiacsympatheticdenervationinpatientswithhereditaryventricular
1991;84:1136–1144. arrhythmias.PacingClinElectrophysiol2017;40:232–241.
932. SchwartzPJ,AckermanMJ,AntzelevitchC,BezzinaCR,BorggrefeM,CuneoBF, 958. Waddell-SmithKE,ErtresvaagKN,LiJ,ChaudhuriK,CrawfordJR,HamillJK,etal.
Physicalandpsychologicalconsequencesofleftcardiacsympatheticdenervationin
etal.Inheritedcardiacarrhythmias.NatRevDisPrimers2020;6:58.
933. AndersenED,KrasilnikoffPA,OvervadH.Intermittentmuscularweakness,extra- long-QTsyndromeandcatecholaminergicpolymorphicventriculartachycardia. CircArrhythmElectrophysiol2015;8:1151–1158.
systoles,andmultipledevelopmentalanomalies.Anewsyndrome?ActaPaediatr
Scand1971;60:559–564. 959. AndersonHN,BosJM,RohatgiRK,AckermanMJ.Theeffectofleftcardiacsympa-
934. TawilR,PtacekLJ,PavlakisSG,DeVivoDC,PennAS,OzdemirC,etal.Andersen’s thetic denervation on exercise in patients with long QT syndrome. JACC Clin
Electrophysiol2019;5:1084–1090.
syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dys-
morphicfeatures.AnnNeurol1994;35:326–330. 960. BosJM,BosKM,JohnsonJN,MoirC,AckermanMJ.Leftcardiacsympatheticde-
nervation in long QT syndrome: analysis of therapeutic nonresponders. Circ
935. SplawskiI,TimothyKW,DecherN,KumarP,SachseFB,BeggsAH,etal.Severe
ArrhythmElectrophysiol2013;6:705–711.
arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc
NatlAcadSciUSA2005;102:8089–8096;discussion8086–8088. 961. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM.
Electrophysiologic testing in patients with the long QT syndrome. Circulation
936. JervellA,Lange-NielsenF.Congenitaldeaf-mutism,functionalheartdiseasewith
prolongationoftheQ-Tintervalandsuddendeath.AmHeartJ1957;54:59–68.
1985;71:63–71.
962. ZarebaW,MossAJ,DaubertJP,HallWJ,RobinsonJL,AndrewsM.Implantablecar-
937. SchwartzPJ,MossAJ,VincentGM,CramptonRS.Diagnosticcriteriaforthelong
QTsyndrome.Anupdate.Circulation1993;88:782–784. dioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc
Electrophysiol2003;14:337–341.
938. RautaharjuPM,ZhangZ-M,PrineasR,HeissG.AssessmentofprolongedQTand
JTintervalsinventricularconductiondefects.AmJCardiol2004;93:1017–1021. 963. SchwartzPJ,SpazzoliniC,PrioriSG,CrottiL,VicentiniA,LandolinaM,etal.Who
are the long-QT syndrome patients who receive an implantable cardioverter-
939. ViskinS,PostemaPG,BhuiyanZA,RossoR,KalmanJM,VohraJK,etal.There-
defibrillatorandwhathappenstothem?:DatafromtheEuropeanlong-QTsyn-
sponseoftheQTintervaltothebrieftachycardiaprovokedbystanding:abedside drome implantable cardioverter-defibrillator (LQTS ICD) registry. Circulation
testfordiagnosinglongQTsyndrome.JAmCollCardiol2010;55:1955–1961.
2010;122:1272–1282.
940. Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, Marino M, et al.
964. DelannoyE,SacherF,MauryP,MaboP,MansouratiJ,MagninI,etal.Cardiacchar-
Interplaybetweengeneticsubstrate,QTcduration,andarrhythmiariskinpatients
acteristicsandlong-termoutcomeinAndersen-Tawilsyndromepatientsrelatedto
withlongQTsyndrome.JAmCollCardiol2018;71:1663–1671.
KCNJ2mutation.Europace2013;15:1805–1811.
941. BehrER,RodenD.Drug-inducedarrhythmia:pharmacogenomicprescribing?Eur
965. InoueYY,AibaT,KawataH,SakaguchiT,MitsumaW,MoritaH,etal.Different
HeartJ2013;34:89–95.
responsestoexercisebetweenAndersen-Tawilsyndromeandcatecholaminergic
942. WeekePE,KellemannJS,JespersenCB,TheiladeJ,KantersJK,HansenMS,etal. polymorphicventriculartachycardia.Europace2018;20:1675–1682.
Long-termproarrhythmicpharmacotherapyamongpatientswithcongenitallong 966. Krych M, Biernacka EK, Ponińska J, Kukla P, Filipecki A, Gajda R, et al.
QT syndrome and risk of arrhythmia and mortality. Eur Heart J 2019;40:
Andersen-Tawilsyndrome:clinicalpresentationandpredictorsofsymptomaticar-
3110–3117. rhythmias—possible role of polymorphisms K897T in KCNH2 and H558R in
943. SchwartzPJ,PrioriSG,SpazzoliniC,MossAJ,VincentGM,NapolitanoC,etal. SCN5Agene.JCardiol2017;70:504–510.
Genotype-phenotypecorrelationinthelong-QTsyndrome:gene-specifictriggers
967. MazzantiA,GuzD,TrancuccioA,PaganE,KukavicaD,ChargeishviliT,etal.
forlife-threateningarrhythmias.Circulation2001;103:89–95. NaturalhistoryandriskstratificationinAndersen-Tawilsyndrometype1.JAm
944. ChockalingamP,CrottiL,GirardengoG,JohnsonJN,HarrisKM,vanderHeijdenJF, CollCardiol2020;75:1772–1784.
etal.Notallbeta-blockersareequalinthemanagementoflongQTsyndrome 968. ZhangL,BensonDW,Tristani-FirouziM,PtacekLJ,TawilR,SchwartzPJ,etal.
types1and2:higherrecurrenceofeventsundermetoprolol.JAmCollCardiol ElectrocardiographicfeaturesinAndersen-TawilsyndromepatientswithKCNJ2
2012;60:2092–2099.
mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.
945. AhnJ,KimHJ,ChoiJ-I,LeeKN,ShimJ,AhnHS,etal.Effectivenessofbeta-blockers Circulation2005;111:2720–2726.
dependingonthegenotypeofcongenitallong-QTsyndrome:ameta-analysis.PLoS 969. HorigomeH,IshikawaY,KokubunN,YoshinagaM,SumitomoN,LinL,etal.
One2017;12:e0185680. Multivariate analysis of TU wave complex on electrocardiogram in
946. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Andersen-TawilsyndromewithKCNJ2mutations.AnnNoninvasiveElectrocardiol
AssociationoflongQTsyndromelociandcardiaceventsamongpatientstreated 2020;25:e12721.
withbeta-blockers.JAMA2004;292:1341–1344. 970. MiyamotoK,AibaT,KimuraH,HayashiH,OhnoS,YasuokaC,etal.Efficacyand
947. Mazzanti A, Trancuccio A, Kukavica D, Pagan E, Wang M, Mohsin M, et al. safetyofflecainideforventriculararrhythmiasinpatientswithAndersen-Tawilsyn-
Independentvalidationandclinicalimplicationsoftheriskpredictionmodelfor dromewithKCNJ2mutations.HeartRhythm2015;12:596–603.
longQTsyndrome(1-2-3-LQTS-Risk).Europace2021;24:697–698. 971. RadwańskiPB,Greer-ShortA,PoelzingS.InhibitionofNa+channelsameliorates
948. Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M, et al. arrhythmiasinadrug-inducedmodelofAndersen-Tawilsyndrome.HeartRhythm
Gene-specific therapy with mexiletine reduces arrhythmic events in patients 2013;10:255–263.
withlongQTsyndrometype3.JAmCollCardiol2016;67:1053–1058. 972. Tristani-FirouziM,JensenJL,DonaldsonMR,SansoneV,MeolaG,HahnA,etal.
949. RuanY,LiuN,BloiseR,NapolitanoC,PrioriSG.GatingpropertiesofSCN5Amu- Functional and clinical characterization of KCNJ2 mutations associated with
tationsandthe responsetomexiletineinlong-QTsyndrometype3 patients. LQT7(Andersensyndrome).JClinInvest2002;110:381–388.
Circulation2007;116:1137–1144. 973. AntzelevitchC,BrugadaP,BorggrefeM,BrugadaJ,BrugadaR,CorradoD,etal.
950. Zhu W, Mazzanti A, Voelker TL, Hou P, Moreno JD, Angsutararux P, et al. Brugadasyndrome:reportofthesecondconsensusconference:endorsedbythe
Predictingpatientresponsetotheantiarrhythmicmexiletinebasedongeneticvari- HeartRhythmSocietyandtheEuropeanHeartRhythmAssociation.Circulation
ation.CircRes2019;124:539–552. 2005;111:659–670.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4123
974.SavastanoS,RordorfR,VicentiniA,PetracciB,TaravelliE,CastellettiS,etal.A Brugada syndrome at low risk of sudden cardiac death. Cardiology 2020;145:
comprehensiveelectrocardiographic,molecular,andechocardiographicstudyof 413–420.
Brugadasyndrome:validationofthe2013diagnosticcriteria.HeartRhythm2014; 999. ScroccoC,Ben-HaimY,DevineB,Tome-EstebanM,PapadakisM,SharmaS,etal.
11:1176–1183. Roleofsubcutaneousimplantablelooprecorderforthediagnosisofarrhythmiasin
975.Richter S,SarkozyA,PaparellaG,HenkensS,BoussyT,ChierchiaG-B,etal. Brugada syndrome: a United Kingdom single-center experience. Heart Rhythm
Numberofelectrocardiogramleadsdisplayingthediagnosticcoved-typepattern 2022;19:70–78.
inBrugadasyndrome:adiagnosticconsensuscriteriontoberevised.EurHeartJ 1000. SieiraJ,BrugadaP.Brugadasyndrome:definingtheriskinasymptomaticpatients.
2010;31:1357–1364. ArrhythmElectrophysiolRev2016;5:164–169.
976.VeltmannC,PapavassiliuT,KonradT,DoeschC,KuschykJ,StreitnerF,etal. 1001. NishizakiM,SakuradaH,YamawakeN,Ueda-TatsumotoA,HiraokaM.Lowrisk
InsightsintothelocationoftypeIECGinpatientswithBrugadasyndrome:correl- forarrhythmiceventsinasymptomaticpatientswithdrug-inducedtype1ECG.
ationofECGandcardiovascularmagneticresonanceimaging.HeartRhythm2012; Dopatientswithdrug-inducedBrugadatypeECGhavepoorprognosis?(Con).
9:414–421. CircJ2010;74:2464–2473.
977.AdlerA,RossoR,ChorinE,HavakukO,AntzelevitchC,ViskinS.Riskstratification 1002. ConteG,deAsmundisC,SieiraJ,CiconteG,DiGiovanniG,ChierchiaG-B,etal.
inBrugadasyndrome:clinicalcharacteristics,electrocardiographicparameters,and Prevalence and clinical impact of early repolarization pattern and
auxiliarytesting.HeartRhythm2016;13:299–310.
QRS-fragmentationinhigh-riskpatientswithBrugadasyndrome.CircJ2016;80:
978.HasdemirC,PayzinS,KocabasU,SahinH,YildirimN,AlpA,etal.Highprevalence 2109–2116.
ofconcealedBrugadasyndromeinpatientswithatrioventricularnodalreentrant 1003. KataokaN,MizumakiK,NakataniY,SakamotoT,YamaguchiY,TsujinoY,etal.
tachycardia.HeartRhythm2015;12:1584–1594. PacedQRSfragmentationisassociatedwithspontaneousventricularfibrillation
979.BehrER,Ben-HaimY,AckermanMJ,KrahnAD,WildeAAM.Brugadasyndrome inpatientswithBrugadasyndrome.HeartRhythm2016;13:1497–1503.
andreducedrightventricularoutflowtractconductionreserve:afinalcommon 1004. ProbstV,GoronflotT,AnysS,TixierR,BriandJ,BerthomeP,etal.Robustness
pathway?EurHeartJ2021;42:1073–1081.
and relevance of predictive score in sudden cardiac death for patients with
980.ProbstV,VeltmannC,EckardtL,MeregalliPG,GaitaF,TanHL,etal.Long-term Brugadasyndrome.EurHeartJ2021;42:1687–1695.
prognosis of patients diagnosed with Brugada syndrome: results from the 1005. HonarbakhshS,ProvidenciaR,Garcia-HernandezJ,MartinCA,HunterRJ,Lim
FINGERBrugadasyndromeregistry.Circulation2010;121:635–643.
WY, et al. A primary prevention clinical risk score model for patients with
981.AminAS,MeregalliPG,BardaiA,WildeAAM,TanHL.Feverincreasestheriskfor Brugadasyndrome(BRUGADA-RISK).JACCClinElectrophysiol2021;7:210–222.
cardiacarrestintheBrugadasyndrome.AnnInternMed2008;149:216–218.
1006. AndorinA,GourraudJ-B,MansouratiJ,FouchardS,leMarecH,MauryP,etal.The
982.AdlerA,TopazG,HellerK,ZeltserD,OhayonT,RozovskiU,etal.Fever-induced
QUIDAMstudy:hydroquinidinetherapyforthemanagementofBrugadasyn-
Brugadapattern:howcommonisitandwhatdoesitmean?HeartRhythm2013;10: dromepatientsathigharrhythmicrisk.HeartRhythm2017;14:1147–1154.
1375–1382.
1007. BelhassenB,RahkovichM,MichowitzY,GlickA,ViskinS.ManagementofBrugada
983.PrioriSG,NapolitanoC,GaspariniM,PapponeC,DellaBellaP,GiordanoU,etal.
syndrome:thirty-three-yearexperienceusingelectrophysiologicallyguidedther-
NaturalhistoryofBrugadasyndrome:insightsforriskstratificationandmanage-
apy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol 2015;8:
ment.Circulation2002;105:1342–1347.
1393–1402.
984.RizzoA,BorioG,SieiraJ,VanDoorenS,OvereinderI,BalaG,etal.Ajmalinetesting
1008. OhgoT,OkamuraH,NodaT,SatomiK,SuyamaK,KuritaT,etal.Acuteand
andtheBrugadasyndrome.AmJCardiol2020;135:91–98.
chronicmanagementinpatientswithBrugadasyndromeassociatedwithelectrical
985.Poli S, Toniolo M, Maiani M, Zanuttini D, Rebellato L, Vendramin I, et al. stormofventricularfibrillation.HeartRhythm2007;4:695–700.
Managementofuntreatableventriculararrhythmiasduringpharmacologicchal-
1009. NademaneeK,RajuH,deNoronhaSV,PapadakisM,RobinsonL,RotheryS,etal.
lengeswithsodiumchannelblockersforsuspectedBrugadasyndrome.Europace
Fibrosis,connexin-43,andconductionabnormalitiesintheBrugadasyndrome.
2018;20:234–242.
JAmCollCardiol2015;66:1976–1986.
986.HasdemirC,JuangJJ-M,KoseS,KocabasU,OrmanMN,PayzinS,etal.Coexistence
1010. NademaneeK,HaissaguerreM,HociniM,NogamiA,ChenitiG,DuchateauJ,etal.
ofatrioventricularaccessorypathwaysanddrug-inducedtype1Brugadapattern.
PacingClinElectrophysiol2018;41:1078–1092.
Mappingandablationofventricularfibrillationassociatedwithearlyrepolarization
syndrome.Circulation2019;140:1477–1490.
987.ProbstV,WildeAAM,BarcJ,SacherF,BabutyD,MaboP,etal.SCN5Amutations
1011. NademaneeK,VeerakulG,ChandanamatthaP,ChaothaweeL,Ariyachaipanich
andtheroleofgeneticbackgroundinthepathophysiologyofBrugadasyndrome.
CircCardiovascGenet2009;2:552–557. A, Jirasirirojanakorn K, et al. Prevention of ventricular fibrillation episodes in
Brugadasyndromebycatheterablationovertheanteriorrightventricularoutflow
988.MeregalliPG,TanHL,ProbstV,KoopmannTT,TanckMW,BhuiyanZA,etal.Type
tractepicardium.Circulation2011;123:1270–1279.
ofSCN5Amutationdeterminesclinicalseverityanddegreeofconductionslowing
inloss-of-functionsodiumchannelopathies.HeartRhythm2009;6:341–348. 1012. ZhangP,TungR,ZhangZ,ShengX,LiuQ,JiangR,etal.Characterizationofthe
epicardialsubstrateforcatheterablationofBrugadasyndrome.HeartRhythm
989.IshikawaT,KimotoH,MishimaH,YamagataK,OgataS,AizawaY,etal.Functionally
2016;13:2151–2158.
validatedSCN5Avariantsallowinterpretationofpathogenicityandpredictionof
lethaleventsinBrugadasyndrome.EurHeartJ2021;42:2854–2863. 1013. HaïssaguerreM,ExtramianaF,HociniM,CauchemezB,JaïsP,CabreraJA,etal.
990.GehiAK,DuongTD,MetzLD,GomesJA,MehtaD.Riskstratificationofindividuals Mapping and ablation of ventricular fibrillation associated with long-QT and
with the Brugada electrocardiogram:ameta-analysis.J Cardiovasc Electrophysiol
Brugadasyndromes.Circulation2003;108:925–928.
2006;17:577–583. 1014. BrugadaJ,PapponeC,BerruezoA,VicedominiG,MangusoF,CiconteG,etal.
991.McNamaraDA,GoldbergerJJ,BerendsenMA,HuffmanMD.Implantabledefibril- Brugadasyndromephenotypeeliminationbyepicardialsubstrateablation.Circ
latorsversusmedicaltherapyforcardiacchannelopathies.CochraneDatabaseSyst
ArrhythmElectrophysiol2015;8:1373–1381.
Rev2015;2015:CD011168. 1015. PapponeC,BrugadaJ,VicedominiG,CiconteG,MangusoF,SavianoM,etal.
992.PrioriSG,GaspariniM,NapolitanoC,DellaBellaP,OttonelliAG,SassoneB,etal. Electricalsubstrateeliminationin135consecutivepatientswithBrugadasyn-
RiskstratificationinBrugadasyndrome:resultsofthePRELUDE(PRogrammed drome.CircArrhythmElectrophysiol2017;10:e005053.
ELectricalstimUlationpreDictivevaluE)registry.JAmCollCardiol2012;59:37–45. 1016. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, et al.
993.DereciA,YapS-C,SchinkelAFL.Meta-analysisofclinicaloutcomeafterimplantable Genotype-phenotypecorrelationofSCN5Amutationfortheclinicalandelectro-
cardioverter-defibrillatorimplantationinpatientswithBrugadasyndrome.JACC cardiographiccharacteristicsofprobandswithBrugadasyndrome:aJapanese
ClinElectrophysiol2019;5:141–148. multicenterregistry.Circulation2017;135:2255–2270.
994.ConteG,SieiraJ,CiconteG,deAsmundisC,ChierchiaG-B,BaltogiannisG,etal. 1017. HaïssaguerreM,DervalN,SacherF,JeselL,DeisenhoferI,deRoyL,etal.Sudden
Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year cardiac arrest associated with early repolarization. N Engl J Med 2008;358:
single-centerexperience.JAmCollCardiol2015;65:879–888. 2016–2023.
995.MasciaG,DellaBonaR,AmeriP,CanepaM,PortoI,BrignoleM.Brugadasyndrome 1018. RossoR,KoganE,BelhassenB,RozovskiU,ScheinmanMM,ZeltserD,etal.
andsyncope:asystematicreview.JCardiovascElectrophysiol2020;31:3334–3338. J-pointelevationinsurvivorsofprimaryventricularfibrillationandmatchedcon-
996.SubramanianM,PrabhuMA,HarikrishnanMS,ShekharSS,PaiPG,NatarajanK.The trol subjects: incidence and clinical significance. J Am Coll Cardiol 2008;52:
utilityofexercisetestinginriskstratificationofasymptomaticpatientswithtype1 1231–1238.
Brugadapattern.JCardiovascElectrophysiol2017;28:677–683. 1019. MacfarlanePW,AntzelevitchC,HaissaguerreM,HuikuriHV,PotseM,RossoR,
997.KubalaM,AïssouL,TraulléS,GugenheimA-L,HermidaJ-S.Useofimplantableloop etal.Theearlyrepolarizationpattern:aconsensuspaper.JAmCollCardiol2015;
recordersinpatientswithBrugadasyndromeandsuspectedriskofventricularar- 66:470–477.
rhythmia.Europace2012;14:898–902. 1020. TikkanenJT,Anttonen O,JunttilaMJ, Aro AL,KerolaT, Rissanen HA,etal.
998.SakhiR,AssafA,TheunsDAMJ,VerhagenJMA,Szili-TorokT,Roos-HesselinkJW, Long-termoutcomeassociatedwithearlyrepolarizationonelectrocardiography.
et al. Outcome of insertable cardiac monitors in symptomatic patients with NEnglJMed2009;361:2529–2537.
Downloaded
from

by
guest
on
22
January
2026

4124 ESCGuidelines
1021. Sinner MF, Reinhard W, Müller M, Beckmann B-M, Martens E, Perz S, et al. 1045. PrioriSG,NapolitanoC,MemmiM,ColombiB,DragoF,GaspariniM,etal.
AssociationofearlyrepolarizationpatternonECGwithriskofcardiacandall- Clinicalandmolecularcharacterizationofpatientswithcatecholaminergicpoly-
cause mortality: a population-based prospective cohort study (MONICA/ morphicventriculartachycardia.Circulation2002;106:69–74.
KORA).PLoSMed2010;7:e1000314. 1046. KrahnAD,GollobM,YeeR,GulaLJ,SkanesAC,WalkerBD,etal.Diagnosisof
1022. NunnLM,Bhar-AmatoJ,LoweMD,MacfarlanePW,RogersP,McKennaWJ,etal. unexplained cardiac arrest: role of adrenaline and procainamide infusion.
PrevalenceofJ-pointelevationinsuddenarrhythmicdeathsyndromefamilies.
Circulation2005;112:2228–2234.
JAmCollCardiol2011;58:286–290. 1047. HayashiM,DenjoyI,ExtramianaF,MaltretA,BuissonNR,LupoglazoffJ-M,etal.
1023. WatanabeH,NogamiA,OhkuboK,KawataH,HayashiY,IshikawaT,etal. Incidenceandriskfactorsofarrhythmiceventsincatecholaminergicpolymorphic
ElectrocardiographiccharacteristicsandSCN5Amutationsinidiopathicventricu-
ventriculartachycardia.Circulation2009;119:2426–2434.
lar fibrillation associated with early repolarization. Circ Arrhythm Electrophysiol 1048. LerenIS,SaberniakJ,MajidE,HalandTF,EdvardsenT,HaugaaKH.Nadololde-
2011;4:874–881. creases the incidence and severity of ventricular arrhythmias during exercise
1024. ChauveauS,JaninA,TillM,MorelE,ChevalierP,MillatG.Earlyrepolarizationsyn-
stresstestingcomparedwithβ1-selectiveβ-blockersinpatientswithcatechola-
minergicpolymorphicventriculartachycardia.HeartRhythm2016;13:433–440.
dromecausedbydenovoduplicationofKCND3detectedbynext-generationse-
quencing.HeartRhythmCaseRep2017;3:574–578. 1049. PeltenburgPJ,KallasD,BosJM,LieveKVV,FranciosiS,RostonTM,etal.Aninter-
nationalmulticentercohortstudyonβ-blockersforthetreatmentofsymptom-
1025. TakayamaK,OhnoS,DingW-G,AshiharaT,FukumotoD,WadaY,etal.Ade
atic children with catecholaminergic polymorphic ventricular tachycardia.
novo gain-of-function KCND3 mutation in early repolarization syndrome.
HeartRhythm2019;16:1698–1706.
Circulation2022;145:333–344.
1050. vanderWerfC,NederendI,HofmanN,vanGelovenN,EbinkC,Frohn-Mulder
1026. RossoR,GliksonE,BelhassenB,KatzA,HalkinA,SteinvilA,etal.Distinguishing
‘benign’from‘malignantearlyrepolarization’:thevalueoftheST-segmentmorph- IME,etal.Familialevaluationincatecholaminergicpolymorphicventriculartachy-
cardia: disease penetrance and expression in cardiac ryanodine receptor
ology.HeartRhythm2012;9:225–229.
mutation-carryingrelatives.CircArrhythmElectrophysiol2012;5:748–756.
1027. TikkanenJT,JunttilaMJ,AnttonenO,AroAL,LuttinenS,KerolaT,etal.Earlyre- 1051. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al.
polarization: electrocardiographic phenotypes associated with favorable long-
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in
termoutcome.Circulation2011;123:2666–2673. miceandhumans.NatMed2009;15:380–383.
1028. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, 1052. WangG,ZhaoN,ZhongS,WangY,LiJ.Safetyandefficacyofflecainideforpa-
BhuripanyoK,etal.Defibrillatorversusbeta-blockersforunexplainedDeathin
tientswithcatecholaminergicpolymorphicventriculartachycardia:asystematic
Thailand(DEBUT):arandomizedclinicaltrial.Circulation2003;107:2221–2226.
reviewandmeta-analysis.Medicine(Baltimore)2019;98:e16961.
1029. BrugadaJ,BrugadaR,BrugadaP.Pharmacologicalanddeviceapproachtotherapy 1053. vanderWerfC,KannankerilPJ,SacherF,KrahnAD,ViskinS,LeenhardtA,etal.
of inherited cardiac diseases associated with cardiac arrhythmias and sudden Flecainidetherapyreducesexercise-inducedventriculararrhythmiasinpatients
death.JElectrocardiol2000;33:41–47.
with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol
1030. HaïssaguerreM,SacherF,NogamiA,KomiyaN,BernardA,ProbstV,etal. 2011;57:2244–2254.
Characteristicsofrecurrentventricularfibrillationassociatedwithinferolateral 1054. PadfieldGJ,AlAhmariL,LieveKVV,AlAhmariT,RostonTM,WildeAA,etal.
earlyrepolarizationroleofdrugtherapy.JAmCollCardiol2009;53:612–619. Flecainidemonotherapyisanoptionforselectedpatientswithcatecholaminergic
1031. AizawaY,ChinushiM,HasegawaK,NaikiN,HorieM,KanekoY,etal.Electrical polymorphicventriculartachycardiaintolerantofβ-blockade.HeartRhythm2016;
storminidiopathicventricularfibrillationisassociatedwithearlyrepolarization. 13:609–613.
JAmCollCardiol2013;62:1015–1019. 1055. Roses-NoguerF,JarmanJWE,ClagueJR,TillJ.Outcomesofdefibrillatortherapy
1032. PatocskaiB,Barajas-MartinezH,HuD,GurabiZ,KonczI,AntzelevitchC.Cellular incatecholaminergicpolymorphicventriculartachycardia.HeartRhythm2014;11:
andionicmechanismsunderlyingthe effectsof cilostazol,milrinone,andiso- 58–66.
proterenoltosuppressarrhythmogenesisinanexperimentalmodelofearlyrepo- 1056. DeFerrariGM,DusiV,SpazzoliniC,BosJM,AbramsDJ,BerulCI,etal.Clinical
larizationsyndrome.HeartRhythm2016;13:1326–1334. managementofcatecholaminergicpolymorphicventriculartachycardia:therole
1033. Nam G-B, Kim Y-H, Antzelevitch C. Augmentation of J waves and electrical ofleftcardiacsympatheticdenervation.Circulation2015;131:2185–2193.
stormsinpatientswithearlyrepolarization.NEnglJMed2008;358:2078–2079. 1057. RostonTM,JonesK,HawkinsNM,BosJM,SchwartzPJ,PerryF,etal.Implantable
1034. Rodríguez-CapitánJ,Fernández-MeseguerA,García-PinillaJM,Calvo-BonachoE, cardioverter-defibrillatoruseincatecholaminergicpolymorphicventriculartachy-
Jiménez-NavarroM,García-MargalloT,etal.Frequencyofdifferentelectrocar- cardia:asystematicreview.HeartRhythm2018;15:1791–1799.
diographicabnormalitiesinalargecohortofSpanishworkers.Europace2017; 1058. vanderWerfC,LieveKV,BosJM,LaneCM,DenjoyI,Roses-NoguerF,etal.
19:1855–1863. Implantablecardioverter-defibrillatorsinpreviouslyundiagnosedpatientswithca-
1035. SunG-Z,YeN,ChenY-T,ZhouY,LiZ,SunY-X.Earlyrepolarizationpatternin techolaminergicpolymorphicventriculartachycardiaresuscitatedfromsudden
thegeneralpopulation:prevalenceandassociatedfactors.IntJCardiol2017;230:
cardiacarrest.EurHeartJ2019;40:2953–2961.
614–618. 1059. LeenhardtA,LucetV,DenjoyI,GrauF,NgocDD,CoumelP.Catecholaminergic
1036. WuS-H,LinX-X,ChengY-J,QiangC-C,ZhangJ.Earlyrepolarizationpatternand polymorphicventriculartachycardiainchildren.A7-yearfollow-upof21patients.
riskforarrhythmiadeath:ameta-analysis.JAmCollCardiol2013;61:645–650. Circulation1995;91:1512–1519.
1060. KannankerilPJ,MooreJP,CerroneM,PrioriSG,KerteszNJ,RoPS,etal.Efficacyof
1037. MalhiN,SoPP,CheungCC,LaksmanZWM,HealeyJS,ChauhanVS,etal.Early
flecainideinthetreatmentofcatecholaminergicpolymorphicventriculartachy-
repolarizationpatterninheritanceinthecardiacarrestsurvivorswithpreserved
ejectionfractionregistry(CASPER).JACCClinElectrophysiol2018;4:1473–1479.
cardia:arandomizedclinicaltrial.JAMACardiol2017;2:759–766.
1061. GollobMH,RedpathCJ,RobertsJD.TheshortQTsyndrome:proposeddiagnos-
1038. Sinner MF, Porthan K, Noseworthy PA, Havulinna AS, Tikkanen JT,
ticcriteria.JAmCollCardiol2011;57:802–812.
Müller-NurasyidM,etal.Ameta-analysisofgenome-wideassociationstudiesof
1062. ThorsenK,DamVS,Kjaer-SorensenK,PedersenLN,SkeberdisVA,JurevičiusJ,
the electrocardiographic early repolarization pattern. Heart Rhythm 2012;9:
et al. Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger 1627–1634.
AE3causesshortQTsyndrome.NatCommun2017;8:1696.
1039. AdhikarlaC,BogaM,WoodAD,FroelicherVF.Naturalhistoryoftheelectrocar-
1063. MazzantiA,KanthanA,MonteforteN,MemmiM,BloiseR,NovelliV,etal.Novel
diographicpatternofearlyrepolarizationinambulatorypatients.AmJCardiol
insightintothenaturalhistoryofshortQTsyndrome.JAmCollCardiol2014;63:
2011;108:1831–1835.
1300–1308.
1040. MahidaS,DervalN,SacherF,LeenhardtA,DeisenhoferI,BabutyD,etal.Roleof
1064. DhutiaH,MalhotraA,ParpiaS,GabusV,FinocchiaroG,MellorG,etal.The
electrophysiologicalstudiesinpredictingriskofventriculararrhythmiainearlyre- prevalenceandsignificanceofashortQTintervalin18825low-riskindividuals
polarizationsyndrome.JAmCollCardiol2015;65:151–159. includingathletes.BrJSportsMed2016;50:124–129.
1041. Aizawa Y, Sato A, Watanabe H, Chinushi M, Furushima H, Horie M, et al. 1065. GallagherMM,MaglianoG,YapYG,PadulaM,MorgiaV,PostorinoC,etal.
DynamicityoftheJ-waveinidiopathicventricularfibrillationwithaspecialrefer- DistributionandprognosticsignificanceofQTintervalsinthelowesthalfcentile
encetopause-dependentaugmentationoftheJ-wave.JAmCollCardiol2012;59: in12,012apparentlyhealthypersons.AmJCardiol2006;98:933–935.
1948–1953.
1066. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV.
1042. Priori SG, Mazzanti A, Santiago DJ, Kukavica D, Trancuccio A, Kovacic JC. Prevalenceandprognostic significance of shortQT intervalin amiddle-aged
Precision medicine in catecholaminergic polymorphic ventricular tachycardia: Finnishpopulation.Circulation2007;116:714–720.
JACCfocusseminar5/5.JAmCollCardiol2021;77:2592–2612. 1067. KobzaR,RoosM,NiggliB,AbächerliR,LupiGA,FreyF,etal.Prevalenceoflong
1043. BezzinaCR,LahrouchiN,PrioriSG.Geneticsofsuddencardiacdeath.CircRes andshortQTinayoungpopulationof41,767predominantlymaleSwisscon-
2015;116:1919–1936. scripts.HeartRhythm2009;6:652–657.
1044. KimuraH,ZhouJ,KawamuraM,ItohH,MizusawaY,DingW-G,etal.Phenotype 1068. GiustettoC,SchimpfR,MazzantiA,ScroccoC,MauryP,AnttonenO,etal.
variabilityinpatientscarryingKCNJ2mutations.CircCardiovascGenet2012;5: Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol
344–353. 2011;58:587–595.
Downloaded
from

by
guest
on
22
January
2026

ESCGuidelines 4125
1069.El-BattrawyI,BeslerJ,LiebeV,SchimpfR,TülümenE,RudicB,etal.Long-term 1093. European Society of Gynecology (ESG), Association for European Paediatric
follow-upofpatientswithshortQTsyndrome:clinicalprofileandoutcome.J Cardiology (AEPC), German Society for Gender Medicine (DGesGM),
AmHeartAssoc2018;7:e010073. Regitz-ZagrosekV,BlomstromLundqvistC,BorghiC,etal.ESCGuidelineson
1070.MazzantiA,MaragnaR,VacantiG,KostopoulouA,MarinoM,MonteforteN,etal. themanagementofcardiovasculardiseasesduringpregnancy:thetaskforceon
Hydroquinidinepreventslife-threateningarrhythmiceventsinpatientswithshort theManagementofCardiovascularDiseasesduringPregnancyoftheEuropean
QTsyndrome.JAmCollCardiol2017;70:3010–3015. SocietyofCardiology(ESC).EurHeartJ2011;32:3147–3197.
1071.El-BattrawyI,BeslerJ,LiX,LanH,ZhaoZ,LiebeV,etal.Impactofantiarrhythmic 1094. RashbaEJ,ZarebaW,MossAJ,HallWJ,RobinsonJ,LocatiEH,etal.Influenceof
drugsontheoutcomeofshortQTsyndrome.FrontPharmacol2019;10:771. pregnancyontheriskforcardiaceventsinpatientswithhereditarylongQTsyn-
1072.MalikM.Drug-inducedQT/QTcintervalshortening:lessonsfromdrug-induced drome.LQTSinvestigators.Circulation1998;97:451–456.
QT/QTcprolongation.DrugSaf2016;39:647–659. 1095. IshibashiK,AibaT,KamiyaC,MiyazakiA,SakaguchiH,WadaM,etal.Arrhythmia
1073.Giustetto C, Scrocco C, Schimpf R, Maury P, Mazzanti A, Levetto M, et al. riskandβ-blockertherapyinpregnantwomenwithlongQTsyndrome.Heart
UsefulnessofexercisetestinthediagnosisofshortQTsyndrome.Europace 2017;103:1374–1379.
2015;17:628–634. 1096. CheungCC,LieveKV,RostonTM,vanderReeMH,DeyellMW,AndradeJG,
1074.MasonJW,RamsethDJ,ChanterDO,MoonTE,GoodmanDB,MendzelevskiB. etal.Pregnancyincatecholaminergicpolymorphicventriculartachycardia.JACC
Electrocardiographicreferencerangesderivedfrom79,743ambulatorysubjects.J ClinElectrophysiol2019;5:387–394.
Electrocardiol2007;40:228–234. 1097. WuL,LiangE,FanS,ZhengL,HuF,LiuS,etal.Effectofpregnancyinarrhythmo-
1075.BunS-S,MauryP,GiustettoC,DeharoJ-C.Electricalstorminshort-QTsyn- genicrightventricularcardiomyopathy.AmJCardiol2020;125:613–617.
dromesuccessfullytreatedwithIsoproterenol.JCardiovascElectrophysiol2012; 1098. BauceB,DalientoL,FrigoG,RussoG,NavaA.Pregnancyinwomenwitharrhyth-
23:1028–1030. mogenicrightventricularcardiomyopathy/dysplasia.EurJObstetGynecolReprod
1076.Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al. Biol2006;127:186–189.
Prospectivemulticenterstudyofpregnancyoutcomesinwomenwithheartdis- 1099. GandjbakhchE,VarletE,DuthoitG,FressartV,CharronP,HimbertC,etal.
ease.Circulation2001;104:515–521. Pregnancyandnewbornoutcomesinarrhythmogenicrightventricularcardiomy-
1077.DrenthenW,PieperPG,Roos-HesselinkJW,vanLottumWA,VoorsAA,Mulder opathy/dysplasia.IntJCardiol2018;258:172–178.
BJM,etal.Outcomeofpregnancyinwomenwithcongenitalheartdisease:alit- 1100. Rodríguez-MañeroM,Casado-ArroyoR,SarkozyA,LeysenE,SieiraJA,Namdar
eraturereview.JAmCollCardiol2007;49:2303–2311. M,etal.TheclinicalsignificanceofpregnancyinBrugadasyndrome.RevEspCardiol
1078.Roos-Hesselink JW, Ruys TPE, Stein JI, Thilén U, Webb GD, Niwa K, et al. (EnglEd)2014;67:176–180.
Outcomeofpregnancyinpatientswithstructuralorischaemicheartdisease:re- 1101. BenitoB,BerruezoA.Brugadasyndromeandpregnancy:delvingintotheroleof
sultsofaregistryoftheEuropeanSocietyofCardiology.EurHeartJ2013;34: sexhormonesinionchannelopathies.RevEspCardiol(EnglEd)2014;67:165–167.
657–665. 1102. OstrowskaB,KommataB,MalmborgH,LundqvistCB.Arrhythmiasinpregnancy.
1079.Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, ESCCardioMed.3rded.OxfordUniversityPress;2022,p2868–2870.
FurokawaT,etal.Sexdifferencesincardiacarrhythmia:aconsensusdocument 1103. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al.
of the European HeartRhythm Association, endorsedby the HeartRhythm Evaluationofbromocriptineinthetreatmentofacutesevereperipartumcardio-
SocietyandAsiaPacificHeartRhythmSociety.Europace2018;20:1565–1565ao. myopathy:aproof-of-conceptpilotstudy.Circulation2010;121:1465–1473.
1080.Regitz-ZagrosekV,Roos-HesselinkJW,BauersachsJ,Blomström-LundqvistC, 1104. Hilfiker-KleinerD,HaghikiaA,BerlinerD,Vogel-ClaussenJ,SchwabJ,FrankeA,
CífkováR,DeBonisM,etal.2018ESCGuidelinesforthemanagementofcardio- etal.Bromocriptineforthetreatmentofperipartumcardiomyopathy:amulticen-
vasculardiseasesduringpregnancy.EurHeartJ2018;39:3165–3241. trerandomizedstudy.EurHeartJ2017;38:2671–2679.
1081.SilversidesCK,HarrisL,HabererK,SermerM,ColmanJM,SiuSC.Recurrence 1105. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD.
ratesofarrhythmiasduringpregnancyinwomenwithprevioustachyarrhythmia Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol
andimpactonfetalandneonataloutcomes.AmJCardiol2006;97:1206–1212. 2015;26:698–702.
1082.SliwaK,MebazaaA,Hilfiker-KleinerD,PetrieMC,MaggioniAP,LarocheC,etal. 1106. WangZ,ChenYW,JiangYH,SunLP,ChenXJ,TaoHL,etal.Electrophysiological
Clinicalcharacteristicsofpatientsfromtheworldwideregistryonperipartumcar- characteristicsandtherapeuticefficacyofradiofrequencyablationoffocalatrial
diomyopathy(PPCM):EURObservationalResearchProgrammeinconjunction tachycardia originating from the right atrial appendage during pregnancy.
withtheHeartFailureAssociationoftheEuropeanSocietyofCardiologyStudy ZhonghuaXinXueGuanBingZaZhi2020;48:859–865.
GrouponPPCM.EurJHeartFail2017;19:1131–1141. 1107. TuzcuV,KilincOU.Implantablecardioverterdefibrillatorimplantationwithout
1083.WareJS,LiJ,MazaikaE,YassoCM,DeSouzaT,CappolaTP,etal.Sharedgenetic using fluoroscopy in a pregnant patient. Pacing Clin Electrophysiol 2012;35:
predispositioninperipartumanddilatedcardiomyopathies.NEnglJMed2016; e265–266.
374:233–241. 1108. FröhlichGM,HolzmeisterJ,HüblerM,HüblerS,WolfrumM,EnseleitF,etal.
1084.WangY-C,ChenC-H,SuH-Y,YuM-H.Theimpactofmaternalcardioversionon Prophylacticimplantablecardioverterdefibrillatortreatmentinpatientswithend-
fetalhaemodynamics.EurJObstetGynecolReprodBiol2006;126:268–269. stageheartfailureawaitinghearttransplantation.Heart2013;99:1158–1165.
1085.BarnesEJ,EbenF,PattersonD.Directcurrentcardioversionduringpregnancy 1109. SandnerSE,WieselthalerG,ZuckermannA,TaghaviS,SchmidingerH,PacherR,
shouldbeperformedwithfacilitiesavailableforfetalmonitoringandemergency etal.Survivalbenefitoftheimplantablecardioverter-defibrillatorinpatientson
caesareansection.BJOG2002;109:1406–1407. thewaitinglistforcardiactransplantation.Circulation2001;104:I171–176.
1086.MiyoshiT,KamiyaCA,KatsuragiS,UedaH,KobayashiY,HoriuchiC,etal.Safety 1110. AlgalarrondoV,PeraultR,BoriesM-C,NarayananK,GarciaR,CombesN,etal.
andefficacyofimplantablecardioverter-defibrillatorduringpregnancyandafter Prophylacticimplantablecardioverterdefibrillatorsforprimaryprevention:From
delivery.CircJ2013;77:1166–1170. implantationtohearttransplantation.ArchCardiovascDis2018;111:758–765.
1087.Abello M, Peinado R, Merino JL, Gnoatto M, Mateos M, Silvestre J, et al. 1111. Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E,
Cardioverterdefibrillatorimplantationinapregnantwomanguidedwithtranse- Rangel-SousaD,Esteve-RuizIM,etal.Implantablecardioverterdefibrillatorfor
sophagealechocardiography.PacingClinElectrophysiol2003;26:1913–1914. primarypreventioninpatientswithsevereventriculardysfunctionawaitingheart
1088.HartzJ,ClarkBC,ItoS,SherwinED,BerulCI.Transvenousnonfluoroscopicpace- transplantation.TransplantProc2013;45:3659–3661.
makerimplantationduringpregnancyguidedby3-dimensionalelectroanatomic 1112. PezawasT,GrimmM,RistlR,KivaranovicD,MoserFT,LauferG,etal.Primary
mapping.HeartRhythmCaseRep2017;3:490–492. preventivecardioverter-defibrillatorimplantation(Pro-ICD)inpatientsawaiting
1089.BauersachsJ,KönigT,vanderMeerP,PetrieMC,Hilfiker-KleinerD,MbakwemA, hearttransplantation.Aprospective,randomized,controlled12-yearfollow-up
etal.Pathophysiology,diagnosisandmanagementofperipartumcardiomyopathy: study.TransplInt2015;28:34–41.
apositionstatementfromtheHeartFailureAssociationoftheEuropeanSociety 1113. KaoAC,KrauseSW,HandaR,KariaD,ReyesG,BiancoNR,etal.Wearablede-
ofCardiologyStudyGrouponperipartumcardiomyopathy.EurJHeartFail2019; fibrillator use in heart failure (WIF): results of a prospective registry. BMC
21:827–843. CardiovascDisord2012;12:123.
1090.DunckerD,KönigT,HohmannS,BauersachsJ,VeltmannC.Avoidinguntimely 1114. AlbaAC,ForoutanF,HingNKVNF,FanC-PS,ManlhiotC,RossHJ.Incidenceand
implantable cardioverter/defibrillator implantation by intensified heart failure predictorsofsuddencardiacdeathafterhearttransplantation:asystematicre-
therapyoptimizationsupportedbythewearablecardioverter/defibrillator-the viewandmeta-analysis.ClinTransplant2018;32:e13206.
PROLONGstudy.JAmHeartAssoc2017;6:e004512. 1115. VakilK,TaimehZ,SharmaA,AbidiKS,ColvinM,LuepkerR,etal.Incidence,pre-
1091.DunckerD,WestenfeldR,KonradT,PfefferT,CorreiadeFreitasCA,PfisterR, dictors,andtemporaltrendsofsuddencardiacdeathafterhearttransplantation.
etal.Riskforlife-threateningarrhythmiainnewlydiagnosedperipartumcardio- HeartRhythm2014;11:1684–1690.
myopathywithlowejectionfraction:aGermanmulti-centreanalysis.ClinRes 1116. AlbaAC,FanC-PS,ManlhiotC,DipchandAI,StehlikJ,RossHJ.Theevolvingrisk
Cardiol2017;106:582–589. ofsuddencardiacdeathafterhearttransplant.AnanalysisoftheISHLTthoracic
1092.JeejeebhoyFM,ZelopCM,LipmanS,CarvalhoB,JoglarJ,MhyreJM,etal.Cardiac transplantregistry.ClinTransplant2019;33:e13490.
arrestinpregnancy:ascientificstatementfromtheAmericanheartassociation. 1117. EskanderMA,AdlerE,HoffmayerKS.Arrhythmiasandsuddencardiacdeathin
Circulation2015;132:1747–1773. post-cardiactransplantpatients.CurrOpinCardiol2020;35:308–311.
Downloaded
from

by
guest
on
22
January
2026

4126 ESCGuidelines
1118. TsaiVW,CooperJ,GaranH,NataleA,PtaszekLM,EllinorPT,etal.Theefficacy stand from the European Association of Cardiovascular Prevention and
ofimplantablecardioverter-defibrillatorsinhearttransplantrecipients:results Rehabilitation (EACPR), section of Sports Cardiology. Eur Heart J 2011;32:
fromamulticenterregistry.CircHeartFail2009;2:197–201. 2119–2124.
1119. KleinHU,MeltendorfU.Bridgingatemporaryhighriskofsuddenarrhythmic 1140. DreznerJA,OwensDS,PrutkinJM,SalernoJC,HarmonKG,ProsiseS,etal.
death.Experiencewiththewearablecardioverterdefibrillator.PACE2010;33: Electrocardiographic Screening in National Collegiate Athletic Association
353–367. Athletes.AmJCardiol2016;118:754–759.
1120. CorradoD,ZorziA.Suddendeathinathletes.IntJCardiol2017;237:67–70. 1141. ErbelR,MöhlenkampS,MoebusS,SchmermundA,LehmannN,StangA,etal.
1121. RajanD,GarciaR,SvaneJ,Tfelt-HansenJ.Riskofsports-relatedsuddencardiac Coronary risk stratification, discrimination, and reclassification improvement
deathinwomen.EurHeartJ2021;43:1198–1206. based on quantification of subclinical coronary atherosclerosis: the Heinz
1122. CorradoD,BassoC,SchiavonM,ThieneG.Screeningforhypertrophiccardiomy- NixdorfRecallstudy.JAmCollCardiol2010;56:1397–1406.
opathyinyoungathletes.NEnglJMed1998;339:364–369. 1142. YeboahJ,McClellandRL,PolonskyTS,BurkeGL,SibleyCT,O’LearyD,etal.
1123. MalhotraA,DhutiaH,FinocchiaroG,GatiS,BeasleyI,CliftP,etal.Outcomesof Comparisonofnovelriskmarkersforimprovementincardiovascularriskassess-
cardiacscreeninginadolescentsoccerplayers.NEnglJMed2018;379:524–534. mentinintermediate-riskindividuals.JAMA2012;308:788–795.
1124. CorradoD,PellicciaA,BjørnstadHH,VanheesL,BiffiA,BorjessonM,etal. 1143. PapponeC,VicedominiG,MangusoF,SavianoM,BaldiM,PapponeA,etal.
Cardiovascularpre-participationscreeningofyoungcompetitiveathletesforpre- Wolff-Parkinson-Whitesyndromeintheeraofcatheterablation:insightsfrom
ventionofsuddendeath:proposalforacommonEuropeanprotocol.Consensus aregistrystudyof2169patients.Circulation2014;130:811–819.
StatementoftheStudyGroupofSportCardiologyoftheWorkingGroupof 1144. ObeyesekereMN,Leong-SitP,MasselD,ManlucuJ,ModiS,KrahnAD,etal.Risk
Cardiac Rehabilitation and Exercise Physiology and the Working Group of ofarrhythmiaandsuddendeathinpatientswithasymptomaticpreexcitation:a
MyocardialandPericardialDiseasesoftheEuropeanSocietyofCardiology.Eur meta-analysis.Circulation2012;125:2308–2315.
HeartJ2005;26:516–524.
1145. HeidbuchelH,AdamiPE,AntzM,BraunschweigF,DeliseP,ScherrD,etal.
1125. CorradoD,SchmiedC,BassoC,BorjessonM,SchiavonM,PellicciaA,etal.Riskof Recommendationsforparticipationinleisure-timephysicalactivityandcompeti-
sports:doweneedapre-participationscreeningforcompetitiveandleisureath- tivesportsinpatientswitharrhythmiasandpotentiallyarrhythmogeniccondi-
letes?EurHeartJ2011;32:934–944.
tions:part1:supraventriculararrhythmias.ApositionstatementoftheSection
1126. Baggish AL, Hutter AM, Wang F, Yared K, Weiner RB, Kupperman E, et al. of Sports Cardiology and Exercise from the European Association of
Cardiovascularscreeningincollegeathleteswithandwithoutelectrocardiog-
Preventive Cardiology (EAPC) and the European Heart Rhythm Association
raphy:across-sectionalstudy.AnnInternMed2010;152:269–275.
(EHRA),both associationsof the European Society of Cardiology. EurJ Prev
1127. CorradoD,BassoC,PaveiA,MichieliP,SchiavonM,ThieneG.Trendsinsudden Cardiol2020;28:1539–1551.
cardiovasculardeathinyoungcompetitiveathletesafterimplementationofapre-
1146. PapponeC,SantinelliV,MangusoF,AugelloG,SantinelliO,VicedominiG,etal.A
participationscreeningprogram.JAMA2006;296:1593–1601.
randomizedstudyofprophylacticcatheterablationinasymptomaticpatientswith
1128. SharmaS,EstesNAM,VetterVL,CorradoD.Clinicaldecisions.Cardiacscreening theWolff-Parkinson-Whitesyndrome.NEnglJMed2003;349:1803–1811.
beforeparticipationinsports.NEnglJMed2013;369:2049–2053.
1147. PerryJC,GarsonA.SupraventriculartachycardiaduetoWolff-Parkinson-White
1129. SartoP,ZorziA,MerloL,VessellaT,PegoraroC,GiorgianoF,etal.Serialversus
syndromeinchildren:earlydisappearanceandlaterecurrence.JAmCollCardiol
single cardiovascular screening of adolescent athletes. Circulation 2021;143: 1990;16:1215–1220.
1729–1731.
1148. Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm
1130. Steinvil A, Chundadze T, Zeltser D, Rogowski O, Halkin A, Galily Y, et al.
Society(HRS),AmericanCollegeofCardiologyFoundation(ACCF),American
Mandatoryelectrocardiographicscreeningofathletestoreducetheirriskforsud-
dendeathprovenfactorwishfulthinking?JAmCollCardiol2011;57:1291–1296. Heart Association (AHA), American Academy of Pediatrics (AAP), Canadian
HeartRhythmSociety(CHRS),etal.PACES/HRSexpertconsensusstatement
1131. Corrado D, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, et al.
on the management of the asymptomatic young patient with a
Recommendationsforinterpretationof12-leadelectrocardiogramintheathlete.
EurHeartJ2010;31:243–259. Wolff-Parkinson-White(WPW,ventricularpreexcitation)electrocardiographic
pattern: developed in partnership between the Pediatric and Congenital
1132. SharmaS,DreznerJA,BaggishA,PapadakisM,WilsonMG,PrutkinJM,etal.
Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS).
Internationalrecommendationsforelectrocardiographicinterpretationinath-
letes.EurHeartJ2018;39:1466–1480. EndorsedbythegoverningbodiesofPACES,HRS,theAmericanCollegeof
Cardiology Foundation (ACCF), the American Heart Association (AHA), the
1133. Crescenzi C, Zorzi A, Vessella T, Martino A, Panattoni G, Cipriani A, et al.
American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm
Predictorsofleftventricularscarusingcardiacmagneticresonanceinathletes
withapparentlyidiopathicventriculararrhythmias.JAmHeartAssoc2021;10:
Society(CHRS).HeartRhythm2012;9:1006–1024.
e018206. 1149. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I.
1134. PiepoliMF,HoesAW,AgewallS,AlbusC,BrotonsC,CatapanoAL,etal.2016
Applicabilityofariskscoreforpredictionofthelong-term(8-year)benefitof
European Guidelineson cardiovasculardiseaseprevention in clinicalpractice:
theimplantablecardioverter-defibrillator.JAmCollCardiol2012;59:2075–2079.
TheSixthJointtaskforceoftheEuropeanSocietyofCardiologyandOther 1150. Expósito V, Rodríguez-Mañero M, González-Enríquez S, Arias MA,
SocietiesonCardiovascularDiseasePreventioninClinicalPractice(constituted Sánchez-GómezJM,AndrésLaHuertaA,etal.Primarypreventionimplantable
byrepresentativesof10societiesandbyinvitedexperts)Developedwiththespe-
cardioverter-defibrillatorandcardiacresynchronizationtherapy-defibrillatorin
cialcontributionoftheEuropeanAssociationforCardiovascularPrevention& elderly patients: results of a Spanish multicentre study. Europace 2016;18:
Rehabilitation(EACPR).EurHeartJ2016;37:2315–2381. 1203–1210.
1135. Rizzo M, Spataro A, Cecchetelli C, Quaranta F, Livrieri S, Sperandii F, et al. 1151. AlhakakA,ØstergaardL,ButtJH,VintherM,PhilbertBT,JacobsenPK,etal.
Structuralcardiacdiseasediagnosedbyechocardiographyinasymptomaticyoung Cause-specific death and risk factors of one-year mortality after implantable
malesoccerplayers:implicationsforpre-participationscreening.BrJSportsMed cardioverter-defibrillator implantation: a nationwide study. Eur Heart J Qual
2012;46:371–373. CareClinOutcomes2022;8:39–49.
1136. HeidbuchelH,ArbeloE,D’AscenziF,BorjessonM,BovedaS,CastellettiS,etal. 1152. PoupinP,BouletiC,DegandB,PaccalinM,LeGalF,BureauM-L,etal.Prognostic
Recommendationsforparticipationinleisure-timephysicalactivityandcompeti- valueofCharlsonComorbidityIndexintheelderlywithacardioverterdefibrilla-
tivesportsofpatientswitharrhythmiasandpotentiallyarrhythmogeniccondi- torimplantation.IntJCardiol2020;314:64–69.
tions. Part 2: ventricular arrhythmias, channelopathies, and implantable 1153. AktaaS,BatraG,WallentinL,BaigentC,ErlingeD,JamesS,etal.Europeansociety
defibrillators.Europace2021;23:147–148. ofcardiologymethodologyforthedevelopmentofqualityindicatorsforthequan-
1137. DreznerJA,PetersonDF,SiebertDM,ThomasLC,Lopez-AndersonM,Suchsland tificationofcardiovascularcareandoutcomes.EurHeartJQualCareClinOutcomes
MZ,etal.Survivalafterexercise-relatedsuddencardiacarrestinyoungathletes: 2022;8:4–13.
canwedobetter?SportsHealth2019;11:91–98. 1154. MinchinM,RolandM,RichardsonJ,RowarkS,GuthrieB.Qualityofcareinthe
1138. DreznerJA,RogersKJ,HorneffJG.AutomatedexternaldefibrillatoruseatNCAA UnitedKingdomafterremovaloffinancialincentives.NEnglJMed2018;379:
DivisionIIandIIIuniversities.BrJSportsMed2011;45:1174–1178. 948–957.
1139. BorjessonM,SerratosaL,CarreF,CorradoD,DreznerJ,DugmoreDL,etal. 1155. SongZ,JiY,SafranDG,ChernewME.Healthcarespending,utilization,andquality
Consensusdocumentregardingcardiovascularsafetyatsportsarenas:position 8yearsintoglobalpayment.NEnglJMed2019;381:252–263.
Downloaded
from

by
guest
on
22
January
2026
